

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA  
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and  
right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:29:18 ON 26 MAY 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:29:29 ON 26 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0  
DICTIONARY FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 09912163.1

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*


NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADDEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN

L1 STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1 STR



G1 NH,X,Hy

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1

SAMPLE SEARCH INITIATED 14:29:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3808 TO ITERATE

26.3% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 72461 TO 79859

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=&gt; s l1 sss full

FULL SEARCH INITIATED 14:30:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 74649 TO ITERATE

100.0% PROCESSED 74649 ITERATIONS

55 ANSWERS

SEARCH TIME: 00.00.04

L3 55 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 14:30:10 ON 26 MAY 2003



USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 May 2003 VOL 138 ISS 22  
FILE LAST UPDATED: 25 May 2003 (20030525/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 22 L3

=> d 14 fbib hitstr abs total

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 2001:568374 CAPLUS

DN 135:152793

TI Preparation of optically active oxazolidinedione derivatives for treatment of diabetes, hyperlipidemia, inflammation, and arteriosclerosis

IN Momose, Yu; Kodaka, Hiroyuki

PA Takeda Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 2001213880	A2	20010807	JP 2000-24773	20000128
				JP 2000-24773	20000128

IT 352662-19-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of optically active oxazolidinedione derivs. for treatment of diabetes and hyperlipidemia and inflammation and arteriosclerosis)

RN 352662-19-2 CAPLUS

CN Benzenepentanoic acid, 4-[(5-methyl-2-phenyl-4-thiazolyl)methoxy]-.alpha.-[(2R)-3,3,3-trifluoro-1-oxo-2-(1-oxo-3-phenylpropoxy)-2-phenylpropoxy]-, monomethyl ester, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Claimed are (R)-(+)-5-[3-[4-[(5-methyl-2-phenyl-4-thiazolyl)methoxy]phenyl]propyl]-2,4-oxazolidinedione (I), salts and crystals thereof. Also claimed is the prepn. of I by cyclization of (R)-2-ethoxycarbonyloxy-5-[4-[(5-methyl-2-phenyl-4-thiazolyl)methoxy]phenyl]pentanamide. I at 0.2 mg/kg/day for one week gave 18% decrease of plasma glucose in Wistar fatty rats. Formulations are given.

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 2001:57805 CAPLUS

DN 134:252075

TI    Synthesis of enantiopure homoallylic ethers by reagent controlled facial selective allylation of chiral ketones

AU Tietze, Lutz F.; Weigand, Berthold; Volkel, Ludwig; Wulff, Christian;  
Bittner, Christian

CS Institut für Organische Chemie Georg-August-Universität Göttingen,  
Göttingen, 37077, Germany

SO Chemistry--A European Journal (2001), 7(1), 161-168

CODEN: CEUJED; ISSN: 0947-6539

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

OS CASREACT 134:252075


IT 330798-68-0P 330798-69-1P


RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of enantiopure homoallylic ethers by reagent controlled  
facial selective allylation of chiral ketones)

RN 330798-68-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1S,2S)-1-methyl-2-[[ (1R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 330798-69-1 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 330798-62-4P 330798-63-5P 330798-73-7P  
330798-76-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of enantiopure homoallylic ethers by reagent controlled  
facial selective allylation of chiral ketones)

RN 330798-62-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1S,2S)-1-methyl-2-[[ (1S)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 330798-63-5 CAPLUS

CN    Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI)    (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 330798-73-7 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1R)-1-methyl-1-(2-phenylpropyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 330798-76-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-(2-phenylpropyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI




AB The stereoselective allylation of chiral Me ketones to give tertiary homoallylic ethers, which can easily be transformed into homoallylic alcs., is described. Reaction of the enantiopure ketones (I), (R)-Me<sub>2</sub>CH(CH<sub>2</sub>)<sub>3</sub>CH(.beta.Me)CH<sub>2</sub>COMe, (R)-MeCH(.beta.OSiPh<sub>2</sub>CMe<sub>3</sub>)CH<sub>2</sub>COMe, (S)-MeCH(.alpha.Ph)CH<sub>2</sub>COMe and the racemic ketones MeCH(OSiPh<sub>2</sub>CMe<sub>3</sub>)CH<sub>2</sub>COMe, MeCH(Ph)CH<sub>2</sub>COMe, MeCH<sub>2</sub>CH(Ph)COMe, MeCH<sub>2</sub>CH(Me)COMe with the norpseudoephedrine deriv. and allylsilane in the presence of a catalytic amt. of trifluoromethanesulfonic acid, led to a series of homoallylic ethers with good to excellent diastereoselectivity (85:15 to > 97:3). The allylation is reagent controlled and nearly independent from the stereogenic centers in the substrates. A partial kinetic resoln. was obsd. using the racemic ketones. In the reaction of the chiral ketones with the achiral reagents ethoxytrimethylsilane and allylsilane only a low diastereoselectivity was obsd.

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2003 ACS  
AN 2000:845053 CAPLUS  
DN 134:115714  
TI SuperQuat, (S)-4-benzyl-5,5-dimethyloxazolidin-2-one for the asymmetric synthesis of .alpha.-substituted aldehydes  
AU Bull, Steven D.; Davies, Stephen G.; Nicholson, Rebecca L.; Sangane, Hitesh J.; Smith, Andrew D.  
CS The Dyson Perrins Laboratory, University of Oxford, Oxford, OX1 3QY, UK  
SO Tetrahedron: Asymmetry (2000), 11(17), 3475-3479  
CODEN: TASYE3; ISSN: 0957-4166  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 134:115714  
IT 320606-37-9P 320606-39-1P 320606-41-5P  
320606-43-7P 320606-45-9P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(using (S)-4-benzyl-5,5-dimethyloxazolidin-2-one for the asym. synthesis of .alpha.-substituted aldehydes)  
RN 320606-37-9 CAPLUS  
CN Benzene, [(2S)-2-methyl-3-[(1R)-2,2,2-trifluoro-1-methoxy-1-phenylethoxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 320606-39-1 CAPLUS

CN Benzene, [(2S)-2-[[ (1R)-2,2,2-trifluoro-1-methoxy-1-phenylethoxy]methyl]-4-pentenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 320606-41-5 CAPLUS

CN Benzene, [(2S)-5-methyl-2-[[ (1R)-2,2,2-trifluoro-1-methoxy-1-phenylethoxy]methyl]-4-hexenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 320606-43-7 CAPLUS

CN Benzene, [(2R)-4-methyl-2-[[ (1R)-2,2,2-trifluoro-1-methoxy-1-phenylethoxy]methyl]pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 320606-45-9 CAPLUS

CN Benzene, [(2R)-2-[[ (1R)-2,2,2-trifluoro-1-methoxy-1-phenylethoxy]methyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Redn. of .alpha.-substituted-(S)-N-acyl-4-benzyl-5,5-dimethyloxazolidin-2-ones with DIBAL-H in CH<sub>2</sub>Cl<sub>2</sub> affords .alpha.-substituted aldehydes with no loss of stereochem. integrity at their .alpha.-center.

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1999:292590 CAPLUS

DN 130:338021

TI Preparation of arylacetic amide derivatives as a preventive or remedy for urinary disorders

IN Kaihoh, Terumitsu; Okada, Tomomi; Takahashi, Yoshinori; Mizuno, Hiroyuki; Honda, Haruyoshi; Sato, Susumo

PA SSP Co., Ltd., Japan

SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 913393	A2	19990506	EP 1998-120422	19981028
	EP 913393	A3	19990526		
	EP 913393	B1	20030212		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 11193271	A2	19990721	JP 1997-300352 A	19971031
				JP 1998-290576	19981013
				JP 1997-300352 A	19971031
	US 6060485	A	20000509	US 1998-181091	19981028
				JP 1997-300352 A	19971031
	CN 1222510	A	19990714	CN 1998-122655	19981030
				JP 1997-300352 A	19971031
	TW 442470	B	20010623	TW 1998-87118071	19981030
				JP 1997-300352 A	19971031


OS MARPAT 130:338021

IT 224034-69-9P 224034-79-1P 224034-80-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of arylacetic amide derivs. as a preventive or remedy for urinary disorders)


RN 224034-69-9 CAPLUS

CN Benzeneacetamide, .alpha.-cyclopentyl-4-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]-.alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 224034-79-1 CAPLUS

CN Benzeneacetamide, .alpha.-cyclopentyl-3-methoxy-N-[1-(phenylmethyl)-4-piperidiny]-.alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 224034-80-4 CAPLUS

CN Benzeneacetamide, 3-chloro-.alpha.-cyclopentyl-N-[1-(phenylmethyl)-4-piperidiny]-.alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = (un)substituted arom. hydrocarbon or heteroarom. group; R2, R3 = (un)substituted hydrocarbon or heterocyclic



group; R4 = H, (un)substituted hydrocarbon or heterocyclic group; n = 0-1] and their salts which have both excellent anticholinergic action and calcium antagonism and at the same time have high selectivity to bladder, so that they are useful as preventives or remedies for urinary disorders, were prepd. Thus, treatment of N-(1-benzyl-4-piperidiny1)-2-hydroxy-3-methyl-2-phenylbutanamide with NaH in DMF followed by addn. of BuI and a soln. of Bu4NI in DMF afforded 28% I [R1 = Ph; R2 = iPr; R3 = Bu; R4 = PhCH2; n = 0] which showed ID50 of 9.8 mg/kg against bladder contraction in rats.

L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1998:625620 CAPLUS

DN 129:316000

TI Synthesis of enantiopure homoallylic alcohols by a highly selective asymmetric allylation of ketones

AU Tietze, Lutz F.; Schiemann, Kai; Wegner, Christoph; Wulff, Christian

CS Institute Organic Chemistry, Georg-August-Universitat Gottingen, Gottingen, D-37077, Germany

SO Chemistry--A European Journal (1998), 4(9), 1862-1869

CODEN: CEUJED; ISSN: 0947-6539

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

OS CASREACT 129:316000

IT 165823-95-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of enantiopure homoallylic alcs. by asym. allylation of ketones)

RN 165823-95-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[(1S)-1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB A highly selective asym. domino allylation of aliph. ketones is described. When Me ketones, (R,R)-Me2SiOCHPhCHMeNHCOCF3, and CH2:CHCH2SiMe3 react in the presence of catalytic amts. of trifluoromethanesulfonic acid, the homoallylic ethers are produced with up to 24:1 diastereoselectivity and 89% yield. Ether cleavage using lithium or sodium in liq. ammonia gives the homoallylic alcs. in 75 to 95% yield and up to 92% ee. Even EtCOMe, the most difficult example, showed a stereoselectivity of 9:1 at -78.degree.C and 24:1 at -109.degree.C. In addn., the allylation of protected hydroxyalkyl Me ketones gave the corresponding homoallylic

ethers with a diastereoselectivity of up to >244:1 and 98% yield. In contrast, Et alkyl ketones have a low selectivity.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1997:639948 CAPLUS

DN 127:307269

TI Preparation of optically active succinic acid derivatives. I. Optical resolution of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionic acid

AU Yamaguchi, Toshiaki; Yanagi, Takashi; Hokari, Hiroshi; Mukaiyama, Yuko;  
Kamijo, Tetsuhide; Yamamoto, Iwao

CS    Kinsey Pharmaceutical Co., Ltd., Central Research Laboratories, Hotaka,  
399-83, Japan

SO Chemical & Pharmaceutical Bulletin (1997), 45(9), 1518-1520

CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English


IT 197447-44-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(optical resolu. of benzyl(hexahydroisindolylcarbonyl)propionic acid)

RN 197447-44-2 CAPLUS

CN 2H-Isoindole-2-butanoic acid, octahydro-.gamma.-oxo-.alpha.-(phenylmethyl)-  
, 2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl ester, [2(.alpha.S)-  
[2[R\*(R\*)],3a.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 197447-45-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(optical resoln. of benzyl(hexahydroisoindolylcarbonyl)propionic  
acid)

RN 197447-45-3 CAPLUS

CN 2H-Isoindole-2-butanolic acid, octahydro-.gamma.-oxo-.alpha.-(phenylmethyl)-  
, 2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl ester, [2(.alpha.R)-  
[2[R\*(S\*)],3a.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB Optical resolu. of 2-benzyl-3-(cis-hexahydroisoidolin-2-ylcarbonyl)propionic acid (I) was accomplished by two methods. Thus, I was esterified with (S)-N-benzylmandelamide and the resulting diastereomeric esters were sepd. by column chromatog. on silica gel. One of the diastereomers was hydrolyzed to give the optically active acid (-)-I. The abs. configuration of (-)-I was established as S by comparison with an authentic sample. The alternative method was resolu. using an optically active amine. Treatment of a soln. of the racemic acid I with 0.65 equiv of (R)-1-(1-naphthyl)ethylamine in ethanol gave the salt in 23.2% yield with an optical purity of 96.8% ee.

L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1996:96240 CAPLUS

DN 124:260514

TI Transformations of isoxazolidine and dihydropyran derivatives to optically active compounds

AU Diaz-Ortiz, Angel; Diez-Barra, Enrique; de la Hoz, Antonio; Prieto, Pilar; Moreno, Andres

CS Fac. Quimica, Univ. Castilla-La Mancha, Ciudad Real, E-13071, Spain

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1996), (3), 259-63

CODEN: JCPRB4; ISSN: 0300-922X

PB Royal Society of Chemistry

DT Journal


LA English

IT 174814-84-7P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(hydrolysis and hydrogenation of spiroisoxazolidines and spirodihydropyrans)

RN 174814-84-7 CAPLUS

CN Benzenepentanoic acid, .delta.-oxo-.beta.-phenyl-, 2-chloro-1,2-diphenylethyl ester (9CI) (CA INDEX NAME)



GI



AB Isoxazolidine and dihydropyran spiro derivs., e.g. I, can be easily transformed, by hydrolysis and hydrogenolysis, to give .delta.-keto esters, .delta.-keto acids, .beta.-amino esters, e.g., (S)-MeO2CCH2CHPhNPhCl, .beta.-amino acids and 3-amino alcs. in good yields. Starting from optically active compds., enantiomerically pure products are obtained. In some cases, reactions were induced by microwave irradiation.

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1995:835557 CAPLUS

DN 123:256542

TI Preparation of annelated dihydropyridines

IN Roos, Otto; Loesel, Walter; Arndts, Dietrich

PA Boehringer Ingelheim KG, Germany

SO Ger. Offen., 28 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4343683	A1	19950622	DE 1993-4343683	19931221
	CA 2178209	AA	19950629	CA 1994-2178209	19941214
				DE 1993-4343683A	19931221
	WO 9517389	A1	19950629	WO 1994-EP4150	19941214
	W: AU, CA, CN, JP, KR, PL, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				DE 1993-4343683A	19931221
	AU 9512433	A1	19950710	AU 1995-12433	19941214
	AU 699208	B2	19981126		
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	EP 736011	A1	19961009	EP 1995-903342	19941214
	EP 736011	B1	20000726		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	CN 1138325	A	19961218	CN 1994-194572	19941214
	CN 1044905	B	19990901		
				DE 1993-4343683A	19931221
	JP 09506882	T2	19970708	JP 1994-517154	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	RU 2136664	C1	19990910	RU 1996-115153	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	AT 194978	E	20000815	AT 1995-903342	19941214
				DE 1993-4343683A	19931221

ES 2149958	T3	20001116	WO 1994-EP4150 W 19941214
ZA 9410115	A	19950621	ES 1995-903342 19941214
US 5661157	A	19970826	DE 1993-4343683A 19931221
TW 404941	B	20000911	ZA 1994-10115 19941220
US 5968948	A	19991019	DE 1993-4343683A 19931221
US 6136819	A	20001024	US 1994-360867 19941221
			DE 1993-4343683A 19931221
			TW 1994-83112295 19941228
			DE 1993-4343683A 19931221
			US 1997-857643 19970516
			DE 1993-4343683A 19931221
			US 1994-360867 A319941221
			US 1999-329443 19990610
			DE 1993-4343683A 19931221
			US 1994-360867 A319941221
			US 1997-857643 A319970516


OS MARPAT 123:256542

IT **168545-16-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of annelated dihydropyridines from)

RN 168545-16-2 CAPLUS

CN Benzeneacetamide, N-[2-(3,4-dimethoxy-2,4-cyclohexadien-1-yl)ethyl]-  
.alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = benzo, thieno, indolo; B = O, S, (un)substituted CH<sub>2</sub>; R<sub>2</sub> = OH, alkoxy, benzyloxy, halogen, alkyl, methanesulfonyloxy, etc.; R<sub>3</sub> = 2- or 3-thienyl, (un)substituted Ph, alkyl, cycloalkylalkyl; R<sub>4</sub> = (un)branched alkenyl or alkynyl, alkoxy, dialkylamino, heterocyclyl, Ph, etc.; m = 0-3] (e.g., II), useful as calcium-channel blockers (no data), are prepd. by the intramol. cyclocondensation of arom. amides (III) (e.g., IV) in the presence of condensing agents (e.g., POCl<sub>3</sub>), and I-contg. formulations are also presented.

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1995:568922 CAPLUS

DN 123:111518

TI Enantioselective Synthesis of Tertiary Homoallylic Alcohols via  
Diastereoselective Addition of Allylsilanes to Ketones

AU Tietze, Lutz F.; Schiemann, Kai; Wegner, Christoph

CS Institute of Organic Chemistry, Georg-August-Universitaet, Goettingen,  
D-37077, Germany


SO Journal of the American Chemical Society (1995), 117(21), 5851-2

CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society


DT Journal  
 LA English  
 OS CASREACT 123:111518  
 IT **165823-95-0P 166021-67-6P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (enantioselective synthesis of tertiary homoallylic alcs. via  
 diastereoselective addn. of allylsilanes to ketones)  
 RN 165823-95-0 CAPLUS  
 CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 166021-67-6 CAPLUS  
 CN Acetamide, 2,2,2-trifluoro-N-[1-methyl-2-[[1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]-, [1R-[1R\*,2R\*(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB Enantiopure tertiary homoallylic alcs.  $\text{CH}_2:\text{CHCH}_2\text{CRMeOH}$  ( $\text{R} = \text{alkyl}$ ) can be obtained from the corresponding homoallylic ethers  $\text{CH}_2:\text{CHCH}_2\text{CRMeOR}_1$  [4,  $\text{R}_1 = \text{residue of (1R,2R)-N-(trifluoroacetyl)norpseudoephedrine}$ ] by treatment with sodium in liq. ammonia. The ethers 4 are formed highly selectively by treatment of the ketones  $\text{MeCOR}$  with the trimethylsilyl ether of N-trifluoroacetyl norpseudoephedrine in the presence of catalytic amts. of  $\text{Me}_3\text{SiB(OTf)}_4$  or  $\text{Me}_3\text{SiOTf/TfOH}$  ( $\text{Tf} = \text{CF}_3\text{SO}_2$ ) followed by addn. of allyltrimethylsilane. The yield was about 90% (based on conversion) and the diastereoselectivity was about 90:10. Using iso-Pr Me ketone a selectivity of >95:5 was obtained; thus only one diastereomer could be detected.


L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2003 ACS  
AN 1992:213702 CAPLUS  
DN 116:213702  
TI Stereoselective aldol reactions. Reaction of chiral ester titanium enolate with aldehydes  
AU Xiang, Yibin; Olivier, Eric; Ouimet, Nathalie  
CS Merck Frosst Cent. Ther. Res., Pointe Claire-Dorval, QC, H9R 4P8, Can.  
SO Tetrahedron Letters (1992), 33(4), 457-60  
CODEN: TELEAY; ISSN: 0040-4039  
DT Journal  
LA English  
OS CASREACT 116:213702  
IT **139954-97-5P 140147-55-3P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 139954-97-5 CAPLUS  
CN Benzenepropanoic acid, .beta.-hydroxy-.alpha.-methyl-,  
2-[[[(4-methylphenyl)sulfonyl]amino]-1-phenylpropyl ester,  
[.alpha.S-[.alpha.R\*(1S\*,2R\*),.beta.S\*]]- (9CI) (CA INDEX NAME)



RN 140147-55-3 CAPLUS  
CN Benzenepropanoic acid, .beta.-hydroxy-.alpha.-methyl-,  
2-[[[(4-methylphenyl)sulfonyl]amino]-1-phenylpropyl ester,  
[.alpha.R-[.alpha.R\*(1R\*,2S\*),.beta.R\*]]- (9CI) (CA INDEX NAME)




IT **140147-56-4P 141117-22-8P**  
RL: PREP (Preparation)  
(stereoselective synthesis of)  
RN 140147-56-4 CAPLUS  
CN Benzenepropanoic acid, .beta.-hydroxy-.alpha.-methyl-,  
2-[[[(4-methylphenyl)sulfonyl]amino]-1-phenylpropyl ester,  
[.alpha.S-[.alpha.R\*(1S\*,2R\*),.beta.R\*]]- (9CI) (CA INDEX NAME)




RN 141117-22-8 CAPLUS

CN Benzenepropanoic acid, .beta.-hydroxy-.alpha.-methyl-,  
 2-[[ (4-methylphenyl)sulfonyl]amino]-1-phenylpropyl ester,  
 [.alpha.R-[(.alpha.R\*(1R\*,2S\*),.beta.S\*)]]- (9CI) (CA INDEX NAME)



GI



AB The chiral ester I was enolized under  $\text{TiCl}_4/\text{Et}_3\text{N}$  conditions and reacted with aldehydes to give moderate to good stereoselectivities. Thus, successive treatment of I with  $\text{TiCl}_4$  in  $\text{CH}_2\text{Cl}_2$ ,  $\text{Et}_3\text{N}$ , and preformed  $\text{BzH-TiCl}_4$  complex gave 85% syn aldol. The chiral auxiliary group can be removed by simple sapon. and recovered.

L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1989:553339 CAPLUS

DN 111:153339

TI Preparation of esterified N-(dibenzocycloheptenylideneethyl)ephedrine derivatives with prolonged antiulcer activity

IN Butelman, Federico

PA Etablissement Texcontor, Liechtenstein

SO Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 313885	A1	19890503	EP 1988-116449	19881005
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4935444	A	19900619	IT 1987-22407	19871023
				US 1988-254220	19881006
				IT 1987-22407	19871023



JP 01135748	A2	19890529	JP 1988-264240	19881021
			IT 1987-22407	19871023
US 4990522	A	19910205	US 1990-487277	19900302
			IT 1987-22407	19871023
			US 1988-254220	19881006

IT **122881-51-0P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and N-alkylation of, with (haloethylidene)dibenzocycloheptene)


RN 122881-51-0 CAPLUS

CN Benzenepropanoic acid, 2-(methylamino)-1-phenylpropyl ester, [R-(R\*,S\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. [I; R = C<sub>9</sub>H<sub>19</sub>, C<sub>15</sub>H<sub>31</sub>, CH(NH<sub>2</sub>)(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>H, (CH<sub>2</sub>)<sub>2</sub>Ph, CMe<sub>3</sub>, p-HOC<sub>6</sub>H<sub>4</sub>, 2-thienyl, 3-pyridyl, 1-amino-2-(5-imidazolyl)ethyl, pamoic acid residue] are prepd. by esterification of ephedrine (II) with RCOCl to give PhCH(O<sub>2</sub>CR)CHMeNHMe (III), followed by N-alkylation with a (haloethylidene)dibenzocycloheptene IV (X = halo). II was esterified by decanoyl chloride (prepd. from the acid) to give 65% III [R = Me(CH<sub>2</sub>)<sub>8</sub>], which was refluxed in MeCN with IV (X = halo, not specified) to give 54% I [R = MeC(CH<sub>2</sub>)<sub>2</sub>]. The latter inhibited stress-induced ulcers in rats with ED<sub>50</sub> of 0.4 and 2.1 mg/kg orally, administered 6 and 36 h prior to commencement of the stress, resp.

L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1988:150014 CAPLUS

DN 108:150014


TI Stereoselective aldol reactions with (R)- and (S)-2-hydroxy-1,2,2-triphenylethyl acetate and related glycol monoacetates

AU Devant, Ralf; Mahler, Ulrike; Braun, Manfred

CS Inst. Org. Chem. Makromol. Chem., Univ. Duesseldorf, Duesseldorf, D-4000/1, Fed. Rep. Ger.


SO Chemische Berichte (1988), 121(3), 397-406  
 CODEN: CHBEAM; ISSN: 0009-2940  
 DT Journal  
 LA German  
 OS CASREACT 108:150014  
 IT **110744-05-3P 110744-06-4P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and base hydrolysis of)  
 RN 110744-05-3 CAPLUS  
 CN Benzenepropanoic acid, .beta.-hydroxy-, 2-hydroxy-1-phenyl-2,2-di-2-  
 thienylethyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 110744-06-4 CAPLUS  
 CN Benzenepropanoic acid, .beta.-hydroxy-, 2-hydroxy-1-phenyl-2,2-di-2-  
 thienylethyl ester, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The enolate  $\text{H}_2\text{C}:\text{C}(\text{OM})\text{OCHPhCPh}_2\text{OM}$  (I;  $\text{M} = \text{Li}, \text{K}, \text{MgCl}$  etc.), formed by double deprotonation of the ester  $\text{HOCPh}_2\text{CHPhO}_2\text{CMe}$  (II), is added to aldehydes. The influences of the enolate gegenion, of the solvent, and of the reaction temp. on the ratio of the isomeric products  $\text{RC}(\text{OH})\text{CO}_2\text{CHPhCPh}_2\text{OH}$  (III;  $\text{R} = \text{Ph}, \text{CHMe}_2, (\text{CH}_2)_3\text{Me}$ ) are studied. The highest degrees of diastereoselectivity were obtained when the magnesium enolate I ( $\text{M} = \text{MgX}$ ) was used. The basic hydrolysis of the adducts III affords .beta.-hydroxy carboxylic acids in corresponding optical purity. Thereby, the chiral auxiliary reagent,  $\text{HOCHPhCPh}_2\text{OH}$  (IV), is recovered. The aldol reaction of the doubly deprotonated esters  $\text{MeCO}_2\text{CHPhR}$  [ $\text{R} = \text{bis}(\text{naphthyl})\text{hydroxymethyl}, \text{bis}(2\text{-methoxyphenyl})\text{hydroxymethyl}, \text{bis}(2\text{-thienyl})\text{hydroxymethyl}$ ] points to the structural parameters, which might be responsible for the high diastereoselectivity of the acetate II. In the mass spectra of IV, II,  $\text{MeCO}_2\text{CHPhCR}_1\text{OH}$  ( $\text{R}_1 = 4\text{-MeOC}_6\text{H}_4, 2\text{-thienyl}$ ), and their deprotonated products, unusual rearrangements were obsd.

L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1984:591513 CAPLUS  
 DN 101:191513  
 TI Cephalosporin derivatives, and prophylactic and therapeutic agents for bacterial infection  
 IN Kakeya, Nobuharu; Nishizawa, Susumu; Tamaki, Satoshi; Kitao, Kazuhiko  
 PA Kyoto Pharmaceutical Industries, Ltd., Japan  
 SO Eur. Pat. Appl., 84 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 108942	A2	19840523	EP 1983-110284	19831015
	EP 108942	A3	19850515		
	EP 108942	B1	19880302		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	WO 8401949	A1	19840524	WO 1982-JP437	19821110
	W: MC			WO 1982-JP437	19821110
	US 4605651	A	19860812	US 1983-540676	19831011
				WO 1982-JP437	19821110
	ZA 8307635	A	19841128	ZA 1983-7635	19831013
				WO 1982-JP437	19821110
	AU 8320199	A1	19840517	AU 1983-20199	19831014
	AU 568094	B2	19871217		
				WO 1982-JP437	19821110
	AT 32724	E	19880315	AT 1983-110284	19831015
				WO 1982-JP437	19821110
				EP 1983-110284	19831015
	NO 8303807	A	19840511	NO 1983-3807	19831019
	NO 162240	B	19890821		
	NO 162240	C	19891129		
				WO 1982-JP437	19821110
	ES 526561	A1	19850416	ES 1983-526561	19831019
				WO 1982-JP437	19821110
	SU 1331432	A3	19870815	SU 1983-3655401	19831019
				WO 1982-JP437	19821110
	FI 8303839	A	19840511	FI 1983-3839	19831020
	FI 75348	B	19880229		
	FI 75348	C	19880609		
				WO 1982-JP437	19821110
	DK 8304818	A	19840511	DK 1983-4818	19831020
				WO 1982-JP437	19821110
	JP 59116292	A2	19840705	JP 1983-197458	19831020
				WO 1982-JP437	19821110
	CA 1239928	A1	19880802	CA 1983-439358	19831020
				WO 1982-JP437	19821110
	ES 532996	A1	19850816	ES 1984-532996	19840531
				WO 1982-JP437	19821110
	ES 532997	A1	19850816	ES 1984-532997	19840531
				WO 1982-JP437	19821110
	SU 1322983	A3	19870707	SU 1984-3827995	19841224
				WO 1982-JP437	19821110

## PATENT FAMILY INFORMATION:

FAN 1987:636362


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	SU 1309912	A3	19870507	SU 1984-3826171	19841224
	WO 8401949	A1	19840524	WO 1982-JP437	19821110
	W: MC			WO 1982-JP437	19821110
	US 4605651	A	19860812	US 1983-540676	19831011
	ZA 8307635	A	19841128	WO 1982-JP437	19821110
	AU 8320199	A1	19840517	ZA 1983-7635	19831013
	AU 568094	B2	19871217	WO 1982-JP437	19821110
	NO 8303807	A	19840511	AU 1983-20199	19831014
	NO 162240	B	19890821	WO 1982-JP437	19821110
	NO 162240	C	19891129	NO 1983-3807	19831019
	ES 526561	A1	19850416	WO 1982-JP437	19821110
	SU 1331432	A3	19870815	ES 1983-526561	19831019
	FI 8303839	A	19840511	WO 1982-JP437	19821110
	FI 75348	B	19880229	SU 1983-3655401	19831019
	FI 75348	C	19880609	WO 1982-JP437	19821110
	DK 8304818	A	19840511	FI 1983-3839	19831020
	JP 59116292	A2	19840705	WO 1982-JP437	19821110
	CA 1239928	A1	19880802	DK 1983-4818	19831020
	ES 532996	A1	19850816	WO 1982-JP437	19821110
	ES 532997	A1	19850816	JP 1983-197458	19831020
	SU 1322983	A3	19870707	WO 1982-JP437	19821110
				CA 1983-439358	19831020
				WO 1982-JP437	19821110
				ES 1984-532996	19840531
				WO 1982-JP437	19821110
				ES 1984-532997	19840531
				WO 1982-JP437	19821110
				SU 1984-3827995	19841224
				WO 1982-JP437	19821110
IT	<b>92602-27-2P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(prepn. of)				
RN	92602-27-2 CAPLUS				
CN	L-Phenylalanine, 2-[[[2-[[[1-(acetyloxy)ethoxy]carbonyl]-3-[[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, monohydrochloride, [6R-[6.alpha.,7.beta.(R*)]]- (9CI) (CA INDEX NAME)				



● HCl

GI



AB Cephalosporins I (R = H, OH; R1 = amino acid residue; R2 = 1-alkanoyloxyalkyl, 1-alkoxycarbonyloxyalkyl, phthalidyl, 5-methyl-2-oxo-1,3-dioxolan-4-ylmethyl; R3 = carbamoyloxymethyl, heterocyclylthiomethyl) were prepd. Thus D-HOCHPhCO2CHPh2 was treated with Me3CO2CNHCH2CO2H to give D-Me3CO2CNHCH2CO2CHPhCO2CHPh2 which was hydrogenolyzed and used to acylate the 7-aminocephem, followed by deblocking, to give I (R = H, R1 = H2NCH2CO, R2 = CH2O2CCMe3, R3 = 1-methyl-5-tetrazolylthiomethyl, II). At a dose corresponding to 125 mg of the free acid II was 38.0% excreted in the urine in 8 h.

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1983:59889 CAPLUS

DN 98:59889

TI Improving intestinal absorption of cephalosporin derivatives

IN Nishikido, Joji; Kodama, Eiji; Shibukawa, Mitsuru

PA Asahi Chemical Industry Co., Ltd., Japan

SO Eur. Pat. Appl., 63 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 60422	A2	19820922	EP 1982-101508	19820226
	EP 60422	A3	19830824		

R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

			JP 1981-26743	19810227
			JP 1981-128688	19810819
JP 57142988	A2	19820903	JP 1981-26743	19810227
JP 58032885	A2	19830225	JP 1981-128688	19810819
US 4465668	A	19840814	US 1982-351613	19820224
			JP 1981-26743	19810227
			JP 1981-128688	19810819


IT **84294-10-0 84330-79-0**

RL: PROC (Process)

(absorption of, by intestine)

RN 84294-10-0 CAPLUS

CN L-Phenylalanine, N-(N-acetyl-L-leucyl)-, 2-[[2-carboxy-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI)  
(CA INDEX NAME)




RN 84330-79-0 CAPLUS

CN L-Phenylalanine, 2-[[2-carboxy-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]-, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 84330-78-9

CMF C27 H27 N7 O6 S2



CM 2

CRN 64-18-6  
CMF C H2 O2

O=CH-OH

IT **84330-75-6P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and intestinal absorption of)

RN 84330-75-6 CAPLUS

CN L-Phenylalanine, N-L-leucyl-, 2-[[2-carboxy-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]-, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 84330-74-5  
CMF C33 H38 N8 O7 S2





CM 2

CRN 64-18-6  
CMF C H2 O2

O=CH-OH

GI





AB Intestinal absorption of cephalosporins with low oral activity is improved by binding to any side chain in the 3-, 4-, or 7-position of a 7-aminocephalosporanic acid deriv., an oligopeptide  $X(NHCHR_1CO)nNHCHR_2CO$  ( $X = H$ , C1-15 alkyl or  $R_3CO$ ;  $R_1$  and  $R_2$  = side chain of an amino acid constituting the oligopeptide;  $R_3 = H$  or C1-15 alkyl or protective group easily removable by acid hydrolysis, hydrogenolysis, or enzyme existing in a living body;  $n = 1-3$ ). Thus, 7-[D-(O-L-leucyl-L-phenylalanyl)mandelamido]-3-[[1-methyl-1H-tetrazol-5-yl)thio]methyl]-3-cephem-4-carboxylic acid monoformate (I) [84330-75-6] was prepd. and administered to male rats at 50 mg/kg. The blood concn. was 4.51 .mu.g/mL 30 min after administration, as compared with 0.29 .mu.g/mL for the cephemcarboxylic acid deriv. without the oligopeptide.

L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1981:139710 CAPLUS

DN 94:139710

TI Synthesis of 3,6-alkyl- or aryl-substituted 1,4-oxazine-2,5-diones

AU Irurre Perez, J.; Sanchez Rosell, M.; Travesa Aijon, F.

CS Dep. Quim. Org., Inst. Quim. Sarria, Barcelona, Spain

SO Anales de Quimica, Serie C: Quimica Organica y Bioquimica (1980), 76(1), 47-9

CODEN: AQSBD6; ISSN: 0211-1357

DT Journal

LA Spanish


IT 77034-52-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and cyclodehydration of)

RN 77034-52-7 CAPLUS


CN Benzenepropanoic acid, .alpha.-oxo-, 2-amino-2-oxo-1-phenylethyl ester, (-)-(9CI) (CA INDEX NAME)

Rotation (-).



GI





AB Oxazinediones I (R = Ph, PhCH<sub>2</sub>, R<sub>1</sub> = Ph; R = p-anisyl, R<sub>1</sub> = Ph, Me) were prepd. by cyclodehydration of RCOCO<sub>2</sub>CHR<sub>1</sub>CONH<sub>2</sub>, which were obtained from RCOCO<sub>2</sub>H and HOCHR<sub>1</sub>CONH<sub>2</sub>. Attempted prepn. of I from HOCHPhCON:CMeco<sub>2</sub>Et resulted only in isomerization to the more stable (E)-isomer.

L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1980:128729 CAPLUS

DN 92:128729

TI Malonic acid derivatives of sterically-hindered piperidines

IN Rody, Jean; Karrer, Friedrich

PA Ciba-Geigy A.-G., Switz.

SO Eur. Pat. Appl., 23 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 2260	A2	19790613	EP 1978-101492	19781201
	EP 2260	A3	19790627		
	EP 2260	B1	19820714		
	R: BE, CH, DE, FR, GB, IT, NL				
	JP 54098777	A2	19790803	CH 1977-14769	19771202
				JP 1978-149583	19781202
				CH 1977-14769	19771202
	US 4237297	A	19801202	US 1979-91630	19791105
				CH 1977-14769	19771202
				US 1978-963537	19781124


IT 72013-67-3P 72013-73-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 72013-67-3 CAPLUS

CN Propanedioic acid, bis(phenylmethyl)-, bis[1-phenyl-2-(2,2,6,6-tetramethyl-1-piperidiny)ethyl] ester, (R\*,R\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 72013-73-1 CAPLUS



CN Propanedioic acid, bis(phenylmethyl)-, bis[1-phenyl-2-(2,2,6,6-tetramethyl-

1-piperidinyl)ethyl] ester, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



AB The title compds I [R1 = H, lower alkyl; R2 = alkyl, alkenyl, PhCH2; R3 = R2, alkyl- or alkoxyphenyl, CN; R4 = H, OH, aliph. group, PhCH2, (acylated) hydroxyalkyl; R5 = H, (substituted) aliph. group, cycloalkyl, aralkyl, or piperidinyl] or II [R1-R3 = same; R6 = H, Me, Et, Ph; R7 = (etherified) OH, (alkylated) NH2] were prepd. for use as light stabilizers for polymers. Thus, (PhCH2)2C(CO2Me)2 reacted with 1-(2-hydroxyethyl)-2,2,6,6-tetramethylpiperidine and LiNH2 in xylene to give II (R1 = R6 = R7 = H, R2 = R3 = PhCH2).

L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1979:121187 CAPLUS

DN 90:121187

TI Aminoalcohol derivative

IN Lambelin, Georges; Roncucci, Romeo; Roba, Joseph; Gillet, Claude; Snyers, Michel

PA Continental Pharma, Belg.

SO Ger. Offen., 48 pp.

CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2817494	A1	19781109	DE 1978-2817494	19780421
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	GB 1603379	A	19811125	GB 1978-27732	19780427
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	GB 1603378	A	19811125	GB 1978-16813	19780427
				GB 1978-16813	19780427
				LU 1977-77237	19770503
	SE 7804897	A	19781104	SE 1978-4897	19780428
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	NL 7804621	A	19781107	NL 1978-4621	19780428
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	CA 1118438	A1	19820216	CA 1978-302239	19780428
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	US 4474977	A	19841002	US 1978-901223	19780428
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	IL 54608	A1	19840131	IL 1978-54608	19780501
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	FI 7801347	A	19781104	FI 1978-1347	19780502
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	DK 7801898	A	19781104	DK 1978-1898	19780502
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	NO 7801554	A	19781106	NO 1978-1554	19780502
	NO 146057	B	19820413		
	NO 146057	C	19820721		
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	ZA 7802507	A	19790725	ZA 1978-2507	19780502
				LU 1977-77236	19770503
	ES 469843	A1	19790916	ES 1978-469843	19780502
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	AT 7803179	A	19800115	AT 1978-3179	19780502
	AT 358020	B	19800811		
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	FR 2389597	A1	19781201	FR 1978-13202	19780503
	FR 2389597	B1	19830819		
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	AU 7835733	A1	19791108	AU 1978-35733	19780503
	AU 517255	B2	19810716		
				LU 1977-77236	19770503

CH 635570	A	19830415	LU 1977-77237	19770503
			CH 1978-4836	19780503
			LU 1977-77236	19770503
JP 53141230	A2	19781208	LU 1977-77237	19770503
JP 59040140	B4	19840928	JP 1978-53627	19780504
			LU 1977-77236	19770503
			LU 1977-77237	19770503
AT 7906288	A	19810715	AT 1979-6288	19790925
AT 366023	B	19820310		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
			AT 1978-3179	19780502


IT **69145-90-0**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. as muscle relaxant)

RN 69145-90-0 CAPLUS


CN Benzenepropanoic acid, 1-[4-[(1-methylethyl)thio]phenyl]-2-(octylamino)propyl ester, hydrochloride, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

## GI




AB One hundred three amino alcs. I [R1 = H, C1-5 alkylthio, alkoxy, alkyl, C5-6 cycloalkylthio, cycloalkoxy, cycloalkyl, halo; R2 = C1-3 alkyl; R3 = C1-8 alkyl, C1-4 alkyl, optionally substituted with Ph, PhO, Bz, (un)substituted with alkyl, alkoxy, halo, C6-18 alkenyl, C5-9 cycloalkyl; R4 = COR5 [R5 = C1-10 alkyl, C2-4 alkenyl, C3-8 cycloalkyl, Ph (un)substituted with C1-3 alkyl, alkoxy, halo, C1-4 alkyl, (un)substituted with C1-3 carbalkoxy, alkoxy, NH2, acylamino, C5-6 cycloalkyl, PhO, Ph, optionally substituted with alkyl, alkoxy, halo, cinnamyl], H], useful as antihypertensives, peripheral vasodilators, muscle relaxants, platelet

aggregation inhibitors, hypolipemics, and thrombosis inhibitors, were prepd. Thus, acylation of 4-Me2CHSC6H4CH(OH)CHMeNH(CH2)7Me by refluxing with AcCl in C6H6 or PrCOCl gave 70 or 52%, resp. of the corresponding 4-Me2CHSC6H4CH(OR4)CHMeNH(CH2)7Me (R4 = Ac, PrCO).

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS  
 AN 1973:147610 CAPLUS  
 DN 78:147610  
 TI Thiamphenicol phenylalaninate  
 IN Saiga, Akisuke; Yamanaka, Motosuke; Sato, Takashi  
 PA Eisai Co., Ltd.  
 SO Jpn. Kokai Tokkyo Koho, 2 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 48004446	B4	19730120	JP 1971-27212	19710427
IT	<b>41570-11-0P</b>				
RL:	SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	41570-11-0	CAPLUS			
CN	L-Phenylalanine, 2-[(dichloroacetyl)amino]-1-[4-(methylsulfonyl)phenyl]-1,3-propanediyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)				



AB A soln. of thiamphenicol and PhCH2CH(NH2)COCl.HCl (1:2 by mole) in anhyd. dioxane was stirred 7 hr at 13-17.degree. to give 61.2% thiamphenicol phenylalaninate, which was sol. and stable in H2O.

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS  
 AN 1972:488521 CAPLUS  
 DN 77:88521  
 TI 7-(D-Mandelamido)cephalosporanic acid derivatives  
 IN Berges, David Alan; Dunn, George Lawrence; Hoover, John R. E.  
 PA Smith Kline and French Laboratories  
 SO Ger. Offen., 54 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2158330	A	19720608	DE 1971-2158330	19711124


US 3701775	A	19721031	US 1970-92860	19701125
ZA 7107133	A	19720726	US 1970-92860	19701125
CA 960662	A1	19750107	ZA 1971-7133	19711026
BE 775458	A1	19720517	US 1970-92860	19701125
GB 1327510	A	19730822	CA 1971-126096	19711026
CH 567515	A	19751015	US 1970-92860	19701125
FR 2115363	A5	19720707	BE 1971-110605	19711117
FR 2115363	B1	19750613	US 1970-92860	19701125
ES 397308	A1	19740516	GB 1971-54335	19711123
NL 7116207	A	19720529	US 1970-92860	19701125
			CH 1971-16996	19711123
			US 1970-92860	19701125
			FR 1971-42022	19711124
			US 1970-92860	19701125
			ES 1971-397308	19711124
			US 1970-92860	19701125
			NL 1971-16207	19711125
			US 1970-92860	19701125

IT **37650-89-8P 37650-90-1P 37651-00-6P**  
**37651-01-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)


RN 37650-89-8 CAPLUS

CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, 2-[[3-  
 [(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-  
 yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI)  
 (CA INDEX NAME)




RN 37650-90-1 CAPLUS

CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, 2-[[3-  
 [(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-  
 yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI)  
 (CA INDEX NAME)




RN 37651-00-6 CAPLUS

CN D-Phenylalanine, 2-[[3-[(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI) (CA INDEX NAME)



RN 37651-01-7 CAPLUS

CN L-Phenylalanine, 2-[[3-[(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI) (CA INDEX NAME)



AB Fifty-nine title compds. [I, R = e.g., N3CH2CO, H2NCH2CO, Boc-L-methionyl (Boc = Me3CO2C), Boc-D-alanyl, L-methionyl, MeSCH2CO, 2-thenoyl, etc., R1 = e.g., OAc, H, MeO], bactericides, were prepd. via O-acylation of I (R = H) in the presence of N, N -carbonyldiimidazole (II). Thus, II and then I (R = H, R1 = OAc) were added to Boc-methionine in THF, the mixt. was kept 20 hr, and the imidazole salt hydrolyzed to give 50% I (R = Boc-methionyl, R1 = OAc), from which the Boc group was cleaved with CF3CO2H.


L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1970:67270 CAPLUS


DN 72:67270

TI Water soluble antibiotic chloramphenicol .beta.-phenylalanine ester salts  
 IN Zumin, Silva T.; Mosna, Sergio  
 PA Pierrel S.p.A.  
 SO Brit., 8 pp.  
 CODEN: BRXXAA  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1173562		19691210	GB	19660425
IT	25613-59-6P 25613-62-1P 25613-63-2P 25613-64-3P 25616-21-1P 25616-22-2P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	25613-59-6 CAPLUS				
CN	Alanine, N-carboxy-3-phenyl-, N-benzyl ester, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p- nitrophenethyl]acetamide (8CI) (CA INDEX NAME)				



RN 25613-62-1 CAPLUS  
 CN Alanine, N-carboxy-3-phenyl-, N-benzyl ester, DL-, diester with  
 D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-  
 nitrophenethyl]acetamide (8CI) (CA INDEX NAME)




RN 25613-63-2 CAPLUS  
 CN Alanine, phenyl-, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-  
 .alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, bis(trifluoroacetate)  
 (8CI) (CA INDEX NAME)

CM 1



CRN 47832-98-4


CMF C29 H30 Cl2 N4 O7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 25613-64-3 CAPLUS

CN Alanine, phenyl-, L-, diester with D-threo-2,2-dichloro-N-[(beta)-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, dihydrochloride (8CI)  
(CA INDEX NAME)



● 2 HCl


RN 25616-21-1 CAPLUS

CN Alanine, N-acetyl-3-phenyl-, L-, compd. with L-phenylalanine diester with D-threo-2,2-dichloro-N-[(beta)-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide (2:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47832-98-4

CMF C29 H30 Cl2 N4 O7




CM 2

CRN 2018-61-3


CMF C11 H13 N O3

Absolute stereochemistry. Rotation (+).



RN 25616-22-2 CAPLUS

CN Alanine, phenyl-, DL-, diester with D-threo-2,2-dichloro-N-[(.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, dihydrobromide (8Cl)  
(CA INDEX NAME)





● 2 HBr

AB Salts of chloramphenicol 1,3-bis(L-.beta.-phenylalaninate) (I) and chloramphenicol 3-L-.beta.-phenylalaninate (II), useful for parenteral administration, with antibiotic activity, were prepd. by reacting D-(-)-threo-1-p-nitrophenyl-2-dichloroacetamido-1,3-propanediol (chloramphenicol) (III) either with N-carbobenzoxy-L-.beta.-phenylalanine (IV) in the presence of dicyclo-hexylcarbodiimide (V) and anhyd. pyridine

(VI) or with IV anhydride (VII) in the presence of VI to give chloramphenicol 1,3-bis(N-carbobenzoxy-L-.beta.-phenylalaninate) (VIII) and chloramphenicol 3-(N-carbobenzoxy-L-.beta.-phenylalaninate) (IX), resp., followed by removal of the protecting group(s) by treatment with aq. HBr or anhyd. CF<sub>3</sub>CO<sub>2</sub>H. I and II are hydrolyzed in vivo to III and phenylalanine. Thus, addn. of 10.30 g V at 15.degree. to a stirred soln. of 29.93 g IV in 150 ml Me<sub>2</sub>CO, and the mixt. stirred 3 hr gave 96.5% VII. Racemic N-carbobenzoxy-DL-.beta.-phenylalanine anhydride (X) (93.5%) was prepd. similarly. III (5.82 g) in 10 ml VI was added to 180 ml of an Me<sub>2</sub>CO soln. of 25.2 g VII and the mixt. stirred 5-6 hr at room temp. and poured on ice-HCl to give, after treatment with 3.5 ml p-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NMe<sub>2</sub> (XI) in dry C<sub>6</sub>H<sub>6</sub> to remove excess VII, 90% VIII, m. 95-7.degree.. Racemic chloramphenicol 1,3-bis(N-carbobenzoxy-.beta.-phenylalaninate) (XII) (94%), a yellow oil, was prepd. similarly from X. IV (22.45 g) and 15 ml VI added to a stirred soln. of 9.69 g III in 60 ml HCONMe<sub>2</sub>, the soln. cooled to -5 to -8.degree., 18.57 g V added slowly, the mixt. stirred 1 hr, kept 3 hr at -5.degree. and poured on a mixt. of 50 ml concd. HCl, 50 ml H<sub>2</sub>O, and 100 g ice gave a ppt., which was centrifuged off and extd. with C<sub>6</sub>H<sub>6</sub>. Treatment of the C<sub>6</sub>H<sub>6</sub> ext. with 3.5 ml XI gave 93% VIII, m. 95-7.degree.. IX, m. 145-7.degree., was prepd. similarly using 19.39 g III, 60 ml HCONMe<sub>2</sub>, 17.96 g IV, 15 ml VI, and 12.38 g V. A mixt. of 17.72 g VIII and 40 ml anhyd. CF<sub>3</sub>CO<sub>2</sub>H refluxed 1 hr in the presence of 8 g resorcinol gave 16.30 g I.CF<sub>3</sub>CO<sub>2</sub>H (XIII). Addn. of XIII to satd. aq. NaHCO<sub>3</sub>, extn. of the free base with CH<sub>2</sub>Cl<sub>2</sub>, and treatment of the ext. with HCl gave I.HCl, m. 220-222.degree. (decompn.). II.HCl, [.alpha.]<sub>D</sub><sup>20</sup> 10.77.degree. (c 2, H<sub>2</sub>O), was prepd. similarly from IX. A soln. of 5 g XII in 60 ml 2.5N HBr in AcOH stirred 10 min at 25 .degree. gave 85% a mixt. of chloramphenicol 1,3-bis(D- and L-.beta.-phenylalaninate-HBr) sepd. by chromatog. XIII (13 g) treated with satd. aq. NaHCO<sub>3</sub>, extn. of the free base with CH<sub>2</sub>Cl<sub>2</sub>, and treatment of the ext. with N-acetyl-L-phenylalanine gave III 1,3-bis(L-.beta.-phenylalaninate N-acetyl-L-phenylalaninate); III 3-(L-.beta.-phenylalaninate N-acetyl-L-phenylalaninate) was prepd. similarly.

L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2003 ACS  
 AN 1969:470266 CAPLUS  
 DN 71:70266  
 TI Bromination of silver and sodium stilbenecarboxylates  
 AU Price, Charles C.; Blunt, Harry W.  
 CS Univ. of Pennsylvania, Philadelphia, PA, USA  
 SO Journal of Organic Chemistry (1969), 34(8), 2484-6  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DT Journal  
 LA English  
 IT **19926-35-3P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 19926-35-3 CAPLUS  
 CN Acrylic acid, 2,3-diphenyl-, ester with 2-bromo-2,3-diphenylhydracrylic acid trimol. ester (8CI) (CA INDEX NAME)





AB The ag salts of cis-PhCH:C(CO<sub>2</sub>H)Ph (cis-I) and trans-I are treated with Br to give mixts. of .alpha.-bromo-.alpha.,.beta.-diphenyl-.beta.-propiolactone (II), a macrocyclic polymer (III), and a linear polymer; II is dissolved in MeOH to give III. cis-I Na salt gives a .beta.-lactone (IV), cis-PhCH:CB<sub>2</sub>Ph, and PhCH<sub>2</sub>COPh (V); V is obtained from trans-I Na salt. It is proposed that IV is a geometrical isomer of II. IV does not give a polymer.

L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2003 ACS

AN 1967:402830 CAPLUS

DN 67:2830

TI Separation of the organic bases by Craig partition. VII. Acyl migration in the stereoisomeric N-(N,N-dimethylphenylalanyl)ephedrine

AU Schoenenberger, Helmut; Fuchsberger, K. D.; Brinkmann, Rolf

CS Univ. Munich, Munich, Fed. Rep. Ger.

SO Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft (1967), 300(2), 126-35

CODEN: APBDAJ; ISSN: 0376-0367

DT Journal


LA German

IT 14355-01-2P 14355-02-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 14355-01-2 CAPLUS


CN Alanine, N,N-dimethyl-3-phenyl-, ester with (-)-pseudoephedrine, dihydrochloride, L- (8CI) (CA INDEX NAME)



● 2 HCl

RN 14355-02-3 CAPLUS

CN Alanine, N,N-dimethyl-3-phenyl-, ester with (-)-pseudoephedrine, dihydrochloride, D- (8CI) (CA INDEX NAME)



2 HCl

AB cf. CA 66: 49281u. The compds. studied were N-(L-N,N-dimethylphenylalanyl)-L-ephedrine (I), N-(D-N,N-dimethylphenylalanyl)-L-ephedrine (II), N-(L-N,N-dimethylphenylalanyl)-L-pseudoephedrine (III), and N-(D-N,N-dimethylphenylalanyl)-L-pseudoephedrine (IV). In every case, only the ester of L-pseudoephedrine resulted, even under mild conditions (room temp., acetone-HCl). Complete inversion of the erythro derivs. occurred. In 2N HCl at 80.degree., the ester from I formed quant. in 10 min. while that from III (retention of configuration) required 25 hrs. With II, 5 hrs. and with IV, 22 hrs. were required. The 4 amides pass through either of 2 cyclic intermediates during the migration, L,L-(V) or D,L-pseudooxazolidine (VI). The rates are explained by steric considerations of the mechanism, V resulting from I via inversion and from III with retention, and VI, from II via inversion and IV with retention. Craig partition as described previously (loc. cit.) was used to sep. and det. the reaction products. Twenty-four partition steps using a solvent mixt. of 0.5M citrate buffer (pH 4/5)-MeOH-CHCl<sub>3</sub> (9:1:10 parts by vol.) were required for sepn. into N- and O-aminoacylephedrines. The O-(L-N,N-dimethylphenylalanyl)-L-pseudoephedrine m. 170-2.degree., [ $\alpha$ ]<sub>D</sub> + 114.degree. (c = 0.0055 g./ml., 5N HCl) and the O-(D-N,N-dimethyl-) ester melts at 174-6.degree., [ $\alpha$ ]<sub>D</sub> 48.degree. (c 0.0055 g./ml., 5N HCl).

=> d cost

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.34	0.83
0.06	0.18
0.00	147.75
100.79	100.79
-----	-----
101.19	249.55
5.06	5.06
-----	-----
106.25	254.61

CAPLUS FEE (5%)

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
-14.32	-14.32

IN FILE 'CAPLUS' AT 14:30:48 ON 26 MAY 2003

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Jun 03 New e-mail delivery for search results now available  
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 11 Oct 24 BEILSTEIN adds new search fields  
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 14 Nov 25 More calculated properties added to REGISTRY  
NEWS 15 Dec 04 CSA files on STN  
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 17 Dec 17 TOXCENTER enhanced with additional content  
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 20 Feb 13 CANCERLIT is no longer being updated  
NEWS 21 Feb 24 METADEX enhancements  
NEWS 22 Feb 24 PCTGEN now available on STN  
NEWS 23 Feb 24 TEMA now available on STN  
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 25 Feb 26 PCTFULL now contains images  
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 27 Mar 20 EVENTLINE will be removed from STN  
NEWS 28 Mar 24 PATDPAFULL now available on STN  
NEWS 29 Mar 24 Additional information for trade-named substances without  
structures available in REGISTRY  
NEWS 30 Apr 11 Display formats in DGENE enhanced  
NEWS 31 Apr 14 MEDLINE Reload  
NEWS 32 Apr 17 Polymer searching in REGISTRY enhanced  
NEWS 33 Apr 21 Indexing from 1947 to 1956 being added to records in CA/CAPLUS  
NEWS 34 Apr 21 New current-awareness alert (SDI) frequency in  
WPIDS/WPINDEX/WPIX  
NEWS 35 Apr 28 RDISCLOSURE now available on STN  
NEWS 36 May 05 Pharmacokinetic information and systematic chemical names  
added to PHAR  
NEWS 37 May 15 MEDLINE file segment of TOXCENTER reloaded  
NEWS 38 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated  
NEWS 39 May 16 CHEMREACT will be removed from STN

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA  
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and  
right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:37:32 ON 26 MAY 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:37:43 ON 26 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0

DICTIONARY FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09912163.2

L1 STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1 STR



G1 NH,X,Hy

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1

SAMPLE SEARCH INITIATED 14:38:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1045 TO ITERATE

95.7% PROCESSED 1000 ITERATIONS

1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 18961 TO 22839

PROJECTED ANSWERS: 1 TO 81

L2 1 SEA SSS SAM L1

=&gt; s l1 sss full

FULL SEARCH INITIATED 14:38:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 20951 TO ITERATE

100.0% PROCESSED 20951 ITERATIONS

24 ANSWERS

SEARCH TIME: 00.00.01

L3 24 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 14:38:21 ON 26 MAY 2003



USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 May 2003 VOL 138 ISS 22  
FILE LAST UPDATED: 25 May 2003 (20030525/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s l3

L4 10 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:57805 CAPLUS  
DN 134:252075  
TI Synthesis of enantiopure homoallylic ethers by reagent controlled facial selective allylation of chiral ketones  
AU Tietze, Lutz F.; Weigand, Berthold; Volkel, Ludwig; Wulff, Christian; Bittner, Christian  
CS Institut fur Organische Chemie Georg-August-Universitat Gottingen, Gottingen, 37077, Germany  
SO Chemistry--A European Journal (2001), 7(1), 161-168  
CODEN: CEUJED; ISSN: 0947-6539  
PB Wiley-VCH Verlag GmbH  
DT Journal  
LA English  
OS CASREACT 134:252075  
IT **330798-68-0P 330798-69-1P**  
RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of enantiopure homoallylic ethers by reagent controlled facial selective allylation of chiral ketones)  
RN 330798-68-0 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[(1S,2S)-1-methyl-2-[[[(1R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330798-69-1 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[[(1S)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

IT 330798-62-4P 330798-63-5P 330798-73-7P  
330798-76-0PRL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of enantiopure homoallylic ethers by reagent controlled  
facial selective allylation of chiral ketones)

RN 330798-62-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1S,2S)-1-methyl-2-[[[(1S)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 330798-63-5 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 330798-73-7 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1R)-1-methyl-1-(2-phenylpropyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 330798-76-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-(2-phenylpropyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The stereoselective allylation of chiral Me ketones to give tertiary homoallylic ethers, which can easily be transformed into homoallylic alcs., is described. Reaction of the enantiopure ketones (I), (R)-Me<sub>2</sub>CH(CH<sub>2</sub>)<sub>3</sub>CH(.beta.Me)CH<sub>2</sub>COMe, (R)-MeCH(.beta.OSiPh<sub>2</sub>CMe<sub>3</sub>)CH<sub>2</sub>COMe, (S)-MeCH(.alpha.Ph)CH<sub>2</sub>COMe and the racemic ketones MeCH(OSiPh<sub>2</sub>CMe<sub>3</sub>)CH<sub>2</sub>COMe, MeCH(Ph)CH<sub>2</sub>COMe, MeCH<sub>2</sub>CH(Ph)COMe, MeCH<sub>2</sub>CH(Me)COMe with the norpseudoephedrine deriv. and allylsilane in the presence of a catalytic amt. of trifluoromethanesulfonic acid, led to a series of homoallylic ethers with good to excellent diastereoselectivity (85:15 to > 97:3). The allylation is reagent controlled and nearly independent from the stereogenic centers in the substrates. A partial kinetic resolu. was obsd. using the racemic ketones. In the reaction of the chiral ketones with the achiral reagents ethoxytrimethylsilane and allylsilane only a low diastereoselectivity was obsd.

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1998:625620 CAPLUS

DN 129:316000

TI Synthesis of enantiopure homoallylic alcohols by a highly selective asymmetric allylation of ketones

AU Tietze, Lutz F.; Schiemann, Kai; Wegner, Christoph; Wulff, Christian

CS Institute Organic Chemistry, Georg-August-Universitat Gottingen, Gottingen, D-37077, Germany

SO Chemistry--A European Journal (1998), 4(9), 1862-1869

CODEN: CEUJED; ISSN: 0947-6539

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

OS CASREACT 129:316000

IT 165823-95-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of enantiopure homoallylic alcs. by asym. allylation of ketones)

RN 165823-95-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[[(1S)-1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB A highly selective asym. domino allylation of aliph. ketones is described. When Me ketones, (R,R)-Me<sub>2</sub>SiOCHPhCHMeNHCOCF<sub>3</sub>, and CH<sub>2</sub>:CHCH<sub>2</sub>SiMe<sub>3</sub> react in the presence of catalytic amts. of trifluoromethanesulfonic acid, the homoallylic ethers are produced with up to 24:1 diastereoselectivity and 89% yield. Ether cleavage using lithium or sodium in liq. ammonia gives the homoallylic alcs. in 75 to 95% yield and up to 92% ee. Even EtCOMe, the most difficult example, showed a stereoselectivity of 9:1 at -78.degree.C and 24:1 at -109.degree.C. In addn., the allylation of protected hydroxyalkyl Me ketones gave the corresponding homoallylic ethers with a diastereoselectivity of up to >244:1 and 98% yield. In contrast, Et alkyl ketones have a low selectivity.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1997:639948 CAPLUS

DN 127:307269

TI Preparation of optically active succinic acid derivatives. I. Optical resolution of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionic acid

AU Yamaguchi, Toshiaki; Yanagi, Takashi; Hokari, Hiroshi; Mukaiyama, Yuko; Kamijo, Tetsuhide; Yamamoto, Iwao

CS Kissei Pharmaceutical Co., Ltd., Central Research Laboratories, Hotaka, 399-83, Japan

SO Chemical & Pharmaceutical Bulletin (1997), 45(9), 1518-1520

CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English


IT **197447-44-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(optical resolu. of benzyl(hexahydroisoindolinylylcarbonyl)propionic acid)

RN 197447-44-2 CAPLUS

CN 2H-Isoindole-2-butanoic acid, octahydro-.gamma.-oxo-.alpha.-(phenylmethyl)-, 2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl ester, [2(.alpha.S)-[2[R\*(R\*)],3a.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 197447-45-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(optical resolu. of benzyl(hexahydroisoindolinylcarbonyl)propionic acid)

RN 197447-45-3 CAPLUS

CN 2H-Isoindole-2-butanoic acid, octahydro-.gamma.-oxo-.alpha.-(phenylmethyl)-  
, 2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl ester, [2(.alpha.R)-  
[2[R\*(S\*)],3a.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB Optical resolu. of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionic acid (I) was accomplished by two methods. Thus, I was esterified with (S)-N-benzylmandelamide and the resulting diastereomeric esters were sepd. by column chromatog. on silica gel. One of the diastereomers was hydrolyzed to give the optically active acid (-)-I. The abs. configuration of (-)-I was established as S by comparison with an authentic sample. The alternative method was resolu. using an optically active amine. Treatment of a soln. of the racemic acid I with 0.65 equiv of (R)-1-(1-naphthyl)ethylamine in ethanol gave the salt in 23.2% yield with an optical purity of 96.8% ee.

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1995:835557 CAPLUS

DN 123:256542

TI Preparation of annelated dihydropyridines

IN Roos, Otto; Loesel, Walter; Arndts, Dietrich

PA Boehringer Ingelheim KG, Germany

SO Ger. Offen., 28 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

PI	DE 4343683	A1	19950622	DE 1993-4343683	19931221
	CA 2178209	AA	19950629	CA 1994-2178209	19941214
				DE 1993-4343683A	19931221
WO	9517389	A1	19950629	WO 1994-EP4150	19941214
	W: AU, CA, CN, JP, KR, PL, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				DE 1993-4343683A	19931221
AU	9512433	A1	19950710	AU 1995-12433	19941214
AU	699208	B2	19981126		
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
EP	736011	A1	19961009	EP 1995-903342	19941214
EP	736011	B1	20000726		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
CN	1138325	A	19961218	CN 1994-194572	19941214
CN	1044905	B	19990901		
				DE 1993-4343683A	19931221
JP	09506882	T2	19970708	JP 1994-517154	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
RU	2136664	C1	19990910	RU 1996-115153	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
AT	194978	E	20000815	AT 1995-903342	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
ES	2149958	T3	20001116	ES 1995-903342	19941214
				DE 1993-4343683A	19931221
ZA	9410115	A	19950621	ZA 1994-10115	19941220
				DE 1993-4343683A	19931221
US	5661157	A	19970826	US 1994-360867	19941221
				DE 1993-4343683A	19931221
TW	404941	B	20000911	TW 1994-83112295	19941228
				DE 1993-4343683A	19931221
US	5968948	A	19991019	US 1997-857643	19970516
				DE 1993-4343683A	19931221
				US 1994-360867 A319941221	
US	6136819	A	20001024	US 1999-329443	19990610
				DE 1993-4343683A	19931221
				US 1994-360867 A319941221	
				US 1997-857643 A319970516	
OS	MARPAT 123:256542				
IT	<b>168545-16-2P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT				
	(Reactant or reagent)				
	(prepn. of annelated dihydropyridines from)				
RN	168545-16-2 CAPLUS				
CN	Benzeneacetamide, N-[2-(3,4-dimethoxy-2,4-cyclohexadien-1-yl)ethyl]- .alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)				



GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = benzo, thieno, indolo; B = O, S, (un)substituted CH<sub>2</sub>; R<sub>2</sub> = OH, alkoxy, benzyloxy, halogen, alkyl, methanesulfonyloxy, etc.; R<sub>3</sub> = 2- or 3-thienyl, (un)substituted Ph, alkyl, cycloalkylalkyl; R<sub>4</sub> = (un)branched alkenyl or alkynyl, alkoxy, dialkylamino, heterocyclyl, Ph, etc.; m = 0-3] (e.g., II), useful as calcium-channel blockers (no data), are prepd. by the intramol. cyclocondensation of arom. amides (III) (e.g., IV) in the presence of condensing agents (e.g., POCl<sub>3</sub>), and I-contg. formulations are also presented.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1995:568922 CAPLUS

DN 123:111518

TI Enantioselective Synthesis of Tertiary Homoallylic Alcohols via Diastereoselective Addition of Allylsilanes to Ketones

AU Tietze, Lutz F.; Schiemann, Kai; Wegner, Christoph

CS Institute of Organic Chemistry, Georg-August-Universitaet, Goettingen, D-37077, Germany

SO Journal of the American Chemical Society (1995), 117(21), 5851-2

CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

OS CASREACT 123:111518


IT **165823-95-0P 166021-67-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(enantioselective synthesis of tertiary homoallylic alcs. via diastereoselective addn. of allylsilanes to ketones)

RN 165823-95-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).






RN 166021-67-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[1-methyl-2-[[1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]-, {1R-[1R\*,2R\*(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Enantiopure tertiary homoallylic alcs.  $\text{CH}_2\text{:CHCH}_2\text{CRMeOH}$  ( $\text{R} = \text{alkyl}$ ) can be obtained from the corresponding homoallylic ethers  $\text{CH}_2\text{:CHCH}_2\text{CRMeOR}_1$  [4,  $\text{R}_1 = \text{residue of (1R,2R)-N-(trifluoroacetyl)norpseudoephedrine}$ ] by treatment with sodium in liq. ammonia. The ethers 4 are formed highly selectively by treatment of the ketones  $\text{MeCOR}$  with the trimethylsilyl ether of N-trifluoroacetylnorpseudoephedrine in the presence of catalytic amts. of  $\text{Me}_3\text{SiB(OTf)}_4$  or  $\text{Me}_3\text{SiOTf/TfOH}$  ( $\text{Tf} = \text{CF}_3\text{SO}_2$ ) followed by addn. of allyltrimethylsilane. The yield was about 90% (based on conversion) and the diastereoselectivity was about 90:10. Using iso-Pr Me ketone a selectivity of >95:5 was obtained; thus only one diastereomer could be detected.

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1989:553339 CAPLUS

DN 111:153339

TI Preparation of esterified N-(dibenzocycloheptenylideneethyl)ephedrine derivatives with prolonged antiulcer activity

IN Butelman, Federico

PA Etablissement Texcontor, Liechtenstein

SO Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 313885	A1	19890503	EP 1988-116449	19881005
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				IT 1987-22407	19871023
	US 4935444	A	19900619	US 1988-254220	19881006
				IT 1987-22407	19871023
	JP 01135748	A2	19890529	JP 1988-264240	19881021
				IT 1987-22407	19871023
	US 4990522	A	19910205	US 1990-487277	19900302
IT	122881-51-0P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT				


(Reactant or reagent)

(prepn. and N-alkylation of, with (haloethylidene)dibenzocycloheptene)


RN 122881-51-0 CAPLUS

CN Benzenepropanoic acid, 2-(methylamino)-1-phenylpropyl ester, [R-(R\*,S\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. [I; R = C<sub>9</sub>H<sub>19</sub>, C<sub>15</sub>H<sub>31</sub>, CH(NH<sub>2</sub>)(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>H, (CH<sub>2</sub>)<sub>2</sub>Ph, CMe<sub>3</sub>, p-HOC<sub>6</sub>H<sub>4</sub>, 2-thienyl, 3-pyridyl, 1-amino-2-(5-imidazolyl)ethyl, pamoic acid residue] are prepd. by esterification of ephedrine (II) with RCOCl to give PhCH(O<sub>2</sub>CR)CHMeNHMe (III), followed by N-alkylation with a (haloethylidene)dibenzocycloheptene IV (X = halo). II was esterified by decanoyl chloride (prepd. from the acid) to give 65% III [R = Me(CH<sub>2</sub>)<sub>8</sub>], which was refluxed in MeCN with IV (X = halo, not specified) to give 54% I [R = MeC(CH<sub>2</sub>)<sub>2</sub>]. The latter inhibited stress-induced ulcers in rats with ED<sub>50</sub> of 0.4 and 2.1 mg/kg orally, administered 6 and 36 h prior to commencement of the stress, resp.

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1979:121187 CAPLUS

DN 90:121187

TI Aminoalcohol derivative

IN Lambelin, Georges; Roncucci, Romeo; Roba, Joseph; Gillet, Claude; Snyers, Michel

PA Continental Pharma, Belg.

SO Ger. Offen., 48 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2817494	A1	19781109	DE 1978-2817494	19780421

GB 1603379	A	19811125	LU 1977-77236	19770503
			LU 1977-77237	19770503
			GB 1978-27732	19780427
			LU 1977-77236	19770503
			LU 1977-77237	19770503
			GB 1978-16813	19780427
GB 1603378	A	19811125	GB 1978-16813	19780427
			LU 1977-77237	19770503
SE 7804897	A	19781104	SE 1978-4897	19780428
			LU 1977-77236	19770503
			LU 1977-77237	19770503
NL 7804621	A	19781107	NL 1978-4621	19780428
			LU 1977-77236	19770503
			LU 1977-77237	19770503
CA 1118438	A1	19820216	CA 1978-302239	19780428
			LU 1977-77236	19770503
			LU 1977-77237	19770503
US 4474977	A	19841002	US 1978-901223	19780428
			LU 1977-77236	19770503
			LU 1977-77237	19770503
IL 54608	A1	19840131	IL 1978-54608	19780501
			LU 1977-77236	19770503
			LU 1977-77237	19770503
FI 7801347	A	19781104	FI 1978-1347	19780502
			LU 1977-77236	19770503
			LU 1977-77237	19770503
DK 7801898	A	19781104	DK 1978-1898	19780502
			LU 1977-77236	19770503
			LU 1977-77237	19770503
NO 7801554	A	19781106	NO 1978-1554	19780502
NO 146057	B	19820413		
NO 146057	C	19820721		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
ZA 7802507	A	19790725	ZA 1978-2507	19780502
			LU 1977-77236	19770503
ES 469843	A1	19790916	ES 1978-469843	19780502
			LU 1977-77236	19770503
			LU 1977-77237	19770503
AT 7803179	A	19800115	AT 1978-3179	19780502
AT 358020	B	19800811		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
FR 2389597	A1	19781201	FR 1978-13202	19780503
FR 2389597	B1	19830819		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
AU 7835733	A1	19791108	AU 1978-35733	19780503
AU 517255	B2	19810716		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
CH 635570	A	19830415	CH 1978-4836	19780503
			LU 1977-77236	19770503
			LU 1977-77237	19770503
JP 53141230	A2	19781208	JP 1978-53627	19780504
JP 59040140	B4	19840928		
			LU 1977-77236	19770503

AT 7906288	A	19810715	LU 1977-77237	19770503
AT 366023	B	19820310	AT 1979-6288	19790925

LU 1977-77236	19770503
LU 1977-77237	19770503
AT 1978-3179	19780502


IT 69145-90-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. as muscle relaxant)

RN 69145-90-0 CAPLUS


CN Benzenepropanoic acid, 1-[4-[(1-methylethyl)thio]phenyl]-2-  
(octylamino)propyl ester, hydrochloride, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

GI



AB One hundred three amino alcs. I [R1 = H, C1-5 alkylthio, alkoxy, alkyl, C5-6 cycloalkylthio, cycloalkoxy, cycloalkyl, halo; R2 = C1-3 alkyl; R3 = C1-8 alkyl, C1-4 alkyl, optionally substituted with Ph, PhO, Bz, (un)substituted with alkyl, alkoxy, halo, C6-18 alkenyl, C5-9 cycloalkyl; R4 = COR5 [R5 = C1-10 alkyl, C2-4 alkenyl, C3-8 cycloalkyl, Ph (un)substituted with C1-3 alkyl, alkoxy, halo, C1-4 alkyl, (un)substituted with C1-3 carbalkoxy, alkoxy, NH2, acylamino, C5-6 cycloalkyl, PhO, Ph, optionally substituted with alkyl, alkoxy, halo, cinnamyl], H], useful as antihypertensives, peripheral vasodilators, muscle relaxants, platelet aggregation inhibitors, hypolipemics, and thrombosis inhibitors, were prepd. Thus, acylation of 4-Me2CHSC6H4CH(OH)CHMeNH(CH2)7Me by refluxing with AcCl in C6H6 or PrCOCl gave 70 or 52%, resp. of the corresponding 4-Me2CHSC6H4CH(OR4)CHMeNH(CH2)7Me (R4 = Ac, PrCO).

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 1973:147610 CAPLUS

DN 78:147610  
 TI Thiamphenicol phenylalaninate  
 IN Saiga, Akisuke; Yamanaka, Motosuke; Sato, Takashi  
 PA Eisai Co., Ltd.  
 SO Jpn. Kokai Tokkyo Koho, 2 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 48004446	B4	19730120	JP 1971-27212	19710427

IT **41570-11-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)

RN 41570-11-0 CAPLUS

CN L-Phenylalanine, 2-[(dichloroacetyl)amino]-1-[4-(methylsulfonyl)phenyl]-1,3-propanediyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)



AB A soln. of thiamphenicol and  $\text{PhCH}_2\text{CH}(\text{NH}_2)\text{COCl} \cdot \text{HCl}$  (1:2 by mole) in anhyd. dioxane was stirred 7 hr at 13-17.degree. to give 61.2% thiamphenicol phenylalaninate, which was sol. and stable in  $\text{H}_2\text{O}$ .

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1970:67270 CAPLUS

DN 72:67270

TI Water soluble antibiotic chloramphenicol .beta.-phenylalanine ester salts

IN Zumin, Silva T.; Mosna, Sergio

PA Pierrel S.p.A.

SO Brit., 8 pp.

CODEN: BRXXAA

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1173562		19691210	GB	19660425

IT **25613-59-6P 25613-62-1P 25613-63-2P**


**25613-64-3P 25616-21-1P 25616-22-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)

RN 25613-59-6 CAPLUS


CN Alanine, N-carboxy-3-phenyl-, N-benzyl ester, L-, diester with  
 D-threo-2,2-dichloro-N-{.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-

nitrophenethyl]acetamide (8CI) (CA INDEX NAME)



RN 25613-62-1 CAPLUS

CN Alanine, N-carboxy-3-phenyl-, N-benzyl ester, DL-, diester with  
D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-  
nitrophenethyl]acetamide (8CI) (CA INDEX NAME)




RN 25613-63-2 CAPLUS

CN Alanine, phenyl-, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-  
.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, bis(trifluoroacetate)  
(8CI) (CA INDEX NAME)

CM 1


CRN 47832-98-4

CMF C29 H30 Cl2 N4 O7




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 25613-64-3 CAPLUS  
CN Alanine, phenyl-, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, dihydrochloride (8CI)  
(CA INDEX NAME)




● 2 HCl

RN 25616-21-1 CAPLUS  
CN Alanine, N-acetyl-3-phenyl-, L-, compd. with L-phenylalanine diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide (2:1) (8CI) (CA INDEX NAME)

CM 1


CRN 47832-98-4  
CMF C29 H30 Cl2 N4 O7




CM 2

CRN 2018-61-3  
CMF C11 H13 N O3

Absolute stereochemistry. Rotation (+).



RN 25616-22-2 CAPLUS  
CN Alanine, phenyl-, DL-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, dihydrobromide (8CI)  
(CA INDEX NAME)




●2 HBr

AB Salts of chloramphenicol 1,3-bis(L-.beta.-phenylalaninate) (I) and chloramphenicol 3-L-.beta.-phenylalaninate (II), useful for parenteral administration, with antibiotic activity, were prepd. by reacting D-(-)-threo-1-p-nitrophenyl-2-dichloroacetamido-1,3-propanediol (chloramphenicol) (III) either with N-carbobenzoxy-L-.beta.-phenylalanine (IV) in the presence of dicyclo-hexylcarbodiimide (V) and anhyd. pyridine (VI) or with IV anhydride (VII) in the presence of VI to give chloramphenicol 1,3-bis(N-carbobenzoxy-L-.beta.-phenylalaninate) (VIII) and chloramphenicol 3-(N-carbobenzoxy-L-.beta.-phenylalaninate) (IX), resp., followed by removal of the protecting group(s) by treatment with aq. HBr or anhyd. CF<sub>3</sub>CO<sub>2</sub>H. I and II are hydrolyzed in vivo to III and phenylalanine. Thus, addn. of 10.30 g V at 15.degree. to a stirred soln. of 29.93 g IV in 150 ml Me<sub>2</sub>CO, and the mixt. stirred 3 hr gave 96.5% VII. Racemic N-carbobenzoxy-DL-.beta.-phenylalanine anhydride (X) (93.5%) was prepd. similarly. III (5.82 g) in 10 ml VI was added to 180 ml of an Me<sub>2</sub>CO soln. of 25.2 g VII and the mixt. stirred 5-6 hr at room temp. and poured on ice-HCl to give, after treatment with 3.5 ml p-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NMe<sub>2</sub> (XI) in dry C<sub>6</sub>H<sub>6</sub> to remove excess VII, 90% VIII, m. 95-7.degree.. Racemic chloramphenicol 1,3-bis(N-carbobenzoxy-.beta.-phenylalaninate) (XII) (94%), a yellow oil, was prepd. similarly from X. IV (22.45 g) and 15 ml VI added to a stirred soln. of 9.69 g III in 60 ml HCONMe<sub>2</sub>, the soln. cooled to -5 to -8.degree., 18.57 g V added slowly, the mixt. stirred 1 hr, kept 3 hr at -5.degree. and poured on a mixt. of 50 ml concd. HCl, 50 ml H<sub>2</sub>O, and 100 g ice gave a ppt., which was centrifuged off and extd.




with C<sub>6</sub>H<sub>6</sub>. Treatment of the C<sub>6</sub>H<sub>6</sub> ext. with 3.5 ml XI gave 93% VIII, m. 95-7.degree.. IX, m. 145-7.degree., was prepd. similarly using 19.39 g III, 60 ml HCONMe<sub>2</sub>, 17.96 g IV, 15 ml VI, and 12.38 g V. A mixt. of 17.72 g VIII and 40 ml anhyd. CF<sub>3</sub>CO<sub>2</sub>H refluxed 1 hr in the presence of 8 g resorcinol gave 16.30 g I.CF<sub>3</sub>CO<sub>2</sub>H (XIII). Addn. of XIII to satd. aq. NaHCO<sub>3</sub>, extn. of the free base with CH<sub>2</sub>Cl<sub>2</sub>, and treatment of the ext. with HCl gave I.HCl, m. 220-222.degree. (decompn.). II.HCl, [.alpha.]<sub>D</sub> 10.77.degree. (c 2, H<sub>2</sub>O), was prepd. similarly from IX. A soln. of 5 g XII in 60 ml 2.5N HBr in AcOH stirred 10 min at 25 .degree. gave 85% a mixt. of chloramphenicol 1,3-bis(D- and L-.beta.-phenylalaninate-HBr) sepd. by chromatog. XIII (13 g) treated with satd. aq. NaHCO<sub>3</sub>, extn. of the free base with CH<sub>2</sub>Cl<sub>2</sub>, and treatment of the ext. with N-acetyl-L-phenylalanine gave III 1,3-bis(L-.beta.-phenylalaninate N-acetyl-L-phenylalaninate); III 3-(L-.beta.-phenylalaninate N-acetyl-L-phenylalaninate) was prepd. similarly.

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS  
 AN 1967:402830 CAPLUS  
 DN 67:2830  
 TI Separation of the organic bases by Craig partition. VII. Acyl migration in the stereoisomeric N-(N,N-dimethylphenylalanyl)ephedrine  
 AU Schoenenberger, Helmut; Fuchsberger, K. D.; Brinkmann, Rolf  
 CS Univ. Munich, Munich, Fed. Rep. Ger.  
 SO Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft (1967), 300(2), 126-35  
 CODEN: APBDAJ; ISSN: 0376-0367  
 DT Journal  
 LA German  
 IT **14355-01-2P 14355-02-3P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 14355-01-2 CAPLUS  
 CN Alanine, N,N-dimethyl-3-phenyl-, ester with (-)-pseudoephedrine, dihydrochloride, L- (8CI) (CA INDEX NAME)




● 2 HCl

RN 14355-02-3 CAPLUS  
 CN Alanine, N,N-dimethyl-3-phenyl-, ester with (-)-pseudoephedrine, dihydrochloride, D- (8CI) (CA INDEX NAME)



2 HCl



● 2 HCl

AB cf. CA 66: 49281u. The compds. studied were N-(L-N,N-dimethylphenylalanyl)-L-ephedrine (I), N-(D-N,N-dimethylphenylalanyl)-L-ephedrine (II), N-(L-N,N-dimethylphenylalanyl)-L-pseudoephedrine (III), and N-(D-N,N-dimethylphenylalanyl)-L-pseudoephedrine (IV). In every case, only the ester of L-pseudoephedrine resulted, even under mild conditions (room temp., acetone-HCl). Complete inversion of the erythro derivs. occurred. In 2N HCl at 80.degree., the ester from I formed quant. in 10 min. while that from III (retention of configuration) required 25 hrs. With II, 5 hrs. and with IV, 22 hrs. were required. The 4 amides pass through either of 2 cyclic intermediates during the migration, L,L-(V) or D,L-pseudooxazolidine (VI). The rates are explained by steric considerations of the mechanism, V resulting from I via inversion and from III with retention, and VI, from II via inversion and IV with retention. Craig partition as described previously (loc. cit.) was used to sep. and det. the reaction products. Twenty-four partition steps using a solvent mixt. of 0.5M citrate buffer (pH 4/5)-MeOH-CHCl<sub>3</sub> (9:1:10 parts by vol.) were required for sepn. into N- and O-aminoacylphenedrines. The O-(L-N,N-dimethylphenylalanyl)-L-pseudoephedrine m. 170-2.degree., [.alpha.]<sub>D</sub><sup>20</sup> + 114.degree. (c = 0.0055 g./ml., 5N HCl) and the O-(D-N,N-dimethyl-) ester melts at 174-6.degree., [.alpha.]<sub>D</sub><sup>20</sup> 48.degree. (c 0.0055 g./ml., 5N HCl).

=> d cost

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.34 0.83
NETWORK CHARGES	0.06 0.18
SEARCH CHARGES	0.00 147.75
DISPLAY CHARGES	43.20 43.20
	-----
	43.60 191.96
CAPLUS FEE (5%)	2.18 2.18
	-----
FULL ESTIMATED COST	45.78 194.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.51 -6.51

IN FILE 'CAPLUS' AT 14:38:52 ON 26 MAY 2003

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEx enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA  
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and  
right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:37:32 ON 26 MAY 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:37:43 ON 26 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0

DICTIONARY FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09912163.2

L1 STRUCTURE UPLOADED

=&gt; d 11

L1 HAS NO ANSWERS

L1 STR



G1 NH,X,Hy

Structure attributes must be viewed using STN Express query preparation.

=&gt; s 11

SAMPLE SEARCH INITIATED 14:38:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1045 TO ITERATE

95.7% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 18961 TO 22839  
PROJECTED ANSWERS: 1 TO 81

L2 1 SEA SSS SAM L1

=&gt; s 11 sss full

FULL SEARCH INITIATED 14:38:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 20951 TO ITERATE

100.0% PROCESSED 20951 ITERATIONS  
SEARCH TIME: 00.00.01

24 ANSWERS

L3 24 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 14:38:21 ON 26 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 May 2003 VOL 138 ISS 22  
FILE LAST UPDATED: 25 May 2003 (20030525/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 13

L4 10 L3

=> d 14 fbib hitstr abs total

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:57805 CAPLUS  
DN 134:252075  
TI Synthesis of enantiopure homoallylic ethers by reagent controlled facial selective allylation of chiral ketones  
AU Tietze, Lutz F.; Weigand, Berthold; Volkel, Ludwig; Wulff, Christian; Bittner, Christian  
CS Institut fur Organische Chemie Georg-August-Universitat Gottingen, Gottingen, 37077, Germany  
SO Chemistry--A European Journal (2001), 7(1), 161-168  
CODEN: CEUJED; ISSN: 0947-6539  
PB Wiley-VCH Verlag GmbH  
DT Journal  
LA English  
OS CASREACT 134:252075  
IT **330798-68-0P 330798-69-1P**  
RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of enantiopure homoallylic ethers by reagent controlled facial selective allylation of chiral ketones)  
RN 330798-68-0 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[(1S,2S)-1-methyl-2-[[[(1R)-1-methyl-1-{(2S)-2-phenylpropyl]-3-butenyl]oxy}-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330798-69-1 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[[(1S)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

IT 330798-62-4P 330798-63-5P 330798-73-7P  
330798-76-0PRL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of enantiopure homoallylic ethers by reagent controlled  
facial selective allylation of chiral ketones)

RN 330798-62-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1S,2S)-1-methyl-2-[[[(1S)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 330798-63-5 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 330798-73-7 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1R)-1-methyl-1-(2-phenylpropyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330798-76-0 CAPLUS


CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-(2-phenylpropyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI






AB The stereoselective allylation of chiral Me ketones to give tertiary homoallylic ethers, which can easily be transformed into homoallylic alcs., is described. Reaction of the enantiopure ketones (I), (R)-Me<sub>2</sub>CH(CH<sub>2</sub>)<sub>3</sub>CH(.beta.Me)CH<sub>2</sub>COMe, (R)-MeCH(.beta.OSiPh<sub>2</sub>CMe<sub>3</sub>)CH<sub>2</sub>COMe, (S)-MeCH(.alpha.Ph)CH<sub>2</sub>COMe and the racemic ketones MeCH(OSiPh<sub>2</sub>CMe<sub>3</sub>)CH<sub>2</sub>COMe, MeCH(Ph)CH<sub>2</sub>COMe, MeCH<sub>2</sub>CH(Ph)COMe, MeCH<sub>2</sub>CH(Me)COMe with the norpseudoephedrine deriv. and allylsilane in the presence of a catalytic amt. of trifluoromethanesulfonic acid, led to a series of homoallylic ethers with good to excellent diastereoselectivity (85:15 to > 97:3). The allylation is reagent controlled and nearly independent from the stereogenic centers in the substrates. A partial kinetic resolu. was obsd. using the racemic ketones. In the reaction of the chiral ketones with the achiral reagents ethoxytrimethylsilane and allylsilane only a low diastereoselectivity was obsd.

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:625620 CAPLUS  
DN 129:316000  
TI Synthesis of enantiopure homoallylic alcohols by a highly selective asymmetric allylation of ketones  
AU Tietze, Lutz F.; Schiemann, Kai; Wegner, Christoph; Wulff, Christian  
CS Institute Organic Chemistry, Georg-August-Universitat Gottingen, Gottingen, D-37077, Germany  
SO Chemistry--A European Journal (1998), 4(9), 1862-1869  
CODEN: CEUJED; ISSN: 0947-6539  
PB Wiley-VCH Verlag GmbH  
DT Journal  
LA English  
OS CASREACT 129:316000  
IT **165823-95-0P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of enantiopure homoallylic alcs. by asym. allylation of ketones)  
RN 165823-95-0 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB A highly selective asym. domino allylation of aliph. ketones is described. When Me ketones, (R,R)-Me<sub>2</sub>SiOCHPhCHMeNHCOCF<sub>3</sub>, and CH<sub>2</sub>:CHCH<sub>2</sub>SiMe<sub>3</sub> react in the presence of catalytic amts. of trifluoromethanesulfonic acid, the homoallylic ethers are produced with up to 24:1 diastereoselectivity and 89% yield. Ether cleavage using lithium or sodium in liq. ammonia gives the homoallylic alcs. in 75 to 95% yield and up to 92% ee. Even EtCOMe, the most difficult example, showed a stereoselectivity of 9:1 at -78.degree.C and 24:1 at -109.degree.C. In addn., the allylation of protected hydroxyalkyl Me ketones gave the corresponding homoallylic ethers with a diastereoselectivity of up to >244:1 and 98% yield. In contrast, Et alkyl ketones have a low selectivity.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1997:639948 CAPLUS

DN 127:307269

TI Preparation of optically active succinic acid derivatives. I. Optical resolution of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionic acid

AU Yamaguchi, Toshiaki; Yanagi, Takashi; Hokari, Hiroshi; Mukaiyama, Yuko; Kamijo, Tetsuhide; Yamamoto, Iwao

CS Kissei Pharmaceutical Co., Ltd., Central Research Laboratories, Hotaka, 399-83, Japan

SO Chemical & Pharmaceutical Bulletin (1997), 45(9), 1518-1520

CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English


IT 197447-44-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(optical resolu. of benzyl(hexahydroisoindolinylcarbonyl)propionic acid)

RN 197447-44-2 CAPLUS

CN 2H-Isoindole-2-butanoic acid, octahydro-.gamma.-oxo-.alpha.-(phenylmethyl)-, 2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl ester, [2(.alpha.S)-[2[R\*(R\*)],3a.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 197447-45-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(optical resolu. of benzyl(hexahydroisoindolinylcarbonyl)propionic acid)

RN 197447-45-3 CAPLUS

CN 2H-Isoindole-2-butanoic acid, octahydro-.gamma.-oxo-.alpha.-(phenylmethyl)-  
, 2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl ester, [2(.alpha.R)-  
[2[R\*(S\*)],3a.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB Optical resolu. of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionic acid (I) was accomplished by two methods. Thus, I was esterified with (S)-N-benzylmandelamide and the resulting diastereomeric esters were sepd. by column chromatog. on silica gel. One of the diastereomers was hydrolyzed to give the optically active acid (-)-I. The abs. configuration of (-)-I was established as S by comparison with an authentic sample. The alternative method was resolu. using an optically active amine. Treatment of a soln. of the racemic acid I with 0.65 equiv of (R)-1-(1-naphthyl)ethylamine in ethanol gave the salt in 23.2% yield with an optical purity of 96.8% ee.

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1995:835557 CAPLUS

DN 123:256542

TI Preparation of annelated dihydropyridines

IN Roos, Otto; Loesel, Walter; Arndts, Dietrich

PA Boehringer Ingelheim KG, Germany

SO Ger. Offen., 28 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI	DE 4343683	A1	19950622	DE 1993-4343683	19931221
	CA 2178209	AA	19950629	CA 1994-2178209	19941214
				DE 1993-4343683A	19931221
WO	9517389	A1	19950629	WO 1994-EP4150	19941214
	W: AU, CA, CN, JP, KR, PL, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				DE 1993-4343683A	19931221
AU	9512433	A1	19950710	AU 1995-12433	19941214
AU	699208	B2	19981126		
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
EP	736011	A1	19961009	EP 1995-903342	19941214
EP	736011	B1	20000726		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
CN	1138325	A	19961218	CN 1994-194572	19941214
CN	1044905	B	19990901		
				DE 1993-4343683A	19931221
JP	09506882	T2	19970708	JP 1994-517154	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
RU	2136664	C1	19990910	RU 1996-115153	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
AT	194978	E	20000815	AT 1995-903342	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
ES	2149958	T3	20001116	ES 1995-903342	19941214
				DE 1993-4343683A	19931221
ZA	9410115	A	19950621	ZA 1994-10115	19941220
				DE 1993-4343683A	19931221
US	5661157	A	19970826	US 1994-360867	19941221
				DE 1993-4343683A	19931221
TW	404941	B	20000911	TW 1994-83112295	19941228
				DE 1993-4343683A	19931221
US	5968948	A	19991019	US 1997-857643	19970516
				DE 1993-4343683A	19931221
				US 1994-360867 A319941221	
US	6136819	A	20001024	US 1999-329443	19990610
				DE 1993-4343683A	19931221
				US 1994-360867 A319941221	
				US 1997-857643 A319970516	
OS	MARPAT 123:256542				
IT	<b>168545-16-2P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(prepn. of annelated dihydropyridines from)				
RN	168545-16-2 CAPLUS				
CN	Benzeneacetamide, N-[2-(3,4-dimethoxy-2,4-cyclohexadien-1-yl)ethyl]-.alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)				



GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = benzo, thieno, indolo; B = O, S, (un)substituted CH<sub>2</sub>; R<sub>2</sub> = OH, alkoxy, benzyloxy, halogen, alkyl, methanesulfonyloxy, etc.; R<sub>3</sub> = 2- or 3-thienyl, (un)substituted Ph, alkyl, cycloalkylalkyl; R<sub>4</sub> = (un)branched alkenyl or alkynyl, alkoxy, dialkylamino, heterocyclyl, Ph, etc.; m = 0-3] (e.g., II), useful as calcium-channel blockers (no data), are prepd. by the intramol. cyclocondensation of arom. amides (III) (e.g., IV) in the presence of condensing agents (e.g., POCl<sub>3</sub>), and I-contg. formulations are also presented.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1995:568922 CAPLUS

DN 123:111518

TI Enantioselective Synthesis of Tertiary Homoallylic Alcohols via Diastereoselective Addition of Allylsilanes to Ketones

AU Tietze, Lutz F.; Schiemann, Kai; Wegner, Christoph

CS Institute of Organic Chemistry, Georg-August-Universitaet, Goettingen, D-37077, Germany

SO Journal of the American Chemical Society (1995), 117(21), 5851-2

CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

OS CASREACT 123:111518


IT 165823-95-0P 166021-67-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(enantioselective synthesis of tertiary homoallylic alcs. via diastereoselective addn. of allylsilanes to ketones)

RN 165823-95-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 166021-67-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[1-methyl-2-[[1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]-, [1R-[1R\*,2R\*(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Enantiopure tertiary homoallylic alcs.  $\text{CH}_2\text{:CHCH}_2\text{CRMeOH}$  ( $\text{R} = \text{alkyl}$ ) can be obtained from the corresponding homoallylic ethers  $\text{CH}_2\text{:CHCH}_2\text{CRMeOR1}$  [4,  $\text{R1} = \text{residue of (1R,2R)-N-(trifluoroacetyl)norpseudoephedrine}$ ] by treatment with sodium in liq. ammonia. The ethers 4 are formed highly selectively by treatment of the ketones  $\text{MeCOR}$  with the trimethylsilyl ether of N-trifluoroacetylnorpseudoephedrine in the presence of catalytic amts. of  $\text{Me}_3\text{SiB(OTf)}_4$  or  $\text{Me}_3\text{SiOTf/TfOH}$  ( $\text{Tf} = \text{CF}_3\text{SO}_2$ ) followed by addn. of allyltrimethylsilane. The yield was about 90% (based on conversion) and the diastereoselectivity was about 90:10. Using iso-Pr Me ketone a selectivity of >95:5 was obtained; thus only one diastereomer could be detected.

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1989:553339 CAPLUS

DN 111:153339

TI Preparation of esterified N-(dibenzocycloheptenylideneethyl)ephedrine derivatives with prolonged antiulcer activity

IN Butelman, Federico

PA Etablissement Texcontor, Liechtenstein

SO Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 313885	A1	19890503	EP 1988-116449	19881005
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				IT 1987-22407	19871023
	US 4935444	A	19900619	US 1988-254220	19881006
				IT 1987-22407	19871023
	JP 01135748	A2	19890529	JP 1988-264240	19881021
				IT 1987-22407	19871023
	US 4990522	A	19910205	US 1990-487277	19900302
				IT 1987-22407	19871023
				US 1988-254220	19881006

IT 122881-51-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(prepn. and N-alkylation of, with (haloethylidene)dibenzocycloheptene)


RN 122881-51-0 CAPLUS

CN Benzenepropanoic acid, 2-(methylamino)-1-phenylpropyl ester, [R-(R\*,S\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. [I; R = C<sub>9</sub>H<sub>19</sub>, C<sub>15</sub>H<sub>31</sub>, CH(NH<sub>2</sub>)(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>H, (CH<sub>2</sub>)<sub>2</sub>Ph, CMe<sub>3</sub>, p-HOC<sub>6</sub>H<sub>4</sub>, 2-thienyl, 3-pyridyl, 1-amino-2-(5-imidazolyl)ethyl, pamoic acid residue] are prepd. by esterification of ephedrine (II) with RCOCl to give PhCH(O<sub>2</sub>CR)CHMeNHMe (III), followed by N-alkylation with a (haloethylidene)dibenzocycloheptene IV (X = halo). II was esterified by decanoyl chloride (prepd. from the acid) to give 65% III [R = Me(CH<sub>2</sub>)<sub>8</sub>], which was refluxed in MeCN with IV (X = halo, not specified) to give 54% I [R = MeC(CH<sub>2</sub>)<sub>2</sub>]. The latter inhibited stress-induced ulcers in rats with ED<sub>50</sub> of 0.4 and 2.1 mg/kg orally, administered 6 and 36 h prior to commencement of the stress, resp.

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1979:121187 CAPLUS

DN 90:121187

TI Aminoalcohol derivative

IN Lambelin, Georges; Roncucci, Romeo; Roba, Joseph; Gillet, Claude; Snyers, Michel

PA Continental Pharma, Belg.

SO Ger. Offen., 48 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2817494	A1	19781109	DE 1978-2817494	19780421

			LU 1977-77236	19770503
			LU 1977-77237	19770503
GB 1603379	A	19811125	GB 1978-27732	19780427
			LU 1977-77236	19770503
			LU 1977-77237	19770503
			GB 1978-16813	19780427
GB 1603378	A	19811125	GB 1978-16813	19780427
			LU 1977-77237	19770503
SE 7804897	A	19781104	SE 1978-4897	19780428
			LU 1977-77236	19770503
			LU 1977-77237	19770503
NL 7804621	A	19781107	NL 1978-4621	19780428
			LU 1977-77236	19770503
			LU 1977-77237	19770503
CA 1118438	A1	19820216	CA 1978-302239	19780428
			LU 1977-77236	19770503
			LU 1977-77237	19770503
US 4474977	A	19841002	US 1978-901223	19780428
			LU 1977-77236	19770503
			LU 1977-77237	19770503
IL 54608	A1	19840131	IL 1978-54608	19780501
			LU 1977-77236	19770503
			LU 1977-77237	19770503
FI 7801347	A	19781104	FI 1978-1347	19780502
			LU 1977-77236	19770503
			LU 1977-77237	19770503
DK 7801898	A	19781104	DK 1978-1898	19780502
			LU 1977-77236	19770503
			LU 1977-77237	19770503
NO 7801554	A	19781106	NO 1978-1554	19780502
NO 146057	B	19820413		
NO 146057	C	19820721		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
ZA 7802507	A	19790725	ZA 1978-2507	19780502
			LU 1977-77236	19770503
ES 469843	A1	19790916	ES 1978-469843	19780502
			LU 1977-77236	19770503
			LU 1977-77237	19770503
AT 7803179	A	19800115	AT 1978-3179	19780502
AT 358020	B	19800811		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
FR 2389597	A1	19781201	FR 1978-13202	19780503
FR 2389597	B1	19830819		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
AU 7835733	A1	19791108	AU 1978-35733	19780503
AU 517255	B2	19810716		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
CH 635570	A	19830415	CH 1978-4836	19780503
			LU 1977-77236	19770503
			LU 1977-77237	19770503
JP 53141230	A2	19781208	JP 1978-53627	19780504
JP 59040140	B4	19840928		
			LU 1977-77236	19770503



AT 7906288	A	19810715	LU 1977-77237	19770503
AT 366023	B	19820310	AT 1979-6288	19790925

LU 1977-77236	19770503
LU 1977-77237	19770503
AT 1978-3179	19780502


IT 69145-90-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. as muscle relaxant)

RN 69145-90-0 CAPLUS


CN Benzenepropanoic acid, 1-[4-[(1-methylethyl)thio]phenyl]-2-  
(octylamino)propyl ester, hydrochloride, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

GI




AB One hundred three amino alcs. I [R1 = H, C1-5 alkylthio, alkoxy, alkyl, C5-6 cycloalkylthio, cycloalkoxy, cycloalkyl, halo; R2 = C1-3 alkyl; R3 = C1-8 alkyl, C1-4 alkyl, optionally substituted with Ph, PhO, Bz, (un)substituted with alkyl, alkoxy, halo, C6-18 alkenyl, C5-9 cycloalkyl; R4 = COR5 [R5 = C1-10 alkyl, C2-4 alkenyl, C3-8 cycloalkyl, Ph (un)substituted with C1-3 alkyl, alkoxy, halo, C1-4 alkyl, (un)substituted with C1-3 carbalkoxy, alkoxy, NH2, acylamino, C5-6 cycloalkyl, PhO, Ph, optionally substituted with alkyl, alkoxy, halo, cinnamyl], H], useful as antihypertensives, peripheral vasodilators, muscle relaxants, platelet aggregation inhibitors, hypolipemics, and thrombosis inhibitors, were prepd. Thus, acylation of 4-Me2CHSC6H4CH(OH)CHMeNH(CH2)7Me by refluxing with AcCl in C6H6 or PrCOCl gave 70 or 52%, resp. of the corresponding 4-Me2CHSC6H4CH(OR4)CHMeNH(CH2)7Me (R4 = Ac, PrCO).

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1973:147610 CAPLUS

DN 78:147610  
 TI Thiamphenicol phenylalaninate  
 IN Saiga, Akisuke; Yamanaka, Motosuke; Sato, Takashi  
 PA Eisai Co., Ltd.  
 SO Jpn. Kokai Tokkyo Koho, 2 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 48004446	B4	19730120	JP 1971-27212	19710427
IT	<b>41570-11-0P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	41570-11-0 CAPLUS				
CN	L-Phenylalanine, 2-[(dichloroacetyl)amino]-1-[4-(methylsulfonyl)phenyl]-1,3-propanediyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)				




AB A soln. of thiamphenicol and  $\text{PhCH}_2\text{CH}(\text{NH}_2)\text{COCl} \cdot \text{HCl}$  (1:2 by mole) in anhyd. dioxane was stirred 7 hr at 13-17.degree. to give 61.2% thiamphenicol phenylalaninate, which was sol. and stable in  $\text{H}_2\text{O}$ .

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS  
 AN 1970:67270 CAPLUS  
 DN 72:67270  
 TI Water soluble antibiotic chloramphenicol .beta.-phenylalanine ester salts  
 IN Zumin, Silva T.; Mosna, Sergio  
 PA Pierrel S.p.A.  
 SO Brit., 8 pp.  
 CODEN: BRXXAA  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1173562		19691210	GB	19660425
IT	<b>25613-59-6P 25613-62-1P 25613-63-2P</b> <b>25613-64-3P 25616-21-1P 25616-22-2P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	25613-59-6 CAPLUS				
CN	Alanine, N-carboxy-3-phenyl-, N-benzyl ester, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-				

nitrophenethyl]acetamide (8CI) (CA INDEX NAME)



RN 25613-62-1 CAPLUS

Alanine, N-carboxy-3-phenyl-, N-benzyl ester, DL-, diester with  
D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-  
nitrophenethyl]acetamide (8CI) (CA INDEX NAME)




RN 25613-63-2 CAPLUS

CN Alanine, phenyl-, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, bis(trifluoroacetate) (8CI) (CA INDEX NAME)

CM 1


CRN 47832-98-4

CMF C29 H30 C12 N4 O7




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 25613-64-3 CAPLUS  
CN Alanine, phenyl-, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, dihydrochloride (8CI)  
(CA INDEX NAME)




● 2 HCl

RN 25616-21-1 CAPLUS  
CN Alanine, N-acetyl-3-phenyl-, L-, compd. with L-phenylalanine diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide (2:1) (8CI) (CA INDEX NAME)

CM 1


CRN 47832-98-4  
CMF C29 H30 Cl2 N4 O7




CM 2

CRN 2018-61-3  
CMF C11 H13 N O3

Absolute stereochemistry. Rotation (+).



RN 25616-22-2 CAPLUS  
CN Alanine, phenyl-, DL-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, dihydrobromide (8CI)  
(CA INDEX NAME)




●2 HBr

AB Salts of chloramphenicol 1,3-bis(L-.beta.-phenylalaninate) (I) and chloramphenicol 3-L-.beta.-phenylalaninate (II), useful for parenteral administration, with antibiotic activity, were prepd. by reacting D-(-)-threo-1-p-nitrophenyl-2-dichloroacetamido-1,3-propanediol (chloramphenicol) (III) either with N-carbobenzoxy-L-.beta.-phenylalanine (IV) in the presence of dicyclo-hexylcarbodiimide (V) and anhyd. pyridine (VI) or with IV anhydride (VII) in the presence of VI to give chloramphenicol 1,3-bis(N-carbobenzoxy-L-.beta.-phenylalaninate) (VIII) and chloramphenicol 3-(N-carbobenzoxy-L-.beta.-phenylalaninate) (IX), resp., followed by removal of the protecting group(s) by treatment with aq. HBr or anhyd. CF<sub>3</sub>CO<sub>2</sub>H. I and II are hydrolyzed in vivo to III and phenylalanine. Thus, addn. of 10.30 g V at 15.degree. to a stirred soln. of 29.93 g IV in 150 ml Me<sub>2</sub>CO, and the mixt. stirred 3 hr gave 96.5% VII. Racemic N-carbobenzoxy-DL-.beta.-phenylalanine anhydride (X) (93.5%) was prepd. similarly. III (5.82 g) in 10 ml VI was added to 180 ml of an Me<sub>2</sub>CO soln. of 25.2 g VII and the mixt. stirred 5-6 hr at room temp. and poured on ice-HCl to give, after treatment with 3.5 ml p-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NMe<sub>2</sub> (XI) in dry C<sub>6</sub>H<sub>6</sub> to remove excess VII, 90% VIII, m. 95-7.degree.. Racemic chloramphenicol 1,3-bis(N-carbobenzoxy-.beta.-phenylalaninate) (XII) (94%), a yellow oil, was prepd. similarly from X. IV (22.45 g) and 15 ml VI added to a stirred soln. of 9.69 g III in 60 ml HCONMe<sub>2</sub>, the soln. cooled to -5 to -8.degree., 18.57 g V added slowly, the mixt. stirred 1 hr, kept 3 hr at -5.degree. and poured on a mixt. of 50 ml concd. HCl, 50 ml H<sub>2</sub>O, and 100 g ice gave a ppt., which was centrifuged off and extd.


with C<sub>6</sub>H<sub>6</sub>. Treatment of the C<sub>6</sub>H<sub>6</sub> ext. with 3.5 ml XI gave 93% VIII, m. 95-7.degree.. IX, m. 145-7.degree., was prepd. similarly using 19.39 g III, 60 ml HCONMe<sub>2</sub>, 17.96 g IV, 15 ml VI, and 12.38 g V. A mixt. of 17.72 g VIII and 40 ml anhyd. CF<sub>3</sub>CO<sub>2</sub>H refluxed 1 hr in the presence of 8 g resorcinol gave 16.30 g I.CF<sub>3</sub>CO<sub>2</sub>H (XIII). Addn. of XIII to satd. aq. NaHCO<sub>3</sub>, extn. of the free base with CH<sub>2</sub>Cl<sub>2</sub>, and treatment of the ext. with HCl gave I.HCl, m. 220-222.degree. (decompn.). II.HCl, [.alpha.]<sub>D</sub> 10.77.degree. (c 2, H<sub>2</sub>O), was prepd. similarly from IX. A soln. of 5 g XII in 60 ml 2.5N HBr in AcOH stirred 10 min at 25 .degree. gave 85% a mixt. of chloramphenicol 1,3-bis(D- and L-.beta.-phenylalaninate-HBr) sepd. by chromatog. XIII (13 g) treated with satd. aq. NaHCO<sub>3</sub>, extn. of the free base with CH<sub>2</sub>Cl<sub>2</sub>, and treatment of the ext. with N-acetyl-L-phenylalanine gave III 1,3-bis(L-.beta.-phenylalaninate N-acetyl-L-phenylalaninate); III 3-(L-.beta.-phenylalaninate N-acetyl-L-phenylalaninate) was prepd. similarly.

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS  
 AN 1967:402830 CAPLUS  
 DN 67:2830  
 TI Separation of the organic bases by Craig partition. VII. Acyl migration in the stereoisomeric N-(N,N-dimethylphenylalanyl)ephedrines  
 AU Schoenenberger, Helmut; Fuchsberger, K. D.; Brinkmann, Rolf  
 CS Univ. Munich, Munich, Fed. Rep. Ger.  
 SO Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft (1967), 300(2), 126-35  
 CODEN: APBDAJ; ISSN: 0376-0367  
 DT Journal  
 LA German  
 IT **14355-01-2P 14355-02-3P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 14355-01-2 CAPLUS  
 CN Alanine, N,N-dimethyl-3-phenyl-, ester with (-)-pseudoephedrine, dihydrochloride, L- (8CI) (CA INDEX NAME)




● 2 HCl

RN 14355-02-3 CAPLUS  
 CN Alanine, N,N-dimethyl-3-phenyl-, ester with (-)-pseudoephedrine, dihydrochloride, D- (8CI) (CA INDEX NAME)



2 HCl



● 2 HCl

AB cf. CA 66: 49281u. The compds. studied were N-(L-N,N-dimethylphenylalanyl)-L-ephedrine (I), N-(D-N,N-dimethylphenylalanyl)-L-ephedrine (II), N-(L-N,N-dimethylphenylalanyl)-L-pseudoephedrine (III), and N-(D-N,N-dimethylphenylalanyl)-L-pseudoephedrine (IV). In every case, only the ester of L-pseudoephedrine resulted, even under mild conditions (room temp., acetone-HCl). Complete inversion of the erythro derivs. occurred. In 2N HCl at 80.degree., the ester from I formed quant. in 10 min. while that from III (retention of configuration) required 25 hrs. With II, 5 hrs. and with IV, 22 hrs. were required. The 4 amides pass through either of 2 cyclic intermediates during the migration, L,L-(V) or D,L-pseudooxazolidine (VI). The rates are explained by steric considerations of the mechanism, V resulting from I via inversion and from III with retention, and VI, from II via inversion and IV with retention. Craig partition as described previously (loc. cit.) was used to sep. and det. the reaction products. Twenty-four partition steps using a solvent mixt. of 0.5M citrate buffer (pH 4/5)-MeOH-CHCl<sub>3</sub> (9:1:10 parts by vol.) were required for sepn. into N- and O-aminoacylphenedrines. The O-(L-N,N-dimethylphenylalanyl)-L-pseudoephedrine m. 170-2.degree., [ $\alpha$ ]<sub>D</sub><sup>20</sup> + 114.degree. (c = 0.0055 g./ml., 5N HCl) and the O-(D-N,N-dimethyl-) ester melts at 174-6.degree., [ $\alpha$ ]<sub>D</sub><sup>20</sup> 48.degree. (c 0.0055 g./ml., 5N HCl).

=> d cost

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
CONNECT CHARGES	0.34 0.83
NETWORK CHARGES	0.06 0.18
SEARCH CHARGES	0.00 147.75
DISPLAY CHARGES	43.20 43.20
	-----
	43.60 191.96
CAPLUS FEE (5%)	2.18 2.18
	-----
FULL ESTIMATED COST	45.78 194.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.51 -6.51

IN FILE 'CAPLUS' AT 14:38:52 ON 26 MAY 2003

=>


Uploading 09912163.3

L5 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR




G1 NH,X,Hy

Structure attributes must be viewed using STN Express query preparation.

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 NH,X,Hy



Structure attributes must be viewed using STN Express query preparation.

=> s 15

**REGISTRY INITIATED**

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 14:42:51 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2 TO 124  
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

L7 0 L6

=> s 15

**REGISTRY INITIATED**

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 14:43:29 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2 TO 124  
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L5

L9 0 L8

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.42	198.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-6.51

FILE 'REGISTRY' ENTERED AT 14:43:39 ON 26 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0  
DICTIONARY FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s 15

SAMPLE SEARCH INITIATED 14:43:43 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2 TO 124  
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L5

=> s 15 sss full

FULL SEARCH INITIATED 14:43:49 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 63 TO ITERATE

100.0% PROCESSED 63 ITERATIONS 19 ANSWERS  
SEARCH TIME: 00.00.01

L11 19 SEA SSS FUL L5

=> file caplu

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	148.15	346.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-6.51

FILE 'CAPLUS' ENTERED AT 14:43:55 ON 26 MAY 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 May 2003 VOL 138 ISS 22  
 FILE LAST UPDATED: 25 May 2003 (20030525/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11

L12 1 L11

=> d l12 fbib hitstr abs total

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

AN 2002:157723 CAPLUS

DN 136:216523

TI Preparation of phenylethanol(mono/di)amines and  
 phenylalkylethanol(mono/di)amines as sodium channel blockers

IN Fuchs, Klaus; Stransky, Werner; Grauert, Matthias; Carter, Adrian; Gaida,  
 Wolfram; Weiser, Thomas; Ensinger, Helmut

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002016308	A1	20020228	WO 2001-EP9036	20010804
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10040901 A1 20020314  
 US 2002042410 A1 20020411

DE 2000-10040901A 20000818

DE 2000-10040901 20000818

US 2001-912163 20010724

DE 2000-10040901A 20000818

US 2000-228675PP 20000829

AU 2001091737 A5 20020304

AU 2001-91737 20010804

DE 2000-10040901A 20000818

WO 2001-EP9036 W 20010804

EP 1311471 A1 20030521

EP 2001-971870 20010804

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

DE 2000-10040901A 20000818

WO 2001-EP9036 W 20010804

OS MARPAT 136:216523

IT 401938-19-0P 401938-31-6P 401938-36-1P

401938-38-3P 401938-45-2P 401938-49-6P

401938-53-2P 401938-55-4P 401938-57-6P

401938-61-2P 401938-63-4P 401938-69-0P

401938-73-6P 401938-77-0P 401939-56-8P

401939-58-0P 401939-80-8P 401939-82-0P



401939-84-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(prepn. of phenylethanamines and phenylalkylethanamines as sodium  
 channel blockers)


RN 401938-19-0 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-N-(2-ethylbutyl)-  
 2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-31-6 CAPLUS

CN Benzeneethanamine, N-(cyclopropylmethyl)-.beta.-[3-(2,6-  
 difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-36-1 CAPLUS

CN Benzeneethanamine, N-(3-cyclohexen-1-ylmethyl)-.beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-38-3 CAPLUS

CN Benzeneethanamine, N-butyl-.beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)





RN 401938-45-2 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401938-49-6 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-N-(2,2-dimethylpropyl)-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-53-2 CAPLUS

CN Benzeneethanamine, N-(cyclohexylmethyl)-.beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 401938-55-4 CAPLUS


CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 401938-57-6 CAPLUS


CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-

(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 401938-61-2 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-[[4-(1-methylethenyl)-1-cyclohexen-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 401938-63-4 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)





RN 401938-69-0 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-N-(3,3-dimethylbutyl)-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-73-6 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)



RN 401938-77-0 CAPLUS


CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 401939-56-8 CAPLUS



CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-propyl- (9CI) (CA INDEX NAME)






RN 401939-58-0 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)





RN 401939-80-8 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-N-ethyl-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401939-82-0 CAPLUS

CN Benzenepropanamine, N-[2-[3-(2,6-difluorophenyl)propoxy]-2-(2,6-dimethylphenyl)ethyl]- (9CI) (CA INDEX NAME)





RN 401939-84-2 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-4-pentenyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1 = OH, CF3, NO2, CN, halo, C1-8 alkyl, halo, C1-8 alkoxy; R2, R3, R4 independently = halo, C1-8 alkyl, OH, NO2, CN, C1-8 alkoxy, CF3; R5, R6 independently = C1-8 alkyl, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, NH2, OH, O, COOH, CONH2; A = C1-5 alkylene, C2-4 alkenylene, C3-4 alkylene; X = NH, N(CHO), halo, O, etc.] are prepd. The invention further relates to a method for producing said compds. and to their compn. in use as medicaments. Title compds. I are used as blockers of the voltage-dependent sodium channel and can be used for diseases that are assocd. with a functional disorder caused by hyperexcitability. Thus, the title compd. II was prepd. from trifluoroacetic anhydride, 2,6-dimethylbenzaldehyde, which was prepd. from 2-bromo-3-dimethylbenzene, and 2-(3-bromopropyl)-1,3-difluorobenzene, which was prepd. from di-Et malonate and 2,6-difluorobenzyl bromide.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d cost

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.34	5.25
NETWORK CHARGES	0.06	0.96
SEARCH CHARGES	0.00	295.50
DISPLAY CHARGES	4.32	47.52
	4.72	349.23
CAPLUS FEE (5%)	0.23	2.57
FULL ESTIMATED COST	4.95	351.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE

ENTRY

-0.65

TOTAL

SESSION

-7.16

IN FILE 'CAPLUS' AT 14:44:22 ON 26 MAY 2003

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEx enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA  
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and  
right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:16:37 ON 26 MAY 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:16:42 ON 26 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0  
DICTIONARY FILE UPDATES: 25 MAY 2003 HIGHEST RN 519753-05-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09912163.4

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,N,NH

G2 Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:17:18 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13957 TO ITERATE

7.2% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 272072 TO 286208  
PROJECTED ANSWERS: 55 TO 503

L2 1 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 15:17:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 280434 TO ITERATE

100.0% PROCESSED 280434 ITERATIONS  
SEARCH TIME: 00.00.13

436 ANSWERS

L3 436 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.55

148.76

FILE 'CAPLUS' ENTERED AT 15:17:45 ON 26 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 May 2003 VOL 138 ISS 22

FILE LAST UPDATED: 25 May 2003 (20030525/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; s 13

L4 148 L3

=&gt; s 14 and overstimulation

L5 0 L4 AND OVERSTIMULATION

=&gt; s 14 and neurodegeneration

L6 0 L4 AND NEURODEGENERATION

=&gt; s 14 and AD

L7 0 L4 AND AD

=&gt; s 14 and stroke

L8 0 L4 AND STROKE

=&gt; d 14 fbib hitstr abs total

L4 ANSWER 1 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2002:849669 CAPLUS

DN 137:346158

TI Pentapeptide compounds, their preparation, and their use

IN Doronina, Svetlana; Senter, Peter D.; Toki, Brian E.

PA Seattle Genetics, Inc., USA

SO PCT Int. Appl., 161 pp.



CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002088172	A2	20021107	WO 2002-US13435	20020430
	WO 2002088172	A3	20030227		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2001-845786 A	20010430
				US 2001-1191 A	20011101
	US 2003083263	A1	20030501	US 2001-845786	20010430
OS	MARPAT 137:346158				
IT	<b>474645-11-9DP</b> , monoclonal antibody conjugates				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(pentapeptide compd. prepn. and use)				
RN	474645-11-9 CAPLUS				
CN	L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[[(1R,2S)-2-[[6-[[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]hydrazono]-1-oxo-6-phenylhexyl]oxy]-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



IT 474645-11-9 474645-18-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(pentapeptide compd. prepn. and use)

RN 474645-11-9 CAPLUS


CN L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-  
[[[(1R,2S)-2-[[6-[[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-  
oxohexyl]hydrazono]-1-oxo-6-phenylhexyl]oxy]-1-methyl-2-phenylethyl]amino]-  
1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-  
methylpropyl]-4-oxobutyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 474645-18-6 CAPLUS


CN L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[[(1R,2S)-2-[(1,6-dioxo-6-phenylhexyl)oxy]-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




IT 474645-11-9DP, mercaptoethanol adducts

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(pentapeptide compd. prepn. and use)


RN 474645-11-9 CAPLUS

CN L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-  
[[[(1R,2S)-2-[[6-[[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-  
oxohexyl]hydrazono]-1-oxo-6-phenylhexyl]oxy]-1-methyl-2-phenylethyl]amino]-  
1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-  
methylpropyl]-4-oxobutyl]-N-methyl- (9CI) (CA INDEX NAME)Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



AB Pentapeptide compds. are disclosed. The compds. have biol. activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed. Prepn. of compds. of the invention is described.

L4 ANSWER 2 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2002:805207 CAPLUS

DN 138:153819

TI Novel peptide-heterocycle hybrids: Synthesis and preliminary studies on calpain inhibition

AU Mann, Enrique; Chana, Antonio; Sanchez-Sancho, Francisco; Puerta, Carmen; Garcia-Merino, Antonio; Herradon, Bernardo

CS Instituto de Quimica Organica General, C.S.I.C., Juan de la Cierva 3, Madrid, 28006, Spain

SO Advanced Synthesis & Catalysis (2002), 344(8), 855-867

CODEN: ASCAF7; ISSN: 1615-4150

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

IT 496803-30-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(prepn. of oligopeptide-heterocycle conjugates as calpain inhibition agents)

RN 496803-30-6 CAPLUS

CN L-Phenylalanine, (2R)-2-phenyl-N-[(2Z)-[(11aS)-1,3,4,11a-tetrahydro-6-oxo-2H-benzo[b]quinolizin-11(6H)-ylidene]acetyl]glycyl-L-phenylalanyl-(2R)-2-phenylglycyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.



IT 496802-68-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of oligopeptide-heterocycle conjugates as calpain inhibition agents)

RN 496802-68-7 CAPLUS


CN L-Phenylalanine, (2R)-2-phenylglycyl-L-phenylalanyl-(2R)-2-phenylglycyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 496802-67-6

CMF C35 H36 N4 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



AB New peptidic compds., having peptide chains linked to bi- and tricyclic heterocycles (peptide-heterocycle hybrids), have been synthesized. The

heterocyclic components are derivs. of partially reduced isoquinoline and pyrido[1,2-b]isoquinoline bearing .alpha.,.beta.-unsatd. carbonyl functionalities. The heterocyclic compds. have been used as acylating agents in coupling reactions with short N-protected peptides. Based on our interest on potential calpain inhibitors, we have used short (2-4 amino acids) peptides with hydrophobic amino acids of the two enantiomeric series. We report preliminary studies on the inhibition of calpain, with some compds. having IC50 values in the nanomolar range.

RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2002:671743 CAPLUS

DN 137:201608

TI Synthesis of antibacterial siderophore-amino acid/peptide-antibiotic conjugates for therapeutic use

IN Wittmann, Steffen; Heinisch, Lothar; Mollmann, Ute

PA Grunenthal GmbH, Germany

SO Ger. Offen., 10 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10111163	A1	20020905	DE 2001-10111163	20010301
	WO 2002070017	A1	20020912	WO 2002-EP2074	20020227
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				DE 2001-10111163A	20010301

OS MARPAT 137:201608

IT **439152-40-6P 454472-75-4P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of for use as antibacterial agents)

RN 439152-40-6 CAPLUS

CN Glycinamide, N2,N5-bis[2,3-bis(acetyloxy)benzoyl]-L-ornithyl-L-phenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 454472-75-4 CAPLUS

CN Glycinamide, N2,N5-bis[2,3-bis(acetyloxy)benzoyl]-L-ornithyl-L-phenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, monosodium salt, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

GI





AB The invention concerns siderophore-amino acid/peptide-antibiotic conjugates (e.g., I) capable of utilizing the bacterial iron transport mechanism for use as antibacterial agents. Thus, I was prepd. by condensation of N-[N2,N5-bis(2,3-diacetoxybenzoyl)-L-ornithinyl]-L-O-benzyl-serine and ampicillin, with further reaction to prep. the sodium salt. In antibacterial tests against a panel of organisms, title compds. had activities comparable or better than azlocillin, ampicillin, or meropenem.

L4 ANSWER 4 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2002:588657 CAPLUS

DN 138:165595

TI Biomimetic synthesis and optimization of cyclic peptide antibiotics

AU Kohli, Rahul M.; Walsh, Christopher T.; Burkart, Michael D.

CS Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA

SO Nature (London, United Kingdom) (2002), 418(6898), 658-661  
CODEN: NATUAS; ISSN: 0028-0836

PB Nature Publishing Group

DT Journal

LA English

IT 484014-59-7D, immobilized, on polyethylene glycol amide resin

484014-60-0D, immobilized, on polyethylene glycol amide resin

RL: CRG (Combinatorial reagent); RGT (Reagent); CMBI (Combinatorial study); RACT (Reactant or reagent)


(biomimetic synthesis and optimization of cyclic peptide antibiotics)

RN 484014-59-7 CAPLUS


CN L-Leucine, D-phenylalanyl-L-prolyl-L-phenylalanyl-(2S)-2-phenylglycyl-L-asparaginyl-L-glutaminyl-L-tyrosyl-L-valyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 484014-60-0 CAPLUS


CN L-Leucine, D-phenylalanyl-L-prolyl-L-phenylalanyl-(2R)-2-phenylglycyl-L-asparaginyl-L-glutaminyl-L-tyrosyl-L-valyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB Mols. in nature are often brought to a bioactive conformation by ring formation (macrocyclization). A recurrent theme in the enzymic synthesis of macrocyclic compds. by non-ribosomal and polyketide synthetases is the tethering of activated linear intermediates through thioester linkages to carrier proteins, in a natural analogy to solid-phase synthesis. A terminal thioesterase domain of the synthetase catalyzes release from the tether and cyclization. Here we show that an isolated thioesterase can catalyze the cyclization of linear peptides immobilized on a solid-phase support modified with a biomimetic linker, offering the possibility of merging natural-product biosynthesis with combinatorial solid-phase chem. Starting from the cyclic decapeptide antibiotic tyrocidine A, this chemoenzymic approach allows us to diversify the linear peptide both to probe the enzymol. of the macrocyclizing enzyme, TycC thioesterase, and to create a library of cyclic peptide antibiotic products. We have used this method to reveal natural-product analogs of potential therapeutic utility; these compds. have an increased preference for bacterial over eukaryotic

membranes and an improved spectrum of activity against some common bacterial pathogens.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:540135 CAPLUS  
DN 137:108295  
TI Vaccines comprising all-D fibril peptides for prevention and treatment of Alzheimer's and amyloid-related diseases  
IN Chalifour, Robert; Hebert, Lise; Kong, Xianqi; Gervais, Francine  
PA Can.  
SO U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 724,842.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002094335	A1	20020718	US 2001-867847	20010529
			US 1999-168594PP	19991129
			US 2000-724842 A2	20001128
WO 2002096937	A2	20021205	WO 2002-CA763	20020529
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-867847 A	20010529

# PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:416788				
PI WO 2001039796	A2	20010607	WO 2000-CA1413	20001129
WO 2001039796	A3	20011206		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-168594PP	19991129
			US 2000-724842 A	20001128
BR 2000016022	A	20020806	BR 2000-16022	20001129
			US 1999-168594PP	19991129
			US 2000-724842 A	20001128
			WO 2000-CA1413 W	20001129
EP 1235587	A2	20020904	EP 2000-981111	20001129
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

			US 1999-168594PP 19991129
			US 2000-724842 A 20001128
			WO 2000-CA1413 W 20001129
NO 2002002531	A	20020712	NO 2002-2531 20020528
			US 1999-168594PP 19991129
			US 2000-724842 A 20001128
			WO 2000-CA1413 W 20001129


IT 342878-09-5

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vaccines comprising all-D fibril peptides for prevention and treatment of Alzheimer's and amyloid-related diseases)

RN 342878-09-5 CAPLUS

CN D-Alaninamide, D-lysyl-D-leucyl-D-valyl-D-phenylalanyl-(2R)-2-phenylglycyl-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The present invention relates to a stereochem. based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks assocd. with using naturally occurring peptides, proteins or immunogens. The vaccine comprises fibril peptides consisting of all- D-amino acids.

L4 ANSWER 6 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2002:311304 CAPLUS

DN 137:149471

TI New CSPs based on peptidomimetics: efficient chiral selectors in enantioselective separations

AU Burguete, M. Isabel; Frechet, Jean M. J.; Garcia-Verdugo, Eduardo; Janco, Miroslav; Luis, Santiago V.; Svec, Frantisek; Vicent, Maria J.; Xu, Mingcheng

CS Department of Inorganic and Organic Chemistry, E.S.T.C.E. Universitat Jaume I, Castellon, E-12080, Spain

SO Polymer Bulletin (Berlin, Germany) (2002), 48(1), 9-15

CODEN: POBUDR; ISSN: 0170-0839

PB Springer-Verlag

DT Journal

LA English

IT 253426-92-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(in prepn. of chiral stationary phases based on peptidomimetics for

enantioselective sepn.)

RN 253426-92-5 CAPLUS

CN Benzenepropanamide, N,N'-[(1S,2S)-1,2-diphenyl-1,2-ethanediyl]bis[.alpha.-amino-, (.alpha.S,.alpha.'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 444647-79-4P


RL: ARU (Analytical role, unclassified); RCT (Reactant); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); RACT (Reactant or reagent)

(peptidomimetics; prepn. of chiral stationary phases based on peptidomimetics for enantioselective sepn.)

RN 444647-79-4 CAPLUS

CN Benzenepropanamide, N,N'-[(1S,2S)-1,2-diphenyl-1,2-ethanediyl]bis[.alpha.-[(2-methyl-1-oxo-2-propenyl)amino]-, (.alpha.S,.alpha.'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB Two different families of peptidomimetics were synthesized and used as chiral selectors for enantioselective chromatog. The functionalization of compds. with multiple nitrogen atoms allows their use in the prepn. of chiral stationary phases (CSPs), with acrylic or styryl comonomers, in both bead and monolithic formats. Some of these sepn. media, having the appropriate morphol. properties for their use in chromatog. columns, were able to efficiently discriminate enantiomers of amino acid derivs. and pharmaceuticals such as oxazepam.

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2002:251248 CAPLUS  
 DN 137:60114  
 TI New synthetic siderophores and their .beta.-lactam conjugates based on diamino acids and dipeptides  
 AU Wittmann, S.; Schnabelrauch, M.; Scherlitz-Hofmann, I.; Mollmann, U.; Ankel-Fuchs, D.; Heinisch, L.  
 CS Hans Knoll Institute for Natural Product Research, Jena, Jena, D-07745, Germany  
 SO Bioorganic & Medicinal Chemistry (2002), 10(6), 1659-1670  
 CODEN: BMECEP; ISSN: 0968-0896  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 137:60114  
 IT 439152-40-6P  
 RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (new synthetic siderophores and their .beta.-lactam conjugates based on diamino acids and dipeptides)  
 RN 439152-40-6 CAPLUS  
 CM Glycinamide, N2,N5-bis[2,3-bis(acetyloxy)benzoyl]-L-ornithyl-L-phenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Linking of siderophores to antibiotics improves the penetration and therefore increases the antibacterial activity of the antibiotics. We synthesized the acylated catecholates and hydroxamates as siderophore components for antibiotic conjugates to reduce side effects of unprotected catecholate and hydroxamate moieties. In this paper, we report on bis- and tris-catecholates and mixed catecholate hydroxamates based on diamino acids or dipeptides. These compds. were active as siderophores in a growth promotion assay under Fe limitation. Most of the conjugates with .beta.-lactams showed high in vitro activity against Gram-neg. bacteria, esp. *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella pneumoniae*, *Serratia marcescens*, and *Stenotrophomonas maltophilia*. The compds. with enhanced antibacterial activity use active Fe uptake routes to penetrate the bacterial outer membrane barrier, demonstrated by assays with mutants

deficient in components of the Fe transport system. Correlation between chem. structure and biol. activity was studied.

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2002:157723 CAPLUS

DN 136:216523

TI Preparation of phenylethanol(mono/di)amines and phenylalkylethanol(mono/di)amines as sodium channel blockers

IN Fuchs, Klaus; Stransky, Werner; Grauert, Matthias; Carter, Adrian; Gaida, Wolfram; Weiser, Thomas; Ensinger, Helmut

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002016308	A1	20020228	WO 2001-EP9036	20010804
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10040901	A1	20020314	DE 2000-10040901A	20000818
	US 2002042410	A1	20020411	US 2001-912163	20010724
				DE 2000-10040901A	20000818
				US 2000-228675PP	20000829
AU	2001091737	A5	20020304	AU 2001-91737	20010804
				DE 2000-10040901A	20000818
				WO 2001-EP9036 W	20010804
EP	1311471	A1	20030521	EP 2001-971870	20010804
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				DE 2000-10040901A	20000818
				WO 2001-EP9036 W	20010804

CS MARPAT 136:216523

IT 401938-19-0P 401938-31-6P 401938-36-1P  
401938-38-3P 401938-45-2P 401938-49-6P  
401938-53-2P 401938-55-4P 401938-57-6P  
401938-61-2P 401938-63-4P 401938-69-0P  
401938-73-6P 401938-75-8P 401938-77-0P  
401939-43-3P 401939-56-8P 401939-58-0P  
401939-80-8P 401939-82-0P 401939-84-2P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylethanolamines and phenylalkylethanolamines as sodium channel blockers)

RN 401938-19-0 CAPLUS




CN Benzeethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-N-(2-ethylbutyl)-  
2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-31-6 CAPLUS

CN Benzeethanamine, N-(cyclopropylmethyl)-.beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-36-1 CAPLUS

CN Benzeethanamine, N-(3-cyclohexen-1-ylmethyl)-.beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-38-3 CAPLUS

CN Benzeneethanamine, N-butyl-.beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)





RN 401938-45-2 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401938-49-6 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-N-(2,2-dimethylpropyl)-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-53-2 CAPLUS

CN Benzeneethanamine, N-(cyclohexylmethyl)-.beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-55-4 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 401938-57-6 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 401938-61-2 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-[[4-(1-methylethenyl)-1-cyclohexen-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 401938-63-4 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)





RN 401938-69-0 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-N-(3,3-dimethylbutyl)-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-73-6 CAPLUS

CN Benzenethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 401938-75-8 CAPLUS

CN Benzeneethanamine, N-cyclohexyl-.beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401938-77-0 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 401939-43-3 CAPLUS

CN 1,2-Ethanediamine, N2-cyclohexyl-N1-[3-(2,6-difluorophenyl)propyl]-1-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)





RN 401939-56-8 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 401939-58-0 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)





RN 401939-80-8 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-N-ethyl-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 401939-82-0 CAPLUS

CN Benzenepropanamine, N-[2-[3-(2,6-difluorophenyl)propoxy]-2-(2,6-dimethylphenyl)ethyl]- (9CI) (CA INDEX NAME)





RN 401939-84-2 CAPLUS

CN Benzeneethanamine, .beta.-[3-(2,6-difluorophenyl)propoxy]-2,6-dimethyl-N-4-pentenyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1 = OH, CF3, NO2, CN, halo, C1-8 alkyl, halo, C1-8 alkoxy; R2, R3, R4 independently = halo, C1-8 alkyl, OH, NO2, CN, C1-8 alkoxy, CF3; R5, R6 independently = C1-8 alkyl, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, NH2, OH, O, COOH, CONH2; A = C1-5 alkylene, C2-4 alkenylene, C3-4 alkylene; X = NH, N(CHO), halo, O, etc.] are prepd. The invention further relates to a method for producing said compds. and to their compn. in use as medicaments. Title compds. I are used as blockers of the voltage-dependent sodium channel and can be used for diseases that are assocd. with a functional disorder caused by hyperexcitability. Thus, the title compd. II was prepd. from trifluoroacetic anhydride, 2,6-dimethylbenzaldehyde, which was prepd. from 2-bromo-3-dimethylbenzene, and 2-(3-bromopropyl)-1,3-difluorobenzene, which was prepd. from di-Et malonate and 2,6-difluorobenzyl bromide.


RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:116966 CAPLUS  
DN 137:125377  
TI Solution and solid-Phase synthesis of potent inhibitors of hepatitis C Virus NS3 proteinase  
AU Beevers, Rebekah; Carr, Maria G.; Jones, Philip S.; Jordan, Steven; Kay, Paul B.; Lazell, Robert C.; Raynham, Tony M.  
CS Department of Chemistry, Roche Discovery Welwyn, Hertfordshire, Welwyn Garden City, AL7 3AY, UK  
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 641-643  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal



LA English  
 OS CASREACT 137:125377  
 IT 254439-10-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and biol. activity of peptide .alpha.-ketoamides as potent inhibitors of hepatitis C virus NS3 proteinase)  
 RN 254439-10-6 CAPLUS  
 CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-L-.alpha.-aspartyl-L-.alpha.-glutamyl-2-methyl-L-phenylalanyl-(2S)-2-phenylglycyl-N-[(1S)-1-(aminooxoacetyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A versatile route for the synthesis of homochiral .alpha.-ketoamide analogs of amino acids is described. Incorporation of this functionality into peptide sequences using either soln. or solid-phase chem. resulted in potent inhibitors of the hepatitis C virus (HCV) NS3 proteinase.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:31402 CAPLUS  
 DN 136:102190  
 TI Preparation of substituted amines to treat Alzheimer's disease  
 IN Maillaird, Michel; Hom, Court; Gailunas, Andrea; Jagodzinska, Barbara; Fang, Lawrence Y.; John, Varghese; Freskos, John N.; Pulley, Shon R.; Beck, James P.; Tenbrink, Ruth E.  
 PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company  
 SO PCT Int. Appl., 651 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002512	A2	20020110	WO 2001-US21012	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,				

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
 TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
 MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 2000-215323PP 20000630  
 US 2000-252736PP 20001122  
 US 2000-255956PP 20001215  
 US 2001-268497PP 20010213  
 US 2001-279779PP 20010329  
 US 2001-295589PP 20010604  
 US 2001-896139 20010629  
 US 2000-215323PP 20000630  
 US 2000-252736PP 20001122  
 US 2000-255956PP 20001215  
 US 2001-268497PP 20010213  
 US 2001-279779PP 20010329  
 US 2001-295589PP 20010604  
 NO 2002-6199 20021223  
 US 2000-215323PP 20000630  
 US 2000-252736PP 20001122  
 US 2000-255956PP 20001215  
 US 2001-268497PP 20010213  
 US 2001-279779PP 20010329  
 US 2001-295589PP 20010604  
 WO 2001-US21012W 20010629

## PATENT FAMILY INFORMATION:

FAN 2002:31396

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002505	A2	20020110	WO 2001-US20852	20010629
	WO 2002002505	A3	20020801		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2000-215323PP		20000630		
US 2002016320	A1	20020207	US 2001-896874	20010629	
			US 2000-215323PP	20000630	
EP 1299349	A2	20030409	EP 2001-950719	20010629	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2000-215323PP		20000630		
	WO 2001-US20852W		20010629		
US 2003096864	A1	20030522	US 2001-895871	20010629	
			US 2000-215323PP	20000630	

FAN 2002:31397

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2002002506	A2	20020110	WO 2001-US20930	20010629
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002016320	A1	20020207	US 2000-215323PP	20000630
				US 2001-896874	20010629
				US 2000-215323PP	20000630
EP	1299352	A2	20030409	EP 2001-952352	20010629
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2000-215323PP	20000630
				WO 2001-US20930W	20010629
US	2003096864	A1	20030522	US 2001-895871	20010629
				US 2000-215323PP	20000630
FAN	2002:31408				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002518	A2	20020110	WO 2001-US20856	20010629
	WO 2002002518	A3	20020808		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000-215323PP	20000630
AU	2001073094	A5	20020114	AU 2001-73094	20010629
				US 2000-215323PP	20000630
				WO 2001-US20856W	20010629
US	2002016320	A1	20020207	US 2001-896874	20010629
				US 2000-215323PP	20000630
US	2003096864	A1	20030522	US 2001-895871	20010629
				US 2000-215323PP	20000630
FAN	2002:31410				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002520	A2	20020110	WO 2001-US21000	20010702
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

US 2002143177 A1 20021003  
 AU 2001073132 A5 20020114

US 2000-215323PP 20000630  
 US 2001-895843 A 20010629  
 US 2001-895843 20010629  
 US 2000-215323PP 20000630  
 AU 2001-73132 20010702  
 US 2000-215323PP 20000630  
 US 2001-895843 A 20010629  
 WO 2001-US21000W 20010702

OS MARPAT 136:102190

IT 388063-36-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted amines for treating Alzheimer's disease)

RN 388063-36-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[(1S)-2-[(2-methylpropyl)amino]-2-oxo-1-phenylethyl]amino]propyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 388073-92-5 388075-22-7


RL: RCT (Reactant); RACT (Reactant or reagent)


(prepn. of substituted amines for treating Alzheimer's disease)

RN 388073-92-5 CAPLUS

CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[(1S)-2-[(2-methylpropyl)amino]-2-oxo-1-phenylethyl]amino]-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 388075-22-7 CAPLUS

CN Benzeneacetamide, .alpha.-[[ (2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino]-N-(2-methylpropyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; R4 = XR; X = CO, SO2, a bond, etc.; R = Ph,

naphthyl, indanyl, etc.; R5 = (un)substituted alkyl, (CH<sub>2</sub>)<sub>0-3</sub>cycloalkyl, etc.], useful in treating Alzheimer's disease and other similar diseases, were prepd. Thus, reacting (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate with 5-methyl-N,N-dipropylisophthalamide in the presence of Et<sub>3</sub>N, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in DMF afforded (1S,2R)-II. The compds. I exhibit an IC<sub>50</sub> of < 50 .mu.M against beta-secretase.

L4 ANSWER 11 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2001:851126 CAPLUS

DN 135:371760

TI Preparation of pyrazolylpyrimidines and analogs as TNF-.alpha. signaling modulators

IN Sneddon, Scott F.; Kane, John L.; Hirth, Bradford H.; Vinick, Fred; Qiao, Shuang; Nahill, Sharon R.

PA Genzyme Corporation, USA

SO PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087849	A2	20011122	WO 2001-US15027	20010510
	WO 2001087849	A3	20020606		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-203784PP	20000512
				US 2000-205213PP	20000518
	US 2002119988	A1	20020829	US 2001-852965	20010510
				US 2000-203784PP	20000512
				US 2000-205213PP	20000518
	EP 1294699	A2	20030326	EP 2001-933253	20010510
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-203784PP	20000512
				US 2000-205213PP	20000518
				WO 2001-US15027W	20010510
	NO 2002005405	A	20030109	NO 2002-5405	20021111
				US 2000-203784PP	20000512
				US 2000-205213PP	20000518
				WO 2001-US15027W	20010510

OS HARPAT 135:371760


IT 374080-34-9P 374080-37-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrazolylpyrimidines and analogs as TNF-.alpha. signaling modulators)


PN 374080-34-9 CAPLUS

CN Benzenepropanamide, N-[2-(aminocarbonyl)phenyl]-N-[1-[3-(4-methoxyphenoxy)phenyl]-2-oxo-2-[[ (3,4,5-trimethoxyphenyl)methyl]amino]ethyl]-.beta.-phenyl- (9CI) (CA INDEX NAME)




RN 374080-37-2 CAPLUS

CN Benzenepentanamide, N-[1-(3-cyanophenyl)-2-[(2,2-diphenylethyl)amino]-2-oxoethyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1 = H or NH2; R2 = ZZ3(CH2)nR; R = (un)substituted Ph

or -heterocyclyl; R4 = (alkyl-substituted) 2-pyridinyl or -pyrazinyl; Z = (un)substituted pyrazole-1,4-diyl; Z1,Z2 = N or CH; Z3 = O, CH2, S, SO2; n = 0-2] were prepd. Thus, 4-(Me2HC)C6H4OH was condensed with (MeCO)2CHN2 and the product cyclocondensed with 4-(2-pyridinyl)-2-pyrimidinylhydrazine to give title compd. II. Data for biol. activity of I were given.

L4 ANSWER 12 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2001:818819 CAPLUS

DN 136:118732

TI A Rapid Access to Biaryl Ether Containing Macrocycles by Pairwise Use of Ugi 4CR and Intramolecular SNAr-Based Cycloetherification

AU Cristau, Pierre; Vors, Jean-Pierre; Zhu, Jieping

CS Institut de Chimie des Substances Naturelles, CNRS, Gif-sur-Yvette, 91198, Fr.

SO Organic Letters (2001), 3(25), 4079-4082

CODEN: ORLEF7; ISSN: 1523-7060

PB American Chemical Society

DT Journal

LA English

OS CASREACT 136:118732

IT 389634-87-1P 389634-98-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of biaryl ether-contg. macrocycles by Ugi four component reaction and intramol. SNAr-based cycloetherification)

RN 389634-87-1 CAPLUS

CN D-Phenylalanine, (2R)-N-[3-(3-hydroxyphenyl)-1-oxopropyl]-2-phenyl-N-(phenylmethyl)glycyl-4-fluoro-3-nitro-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 389634-98-4 CAPLUS



CN D-Phenylalanine, (2S)-N-[3-(3-hydroxyphenyl)-1-oxopropyl]-2-phenyl-N-(phenylmethyl)glycyl-4-fluoro-3-nitro-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





GI



AB An Ugi reaction promoted by ammonium chloride in aprotic solvent is documented here for the first time. From readily accessible starting materials, macrocycles with an endo aryl-aryl ether bond are synthesized in only two steps, Ugi four-component reaction (Ugi 4CR) and an intramol. SNAr reaction. The nitro group serves as an activator for the macrocyclization and provides a handle for the introduction of functional group diversity. For example, dipeptide amide I was obtained in an Ugi 4CR from isonitrile II, PhCHO, PhCH<sub>2</sub>NH<sub>2</sub> and 3-hydroxyphenylacetic acid in the presence of NH<sub>4</sub>Cl- in toluene at 0.degree. for 20 h. Cycloetherification of I took place in the presence of K<sub>2</sub>CO<sub>3</sub> in DMF for 3 h to give macrocycle III in 80% yield.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:631914 CAPLUS  
DI 135:195426

TI Preparation of malonic acid amide derivatives as inhibitors of blood clotting factor Xa

IN Al-Obeidi, Fahad; Walser, Armin; Wildgoose, Peter

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO Eur. Pat. Appl., 69 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1127884	A1	20010829	EP 2000-104041	20000226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2001008694	A	20021210	BR 2001-8694	20010121
				EP 2000-104041 A	20000226
				WO 2001-EP1928 W	20010221
	WO 2001062735	A1	20010830	WO 2001-EP1928	20010221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				EP 2000-104041 A	20000226
	EP 1265867	A1	20021218	EP 2001-907546	20010221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				EP 2000-104041 A	20000226
				WO 2001-EP1928 W	20010221
	US 2002022596	A1	20020221	US 2001-790641	20010223
				EP 2000-104041 A	20000226
	NO 2002004040	A	20020924	NO 2002-4040	20020823
				EP 2000-104041 A	20000226
				WO 2001-EP1928 W	20010221
OS	MARPAT 135:195426				
IT	356544-17-7P 356544-20-2P 356544-22-4P 356544-24-6P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug; prepn. of malonic acid amide derivs. as inhibitors of blood clotting factor Xa)				
RN	356544-17-7 CAPLUS				
CN	L-Argininamide, 2-[[4-(aminoiminomethyl)phenyl]methyl]-N-methyl-3-oxo-.beta.-alanyl-(2S)-2-phenylglycyl-, trifluoroacetate (9CI) (CA INDEX NAME)				
CM	1				
CRN	356544-16-6				
CMF	C26 H35 N9 O4				


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 356544-20-2 CAPLUS


CI L-Argininamide, 2-[[4-(aminoiminomethyl)phenyl]methyl]-N,N-dimethyl-3-oxo-  
 .beta.-alanyl-(2S)-2-phenylglycyl-, trifluoroacetate (9CI) (CA INDEX  
 NAME)

CM 1

CRN 356544-19-9

CMF C27 H37 N9 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 356544-22-4 CAPLUS


CN L-Argininamide, 2-[[4-(aminoiminomethyl)phenyl]methyl]-3-oxo-N-2-propenyl-.beta.-alanyl-(2S)-2-phenylglycyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 356544-21-3

CMF C28 H37 N9 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 356544-24-6 CAPLUS


CN L-Argininamide, 2-[[4-(aminoiminomethyl)phenyl]methyl]-3-oxo-N-phenyl-.beta.-alanyl-(2S)-2-phenylglycyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 356544-23-5

CMF C31 H37 N9 O4


Absolute stereochemistry.




CM 2

CRN 76-05-1


CMF C2 H F3 O2




GI



I



II



III


AB Title compds. I [ $\text{R}_1$  = H, alk(en)yl, aryl(alkyl);  $\text{R}_2$  = H, alkyl;  $\text{R}_3$  = aryl;

R4 = H, alkyl, etc.; R5 = (cyclo)alkyl, cycloalkyl-alkyl, aryl(alkyl), etc.; R6 = NH<sub>2</sub>, OH or substituted derivs.) are prepd. Examples included 3 synthetic procedures (including a general solid phase method), over 100 compds. prepd. and 8 bioassays (data provided for 1 of the bioassays). For instance, benzyl Me amine was treated with bis(trimethylsilyl)acetamide (DCM, reflux, 3 h) followed by addn. of 4-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)methyl]benzonitrile (DCM, reflux, 3 h) to give II. II was coupled to (.alpha.S)-amino-cyclohexane-acetic acid Me ester (iPr<sub>2</sub>EtN, HODhbt, DCC, DMF, 10.degree.C) and the resulting amide-nitrile reacted with excess hydroxylamine (EtOH, reflux, 4 h) to give the corresponding N-hydroxy carbamimidoyl deriv. This intermediate was deoxygenated (Pd-H<sub>2</sub>/C), hydrolyzed (HCl aq, CH<sub>3</sub>CN, 4 days @ room temp.) and coupled with (S)-2-amino-5-guanidinopentanoic acid allyl ester (DMF, collidine, HATU) to give III. Isomers of III were sepd. by chromatog. (MPLC, RP18) and isolated as the trifluoroacetic acid salts. An isomer of III had K<sub>i</sub> = 0.0010 .mu.M for factor Xa. The invention also provides methods for the treatment/prevention of (e.g.) thromboembolic diseases.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:557633 CAPLUS  
DN 135:344705  
TI A new silyl linker for reverse-direction solid-phase peptide synthesis  
AU Lipshutz, B. H.; Shin, Y.-J.  
CS Department of Chemistry & Biochemistry, University of California, Santa Barbara, CA, 93106, USA  
SO Tetrahedron Letters (2001), 42(33), 5629-5633  
CODEN: TELEAY; ISSN: 0040-4039  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
IT 370866-93-6P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(reverse-direction solid-phase peptide synthesis using  
(chloro)diisopropylsilyl-linked polystyrene)  
RN 370866-93-6 CAPLUS  
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-(2R)-2-phenylglycyl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB Treatment of a free amino acid ester with carbon dioxide followed by exposure to a chlorosilane-contg. polystyrene results in its attachment to the solid support. For example, H-Pro-OAll (All = allyl) was coupled with CO<sub>2</sub> in Et<sub>3</sub>N, followed by the addn. of ClSi(Pr-i)<sub>2</sub>-polystyrene, to give 95% of polystyrene-Si(Pr-i)<sub>2</sub>O<sub>2</sub>C-Pro-OAll (I). The newly formed silyl carbamate can be employed to build polypeptides at the carboxyl terminus. Cleavage of the (poly)peptide using aq. HF in MeCN leads to its free amine form which is isolated as a Boc deriv. Thus, I was utilized in peptide synthesis and Boc-protected in the last step to give Boc-Pro-D-Phg-Phe-OAll (D-Phg = D-phenylglycyl) in 52% overall yield. The polymer support can be easily recycled.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 15 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:4:0630 CAPLUS  
DN 136:2:0452  
TI Synthesis of a number of combined analogs of substance P and litorin  
AU Galyuk, E. N.; Egorova, S. V.; Gurina, E. P.; Golubovich, V. P.; Akhrem, A. A.  
CS Inst. Bioorganic Chem., Belorussian Acad. Sci., Minsk, Russia  
SO Khimiya Prirodnikh Soedinenii (1992), (1), 112-117  
CODEN:KPSUAR; ISSN: 0023-1150  
PB Izdatel'stvo Fan  
DT Journal  
LA Russian  
IT 400748-27-8P 400748-33-6P 400748-68-7P  
400749-12-4P 400749-61-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of substance P and litorin analogs by peptide coupling)  
RN 400748-27-8 CAPLUS  
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-(2S)-2-phenylglycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 400748-33-6 CAPLUS  
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-(2S)-2-phenylglycyl-(2S)-2-phenylglycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 400748-68-7 CAPLUS

CN Glycine, N2-[(1,1-dimethylethoxy)carbonyl]-L-glutaminy-L-phenylalanyl-(2S)-2-phenylglycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 400749-12-4 CAPLUS

CN Glycine, N2-[(1,1-dimethylethoxy)carbonyl]-L-glutaminy-L-phenylalanyl-(2S)-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 400749-61-3 CAPLUS

CN L-Methioninamide, N2-[(1,1-dimethylethoxy)carbonyl]-L-glutaminy-L-phenylalanyl-(2S)-2-phenylglycylglycyl-L-histidyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





IT 400747-92-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

```


      (prepn. of substance P and litorin analogs by peptide coupling)

```

RN 400747-92-4 CAPLUS

CH L-Methioninamide, L-glutaminyL-L-phenylalanyl- (2S)-2-phenylglycylglycyl-L-histidyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB With the aim of obtaining new biol. active compds., we have synthesized nine combined peptides (I)-(IX) consisting of combinations of the C-terminal tripeptide litorin and the hydrophobic central fragments of substance P, and also modified analogs of them. The synthesis of these compds. was achieved by the methods of classical peptide chem. with the condensation of their N-terminal moieties with the C-terminal tripeptide H-His-Phe-Met-NH<sub>2</sub>.

L4 ANSWER 16 OF 148 CAPLUS COPYRIGHT 2000 ACS

AN 2001:416788 CAPLUS

DN 135:18553

TI Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases

IN Chalifour, Robert; Hebert, Lise; Kong, Xiangdi; Gervais, Francine

PA Neurchem Inc., Can.

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001039796	A2	20010607	WO 2000-CA1413	20001129
	WO 2001039796	A3	20011206		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RL:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 1999-168594PP	19991129
				US 2000-724842 A	20001128
BR	2000016022	A	20020806	BR 2000-16022	20001129
				US 1999-168594PP	19991129
				US 2000-724842 A	20001128
				WO 2000-CA1413 W	20001129
EP	1235587	A2	20020904	EP 2000-981111	20001129
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 1999-168594PP	19991129
				US 2000-724842 A	20001128
				WO 2000-CA1413 W	20001129
NO	2002002531	A	20020712	NO 2002-2531	20020528
				US 1999-168594PP	19991129
				US 2000-724842 A	20001128
				WO 2000-CA1413 W	20001129

## PATENT FAMILY INFORMATION:

FAN 2002:510135

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2000094335	A1	20020718	US 2001-867847	20010529
				US 1999-168594PP	19991129
				US 2000-724842 A2	20001128
WO	2001096937	A2	20021205	WO 2002-CA763	20020529
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RL:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2001-867847 A	20010529

IT 342878-09-5P


RL: BA (Biological activity or effecton, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(vaccine for prevention and treatment of Alzheimer's and amyloid related diseases using all-D peptides that elicit immune response to amyloid protein)

RN 342878-09-5 CAPLUS

CN D-Alaninamide, D-lysyl-D-leucyl-D-valyl-D-phenylalanyl-(2R)-2-phenylglycyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The present invention relates to a stereochem. based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawback assocd. with using naturally occurring peptides, proteins or immunogens.

L4 ANSWER 17 OF 148 CAPLUS COPYRIGHT 20 3 ACS

AN 2001:4 2340 CAPLUS

DN 135:231899

TI Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2

AU Dhanak, D.; Christmann, L. T.; Darcy, M. G.; Keenan, R. M.; Knight, S. D.; Lee, J.; Ridgers, L. H.; Sarau, H. M.; Shah, D. H.; White, J. R.; Zhang, L.

CS SmithKline Beecham Pharmaceuticals, Collegeville, PA, 19426-0989, USA

SO Bioorganic & Medicinal Chemistry Letters (2001), 11(11), 1445-1450

CODEN: BMCLE8; ISSN: 0960-894X

PR Elsevier Science Ltd.

DT Journal

LA English

IT 269064-22-4P


RL: RA (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SYN (Synthetic preparation); THU (Therapeutic use); BCOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(discovery of potent and selective phenylalanine derived CCR3 receptor antagonists)

RN 269064-22-4 CAPLUS

CN Glycinamide, N-(1-naphthalenylcarbonyl)-4-nitro-L-phenylalanyl-N,2-diphenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Highly potent CCR3 antagonists have been developed from a previously reported series of phenylalanine ester-based leads. Soln.-phase, parallel synthesis optimization was utilized to identify highly potent, functional CCR3 antagonists.

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2001:16611 CAPLUS

DN 134:266552

TI First and Second Generation Total Synthesis of the Teicoplanin Aglycon

AU Boger, Dale L.; Kim, Seong Heon; Mori, Yoshiki; Meng, Jian-Hui; Rogel, Olivier; Castle, Steven L.; McAtee, J. Jeffrey

CS Department of Chemistry, The Scripps Research Institute, The Skaggs Institute for Chemical Biology, La Jolla, CA, 92037, USA

SO Journal of the American Chemical Society (2001), 123(9), 1862-1871

CODEN: JACSAT; ISSN: 0002-7863

PE American Chemical Society

DT Journal

LA English

OS CASREACT 134:266552




IT 296781-63-0P 331731-43-2P 331731-45-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(first and second generation total synthesis of the teicoplanin aglycon)

RN 296781-63-0 CAPLUS

CN L-Tyrosine, 4-fluoro-3-nitro-N-[[2-(trimethylsilyl)ethoxy]carbonyl]-D-phenylalanyl-(2S)-2-[3-[5-[(1R)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-(phenylmethoxy)ethyl]-2-methoxyphenoxy]-5-methoxyphenyl]glycyl-(2R)-2-(3,5-dihydroxy-4-methoxyphenyl)glycyl-(2R)-2-[2'-[(1S)-1-amino-2-[(2-methoxyethoxy)methoxy]ethyl]-4',6',6'-trimethoxy-1,1'-biphenyl]-3-yl]glycyl-3-chloro-β-hydroxy-, (5S)-lactam, cyclic (3S)-ether, stereoisomer (9CI) (CA INDEX NAME)



PAGE 2-B


$$-\text{OBu-t}$$
$$\text{---O---Ph}$$

RN 331731 43-2 CAPLUS

CN Glycin mide, 4-fluoro-3-nitro-N-.[2-(trimethylsilyl)ethoxy]carbonyl]-D-phenyl lanlyl-N-[(1R)-1-(3,5-dihydroxy-4-methoxyphenyl)-2-hydroxyethyl]-2-[3-[5-(1R)-1-[[1,1-dimethylethoxy]carbonyl]amino]-2-(phenylmethoxy)ethyl]-2-methoxyphenoxy]-5-methoxyphenyl]-, (2S)- (9CI)  
(CA IN EX NAME)



PAGE 2-A




AB Full details of studies leading to the total synthesis of the teicoplanin aglycon are provided. Key elements of the first generation approach (26 steps from constituent amino acids, 1% overall) include the coupling of an EFG tripeptide precursor to the common vancomycin/teicoplanin ABCD ring system and sequential DE macrocyclization of the 16-membered ring with formation of the diaryl ether via a phenoxide nucleophilic arom. substitution of an o-fluoronitroarom. (80%, 3:1 atropisomer diastereoselection) followed by 14-membered FG ring closure by macrolactamization (66%). Subsequent studies have provided a second generation total synthesis which is shorter, more convergent, and highly diastereoselective (22 steps, 2% overall). This was accomplished by altering the order of ring closures such that FG macrolactamization (95%) preceded coupling of the EFG tripeptide to the ABCD ring system and subsequent DE ring closure. Notably, DE macrocyclization via diaryl ether formation on the key intermediate in the latter approach incorporating the intact FG ring system occurred with exceptional diastereoselection for formation of the natural atropisomer (>10:1, 76%) without problematic C23 epimerization provided the basicity of the reaction is minimized.

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE PDF FORMAT


L4 ANSWER 19 OF 148 CAPLUS COPYRIGHT 2003  
AN 2001:57805 CAPLUS  
DN 134:252075  
TI Synthesis of enantiopure homoallylic ethers by reagent controlled facial selective allylation of chiral ketones  
AU Tietze, Lutz F.; Weigand, Berthold; Volker, Ludwig; Wulff, Christian; Bittner, Christian  
CS Institut für Organische Chemie Georg-August Universität Göttingen, Göttingen, 37077, Germany  
SO Chemistry--A European Journal (2001), 7(1), 161-168  
CODEN: CEUJED; ISSN: 0947-6539  
PB Wiley-VCH Verlag GmbH  
DT Journal  
LA English  
OS CASREACT 134:252075  
IT 330798-68-0P 330798-69-1P  
RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of enantiopure homoallylic ethers by reagent controlled facial selective allylation of chiral ketones)  
RN 330798-68-0 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[(1S,2S)-1-methyl-2-[[[(1R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-1-2-[[[(1S)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl]-1,9CI) (CA INDEX NAME)


Absolute stereochemistry.



RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of enantiopure homoallylic alcohols by reagent controlled  
facial selective allylation of chiral ketones)

CN Acetar de, 2,2,2-trifluoro-N-[(1S,2S)-1-methyl-2-[[ (1S)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 3307 18 63-5 CAPLUS



CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 330798-73-7 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 330798-76-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-1-[(2S)-2-phenylpropyl]-3-butenyl]oxy]-2-phenylethyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The stereoselective allylation of chiral ketones to give tertiary homoallylic ethers, which can easily be transformed into homoallylic alcohols, is described. Reaction of the enantiomeric ketones (I), (R)-Me<sub>2</sub>CH(CH<sub>2</sub>)<sub>3</sub>CH(.beta.Me)CH<sub>2</sub>COMe, (R)-Me<sub>2</sub>CH(.beta.OSiPh<sub>2</sub>CMe<sub>3</sub>)CH<sub>2</sub>COMe, (S)-MeCH(.alpha.Ph)CH<sub>2</sub>COMe and the racemic ketones MeCH(.alpha.OSiPh<sub>2</sub>CMe<sub>3</sub>)CH<sub>2</sub>COMe, MeCH(Ph)CH<sub>2</sub>COMe, MeCH(Ph)COMe, MeCH<sub>2</sub>CH(Me)COMe with the norpseudoephedrine deriv. and allylsilane in the presence of a catalytic amt. of trifluoromethanesulfonic acid, led to a series of homoallylic ethers with good to excellent stereoselectivity (85:15 to > 97:3). The allylation is reagent controlled and nearly independent from the stereogenic centers in the substrates. A partial kinetic resolu. was obsd. using the racemic ketones. In the allylation of the chiral ketones with the achiral reagents ethoxytriethylsilane and allylsilane only a low diastereoselectivity was obsd.


RE.CNT 61 THERE ARE 64 CITED REFERENCES FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE INDEX

L4 ANSWER 10 OF 148 CAPLUS COPYRIGHT  
AN 2000:738035 CAPLUS  
DN 133:282086  
TI Preparation of non-peptidyl dipeptides as HIV protease inhibitors  
IN Nakamura, Yuji; Takagi, Eiji; Ozawa, Yoji; Miyama, Akiko  
PA Sankyo Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 29 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	INVENTION NO.	DATE
PI	JP 2000090242	A2	20001017	47536	19990405
				47536	19990405

OS MARPAT 133:282086  
IT 251339-75-0P 300351-43-3P 300351-51-3P  
300351-53-5P 300351-56-8P 300351-59-1P  
300351-67-1P  
RL: BAC (Biological activity or effect); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BICI (Biological study); PREP (Preparation); USES (Uses)  
'Prepn. of non-peptidyl dipeptides as HIV protease inhibitors for prevention or treatment of AIDS'  
RN 251339-75-0 CAPLUS  
CN D-glycero-Pentitol, 5-[acetyl[(1S,2S)-2-methyl-2-(triethylsilyloxy)amino]-2-oxo-1-phenylethyl]amino]-1,2,4,5-tetrahydro-1H-benzodioxole-3-carboxylate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300351-13-3 CAPLUS

CN D-glycero-pentitol, 5-[acetyl[(1S)-2-oxo-1-phenylethyl]amino]-1,2,4,5-tetraethoxy-2-methoxy-2-methylbenzoyl)amino]-1-phenyl-, (3.xi.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300351-51-3 CAPLUS

CN D-erythro-pentitol, 5-[acetyl[(1S)-2-oxo-1-phenylethyl]amino]-1,2,4,5-tetraethoxy-2-methoxy-2-methylbenzoyl)amino]-1-phenyl-, (3.xi.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300351-53-5 CAPLUS

CN L-threo-pentitol, 5-[acetyl[(1S)-2-oxo-1-phenylethyl]amino]-1,2,4,5-tetraethoxy-2-methoxy-2-methylbenzoyl)amino]-1-phenyl-, (3.xi.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300351-56-8 CAPLUS

CN	L-threo-Pentitol, 1,2,4,5-tetradecoxy-diethylethoxy)carbonyl]amino]-5-[(1-phenylmethyl)amino]ethyl]amino]-1-p	[ - 2 -1-phenyl-2- y. )CI) (CA INDEX NAME)
----	---	--


Absolute stereochemistry.



RN 300351-59-1 CAPLUS

CN L-threo-Pentitol, 1,2,4,5-tetradeoxy-2-[(1,1-dimethylethyl)amino]-2-oxo-1-phenylethyl]amino]-1-phenyl-2-[(3,4-dimethoxy carbonyl)amino]-(9CI) CA INDEX NAME)


Absolut · stereochemistry.




RN 300351-67-1 CAPLUS

CN D-glycero-Pentitol, 5-[acetyl[(1S)-2-phenyl-2-  
[[(phenylmethyl)amino]ethyl]amino]-1,2,3,5-tetrahydroxy-2-[(3-hydroxy-2-  
methylbutanoyl)amino]-1-phenyl-, (3S,4S,5S)-] (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. (I; R1 = (un)substituted aralkyloxycarbonyl, or arylcarbonyl; R2 = H, (un)substituted C1-10 alkyl, C2-15 aralkylsulfonyl; R4 = (un)substituted C1-10 alkyl, C2-15 aralkyl, C6-14 aryl, or C7-15 aralkyl; R6 = (un)substituted C1-6 alkyl, C3-8 cycloalkyl], pharmacol. acceptab. are useful for the prevention or treatment of AIDS, are prepd. Thus, N-[(1S,2S)-4-[acetyl-((1S)-1-(tert-butylcarbamoyl)-2-((R)-1-naphthyl)ethyl)amino]-1-benzyl-2-hydroxybutyl]carbamic acid tert-Bu ester and condensed with 3-(3-dimethylaminopropyl)carbodiimide hydrochloride and Et3N at room temp. for 12 h, followed by aq. NaOH and MeOH to give N-[(1S,2S)-4-[acetyl-((1S)-1-(tert-butylcarbamoyl)-2-((R)-1-naphthyl)ethyl)amino]-1-benzyl-2-hydroxybutyl]carbamamide (II). II is active against recombinant HIV protease.

L4 ANSWER 21 OF 148 CAPLUS COPYRIGHT 2

AN 2000:641342 CAPLUS

DN 13:238913

TI Preparation of ketones and amides as

IN Dhonak, Lashyant; Knight, Steven D.

PA Smithline Beecham Corporation, USA

SO PC Int. Appl., 26 pp.

COLEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE
WO 00003172	A1	20000914

W: A, JP, US


RW: AT, BE, CH, CY, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, UA, YU, ZK

ceptor antagonists

TION NO.	DATE
-US5911	20000308


B, GR, IE, IT, LU, MC, NL,






AB The title compds. [I or II; A = OR<sup>1</sup>, alkylaryl, etc.; X = (un)substituted aryl, heteroaryl; B = H, Me, aryl, etc.] are receptor antagonists useful in treating allergic disease, were prepd. and formulated. E.g. a 3-step synthesis of [A = OPh; X = 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>; Y = 1-naphthyl] was given. Compds. I or II are effective at 0.01-40 mg/kg/day (oral administration).

RE.CNT 4 THERE ARE 4 CITED REFERENCES. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 841. 842. 843. 844. 845. 846. 847. 848. 849. 850. 851. 852. 853. 854. 855. 856. 857. 858. 859. 860. 861. 862. 863. 864. 865. 866. 867. 868. 869. 870. 871. 872. 873. 874. 875. 876. 877. 878. 879. 880. 881. 882. 883. 884. 885. 886. 887. 888. 889. 890. 891. 892. 893. 894. 895. 896. 897. 898. 899. 900. 901. 902. 903. 904. 905. 906. 907. 908. 909. 910. 911. 912. 913. 914. 915. 916. 917. 918. 919. 920. 921. 922. 923. 924. 925. 926. 927. 928. 929. 930. 931. 932. 933. 934. 935. 936. 937. 938. 939. 940. 941. 942. 943. 944. 945. 946. 947. 948. 949. 950. 951. 952. 953. 954. 955. 956. 957. 958. 959. 960. 961. 962. 963. 964. 965. 966. 967. 968. 969. 970. 971. 972. 973. 974. 975. 976. 977. 978. 979. 980. 981. 982. 983. 984. 985. 986. 987. 988. 989. 990. 991. 992. 993. 994. 995. 996. 997. 998. 999. 1000. 1001. 1002. 1003. 1004. 1005. 1006. 1007. 1008. 1009. 1010. 1011. 1012. 1013. 1014. 1015. 1016. 1017. 1018. 1019. 1020. 1021. 1022. 1023. 1024. 1025. 1026. 1027. 1028. 1029. 1030. 1031. 1032. 1033. 1034. 1035. 1036. 1037. 1038. 1039. 1040. 1041. 1042. 1043. 1044. 1045. 1046. 1047. 1048. 1049. 1050. 1051. 1052. 1053. 1054. 1055. 1056. 1057. 1058. 1059. 1060. 1061. 1062. 1063. 1064. 1065. 1066. 1067. 1068. 1069. 1070. 1071. 1072. 1073. 1074. 1075. 1076. 1077. 1078. 1079. 1080. 1081. 1082. 1083. 1084. 1085. 1086. 1087. 1088. 1089. 1090. 1091. 1092. 1093. 1094. 1095. 1096. 1097. 1098. 1099. 1100. 1101. 1102. 1103. 1104. 1105. 1106. 1107. 1108. 1109. 1110. 1111. 1112. 1113. 1114. 1115. 1116. 1117. 1118. 1119. 1120. 1121. 1122. 1123. 1124. 1125. 1126. 1127. 1128. 1129. 1130. 1131. 1132. 1133. 1134. 1135. 1136. 1137. 1138. 1139. 1140. 1141. 1142. 1143. 1144. 1145. 1146. 1147. 1148. 1149. 1150. 1151. 1152. 1153. 1154. 1155. 1156. 1157. 1158. 1159. 1160. 1161. 1162. 1163. 1164. 1165. 1166. 1167. 1168. 1169. 1170. 1171. 1172. 1173. 1174. 1175. 1176. 1177. 1178. 1179. 1180. 1181. 1182. 1183. 1184. 1185. 1186. 1187. 1188. 1189. 1190. 1191. 1192. 1193. 1194. 1195. 1196. 1197. 1198. 1199. 1200. 1201. 1202. 1203. 1204. 1205. 1206. 1207. 1208. 1209. 1210. 1211. 1212. 1213. 1214. 1215. 1216. 1217. 1218. 1219. 1220. 1221. 1222. 1223. 1224. 1225. 1226. 1227. 1228. 1229. 1230. 1231. 1232. 1233. 1234. 1235. 1236. 1237. 1238. 1239. 1240. 1241. 1242. 1243. 1244. 1245. 1246. 1247. 1248. 1249. 1250. 1251. 1252. 1253. 1254. 1255. 1256. 1257. 1258. 1259. 1260. 1261. 1262. 1263. 1264. 1265. 1266. 1267. 1268. 1269. 1270. 1271. 1272. 1273. 1274. 1275. 1276. 1277. 1278. 1279. 1280. 1281. 1282. 1283. 1284. 1285. 1286. 1287. 1288. 1289. 1290. 1291. 1292. 1293. 1294. 1295. 1296. 1297. 1298. 1299. 1300. 1301. 1302. 1303. 1304. 1305. 1306. 1307. 1308. 1309. 1310. 1311. 1312. 1313. 1314. 1315. 1316. 1317. 1318. 1319. 1320. 1321. 1322. 1323. 1324. 1325. 1326. 1327. 1328. 1329. 1330. 1331. 1332. 1333. 1334. 1335. 1336. 1337. 1338. 1339. 1340. 1341. 1342. 1343. 1344. 1345. 1346. 1347. 1348. 1349. 1350. 1351. 1352. 1353. 1354. 1355. 1356. 1357. 1358. 1359. 1360. 1361. 1362. 1363. 1364. 1365. 1366. 1367. 1368. 1369. 1370. 1371. 1372. 1373. 1374. 1375. 1376. 1377. 1378. 1379. 1380. 1381. 1382. 1383. 1384. 1385. 1386. 1387. 1388. 1389. 1390. 1391. 1392. 1393. 1394. 1395. 1396. 1397. 1398. 1399. 1400. 1401. 1402. 1403. 1404. 1405. 1406. 1407. 1408. 1409. 1410. 1411. 1412. 1413. 1414. 1415. 1416. 1417. 1418. 1419. 1420. 1421. 1422. 1423. 1424. 1425. 1426. 1427. 1428. 1429. 1430. 1431. 1432. 1433. 1434. 1435. 1436. 1437. 1438. 1439. 1440. 1441. 1442. 1443. 1444. 1445. 1446. 1447. 1448. 1449. 1450. 1451. 1452. 1453. 1454. 1455. 1456. 1457. 1458. 1459. 1460. 1461. 1462. 1463. 1464. 1465. 1466. 1467. 1468. 1469. 1470. 1471. 1472. 1473. 1474. 1475. 1476. 1477. 1478. 1479. 1480. 1481. 1482. 1483. 1484. 1485. 1486. 1487. 1488. 1489. 1490. 1491. 1492. 1493. 1494. 1495. 1496. 1497. 1498. 1499. 1500. 1501. 1502. 1503. 1504. 1505. 1506. 1507. 1508. 1509. 1510. 1511. 1512. 1513. 1514. 1515. 1516. 1517. 1518. 1519. 1520. 1521. 1522. 1523. 1524. 1525. 1526. 1527. 1528. 1529. 1530. 1531. 1532. 1533. 1534. 1535. 1536. 1537. 1538. 1539. 1540. 1541. 1542. 1543. 1544. 1545. 1546. 1547. 1548. 1549. 1550. 1551. 1552. 1553. 1554. 1555. 1556. 1557. 1558. 1559. 1560. 1561. 1562. 1563. 1564. 1565. 1566. 1567. 1568. 1569. 1570. 1571. 1572. 1573. 1574. 1575. 1576. 1577. 1578. 1579. 1580. 1581. 1582. 1583. 1584. 1585. 1586. 1587. 1588. 1589. 1590. 1591. 1592. 1593. 1594. 1595. 1596. 1597. 1598. 1599. 1600. 1601. 1602. 1603. 1604. 1605. 1606. 1607. 1608. 1609. 1610. 1611. 1612. 1613. 1614. 1615. 1616. 1617. 1618. 1619. 1620. 1621. 1622. 1623. 1624. 1625. 1626. 1627. 1628. 1629. 1630. 1631. 1632. 1633. 1634. 1635. 1636. 1637. 1638. 1639. 1640. 1641. 1642. 1643. 1644. 1645. 1646. 1647. 1648. 1649. 1650. 1651. 1652. 1653. 1654. 1655. 1656. 1657. 1658. 1659. 1660. 1661. 1662. 1663. 1664. 1665. 1666. 1667. 1668. 1669. 1670. 1671. 1672. 1673. 1674. 1675. 1676. 1677. 1678. 1679. 1680. 1681. 1682. 1683. 1684. 1685. 1686. 1687. 1688. 1689. 1690. 1691. 1692. 1693. 1694. 1695. 1696. 1697. 1698. 1699. 1700. 1701. 1702. 1703. 1704. 1705. 1706. 1707. 1708. 1709. 1710. 1711. 1712. 1713. 1714. 1715. 1716. 1717. 1718. 1719. 1720. 1721. 1722. 1723. 1724. 1725. 1726. 1727. 1728. 1729. 1730. 1731. 1732. 1733. 1734. 1735. 1736. 1737. 1738. 1739. 1740. 1741. 1742. 1743. 1744. 1745. 1746. 1747. 1748. 1749. 1750. 1751. 1752. 1753. 1754. 1755. 1756. 1757. 1758. 1759. 1760. 1761. 1762. 1763. 1764. 1765. 1766. 1767. 1768. 1769. 1770. 1771. 1772. 1773. 1774. 1775. 1776. 1777. 1778. 1779. 1780. 1781. 1782. 1783. 1784. 1785. 1786. 1787. 1788. 1789. 1790. 1791. 1792. 1793. 1794. 1795. 1796. 1797. 1798. 1799. 1800. 1801. 1802. 1803. 1804. 1805. 1806. 1807. 1808. 1809. 1810. 1811. 1812. 1813. 1814. 1815. 1816. 1817. 1818. 1819. 1820. 1821. 1822. 1823. 1824. 1825. 1826. 1827. 1828. 1829. 1830. 1831. 1832. 1833. 1834. 1835. 1836. 1837. 1838. 1839. 1840. 1841. 1842. 1843. 1844. 1845. 1846. 1847. 1848. 1849. 1850. 1851. 1852. 1853. 1854. 1855. 1856. 1857. 1858. 1859. 1860. 1861. 1862. 1863. 1864. 1865. 1866. 1867. 1868. 1869. 1870. 1871. 1872. 1873. 1874. 1875. 1876. 1877. 1878. 1879. 1880. 1881. 1882. 1883. 1884. 1885. 1886. 1887. 1888. 1889. 1890. 1891. 1892. 1893. 1894. 1895. 1896. 1897. 1898. 1899. 1900. 1901. 1902. 1903. 1904. 1905. 1906. 1907. 1908. 1909. 1910. 1911. 1912. 1913. 1914. 1915. 1916. 1917. 1918. 1919. 1920. 1921. 1922. 1923. 1924. 1925. 1926. 1927. 1928. 1929. 1930. 1931. 1932. 1933. 1934. 1935. 1936. 1937. 1938. 1939. 1940. 1941. 1942. 1943. 1944. 1945. 1946. 1947. 1948. 1949. 1950. 1951. 1952. 1953. 1954. 1955. 1956. 1957. 1958. 1959. 1960. 1961. 1962. 1963. 1964. 1965. 1966. 1967. 1968. 1969. 1970. 1971. 1972. 1973. 1974. 1975. 1976. 1977. 1978. 1979. 1980. 1981. 1982. 1983. 1984. 1985. 1986. 1987. 1988. 1989. 1990. 1991. 1992. 1993. 1994. 1995. 1996. 1997. 1998. 1999. 2000. 2001. 2002. 2003. 2004. 2005. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014. 2015. 2016. 2017. 2018. 2019. 2020. 2021. 2022. 2023. 2024. 2025. 2026. 2027. 2028. 2029. 2030. 2031. 2032. 2033. 2034. 2035. 2036. 2037. 2038. 2039. 2040. 2041. 2042. 2043. 2044. 2045. 2046. 2047. 2048. 2049. 2050. 2051. 2052. 2053. 2054. 2055. 2056. 2057. 2058. 2059. 2060. 2061. 2062. 2063. 2064. 2065. 2066. 2067. 2068. 2069. 2070. 2071. 2072. 2073. 2074. 2075. 2076. 2077. 2078. 2079. 2080. 2081. 2082. 2083. 2084. 2085. 2086. 2087. 2088. 2089. 2090. 2091. 2092. 2093. 2094. 2095. 2096. 2097. 2098. 2099. 2100. 2101. 2102. 2103. 2104. 2105. 2106. 2107. 2108. 2109. 2110. 2111. 2112. 2113. 2114. 2115. 2116. 2117. 2118. 2119. 2120. 2121. 2122. 2123. 2124. 2125. 2126. 2127. 2128. 2129. 2130. 2131. 2132. 2133. 2134. 2135. 2136. 2137. 2138. 2139. 2140. 2141. 2142. 2143. 2144. 2145. 2146. 2147. 2148. 2149. 2150. 2151. 2152. 2153. 2154. 2155. 2156. 2157. 2158. 2159. 2160. 2161. 2162. 2163. 2164. 2165. 2166. 2167. 2168. 2169. 2170. 2171. 2172. 2173. 2174. 2175. 21



GI



AB A solid-phase method for the synthesis of 2,3,4-tetrahydro-.beta.-carboline-contg. peptidomimetics I (AA1, AA2 = Ala, Leu, Phe, Pro, Val, Asp, Gly, etc.) has been developed. The key step in the strategy is the Pictet-Spengler condensation of a tryptophan-contg. fragment with an Fmoc-amino aldehyde.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THIS FORMAT

L4 ANSWER 23 OF 148 CAPLUS COPYRIGHT 2000

AN 2000:13804 CAPLUS

DN 13:13056

TI Synthetic studies on the DEF ring system of ristocetin A via ruthenium-promoted SNAr reaction: problems and solutions using arylamine-Ru complexes

AU Pearson, Anthony J.; Heo, Jung-Nyoung

CS Department of Chemistry, Case Western Reserve University, Cleveland, OH, 44106, USA

SO Tetrahedron Letters (2000), 41(32), 5005-5006

COPIES: 1; EASY; ISSN: 0040-4039

PB Elsevier Science Ltd.

DT Journal Article

LA English

OS CAPLUS DT 133:282056



IT 299179-32-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

Synthetic studies on the DEF ring system of ristocetin A via ruthenium-promoted SNAr reaction using arylserine-Ru complexes)

RN 299179-32-1 CAPLUS

CN Glycylamide, (.beta.R)-4-chloro-N-[(1,1-dimethylethoxy)carbonyl]-.beta.-hydroxy-D-phenylalanyl-(2S)-2-phenylglycyl-2-(3,5-dihydroxy-4-methoxyphenyl)-N-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Ruthenium-promoted intramol. SNAr reaction has allowed the construction of the 16-membered DEF model macrocycle of ristocetin A that incorporates the required arylserine residue as the E ring. The required arylserine was synthesized using the Sharpless asym. hydroxylation reaction starting with (E)-4-chlorocinnamic acid.

RE.CNT 24 HERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 24 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 2000:475632 CAPLUS

DN 133: 64880

TI Arylalkanoylaminoacetamides as blood clotting factor Xa inhibitors

IN Defossa, Elisabeth; Heinelt, Uwe; Klinger, Otmar; Zoller, Gerhard; Matzner, Hans; Al-Obeidi, Fahad D.; Waller, Armin; Wildgoose, Peter

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO PCT Int. appl., 1-0 pp.

CODEN: PIKX22

DT Patent

LA English

FAN.CNT

PATENT NO.	KIND	DATE	PUBLICATION NO.	DATE
PI WO 2000/47548	A1	20000713	WO 99-EP10341	19991223
AC, AL, AM, AT, AU, BA, BB, BC, BR, BY, CA, CH, CN, CR, CU, DE, DK, DM, EE, ES, FI, GE, GH, GM, HR, HU, ID, IL, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TM, TR, TT, TZ, UG, UZ, VN, YU, ZA, ZW, AM, AZ, FY, KG, KZ, MD, RU, TJ, TM, GH, GM, KE, LS, MW, SD, SL, TZ, UG, ZW, AT, BE, CH, CY, DE, EK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				

CG, CI, CM, GA, GN, GU, ML, NE, SN, TD, TG  
 EP 1000001 A 19990102  
 EP 119538 A 19991001  
 EP 100001 19990102  
 AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 CA 23581 AA 20000713 A 9-2358581 19991223  
 EP 100001 A 19990102  
 EP 119538 A 19991001  
 EP 10341W 19991223  
 BR 9916733 A 20010925 EP 16733 19991223  
 EP 100001 A 19990102  
 EP 119538 A 19991001  
 EP 10341W 19991223  
 EP 967001 19991223  
 AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI  
 EP 100001 A 19990102  
 EP 119538 A 19991001  
 EP 10341W 19991223  
 EP 592257 19991223  
 EP 100001 A 19990102  
 EP 119538 A 19991001  
 EP 10341W 19991223  
 ZA 200004772 A 20020513 A 1-4772 20010612  
 EP 100001 A 19990102  
 NO 20003141 A 20010803 EP 1-3141 20010622  
 EP 100001 A 19990102  
 EP 119538 A 19991001  
 EP 10341W 19991223

OS MARPAT 133:104880

IT 283160-50-9P

RL: FNC (Biological activity or effect, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of arylalkanoylaminoacetamides as blood coagulation factor Xa inhibitors)

RN 283160-50-9 CAPLUS


CN L-Ariginamide, (2S)-N-[3-[4-(aminophenyl)phenyl]-1-oxo-2-(3-pyridinyl)propyl]-2-phenylglycyl-, triacetate (9CI) (CA INDEX NAME)

CM

CRN 283160-49-6


CMF 283160 H35 N9 O3

Absolute stereochemistry.



CM

CRM 05-1  
CMP H F3 O2



IT 283162-49-6P 283162-22-1P 283162-23-2P


283162-24-3P 283162-25-4P

RL: N (Synthetic preparation); THU he (Therapeutic use); BIOL (Biological  
study: PREP (Preparation); USES (Uses)  
(Group of arylalkanoylaminoacetamides blood coagulation factor Xa  
inhibitors)

RN 283162-49-6 CAPLUS

CN L-Arylaminamide, (2S)-N-[3-[4-(aminomethyl)phenyl]phenyl]-1-oxo-2-(3-  
pyridinyl)propyl]-2-phenylglycyl- (9- INDEX NAME)

Absolute stereochemistry.




RN 283162-22-1 CAPLUS




phenylpropyl]-2-phenylglycyl- (9CI) A (X NAME)

Absolute stereochemistry.



GI



AB Title compds. were prepd. for use as inhibitors of the blood clotting enzyme factor Xa. Thus, the diamide was repd. in a 9-step synthesis. I<sub>50</sub> = 0.1 μM for factor Xa inhibition.

RE.CNT THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE FULL FORMAT

L4 ANNOTATED 5 OF 148 CAPLUS COPYRIGHT 2003

AN 2003:4:173 CAPLUS

DN 13:4:18

TI Total synthesis of the teicoplanin aglycone

AU Boeck, Dale L.; Kim, Seong Heon; Miyake, Masaharu; Strittmatter, Harald; Weig, Alan-Hui; Mori, Yoshiki; Rogel, Alexander; Castle, Steven L.; McAtee, J. Jeffrey

CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA

SO Journal of the American Chemical Society 122(30), 7416-7417

COPIES: ACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

IT 296781-63-0P

RI: (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)


Total synthesis of teicoplanin aglycone

RN 296781-63-0 CAPLUS



CN L-Serine, 4-fluoro-3-nitro-N-[[2-(trimethylsilyl)ethoxy]carbonyl]-D-

phenylalanyl-(2S)-2-[3-[5-[(1R)-1-[(1S)-1-ethylethoxy)carbonyl]amino]-2-(phenylmethoxy)ethyl]-2-methoxyphenoxy]-5-methoxyphenyl]glycyl-(2R)-2-[3,5-dihydroxy-4-methoxyphenyl]glycyl-(2R)-2-[2-[(1S)-1-amino-2-[(2-methoxyethoxy)methoxy]ethyl]-4',5,6'-trimethoxy[1,1'-biphenyl]-3-yl]glycyl-3-chloro-beta.-hydroxy-, (5.fwdarw.4) lactam, cyclic (3.fwdarw.54)-ether, stereoisomer (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



PAGE 2-B




PAGE 2-B

-OBu-t

-O-CH<sub>2</sub>-CH<sub>2</sub>-

GI



AB Teicoplanin is a complex of five antibiotics isolated from *Actinoplanes teichomyceticus* that are related to vancomycin. The first total synthesis of the teicoplanin aglycon (I) is described. Key elements of the approach include sequential DE and FG ring system introductions onto the common vancomycin/teicoplanin ABCD ring system providing a late stage divergent total synthesis of the two classes of glycopeptide antibiotics. The ring systems were introduced enlisting a nucleophilic arom. substitution reaction of an o-fluoronitroarom. for ring cyclization and formation of the 16-membered DE diaryl ether and a subsequent lactamization of the N-terminus amine for closure of the 14-membered F ring system. The teicoplanin aglycon was obtained in 48% yield identical in all respects with authentic material.

RE.CNT 16 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THIS REFORMAT

L4 ABSTRACT 26 OF 148 CAPLUS COPYRIGHT 2003

AN 2004456736 CAPLUS

DN 13:39228

TI Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)

IN Deffassa, Elisabeth; Heinelt, Uwe; Klein, Otmar; Zoller, Gerhard;

Mattler, Hans; Al-Obeidi, Fahad A.; Walther, Armin; Wildgoose, Peter

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO Eur. Pat. Appl., 76 pp.


CCPNT: FPEXDW

DT Pat  
LA Eng 138  
FAN.CNT

PATENT NO.	KIND	DATE	ATION NO.	DATE
PI EP 011563	A1	20000705	9-100002	19990102
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2350578	AA	20000713	9-2358578	19991223
9-100002 A 19990102				
9-119537 A 19991001				
9-EP10340W 19991223				
WC 001040571	A1	20000713	9-EP10340	19991223
R: AE, AL, AM, AT, AU, AZ, BA, BR, BY, CA, CH, CN, CR, CU, CE, DE, DK, DM, EE, ES, FI, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LK, LR, LS, LT, LU, LV, MA, MF, MG, MK, MN, MW, MX, NO, PT, RO, RU, SD, SE, SG, SI, SF, SL, TJ, TM, TR, TT, TZ, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BT, KG, KZ, MD, RU, TJ, TM				
R: GM, GM, KE, LS, MW, SD, SL, S, UG, ZW, AT, BE, CH, CY, DE, DF, EG, FI, FR, GB, GR, IE, IL, IN, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MI, SN, TD, TG				
9-100002 A 19990102				
9-119537 A 19991001				
BF 011732	A	20010925	9-16732	19991223
9-100002 A 19990102				
9-119537 A 19991001				
9-EP10340W 19991223				
EP 1140878	A1	20011010	9-964667	19991223
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, MC, PT, IF, SI, LT, LV, FI, RO				
9-100002 A 19990102				
9-119537 A 19991001				
9-EP10340W 19991223				
JP 20031420	T2	20021015	10-592279	19991223
9-100002 A 19990102				
9-119537 A 19991001				
9-EP10340W 19991223				
US 646673	B1	20020528	9-473053	19991228
9-100002 A 19990102				
9-119537 A 19991001				
NC 0002983	A	20010615	1-2983	20010615
9-100002 A 19990102				
9-119537 A 19991001				
9-EP10340W 19991223				
OS	MFIAT 130489.28			
IT	280553-99-3P 280554-02-1P 280554-07-6P			
R: N (Biological activity or effect); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); E (Biological study); PREP (Preparation); USES (Uses)				
R: pn. of novel malonic acid derivative; factor Xa inhibitors)				
RN	280553-99-3 APLUS			
CN	L-phenylalanine, (2S)-N-[2-[[4-(aminomethyl)phenyl]methyl]-3-(4-methylphenyl)-1,3-dioxopropyl]-2-phenyl- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.






RN 28 11-02-1 LAPLUS

CN L-phenylalaninamide, (2S)-N-[[2-[[4-(aminomethyl)phenyl]methyl]-1,3-dioxo-3-phenylpropyl]-2-phenylglycyl]-L-phenylalaninamide (CA INDEX NAME)

Absolute stereochemistry.



RN 28 11-07-6 LAPLUS


CN L-phenylalaninamide, (2S)-N-[[2-[[4-(aminomethyl)phenyl]methyl]-3-(4-aminomethylphenyl)-1,3-dioxopropyl]-2-phenylglycyl]-L-phenylalaninamide, mono(trifluoroacetate) (CA INDEX NAME)

CH

CH 30553-94-3

CH C29 H39 N3 O5


Absolute stereochemistry.




CH

CH 76-05-1

CH C. H F3 G2



GI



I

AB The present invention relates to the preparation of new compds. for the inhibition of blood clotting proteins, more particularly, to malonic acid derivs., I (R1 = organoamino, or organoalkoxy, etc.; R2 = H, C1-4 alkyl; R3 = (un)substituted C6-10-aryl-C1-4-alkyl, C1-4-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-10-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, etc.; R4R5 = carbonyl, organo, etc.). Thus, 2-(R,S)-(4-aminobenzyl(piperidin-4-ylcarbonyl)malonamide salt was prepd. in several steps from 2,2-dimethyl[1,3]dioxane-4,6-dione and 4-aminobenzonitrile. I are inhibitors


a factor Xa. The invention  
I, to methods of inhibiting  
clotting, to the use of I in  
which can be treated or  
activity such as thromboembolic  
the prepn. of medicaments to  
further relates to compns.  
with an inert carrier, in  
compd. of formula I together  
substances and auxiliary

ABLE FOR THIS RECORD  
FORMAT

s as CCR-3 receptor



4-107717PP 19981109

Absolutely characteristic.










GI



AB T 1. The compds. [I; A = heterocycle containing N atom and optionally unsatd. and optionally further substituted by a group; R = H, CN, carbonyl, etc.; Y = CH2, (CH2)2, etc.; Z = unsubstituted aryl, etc.; R1 = H, cycloalkyl, alkyl, etc.; R2 = alkyl, polyfluoroalkyl] and the pharmaceutically acceptable salts, useful as inhibitors, were prepd. E.g., the 1-step synthesis of the compound II which showed IC50 of 1.7 nM against PDE 4, was

RE.CN THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN REF. FORMAT

L4 1. OF 148 CAPLUS COPYRIGHT 1993

AN 2. 1992 CAPLUS

DN

TI 1. promoted diaryl ether synthesis the construction of the F-O-G  
m of a teicoplanin model

AU 1. Anthony J.; Belmont, Philip

CS 1. of Chemistry, Case Western Reserve University, Cleveland, OH,

SO

1. Letters (2000), 41(11),

1. LEAY; ISSN: 0040-4039

PB 1. Science Ltd.

DT

LA

IT 272457-86-0P 272457-87-1P 272460-08-0P

1. reactant); SPN (Synthetic product); PREP (Preparation); RACT


(or reagent)

ium-promoted diaryl ether synthesis in the construction of the  
 ring system of teicoplanin (antibiotics)

RN 1 0 CAPLUS

CN 1 1 1, O-methyl-N-[(phenylmethyl) (benzyl)-D-tyrosyl-2-(3-hydroxy-5-  
 methyl)-N-methyl-, (2S)- (9CI) (INDEX NAME)


Absol Chemistry.



RN 1 1 CAPLUS

CN 1 1 1, O-methyl-N-[(phenylmethyl) (benzyl)-D-tyrosyl-2-[3-[5-[(R)-  
 1,1-dimethylethoxy) carbonyl]-methyl]-2-methoxyphenoxy]-5-  
 methyl]-N-methyl-, (2S)- (9CI) (INDEX NAME)

Absol Chemistry.



t-BuO

COO

RN 1 9 CAPLUS



CN 1 1 1, O-methyl-N-[(phenylmethyl) (benzyl)-D-tyrosyl-2-[3-[(1,2,3,4,5,6-.eta.)-5-[(S)-  
 1,1-dimethylethoxy) carbonyl]-methyl]-2-methoxyphenoxy]-5-  
 methyl]-N-methylglycinamidate (hexafluorophosphate(1-))  
 (INDEX NAME)

-O<sup>+</sup>

52 F OLD Ru

PAGE 1-A


t-BuC



PAGE 1-B


—CH<sub>2</sub>

PAGE 2-A





( 4 91-1  
( 0 . H  
,



E

E

IT 2 162 06 7P

1 (synthetic preparation); PPI (reaction)  
 2 (sodium-promoted diaryl ether (in the construction of the  
 3 binding system of teicoplanin (antibiotics)  
 RN 1 CAPLUS  
 CN 1 (+), [(2S)-2-[(1,2,3,4,5,6-dichloro-4-methoxyphenyl)-N-(  
 7 (2-hydroxyethoxy)carbonyl]glycy D-tyrosyl-(2S)-2-(3-hydroxy-  
 8 (phenyl)-N-methylglycinamide, 1,4-cyclopentadien-1-yl)-,  
 9 phosphate(1-) (9CI) (CA 11 11 11)

(



( 1 -05-6

( 11-6 C1 N4 O9 Ru

,



PAGE 2-A




C

C

18-9

C

C



AB A n approach is described for the synthesis of glycopeptide  
 a related to teicoplanin, phenium-promoted diaryl ether  
 f followed by cycloamidation  
 RE.CNT HERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN RMAT

L4 A F 148 CAPLUS COPYRIGHT  
 AN I CAPLUS  
 DN I  
 TI P on of N-(heteroaryl)ureas and serol acyltransferase  
 i  
 IN F Ernest S.  
 PA F ., USA  
 SO U ., Cont.-in-part of U. S. . 890,050, abandoned.  
 Co AM  
 DT F  
 LA I  
 FAN.CH  
 I  
 KIND DATE  
 TION NO. DATE

Patel

5/2003&gt;

PI C A 19991214

343557 19950117

-890050 B219920528

-US3539 W 19930420

-US3539 19930420

A1 19931209

, BG, BR, CA, CZ, DE, JP,

, BE, CH, DE, DK, ES, FR,

, BJ, CF, CG, CI, CM, GA.

, RO, RU, SK, UA, US

, IT, LU, MC, NL, PT, SE,

, NE, SN, TD, TG

890050 A219920528

# PATENT INFORMATION:

FAN

KIND DATE

ION NO. DATE

PI W A1 19931209

US3539 19930420

, BG, BR, CA, CZ, DE, JP,

, BE, CH, DE, DK, ES, FR,

, BJ, CF, CG, CI, CM, CA,

, RO, RU, SK, UA, US

, IT, LU, MC, NL, PT, SE,

, NE, SN, TD, TG

890050 A219920528

A1 19931230

-40283 19930420

-890050 A 19920528

-US3539 A 19930420

-909519 19930420

A1 19950315

, BE, CH, DE, DK, ES, FR,

, IT, LI, LU, NL, PT, SE

890050 A 19920528

US3539 W 19930420

T2 19950420

-500522 19930420

-890050 A 19920528

US3539 W 19930420

C 19970701

-2134359 19930420

-890050 A 19920528

A 19980915

-6421 19930420

-890050 A 19920528

US3539 W 19930420

A2 19931228

-552 19930527

890050 A 19920528

A 19910119

-106774 19930527

890050 A 19920528

A 19941125

-4530 19941125

-890050 A 19920528

-US3539 A 19930420

A 19991214

-343557 19950117

-890050 B219920528

US3539 W 19930420

OS 1 22878

IT 1 12-OP

F Biological activity or effe

s (classified); SIN (Synthetic

ical study; PREP (Prep

of N-(heteroaryl)ureas a

ols)

pt adverse); BSU (Biological

on); THU (Therapeutic use);

SES (Uses)

rol acyltransferase


RN CAPLUS

CM 1,4-bis(ethylthio)-6-methy

nyl)-6-phenylhexyl]- (9CI

nyl]-N'-[2-(2,5-

DEX NAME)



GI



Me

[illegible]

L4 F 148 CAPLUS COPYRIGHT  
AN CAPLUS

DN

TI

11

AU:

CS

CD

50

20

DE

FD  
DTDI  
VILA  
T 03

11

R11

Cij

At

De

Pa

1-alkylphenyl, (un)substituted  
n-substituted (hetero)aryl,  
(un)substituted CH<sub>2</sub>; n = 0-3;  
ferase inhibitors (no data).  
'methylthio)-6-methyl-3-

FILE FOR THIS RECORD  
FORMAT

ino acids, peptide and

Department of Pharmaceutical  
470003, India

```

on); THU (Therapeutic use);
ISES (Uses)
is and peptides as ampicillin

```


carboxy-3,3-dimethyl-7-oxo-4-  
(2R)- (9CI) (CA INDEX NAME)

Page 2

5/2003>




Absolute chemistry. Variation 1.



R/N 2 6- 3 4 CAP: 11

CN B n e r ranamide, N,N'-[(1R,2F-1, b. 1-1,2-ethanediyl]bis[.alpha.-  
aj -, (.alpha.S,.alpha.'S)- (9CI) , FX NAME)

Absol : = chemistry. Rotation (-).



AB 1. Cu(II) complexes of cyclic and chain polyaza compds. were used as catalysts in the benchmark polymerization reaction of styrene with azoacetate. In general, smaller amounts of Cu are needed to catalyze the reaction. The catalytic activity depends on the structure of the ligand, e.g. amine amides are more effective than polyamines, and on the oxidation state of Cu, Cu(II) being more effective than Cu(I). Given that Cu(II) is the active species, these differences in behavior must be related to the properties of the complexes. The nature of the counterion also has a marked influence on the catalytic activity. XAS measurements suggest the presence of oligomeric species. The use of chiral ligands lead to enantiomeric excesses. Chiral ligands can easily be supported on polymers, e.g. polymers and their derivatives can be used as catalysts. Such polymers can be supported on clays and zeolites, exchange and the solids tend to promote the reaction and decrease in the trans/cis

RELCNT 1 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
10 CITATIONS AVAILABLE IN 10 PAGES

L4 1 R 3 148 ABING COPYRI...  
AN 1 7 14 CARING  
DI 1  
TI 1 of 148 148 toamide per 148 antiviral HCV proteinase  
IN 1 148 148 Niger; John, Philip St 148, Paul Brittain; Raynham,  
148 148; Wilson, Francis Xavier  
PL 148 148 La Roche A., Switz.  
SI 148 148, 130 op.  
148 148  
DT 148  
LA 148  
FAH(C)







2002

15

11 0

1. Tumor necrosis factor (TNF)-alpha-  
 2. Solubilization inhibitors  
 3. Case in bone marrow cells  
 4. Methyl-3(S)-methylsuccinyl]-  
 5. Apoptosis of nucleated bone  
 6. Iron patients.  
 7. Also given.

containing compounds and  
inhibitors  
Michael D.; Blanchard,  
Pal, Kollol  
Cambridge, MA, 02139,

9 (19), 2849-2854

```


adverse); BSU (Biological
: BIOL (Biological

a library of dipeptidyl
ments of Cdc25


```

-L-tyrosyl-N2-[2-(1H-

PAGE 1-A



PAGE 2-A



As a four-carbonone, Ugi reaction was rep. a library of  
 identified compounds. In order to explore the requirements of the key  
 methyl phosphonate, 1c25. Several surrogates were  
 incorporated into the Ugi product. The mono- or  
 phosphonate substrate.  
 REFERENCE: HERE ARE 22 REFERENCES FOR THIS RECORD  
 TO CITATIONS AVAILABLE IN THE FILE

LE: 3-148 CAPLW COPYRIGHT  
 AN: 6390 CAPLW  
 DT: 3174

T: Nature activity relationship of  
 carbonyl and phosphonate and TMT-  
 Al: 1961, Yoshino, Ryoichi, Ryoichi,  
 1961, Yoshino, Ryoichi, Ryoichi, Ryoichi,

used inhibitors on  
 ing  
 Yoshi; Yoshino, Koichiro;  
 Yagi; Yagita, Hideo;



0 11 12

the... and iso-Pr groups were  
... these differences in  
... bound FasL and  
... oproteinases, (2) the S1'  
... of MMP-1 and MMP-9, but  
... the S1' site of  
... at of FasL processing  
... ing a more selective

RA... FOR THIS RECORD  
RE...

L... 3... COPYR... A  
A... 13... CA...  
D... 32...  
T... at... amino... a... ose-1,6-bisphosphatase

II... M... Jame... op... Orienti, Kristen Lee;  
... F... Mich... ich, E... ni... e; Jones, Todd Kevin

En...  
S...  
D...  
L...  
En...

PL... NO. DATE  
1... 5552 19990315

EF... GR, IE, IT, LU, MC, NL,

1... 065P P 19980316  
1... 370 19990315  
1... 065P P 19980316  
1... 5552 W 19990315  
1... 0121 19990315  
1... 065P P 19980316  
1... 2505 19990315  
1... 065P P 19980316  
1... 5552 W 19990315  
2... 6045 19990315  
1... 065P P 19980316

Q... 1-... 1325  
I... 244220-93... 244220-94-...


ra... PREP (Preparation); RACT

as... ose-1,6-bisphosphatase

R... A...  
C... 3-ylm... L-phenylalanyl-3-  
... -[5-... (oxy)hexyl]amino]-1-(4-  
... yl... INDEX NAME)


Al... ex... test...

G




RI 142 24 CAPL  
 Cl 142 24 CAPL  
 3-ylmet  
 -[[6-c  
 hyl ester  
 -L-phenylalanyl-3-  
 en. (noxy)hexyl]amino]-1-(4-  
 INDEX NAME)

Al 142 24 CAPL



G



P


'2003>

AB Title compds. [I; R1 = cycloalkyl or aralkyl; R2 = cycloalkylmethyl or (ar)alkyl; R3 = H, F, alkyl, substituted Ph; R4 = H, alkyl, acyl, substituted Ph; R5 = H; R1R5 = atoms to complete a ring] were prepd. Thus, L-R2CH(NH2)CO2Me.HCl (R2 = cyclohexyl), 4-(NC)C6H4CHO, N-Fmoc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, and 4-(CNH2CH2C)C6H4OCH2Ph were subjected to Ugi condensation and the product cyclized to give, after deprotection, I [R1R5 = 2-(H2C)C6H4CH2, R2 = cyclohexylmethyl, R3 = 4-(NC)C6H4, R4 = CH2CH2C6H4(OH)-4]. Data for biol. activity of I were given.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 38 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 1999:581403 CAPLUS  
DN 132:106  
TI Design and synthesis of a novel series of HIV-1 protease inhibitors  
AU Takashiro, E.; Nakamura, Y.; Miyamoto, S.; Ozawa, Y.; Sugiyama, A.; Fujimoto, K.  
CS Exploratory Chemistry Research Laboratories, Sankyo Co. Ltd., Tokyo, Japan  
SO Bioorganic & Medicinal Chemistry (1999), 7(9), 2105-2114  
CODEN: BMECEP; ISSN: 0968-0896  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 132:106  
IT **251339-75-0P 251339-81-8P 251339-82-9P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(design and synthesis of a novel series of HIV-1 protease inhibitors and structure-activity relations)  
RN 251339-75-0 CAPLUS  
CN D-glycero-Pentitol, 5-[acetyl[(1S)-2-[(1,1-dimethylethyl)amino]-2-oxo-1-phenylethyl]amino]-1,2,4,5-tetradeoxy-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-phenyl]-, (3.xi.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 251339-81-8 CAPLUS  
CN D-erythro-Pentitol, 1,2,4,5-tetradeoxy-5-[[[(1S)-2-[(1,1-dimethylethyl)amino]-2-oxo-1-phenylethyl]amino]-2-[(3-hydroxy-2-methylbenzoyl)amino]-1-phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251339-82-9 CAPLUS

CN D-erythro-Pentitol, 5-[acetyl[(1S)-2-[(1,1-dimethylethyl)amino]-2-oxo-1-phenylethyl]amino]-1,2,4,5-tetradexo-2-[(3-hydroxy-2-methylbenzoyl)amino]-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The synthesis and the SAR study of novel pseudo sym. inhibitors of HIV-1 protease are described. Michael addn. of amino acid derivs. to vinyl ketones was utilized to derive a potent (nM) series of HIV-1 protease inhibitors.

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1999:569665 CAPLUS

DN 131:310411

TI Samarium-induced iodine-catalyzed reduction of imines: synthesis of amine derivatives

AU Banik, Bimal K.; Zegrocka, Oliwia; Banik, Indrani; Hackfeld, Linda; Becker, Frederick F.

CS M.D. Anderson Cancer Center, Department of Molecular Pathology, Section of Experimental Pathology, The University of Texas, Houston, TX, 77030, USA

SO Tetrahedron Letters (1999), 40(37), 6731-6734

CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 131:310411

IT 247909-18-8P

RL: SPN (Synthetic preparation); PREP (Preparation)


(samarium-induced iodine-catalyzed redn. of imines derived from arom. amines to secondary monoamines and reductive dimerization of imines derived from arylalkyl amines to secondary diamines)

RN 247909-18-8 CAPLUS

CN 2,3-Butanediamine, N,N'-bis[3-(2-chlorophenyl)propyl]-2,3-bis(3-methoxyphenyl)-, (2R,3S)-rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.




AB Samarium metal induced iodine-catalyzed redn. of the imines to secondary amines was investigated. The imines derived from arom. amines produced monoamines whereas imines from arylalkyl amines gave diamines in good yield.


RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 1999:457798 CAPLUS  
DN 131:228963  
TI Reductive ring cleavage of 1-alkyl-4-benzoylamino-5-phenyl-3-pyrazolidinones with raney-nickel alloy. Synthesis of N-benzoyl-3-alkylamino-3-phenylalanine amides from rel-(4R,5R)-4-benzoylamino-5-phenyl-3-pyrazolidinone  
AU Zupancic, Silvo; Svete, Jurij; Stanovnik, Branko  
CS Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, 1000, Slovenia  
SO Journal of Heterocyclic Chemistry (1999), 36(3), 607-610  
CODEN: JHTCAD; ISSN: 0022-152X  
PB HeteroCorporation  
DT Journal  
LA English  
OS CASREACT 131:228963  
IT **243842-79-7P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(reductive ring cleavage of alkylated pyrazolidinones with raney-nickel alloy in synthesis of amino acids amides)  
RN 243842-79-7 CAPLUS  
CN Benzenepropanamide, .alpha.-(benzoylamino)-.beta.-[(3-phenylpropyl)amino]-, (.alpha.R,.beta.R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



AB Rel-(4R,5R)-4-Benzoylamino-5-phenyl-3-pyrazolidinone was alkylated at position 1 with carbonyl compds. The corresponding rel-(4R,5R)-4-benzoylamino-5-phenyl-3-pyrazolidinone-1-azomethine imines were treated with sodium borohydride to give rel-(4R,5R)-1-alkyl-4-benzoylamino-5-phenyl-3-pyrazolidinones. Redn. of pyrazolidinones with Raney-nickel alloy in methanolic potassium hydroxide furnished rel-(4R,5R)-N-benzoyl-3-alkylamino-3-phenylalanine amides, e.g. I.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1999:292590 CAPLUS

DN 130:338021

TI Preparation of arylacetic amide derivatives as a preventive or remedy for urinary disorders

IN Kaihoh, Terumitsu; Okada, Tomomi; Takahashi, Yoshinori; Mizuno, Hiroyuki; Honda, Haruyoshi; Sato, Susumo

PA SSP Co., Ltd., Japan

SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 913393	A2	19990506	EP 1998-120422	19981028
	EP 913393	A3	19990526		
	EP 913393	B1	20030212		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				JP 1997-300352 A	19971031
	JP 11193271	A2	19990721	JP 1998-290576	19981013

US 6060485	A	20000509	JP 1997-300352 A 19971031
CN 1222510	A	19990714	US 1998-181091 19981028
TW 442470	B	20010623	JP 1997-300352 A 19971031
			CN 1998-122655 19981030
			JP 1997-300352 A 19971031
			TW 1998-87118071 19981030
			JP 1997-300352 A 19971031


OS MARPAT 130:338021

IT **224034-69-9P 224034-79-1P 224034-80-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of arylacetic amide derivs. as a preventive or remedy for urinary disorders)


RN 224034-69-9 CAPLUS

CN Benzeneacetamide, .alpha.-cyclopentyl-4-methoxy-N-[1-(phenylmethyl)-4-piperidiny]-.alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 224034-79-1 CAPLUS

CN Benzeneacetamide, .alpha.-cyclopentyl-3-methoxy-N-[1-(phenylmethyl)-4-piperidiny]-.alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 224034-80-4 CAPLUS

CN Benzeneacetamide, 3-chloro-.alpha.-cyclopentyl-N-[1-(phenylmethyl)-4-piperidiny]-.alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = (un)substituted arom. hydrocarbon or heteroarom. group; R2, R3 = (un)substituted hydrocarbon or heterocyclic group; R4 = H, (un)substituted hydrocarbon or heterocyclic group; n = 0-1] and their salts which have both excellent anticholinergic action and calcium antagonism and at the same time have high selectivity to bladder, so that they are useful as preventives or remedies for urinary disorders, were prepd. Thus, treatment of N-(1-benzyl-4-piperidinyl)-2-hydroxy-3-methyl-2-phenylbutanamide with NaH in DMF followed by addn. of BuI and a soln. of Bu4NI in DMF afforded 28% I [R1 = Ph; R2 = iPr; R3 = Bu; R4 = PhCH2; n = 0] which showed ID50 of 9.8 mg/kg against bladder contraction in rats.

L4 ANSWER 42 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1999:281303 CAPLUS

DN 131:130143

TI Enantioselective synthesis of the chroman moiety of vitamin E

AU Tietze, Lutz F.; Gorlitzer, Jochen; Schuffenhauer, Ansgar; Hubner, Matthias

CS Institute Organic Chemistry, Georg-August-Univ., Gottingen, D-37077, Germany

SO European Journal of Organic Chemistry (1999), (5), 1075-1084

CODEN: EJOCFK; ISSN: 1434-193X

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

OS CASREACT 131:130143

IT **197297-78-2P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(enantioselective synthesis of chroman moiety of vitamin E)

RN 197297-78-2 CAPLUS

CN Acetamide, N-[(1R,2R)-2-[[[(1S)-1-[2-(2,5-dimethoxy-3,4,6-trimethylphenyl)ethyl]-1-methyl-3-butenyl]oxy]-1-methyl-2-phenylethyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 197297-80-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(enantioselective synthesis of chroman moiety of vitamin E)

RN 197297-80-6 CAPLUS

CN Acetamide, N-[(1R,2R)-2-[(S)-1-[2-(2,5-dimethoxy-3,4,6-trimethylphenyl)ethyl]-1-methyl-3-oxopropoxy]-1-methyl-2-phenylethyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB Several approaches for the enantioselective synthesis of the chroman moiety of .alpha.-tocopherol are described.

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1999:139868 CAPLUS

DN 130:196958

TI Preparation of 3-tert-butyl-L-tyrosinamide-containing peptides and related compounds exhibiting a motilin receptor antagonism

IN Kotake, Ken-ichiro; Kozono, Toshiro; Sato, Tsutomu; Takanashi, Hisanori

PA Chugai Seiyaku Kabushiki Kaisha, Japan

SO PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9909053	A1	19990225	WO 1998-JP3627	19980814	
	W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
				JP 1997-255879 A	19970815	
				JP 1998-186802 A	19980528	
	TW 460478	B	20011021	TW 1998-87113211	19980811	
				JP 1997-255879 A	19970815	
				JP 1998-186802 A	19980528	
	CA 2301687	AA	19990225	CA 1998-2301687	19980814	
				JP 1997-255879 A	19970815	
				JP 1998-186802 A	19980528	
				WO 1998-JP3627 W	19980814	
	AU 9886490	A1	19990308	AU 1998-86490	19980814	
	AU 741216	B2	20011129			
				JP 1997-255879 A	19970815	
				JP 1998-186802 A	19980528	
				WO 1998-JP3627 W	19980814	
	JP 2000044595	A2	20000215	JP 1998-229586	19980814	
				JP 1997-255879 A	19970815	
				JP 1998-186802 A	19980528	
	EP 1006122	A1	20000607	EP 1998-937826	19980814	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
				JP 1997-255879 A	19970815	
				JP 1998-186802 A	19980528	
				WO 1998-JP3627 W	19980814	
	US 6255285	B1	20010703	US 2000-485620	20000215	
				JP 1997-255879 A	19970815	
				JP 1998-186802 A	19980528	
				WO 1998-JP3627 W	19980814	
OS	MARPAT 130:196958					
IT	220806-34-8P 220806-55-3P 220806-57-5P					
	220807-12-5P 220807-14-7P 220807-18-1P					
	220807-21-6P 220807-23-8P 220807-24-9P					
	220807-34-1P 220807-43-2P 220807-92-1P					
	220807-93-2P 220807-98-7P 220807-99-8P					
	220808-00-4P 220808-11-7P 220808-24-2P					
	220808-25-3P					
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)					
	(prepn. of 3-tert-butyl-L-tyrosinamide-contg. peptide compds. as motilin receptor antagonists, inhibitors of digestive tract motility, and remedy for high blood motilin)					
RN	220806-34-8 CAPLUS					


CN L-Tyrosinamide, L-phenylalanyl-(2S)-2-phenylglycyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-33-7

CMF C30 H36 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-55-3 CAPLUS


CN L-Tyrosinamide, L-phenylalanyl-(2S)-N-methyl-2-phenylglycyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-54-2

CMF C31 H38 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-57-5 CAPLUS


CN L-Tyrosinamide, L-phenylalanyl-(2R)-N-methyl-2-phenylglycyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-56-4

CMF C31 H38 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2






RN 220807-12-5 CAPLUS

CN L-Tyrosinamide, L-phenylalanyl-(2S)-2-phenylglycyl-3-(1,1-dimethylethyl)-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220807-14-7 CAPLUS


CN L-Tyrosinamide, L-phenylalanyl-(2S)-2-phenylglycyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220807-13-6

CMF C26 H28 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 220807-18-1 CAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-(2R)-2-phenylglycyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220807-17-0  
CMF C30 H36 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220807-21-6 CAPLUS  
CN L-Tyrosinamide, (2R)-N-methyl-N-(2-methyl-1-oxo-3-phenylpropyl)-2-  
phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220807-23-8 CAPLUS

CN L-Tyrosinamide, (2R)-N-[(3R)-1-oxo-3-phenylbutyl]-2-phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220807-24-9 CAPLUS

CN L-Tyrosinamide, (2R)-N-[(3S)-1-oxo-3-phenylbutyl]-2-phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220807-34-1 CAPLUS


CN L-Tyrosinamide, L-tyrosyl-(2S)-2-phenylglycyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220807-33-0

CMF C30 H36 N4 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 220807-43-2 CAPLUS

CN L-Tyrosinamide, (2S)-N-(1-oxo-3-phenylbutyl)-2-phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220807-92-1 CAPLUS


CN L-Tyrosinamide, (.alpha.S)-.alpha.-aminobenzenebutanoyl-(2S)-2-phenylglycyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220807-91-0

CMF C31 H38 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 220807-93-2 CAPLUS

CN L-Tyrosinamide, (2S)-N-(2-methyl-1-oxo-3-phenylpropyl)-2-phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220807-98-7 CAPLUS

CN L-Tyrosinamide, (2S)-N-[(3R)-1-oxo-3-phenylbutyl]-2-phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220807-99-8 CAPLUS

CN L-Tyrosinamide, (2S)-N-[(3S)-1-oxo-3-phenylbutyl]-2-phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-00-4 CAPLUS

CN L-Tyrosinamide, (2S)-N-[(2S)-2-amino-3-phenylpropyl]-2-phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-11-7 CAPLUS

CN L-Tyrosinamide, L-phenylalanyl-(2S)-2-phenylglycyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220808-24-2 CAPLUS


CN L-Tyrosine, L-phenylalanyl-(2S)-2-phenylglycyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220808-23-1

CMF C30 H35 N3 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 220808-25-3 CAPLUS

CN L-Tyrosinamide, (2S)-N-[(2S)-2-amino-3-phenylpropyl]-N-methyl-2-phenylglycyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT **220808-71-9P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 3-tert-butyl-L-tyrosinamide-contg. peptide compds. as motilin receptor antagonists, inhibitors of digestive tract motility, and remedy for high blood motilin)

RN 220808-71-9 CAPLUS



CN L-Tyrosinamide, (2S)-2-phenyl-N-[(2S)-3-phenyl-2-[[ (phenylmethoxy) carbonyl] amino]propyl]glycyl-3-(1,1-dimethylethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



GI





AB Phenethylamine derivs. represented by general formula [I; wherein A represents an amino acid or .alpha.-substituted amino acid residue; R1 represents R6CO, (un)substituted C2-7 linear or branched alkyl, C3-8 alkenyl, or C3-8 alkynyl; R2 represents hydrogen, C1-3 linear or branched alkyl; R3 represents COR7, (un)substituted C1-5 linear or branched alkyl, C2-5 alkenyl, or C2-5 alkynyl; R4 represents H, C1-6 linear or branched alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R5 represents hydroxy or C1-4 n-alkoxy; R6 represents (un)substituted C1-6 linear or branched alkyl, C2-7 alkenyl, or C2-7 alkynyl, optionally benzene- or heterocyclic ring-condensed C3-7 cycloalkyl, (un)substituted C6-12 arom. ring, (un)substituted C3-12 (un)satd. heterocyclic ring, (un)substituted NH2, (un)substituted linear or branched C1-5 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, etc.; and R7 represents H, (un)substituted C1-5 linear or branched alkyl, C3-7 cycloalkyl, (un)substituted NH2, OH, linear or branched alkyl C1-6 alkoxy, or C3-7 cycloalkyloxy] are prepd. Also claimed are a motilin receptor antagonist, an inhibitor of digestive tract motility, and a remedy for high blood motilin. They are also useful for the treatment of irritable bowel syndrome. Thus, N.alpha.-methyl-N-[2-(3-tert-butyl-4-hydroxyphenyl)-1-methylethyl]-L-valinamide was condensed with Boc-Phe-OH using HOBT and DIC in DMF at room temp. for 2.5 days followed by deprotection with CF3CO2H in CH2Cl2 to give the title compd. (II). II in vitro showed IC50 of 1.9 nM for inhibiting the binding of [125I]motilin motilin receptor prepn. from rabbit ileum mucus membrane.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 148 CAPLUS COPYRIGHT 2003 ACS


AN 1999:50263 CAPLUS

DN 130:196468

TI Parallel solid phase synthesis of tetrasubstituted diethylenetriamines via selective amide alkylation and exhaustive reduction of N-acylated dipeptides

AU Nefzi, Adel; Ostresh, John M.; Houghten, Richard A.  
CS Torrey Pines Institute for Molecular Studies, San Diego, CA, 92121, USA  
SO Tetrahedron (1999), 55(2), 335-344  
CODEN: TETRAB; ISSN: 0040-4020  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 130:196468  
IT **220684-81-1P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(parallel solid phase synthesis of tetrasubstituted diethylenetriamines  
via selective amide alkylation and redn. of N-acylated dipeptides)  
RN 220684-81-1 CAPLUS  
CN 1,2-Propanediamine, N1-[(1S)-2-(methylamino)-1-phenylethyl]-3-phenyl-N2-(2-phenylethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB Polyamines are a rapidly developing area of vital importance to biomedical science. Selective N-alkylation followed by N-terminal acylation and the complete redn. of carbonyl amide bonds enables the prepn. by parallel solid phase synthesis of a wide range of N1,N5,1,4-tetrasubstituted-1,5-diamino-3-azapentane derivs.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 45 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:726885 CAPLUS  
DN 130:81859  
TI Total syntheses of vancomycin and eremomycin aglycons  
AU Evans, David A.; Wood, Michael R.; Trotter, B. Wesley; Richardson, Timothy I.; Barrow, James C.; Katz, Jeffrey L.  
CS Department of Chemistry & Chemical Biology, Harvard University, Cambridge, MA, 02138, USA  
SO Angewandte Chemie, International Edition (1998), 37(19), 2700-2704  
CODEN: ACIEF5; ISSN: 1433-7851  
PB Wiley-VCH Verlag GmbH  
DT Journal  
LA English  
IT **218901-86-1P 218901-87-2P 218901-88-3P**  
**218902-10-4P 218902-11-5P 218902-12-6P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(total syntheses of vancomycin and eremomycin aglycons)  
RN 218901-86-1 CAPLUS  
CN Glycinamide, (.beta.R)-N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-.beta.-hydroxy-3-nitro-L-phenylalanyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 218901-87-2 CAPLUS

CN Glycinamide, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-[4-methoxy-2-(phenylmethoxy)phenyl]glycyl-(.beta.R)-4-fluoro-.beta.-hydroxy-3-nitro-L-phenylalanyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 218901-88-3 CAPLUS

CN Glycinamide, (2R)-2-[4-methoxy-2-(phenylmethoxy)phenyl]-N-(trifluoroacetyl)glycyl-(.beta.R)-4-fluoro-.beta.-hydroxy-3-nitro-L-phenylalanyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 218902-10-4 CAPLUS

CN Glycinamide, (.beta.R)-3-chloro-N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-.beta.-hydroxy-5-nitro-L-phenylalanyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 218902-11-5 CAPLUS

CN Glycinamide, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-[4-methoxy-2-(phenylmethoxy)phenyl]glycyl-(.beta.R)-3-chloro-4-fluoro-.beta.-hydroxy-5-nitro-L-phenylalanyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 218902-12-6 CAPLUS

CN Glycinamide, (2R)-2-[4-methoxy-2-(phenylmethoxy)phenyl]-N-(trifluoroacetyl)glycyl-(.beta.R)-3-chloro-4-fluoro-.beta.-hydroxy-5-nitro-L-phenylalanyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB The first syntheses of the vancomycin aglycon and the eremomycin aglycon are reported. Relevant methodol. includes new asym. amino acid syntheses and new macrocyclization reactions amenable to the construction of macrocyclic diaryl ether and biaryl-contg. tripeptides. The detailed route given provides vancomycin aglycon in 40 steps (longest linear sequence) from 3,5-dimethoxybenzyl alc. These syntheses provide diastereoselective solns. to each of the biaryl ether and biaryl macrocycles and define a convergent assemblage process which can be extended to a variety of natural and unnatural analogs in the vancomycin

series.

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:719133 CAPLUS  
DN 129:331046  
TI Preparation of amino acid thiadiazole amide MMP inhibitors  
IN Mitchell, Mark Allen; Schostarez, Heinrich Josef; Maggiora, Linda Louise;  
Lindberg, Thomas J.  
PA USA  
SO U.S., 27 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5830869	A	19981103	US 1997-878266	19970618
				US 1997-878266	19970618


OS MARPAT 129:331046

IT **200642-32-6P 200642-33-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of amino acid thiadiazole amide MMP inhibitors)


RN 200642-32-6 CAPLUS

CN Benzenepropanamide, N-[2-[(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)



RN 200642-33-7 CAPLUS

CN Benzenepentanamide, N-[2-[(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)



AB Amino acid derivs. R2CONH-Q-CONHR1 [R1 = 4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl; Q = (un)substituted methylene, ethylene, 1,2-cyclopropanediyl, -cyclobutanediyl, -cyclopentanediy, or

-cyclohexanediyl; R2 = alkyl, (un)substituted Ph or phenylalkyl, 3-indolylalkyl, 9H-fluoren-9-ylmethoxy, alkoxyalkyl, 1-tert-butoxycarbonyl-2-pyrrolyl] were prepd. as MMP inhibitors. Thus, Cbz-NHCHPhCONHR1 (Cbz = benzyloxycarbonyl, same R1), prepd. by amidation reaction, showed  $K_i = 1.21 \mu\text{M}$  for inhibition of stromelysin.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1998:625620 CAPLUS

DN 129:316000

TI Synthesis of enantiopure homoallylic alcohols by a highly selective asymmetric allylation of ketones

AU Tietze, Lutz F.; Schiemann, Kai; Wegner, Christoph; Wulff, Christian

CS Institute Organic Chemistry, Georg-August-Universitat Gottingen, Gottingen, D-37077, Germany

SO Chemistry--A European Journal (1998), 4(9), 1862-1869

CODEN: CEUJED; ISSN: 0947-6539

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

OS CASREACT 129:316000

IT **165823-95-0P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of enantiopure homoallylic alcs. by asym. allylation of ketones)

RN 165823-95-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[(1S)-1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB A highly selective asym. domino allylation of aliph. ketones is described. When Me ketones, (R,R)-Me<sub>2</sub>SiOCHPhCHMeNHCOCF<sub>3</sub>, and CH<sub>2</sub>:CHCH<sub>2</sub>SiMe<sub>3</sub> react in the presence of catalytic amts. of trifluoromethanesulfonic acid, the homoallylic ethers are produced with up to 24:1 diastereoselectivity and 89% yield. Ether cleavage using lithium or sodium in liq. ammonia gives the homoallylic alcs. in 75 to 95% yield and up to 92% ee. Even EtCOMe, the most difficult example, showed a stereoselectivity of 9:1 at -78.degree.C and 24:1 at -109.degree.C. In addn., the allylation of protected hydroxyalkyl Me ketones gave the corresponding homoallylic ethers with a diastereoselectivity of up to >244:1 and 98% yield. In contrast, Et alkyl ketones have a low selectivity.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 48 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1998:479505 CAPLUS

DN 129:122870

TI Preparation of cycloalkyl, lactam, lactone and related compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis

IN Wu, Jing; Tung, Jay S.; Thorsett, Eugene D.; Pleiss, Michael A.; Nissen, Jeffrey S.; Neitz, Jeffrey; Latimer, Lee H.; John, Varghese; Freedman, Stephen; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry, Thomas E.; Dressman, Bruce A.; Cwi, Cynthia L.; Droste, James J.; Henry, Steven S.; Mcdaniel, Stacey L.; Scott, William Leonard; Stucky, Russell D.; Porter, Warren J.

PA Athena Neurosciences, Inc., USA; Eli Lilly & Co.

SO PCT Int. Appl., 889 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9828268	A2	19980702	WO 1997-US22986	19971222
	WO 9828268	A3	19981008		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
				US 1996-64851P P	19961223
				US 1996-64851P P	19961223
				US 1996-780025 A1	19961223
	ZA 9711537	A	19980625	ZA 1997-11537	19971222
				US 1996-780025 A	19961223
	AU 9857007	A1	19980717	AU 1998-57007	19971222
	AU 749658	B2	20020627		
				US 1996-780025 A	19961223
				WO 1997-US22986W	19971222
	EP 951466	A2	19991027	EP 1997-953208	19971222
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
				US 1996-780025 A	19961223
				WO 1997-US22986W	19971222
	CN 1242007	A	20000119	CN 1997-180901	19971222
				US 1996-780025 A	19961223
	BR 9714517	A	20000704	BR 1997-14517	19971222
				US 1996-780025 A	19961223
				WO 1997-US22986W	19971222
	JP 2000511932	T2	20000912	JP 1998-528867	19971222
				US 1996-780025 A	19961223
				WO 1997-US22986W	19971222
	NZ 335583	A	20010330	NZ 1997-335583	19971222
				US 1996-780025 A	19961223
				WO 1997-US22986W	19971222



MX 9905844 A 20000731  
 NO 9903098 A 19990820  
 US 2002045747 A1 20020418  
 US 2002055500 A1 20020509

MX 1999-5844 19990621  
 US 1996-780025 A 19961223  
 WO 1997-US22986W 19971222  
 NO 1999-3098 19990622  
 US 1996-780025 A 19961223  
 WO 1997-US22986W 19971222  
 US 2001-916282 20010730  
 US 1996-64851P P 19961223  
 US 1996-780025 A 19961223  
 US 1997-996422 A319971222  
 US 2001-916440 20010730  
 US 1996-64851P P 19961223  
 US 1996-780025 A 19961223  
 US 1997-996422 A319971222

## PATENT FAMILY INFORMATION:

FAN 1999:425778

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9932453	A1	19990701	WO 1998-US22637	19981029
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 1996-64851P P 19961223 US 1997-996422 A 19971222 US 1998-102726 A 19980622 CA 2307221 AA 19990701 CA 1998-2307221 19981029 US 1997-996422 A 19971222 US 1998-102726 A 19980622 WO 1998-US22637W 19981029 AU 9912777 A1 19990712 AU 1999-12777 19981029 US 1997-996422 A 19971222 US 1998-102726 A 19980622 WO 1998-US22637W 19981029 BR 9812773 A 20001010 BR 1998-12773 19981029 US 1997-996422 A 19971222 US 1998-102726 A 19980622 WO 1998-US22637W 19981029 EP 1042298 A1 20001011 EP 1998-956198 19981029 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO US 1997-996422 A 19971222 US 1998-102726 A 19980622 WO 1998-US22637W 19981029 US 2002068741 A1 20020606 US 2001-915263 20010726 US 1996-64851P P 19961223 US 1997-996422 A319971222 US 2001-915480 20010727 US 2002052359 A1 20020502 US 6544978 B2 20030408 US 1996-64851P P 19961223 US 1997-996422 A319971222 US 2002111343 A1 20020815 US 2001-915547 20010727				

US 2002115652 A1 20020822  
US 6541466 B2 20030401

US 2002123486 A1 20020905

US 2002137738 A1 20020926  
US 6559141 B2 20030506

US 2002151538 A1 20021017

US 2002173504 A1 20021121

US 2002045747 A1 20020418

US 2002055500 A1 20020509

US 1996-64851P P 19961223  
US 1997-996422 A319971222  
US 2001-915362 20010727

US 1996-64851P P 19961223  
US 1997-996422 A319971222  
US 2001-915342 20010727  
US 1996-64851P P 19961223  
US 1997-996422 A319971222  
US 2001-915564 20010727

US 1996-64851P P 19961223  
US 1997-996422 A319971222  
US 2001-915379 20010727  
US 1996-64851P P 19961223  
US 1997-996422 A319971222  
US 2001-915519 20010727  
US 1996-64851P P 19961223  
US 1997-996422 A319971222  
US 2001-916282 20010730  
US 1996-64851P P 19961223  
US 1996-780025 A 19961223  
US 1997-996422 A319971222  
US 2001-916440 20010730  
US 1996-64851P P 19961223  
US 1996-780025 A 19961223  
US 1997-996422 A319971222

OS MARPAT 129:122870


IT **209988-54-5P 209988-58-9P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of cycloalkyl, lactam, lactone and related compds. for inhibiting .beta.-amyloid peptide release and/or its synthesis)

RN 209988-54-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209988-58-9 CAPLUS

CN Benzenebutanamide, N-[(1S)-2-[[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Disclosed are compds.  $R_1ZmNHYNCHpR_2C(X)R_3$  [ $R_1$  = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl or aryl, heteroaryl, or heterocyclic;  $R_2$  and  $R_3$  form a cycloalkyl, cycloalkenyl, heterocyclic, substituted cycloalkyl, or substituted cycloalkenyl ring which is optionally fused;  $X$  = oxo, thioxo, hydroxyl, thiol, or hydro;  $Y$  =  $CHR_4CONH$  where  $R_4$  = (un)substituted alkyl, alkenyl, or alkynyl or cycloalkyl, aryl, heteroaryl, or heterocyclic;  $Z$  is  $TCX'X''CO$  where  $T$  is a bond, O, S,  $NR_5$  ( $R_5$  = H, acyl, alkyl, aryl, or heteroaryl),  $X'$  and  $X''$  are H, OH, or F or  $X'X''$  = oxo;  $m, p = 0, 1$ ;  $n = 0, 1, 2$ ] which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Thus, 3-[[N'-(3,4-methylenedioxyphenylacetyl)-L-alaninyl]amino]-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one was prepd. by coupling of 3-(L-alaninylamino)-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one with 3,4-methylenedioxyphenylacetic acid.

L4 ANSWER 49 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1998:450863 CAPLUS

DN 129:149240

TI Synthesis of tripeptides containing .alpha.,.alpha.-diphenylglycine by the modified Ugi reaction

AU Yamada, Takashi; Omote, Yuichiro; Yamanaka, Yoshinori; Miyazawa, Toshifumi; Kuwata, Shigeru

CS Department Chemistry, Faculty Science, Konan University, Kobe, 658, Japan

SO Synthesis (1998), (7), 991-998

CODEN: SYNTBF; ISSN: 0039-7881

PB Georg Thieme Verlag

DT Journal

LA English

IT **142618-58-4P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of tripeptides contg. .alpha.,.alpha.-diphenylglycine by modified Ugi reaction)

RN 142618-58-4 CAPLUS

CN Glycine, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-2,2-diphenylglycyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A modified Ugi reaction was developed to synthesize tripeptides contg. H<sub>2</sub>NCPH<sub>2</sub>CO<sub>2</sub>H (Dph) together with bulky amino acids. By the use of Ph<sub>2</sub>CNH, N-benzoxycarbonyl (Z) amino acids, and isocyanoacetates, crowded tripeptides such as Z-Aib-Dph-Aib-OMe, Z-Ac6c-Dph-Aib-OMe, and Z-(Dph)<sub>3</sub>-OMe, were synthesized.

L4 ANSWER 50 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1998:405971 CAPLUS

DN 129:81965

TI Preparation of peptidyl 5-amino-1,3,4-thiadiazole-2-thiones

IN Oleksyszyn, Jozef; Jacobson, Alan R.

PA Proscript, Inc., USA; Oleksyszyn, Jozef; Jacobson, Alan R.

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9825949	A1	19980618	WO 1997-US22534	19971209
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9856923	A1	19980703	US 1996-762503	19961209
				AU 1998-56923	19971209
				US 1996-762503	19961209
				WO 1997-US22534	19971209

OS MARPAT 129:81965

IT **186098-00-0P 186098-04-4P 186098-07-7P**

**186098-66-8P 186098-67-9P 209274-75-9P**


**209274-89-5P 209274-90-8P 209275-20-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of peptidyl aminothiadiazolethiones)

RN 186098-00-0 CAPLUS

CN Glycinamide, 4-[bis(phenylmethyl)amino]-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186098-04-4 CAPLUS

CN Glycinamide, N-[(phenylmethoxy) carbonyl]glycyl-L-tyrosyl-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.




RN 186098-07-7 CAPLUS

CN Glycinamide, 1-[(phenylmethoxy) carbonyl]-L-prolyl-L-phenylalanyl-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 186098-66-8 CAPLUS

CN Glycinamide, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysyl-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186098-67-9 CAPLUS

CN Glycinamide, N2-[(phenylmethoxy)carbonyl]-L-lysyl-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209274-75-9 CAPLUS

CN Glycinamide, 1-[(phenylmethoxy)carbonyl]-L-prolyl-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 209274-89-5 CAPLUS

CN Glycinamide, O-(1,1-dimethylethyl)-N-[4-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]benzoyl]-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209274-90-8 CAPLUS

CN Glycinamide, N-[4-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]benzoyl]-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209275-20-7 CAPLUS

CN Glycinamide, N-[(phenylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 186098-36-2P 186098-37-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of peptidyl aminothiadiazoethiones)

RN 186098-36-2 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 186098-37-3 CAPLUS


CN Glycinamide, O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

GI



AB Aminothiadiazoethiones I (Q, A = S, O and one of Q and A is S; R1 = H, alkyl, acyl; Z is an org. radical that does not substantially interfere with matrix metalloproteinase inhibitory activity) were prepd. Thus, 5-[N-[4-(4-tert-butylphenylsulfonylamino)benzoyl]phenylalanylvalylamino]-1,3,4-thiadiazole-2-thione, prepd. by acylation of 5-amino-1,3,4-thiadiazole-2-thione with the phenylalanylvaline deriv., was assayed for stromelysin inhibitory activity (IC50 = 44 nM).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 51 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1998:352865 CAPLUS

DN 129:54603

TI Preparation of antiviral peptide derivatives

IN Attwood, Michael Richard; Hurst, David Nigel; Jones, Philip Stephen; Kay, Paul Brittain; Raynham, Tony Michael; Wilson, Francis Xavier

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9822496	A2	19980528	WO 1997-EP6189	19971107

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,  
 UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG

AU 9855510	A1	19980610	GB 1996-23908	A	19961118
			AU 1998-55510		19971107
			GB 1996-23908	A	19961118
EP 941233	A2	19990915	WO 1997-EP6189	W	19971107
R: DE, ES, FR, GB, IT			EP 1997-951869		19971107
			GB 1996-23908	A	19961118
			WO 1997-EP6189	W	19971107
JP 2000508344	T2	20000704	JP 1998-523153		19971107
JP 3372260	B2	20030127			
			GB 1996-23908	A	19961118
			WO 1997-EP6189	W	19971107
ZA 9710156	A	19980518	ZA 1997-10156		19971111
			GB 1996-23908	A	19961118
US 5866684	A	19990202	US 1997-971036		19971114
			GB 1996-23908	A	19961118
US 6018020	A	20000125	US 1998-96570		19980612
			GB 1996-23908	A	19961118
			US 1997-971036	A3	19971114

OS MARPAT 129:54603


IT **208520-30-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of antiviral peptide derivs.)

RN 208520-30-3 CAPLUS

CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-L-.alpha.-aspartyl-L-.alpha.-glutamyl-2-methyl-L-phenylalanyl-(2S)-2-phenylglycyl-N-(1-borono-3-butenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **208521-66-8P 208521-67-9P 208521-68-0P**

**208521-69-1P 208521-70-4P 208521-84-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(prepn. of antiviral peptide derivs.)

RN 208521-66-8 CAPLUS

CN L-Leucinamide, N-[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]-L-.alpha.-  
aspartyl-L-.alpha.-glutamyl-2-methyl-L-phenylalanyl-(2S)-2-phenylglycyl-N-  
[1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-butenyl]-,  
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208521-67-9 CAPLUS

CN L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-2-methyl-L-phenylalanyl-(2S)-2-  
phenylglycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208521-68-0 CAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-.alpha.-glutamyl-2-  
methyl-L-phenylalanyl-(2S)-2-phenylglycyl-, 1-(1,1-dimethylethyl)  
4-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208521-69-1 CAPLUS

CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-2-methyl-L-phenylalanyl-(2S)-2-phenylglycyl-, 1,2-bis(1,1-dimethylethyl) 5-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208521-70-4 CAPLUS


CN L-Leucine, N-[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-2-methyl-L-phenylalanyl-(2S)-2-phenylglycyl-, 1,2-bis(1,1-dimethylethyl) 5-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 208521-84-0 CAPLUS

CN L-Leucine, N-[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-2-methyl-L-phenylalanyl-(2S)-2-phenylglycyl-,  
1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Peptides R<sub>9</sub>NHCHR<sub>8</sub>CONHCHR<sub>7</sub>CONR<sub>6</sub>CHR<sub>5</sub>CONHCHR<sub>4</sub>CONR<sub>3</sub>CHR<sub>2</sub>CONHCHRR<sub>1</sub> [R = CHO or B(OH)<sub>2</sub>; R<sub>1</sub> = optionally substituted alkyl, alkenyl, alkynyl; R<sub>2</sub> = optionally substituted alkyl; R<sub>3</sub> = H, alkyl; or R<sub>2</sub> and R<sub>3</sub> together represent di- or trimethylene optionally substituted by hydroxy; R<sub>4</sub> = optionally substituted alkyl, alkenyl, aryl, cycloalkyl; R<sub>5</sub> = optionally substituted alkyl, cycloalkyl; R<sub>6</sub> = H, alkyl; R<sub>7</sub> = optionally substituted alkyl, cycloalkyl; R<sub>8</sub> = optionally substituted alkyl; R<sub>9</sub> = alkylcarbonyl, carboxyalkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, alkoxy carbonyl, arylalkoxy carbonyl] or their salts were prepd. for use as antiviral agents. Thus, 2(RS)-[N-[N-[N-[N-[N-(3-carboxypropionyl)-L-.alpha.-aspartyl]-L-.alpha.-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucyl]amino]-4-pentenaldehyde, prepd. via intermediate N-[N-[N-[N-[N-[N-(3-tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-.alpha.-aspartyl]-O-tert-butyl-L-.alpha.-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucine, was assayed for inhibition of ACV protease (IC<sub>50</sub> = 0.09 .mu.Mol/l).

L4 ANSWER 52 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1998:215089 CAPLUS

DN 128:265810

TI Inhibition of Membrane-Type 1 Matrix Metalloproteinase by Hydroxamate Inhibitors: An Examination of the Subsite Pocket

AU Yamamoto, Minoru; Tsujishita, Hideki; Hori, Noriyuki; Ohishi, Yuichi; Inoue, Shintaro; Ikeda, Shoji; Okada, Yasunori

CS New Drug Discovery Research Laboratory, Kanebo Ltd., Osaka, 534, Japan

SO Journal of Medicinal Chemistry (1998), 41(8), 1209-1217

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

IT **188728-61-2P 188728-67-8P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and biol. activity of hydroxamate inhibitors of matrix metalloproteinases)

RN 188728-61-2 CAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]-2-(2-phenylethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188728-67-8 CAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]-2-(3-phenylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 188729-03-5P 188729-04-6P 205526-94-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and biol. activity of hydroxamate inhibitors of matrix metalloproteinases)

RN 188729-03-5 CAPLUS

CN Benzenepentanoic acid, .beta.-[[[2-(methylamino)-2-oxo-1-phenylethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, [S-(R\*,S\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 188729-04-6 CAPLUS

CN Benzenepentanoic acid, .beta.-[[[2-(methylamino)-2-oxo-1-phenylethyl]amino]carbonyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 205526-94-9 CAPLUS

CN Butanediamide, N1-[2-(methylamino)-2-oxo-1-phenylethyl]-2-(2-phenylethyl)-N4-(phenylmethoxy)-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The membrane-type 1 matrix metalloproteinase (MT1-MMP) has been reported to mediate the activation of pro-gelatinase A (proMMP-2), which is assocd. with tumor proliferation and metastasis. MT1-MMP can also digest extracellular matrix (ECM) such as interstitial collagens, gelatin, and proteoglycan and thus may play an important role in pathophysiol. digestion of ECM. The authors studied the inhibitory effect of various hydroxamate MMP inhibitors, including known inhibitors such as BB-94, BB-2516, GM6001, and Ro31-9790, on a deletion mutant of MT1-MMP lacking the transmembrane domain (.DELTA.MT1) to further characterize the enzyme and develop a selective inhibitor for MT1-MMP. The evaluation of the inhibitory activities of various hydroxamates reveals general structural profiles affecting selectivities toward MMPs. In particular, a longer side chain at the P1' position is preferable for the binding to MMP-2, -3, and -9 and MT1-MMP. For the P2' position, an .alpha.-branched alkyl group is crit. for the binding toward .DELTA.MT1, while the introduction of a bulky group at the .alpha.-position of hydroxamic acid seems to diminish the activity against .DELTA.MT1. Summation of the data on the sensitivity of .DELTA.MT1 to various hydroxamate inhibitors indicates that (1) the vol. of the S1' subsite of .DELTA.MT1 is similar to that of MMP-2, -3, and -9, which is bigger than that of MMP-1, and (2) the S1 and S2' subsites are narrower than those in other MMPs. On the basis of these results, the hydroxamates with a P1' phenylpropyl and P2' .alpha.-branched alkyl group were synthesized and evaluated for inhibitory activity. Inhibitors, such as hydroxamate I, showed strong activity against .DELTA.MT1 (IC<sub>50</sub> = 1.9 nM) over MMP-1 (IC<sub>50</sub> = 21 nM), but no selectivity between .DELTA.MT1 and MMP-9 (IC<sub>50</sub> = 1.3 nM). These results are explained using mol. modeling studies conducted on MT1-MMP.

L4 ANSWER 53 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1998:31296 CAPLUS

DN 128:75670

TI Preparation of amino acid thiadiazole amide MMP inhibitors

IN Mitchell, Mark A.; Schostarez, Heinrich J.; Maggiora, Linda L.; Lindberg, Thomas J.



PA Pharmacia and Upjohn Co., USA; Mitchell, Mark A.; Schostarez, Heinrich J.;  
Maggiore, Linda L.; Lindberg, Thomas J.

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9748688	A1	19971224	WO 1997-US9204	19970618
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				
	LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,				
	UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
	GN, ML, MR, NE, SN, TD, TG				
				US 1996-20188P P	19960621
	AU 9734747	A1	19980107	AU 1997-34747	19970618
				US 1996-20188P P	19960621
				WO 1997-US9204 W	19970618
	EP 1021424	A1	20000726	EP 1997-931009	19970618
	EP 1021424	B1	20030226		
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI	
				US 1996-20188P P	19960621
				WO 1997-US9204 W	19970618
	JP 2000514787	T2	20001107	JP 1998-503000	19970618
				US 1996-20188P P	19960621
				WO 1997-US9204 W	19970618
	AT 233251	E	20030315	AT 1997-931009	19970618
				US 1996-20188P P	19960621
				WO 1997-US9204 W	19970618


OS MARPAT 128:75670

IT **200642-32-6P 200642-33-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of amino acid thiadiazole amide MMP inhibitors)


RN 200642-32-6 CAPLUS

CN Benzenepropanamide, N-[2-[(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)




RN 200642-33-7 CAPLUS

CN Benzenepentanamide, N-[2-[(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)



GI



AB Amino acid thiadiazole amides I [Q = (CHR<sub>1</sub>)<sub>n</sub> (R<sub>1</sub> = H, alkyl, Ph, alkylaryl, cycloalkylalkyl, etc. and n = 1 or 2), C3-C6 1,2-cycloalkanediyl; R<sub>2</sub> = alkyl, arylalkyl, 3-indolylalkyl, 9H-fluoren-9-ylmethoxy, alkoxy, alkoxyalkyl, etc. ] were prepd. as MMP inhibitors. Thus, [2-[(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-2-oxo-1-phenylethyl]carbamic acid phenylmethyl ester was prepd. by coupling of 5-amino-1,3,4-thiadiazole-2-thione with Cbz-(+/-)-phenylglycine. The product was tested for inhibition of stromelysin (K<sub>i</sub> = 1,21 .mu.M).

L4 ANSWER 54 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:761604 CAPLUS

DN 128:30398

TI Agonist peptides of thrombin receptor and stimulation of platelet aggregation

IN Coughlin, Shaun R.; Scarborough, Robert M.

PA COR Therapeutics, Inc., USA

SO U.S., 89 pp., Cont.-in-part of U.S. 5,256,766.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5688768	A	19971118	US 1991-789184	19911107
				US 1991-657769 A2	19910219
	US 5256766	A	19931026	US 1991-657769	19910219
	CA 2104394	AA	19920820	CA 1992-2104394	19920219
				US 1991-657769 A	19910219
	WO 9214750	A1	19920903	WO 1992-US1312	19920219
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
	AU 9214568	A1	19920915	AU 1992-14568	19920219

AU 665752 B2 19960118

EP 572553 A1 19931208

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE

JP 06508742 T2 19941006

US 6197541 B1 20010306

US 5759994 A 19980602

US 5798248 A 19980825

US 5849507 A 19981215

US 5856448 A 19990105

US 6024936 A 20000215

US 1991-657769 A 19910219

US 1991-789184 A 19911107

WO 1992-US1312 A 19920219

EP 1992-907700 19920219

US 1991-657769 A 19910219

US 1991-789184 A 19911107

WO 1992-US1312 W 19920219

JP 1992-507331 19920219

US 1991-657769 A 19910219

US 1991-789184 A 19911107

WO 1992-US1312 W 19920219

US 1993-18760 19930217

US 1991-657769 A119910219

US 1991-789184 A319911107

US 1995-475263 19950607

US 1991-657769 A219910219

US 1991-789184 A119911107

US 1995-485886 19950607

US 1991-657769 A219910219

US 1991-789184 A319911107

US 1995-477362 19950607

US 1991-657769 A219910219

US 1991-789184 A319911107

US 1995-477134 19950607

US 1991-657769 A219910219

US 1991-789184 A319911107

US 1995-473489 19950607

US 1991-657769 A219910219

US 1991-789184 A319911107

## PATENT FAMILY INFORMATION:

FAN 1993:116751

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9214750	A1	19920903	WO 1992-US1312	19920219
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
	US 5256766	A	19931026	US 1991-657769	19910219
	US 5688768	A	19971118	US 1991-789184	19911107
				US 1991-657769 A2	19910219
	AU 9214568	A1	19920915	AU 1992-14568	19920219
	AU 665752	B2	19960118		
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
				WO 1992-US1312 A	19920219
	EP 572553	A1	19931208	EP 1992-907700	19920219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
				WO 1992-US1312 W	19920219
	JP 06508742	T2	19941006	JP 1992-507331	19920219
				US 1991-657769 A	19910219

US 1991-789184 A 19911107  
WO 1992-US1312 W 19920219

OS MARPAT 128:30398


IT **145229-80-7P 145230-57-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(agonist peptides of thrombin receptor and stimulation of platelet aggregation)

RN 145229-80-7 CAPLUS

CN L-Arginine, L-seryl-L-phenylalanyl-(2S)-2-phenylglycyl-L-leucyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 145230-57-5 CAPLUS

CN L-Argininamide, L-seryl-L-phenylalanyl-(2S)-2-phenylglycyl-L-leucyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



AB Peptide agonists of the thrombin receptor which are useful for platelet

aggregation are claimed. CDNA encoding the human cell surface receptor for thrombin was cloned and sequenced. Peptides based on the N-terminus of the activated human thrombin receptor were prepd. and tested for agonist activity in platelet aggregation assays. Peptides with EC50's as low as 1.1 .mu.M were produced. Addnl., antagonist peptides, thrombin mutant antagonists, and anti-receptor antibody antagonists were prepd. and tested.

L4 ANSWER 55 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:643193 CAPLUS

DN 127:307517

TI Preparation of enantiopure precursors for the vitamin E synthesis. A comparison of the asymmetric allylation of ketones and the Sharpless bishydroxylation

AU Tietze, Lutz F.; Gorlitzer, Jochen

CS Institut Organische Chemie, Georg-August-Universitat, Goettingen, D-37077, Germany

SO Synlett (1997), (9), 1049-1050

CODEN: SYNLES; ISSN: 0936-5214

PB Thieme

DT Journal

LA English

OS CASREACT 127:307517

IT **197297-78-2P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of vitamin E precursors by asym. allylation of ketones and Sharpless bishydroxylation)

RN 197297-78-2 CAPLUS

CN Acetamide, N-[(1R,2R)-2-[[[(1S)-1-[2-(2,5-dimethoxy-3,4,6-trimethylphenyl)ethyl]-1-methyl-3-butenyl]oxy]-1-methyl-2-phenylethyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **197297-80-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)


(synthesis of vitamin E precursors by asym. allylation of ketones and Sharpless bishydroxylation)

RN 197297-80-6 CAPLUS


CN Acetamide, N-[(1R,2R)-2-[(S)-1-[2-(2,5-dimethoxy-3,4,6-trimethylphenyl)ethyl]-1-methyl-3-oxopropoxy]-1-methyl-2-phenylethyl]-

2,2,2-trifluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



GI



I



II

AB The enantioselective synthesis of the precursors I [R = OH, R1 = Me, R2 = allyl; R = Me, R1 = OH, R2 = CH<sub>2</sub>OH or (S)-CHOHCH<sub>2</sub>OH] and II for the prepn. of enantiopure .alpha.-tocopherol by asym. allylation of the ketone I (RR1 = O, R2 = Me) and Sharpless dihydroxylation of the aliph. alkenes I (RR1 = CH<sub>2</sub>, CHCH<sub>2</sub>OH; R2 = Me) is described.

L4 ANSWER 56 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:639948 CAPLUS

DN 127:307269

TI Preparation of optically active succinic acid derivatives. I. Optical resolution of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionic acid

AU Yamaguchi, Toshiaki; Yanagi, Takashi; Hokari, Hiroshi; Mukaiyama, Yuko; Kamijo, Tetsuhide; Yamamoto, Iwao

CS Kissei Pharmaceutical Co., Ltd., Central Research Laboratories, Hotaka, 399-83, Japan

SO Chemical & Pharmaceutical Bulletin (1997), 45(9), 1518-1520

CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English

IT **197447-44-2P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(optical resolu. of benzyl(hexahydroisoindolinylicarbonyl)propionic acid)

RN 197447-44-2 CAPLUS

CN 2H-Isoindole-2-butanoic acid, octahydro-.gamma.-oxo-.alpha.-(phenylmethyl)-, 2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl ester, [2(.alpha.S)-[2[R\*(R\*)],3a.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT **197447-45-3P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(optical resolu. of benzyl(hexahydroisoindolinylicarbonyl)propionic acid)

RN 197447-45-3 CAPLUS

CN 2H-Isoindole-2-butanoic acid, octahydro-.gamma.-oxo-.alpha.-(phenylmethyl)-, 2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl ester, [2(.alpha.R)-[2[R\*(S\*)],3a.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB Optical resolu. of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionic acid (I) was accomplished by two methods. Thus, I was esterified with (S)-N-benzylmandelamide and the resulting diastereomeric esters were sepd. by column chromatog. on silica gel. One of the diastereomers was hydrolyzed to give the optically active acid (-)-I. The abs. configuration of (-)-I was established as S by comparison with an authentic sample. The alternative method was resolu. using an optically active amine. Treatment of a soln. of the racemic acid I with

0.65 equiv of (R)-1-(1-naphthyl)ethylamine in ethanol gave the salt in 23.2% yield with an optical purity of 96.8% ee.

L4 ANSWER 57 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:565204 CAPLUS

DN 127:248391

TI Synthesis of model tricyclic C-O-D-O-E-F-O-G ring of teicoplanin

AU Bois-Choussy, Michele; Vergne, Caroline; Neuville, Luc; Beugelmans, Rene; Zhu, Jieping

CS Inst. Chimie Substances Naturelles, Gif-sur-Yvette, 91198, Fr.

SO Tetrahedron Letters (1997), 38(33), 5795-5798

CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier

DT Journal

LA English


IT 195608-30-1P 195738-64-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of model tricyclic C-O-D-O-E-F-O-G ring of teicoplanin)

RN 195608-30-1 CAPLUS


CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-3-nitro-D-phenylalanyl-(2S)-2-[3-(1-methylethoxy)phenyl]glycyl-(2R)-2-(3,5-dihydroxy-4-methoxyphenyl)glycyl-(2R)-2-(4-methoxyphenyl)glycyl-3-nitro-, methyl ester, cyclic (3.fwdarw.5)-ether, stereoisomer (9CI) (CA INDEX NAME)



RN 195738-64-8 CAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-3-nitro-D-phenylalanyl-(2S)-2-[3-(1-methylethoxy)phenyl]glycyl-(2R)-2-(3,5-dihydroxy-4-methoxyphenyl)glycyl-(2R)-2-(4-methoxyphenyl)glycyl-3-nitro-, methyl ester, cyclic (3.fwdarw.5)-ether, stereoisomer (9CI) (CA INDEX NAME)





AB Synthesis of model tricyclic C-O-D-O-E-F-O-G rings of teicoplanin by means of efficient SNAr based cycloetherification methodol. is reported.

L4 ANSWER 58 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:547277 CAPLUS

DN 127:162122

TI Preparation of 5-amino-4-hydroxyhexanoic acid derivatives for treatment of AIDS

IN Bold, Guido; Lang, Marc; Fassler, Alexander; Capraro, Hans-georg; Bhagwat, Shripad; Schneider, Peter; Hoogevest, Peter van

PA Ciba-Geigy Corp., USA

SO U.S., 98 pp., Cont.-in-part of U.S. Ser. No. 941,595, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643878	A	19970701	US 1994-207646	19940308
				CH 1991-2689	19910912
				CH 1992-890	19920327
				CH 1992-2007	19920625
				US 1992-941595	19920908
	ZA 9206938	A	19940311	CH 1992-772	19930311
				ZA 1992-6938	19920911
	CN 1089269	A	19940713	CH 1991-2689	19910912
				CN 1993-100044	19930104
				CH 1991-2689	19910912

# PATENT FAMILY INFORMATION:

FAN 1993:650508

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 532466	A2	19930317	EP 1992-810678	19920903
	EP 532466	A3	19930616		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
CH 1991-2689 19910912

			CH 1992-980	19920327
			CH 1992-2007	19920625
JP 05230095	A2	19930907	JP 1992-238424	19920907
			CH 1991-2689	19910912
			CH 1992-980	19920327
			CH 1992-2007	19920625
CA 2077948	AA	19930313	CA 1992-2077948	19920910
			CH 1991-2689	19910912
			CH 1992-980	19920327
			CH 1992-2007	19920625
AU 9222889	A1	19930318	AU 1992-22889	19920910
AU 661018	B2	19950713		
			CH 1991-2689	19910912
			CH 1992-980	19920327
			CH 1992-2007	19920625
IL 103126	A1	19970930	IL 1992-103126	19920910
			CH 1991-2689	19910912
			CH 1992-980	19920327
			CH 1992-2007	19920625
NO 9203533	A	19930315	NO 1992-3533	19920911
			CH 1991-2689	19910912
			CH 1992-980	19920327
			CH 1992-2007	19920625
HU 63632	A2	19930928	HU 1992-2925	19920911
			CH 1991-2689	19910912
			CH 1992-980	19920327
			CH 1992-2007	19920625
ZA 9206938	A	19940311	ZA 1992-6938	19920911
			CH 1991-2689	19910912
PL 169969	B1	19960930	PL 1992-295905	19920911
			CH 1991-2689	19910912
			CH 1992-980	19920327
			CH 1992-2007	19920625
RU 2067585	C1	19961010	RU 1992-5052915	19920911
			CH 1991-2689	19910912
			CH 1992-980	19920327
			CH 1992-2007	19920625
CN 1089269	A	19940713	CN 1993-100044	19930104
			CH 1991-2689	19910912

OS MARPAT 127:162122

IT **165453-86-1P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of aminohydroxyhexanoic acid derivs. for treatment of AIDS)

RN 165453-86-1 CAPLUS

CN Carbamic acid, [2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[2-[[1-[(4-methoxyphenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]amino]-2-oxo-1-phenylethyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5[R\*(R\*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 165453-83-8P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminohydroxyhexanoic acid derivs. for treatment of AIDS)


RN 165453-83-8 CAPLUS

CN Carbamic acid, [2-hydroxy-5-[[2-[[1-[(4-methoxyphenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]amino]-2-oxo-1-phenylethyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5[R\*(R\*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Peptides I [A1, B1 = bond, amino acid residue; A2 = amino acid residue; R1 = H, alkoxycarbonyl, or (un)substituted benzyloxycarbonyl; R2, R3 = (un)substituted Ph or cyclohexyl; R4R5N = (un)substituted morpholino] were prepd. for the treatment of AIDS. Thus, 5(S)-Boc-amino-4(S)-hydroxy-6-cyclohexyl-2(R)-(p-fluorophenylmethyl)hexanoyl-L-Val-L-Phe-morpholin-4-ylamide (Boc = tert-butoxycarbonyl) was prepd. via peptide coupling in soln.

L4 ANSWER 59 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:348120 CAPLUS

DN 127:90113

TI Selective peptidic and peptidomimetic inhibitors of *Candida albicans* myristoylCoA:protein N-myristoyltransferase: a new approach to antifungal therapy

AU Sikorski, James A.; Devadas, Balekudru; Zupec, Mark E.; Freeman, Sandra; Brown, David L.; Lu, Hwang-Fun; Nagarajan, Srinivasan; Mehta, Pramod P.; Wade, Arlene C.; Kishore, Nandini S.; Bryant, Martin L.; Getman, Daniel P.; McWherter, Charles A.; Gordon, Jeffrey I.

CS G. D. Searle Research and Development, Monsanto Company, St. Louis, MO, 63198, USA

SO Biopolymers (1997), 43(1), 43-71

CODEN: BIPMAA; ISSN: 0006-3525

PB Wiley

DT Journal

LA English

IT 190732-34-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(structure activity relations of inhibitors of *Candida albicans* myristoylCoA:protein N-myristoyltransferase and antifungal therapy)

RN 190732-34-4 CAPLUS

CN L-Leucinamide, N-(5-amino-1-oxopentyl)-L-tyrosyl-(2S)-2-phenylglycyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB MyristoylCoA:protein N-myristoyltransferase (NMT) catalyzes the cotranslational covalent attachment of a rare cellular fatty acid, myristate, to the N-terminal Gly residue of a variety of eukaryotic proteins. The myristoyl moiety is often essential for expression of the biol. functions for these proteins. Attachment of C14:0 alone provides barely enough hydrophobicity to allow stable assocn. with membranes. The partitioning of N-myristoyl-proteins is therefore often modulated by "switches" that function through addnl. covalent or noncovalent modifications. *Candida albicans*, the principal cause of systemic fungal infection in immunocompromised humans, contains a single NMT gene that is essential for its viability. The functional properties of the acylCoA binding site of human and *C. albicans* NMT are very similar. However, there are distinct differences in their peptide binding sites. An ADP ribosylation factor (Arf) is included among the few cellular protein substrates of the fungal enzyme. Alanine scanning mutagenesis of an octapeptide derived from an N-terminal Arf sequence (GLYASKLS-NH<sub>2</sub>) disclosed that Gly1, Ser5, and Lys6 play predominant roles in binding. ALYASKLS-NH<sub>2</sub> is an inhibitor competitive for peptide [ $K_i(\text{app}) = 15.3 \pm 6.4 \mu\text{M}$ ] and noncompetitive for myristoylCoA. Remarkably, replacement of the N-terminal tetrapeptide with an 11-aminoundecanoyl group results in a competitive inhibitor (11-aminoundecanoyl-SKLS-NH<sub>2</sub>) that is approx. 40-fold more potent [ $K_i(\text{app}) = 0.40 \mu\text{M}$ ] than the starting octapeptide. Removal of Leu-Ser from the C-terminus generates a competitive dipeptide inhibitor (11-aminoundecanoyl-SK-NH<sub>2</sub>) with a  $K_i(\text{app})$  of 11.7  $\mu\text{M}$ , equiv. to that of the starting octapeptide. A deriv. dipeptide inhibitor contg. a C-terminal N-cyclohexylethyl lysinamide moiety has the advantage of being more potent ( $\text{IC}_{50} = 0.11 \mu\text{M}$ ) and resistant to digestion by cellular carboxypeptidases. Rigidifying the flexible aminoundecanoyl chain results in very potent general NMT inhibitors ( $\text{IC}_{50} = 40\text{--}50 \text{ nM}$ ). Substituting a 2-methyl-imidazole for the N-terminal amine and adding a benzylic  $\alpha$ -Me group with R stereochem. to the rigidifying element produces even more potent inhibitors ( $\text{IC}_{50} = 20\text{--}50 \text{ nM}$ ) that are up to 500-fold selective for the fungal compared to human enzyme. A related less potent member of this series of compds. is fungistatic. Its growth inhibitory effects are assocd. with a redn. in cellular protein N-myristoylation, judged using cellular Arf as a reporter. These studies establish that NMT is a new antifungal target.

L4 ANSWER 60 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:299761 CAPLUS  
 DN 127:30763  
 TI Scanning alanine mutagenesis and de-peptidization of a *Candida albicans* myristoyl-CoA:protein N-myristoyltransferase octapeptide substrate reveals three elements critical for molecular recognition  
 AU McWherter, Charles A.; Rocque, Warren J.; Zupec, Mark E.; Freeman, Sandra K.; Brown, David L.; Devadas, Balekudru; Getman, Daniel P.; Sikorski, James A.; Gordon, Jeffrey I.  
 CS Searle Discovery Res., Monsanto Co., St. Louis, MO, 63198, USA  
 SO Journal of Biological Chemistry (1997), 272(18), 11874-11880  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PB American Society for Biochemistry and Molecular Biology  
 DT Journal  
 LA English  
 IT **190732-34-4**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
 (prepn. of inhibitors and identification of elements crit. for mol. recognition by *Candida albicans* myristoyl-CoA:protein N-myristoyltransferase by scanning alanine mutagenesis and de-peptidization of octapeptide substrate)  
 RN 190732-34-4 CAPLUS  
 CN L-Leucinamide, N-(5-amino-1-oxopentyl)-L-tyrosyl-(2S)-2-phenylglycyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB *Candida albicans* produces a single myristoyl-CoA:protein N-myristoyltransferase (Nmt) that is essential for its viability. An ADP-ribosylation factor (Arf) is included among the few cellular protein substrates of this enzyme. An octapeptide (GLYASKLS-NH<sub>2</sub>) derived from a N-terminal Arf sequence was used as the starting point to identify elements crit. for recognition by the acyl-transferase's peptide-binding site. In vitro kinetic studies, employing purified Nmt and a panel of peptides with single Ala substitutions at each position of GLYASKLS-NH<sub>2</sub>, established that its Gly, Ser, and Lys residues play predominant roles in binding. ALYASKLS-NH<sub>2</sub> was found to be an inhibitor competitive for peptide ( $K_i = 15.3 \pm 6.4 \mu\text{M}$ ) and noncompetitive for myristoyl-CoA ( $K_i = 31.2 \pm 0.7 \mu\text{M}$ ). A survey of 26 derivs. of this inhibitor,

representing (i) a complete alanine scan, (ii) progressive C-terminal truncations, and (iii) manipulation of the phys.-chem. properties of its residues 1, 5, and 6, confirmed the important stereochem. requirements for the N-terminal amine, the .beta.-hydroxyl of Ser, and the .epsilon.-amino group of Lys. Remarkably, replacement of the N-terminal tetrapeptide of ALYASKLS-NH<sub>2</sub> with an 11-aminoundecanoyl group produced a competitive inhibitor, 11-aminoundecanoyl-SKLS-NH<sub>2</sub>, that was 38-fold more potent ( $K_i = 0.40 \pm 0.03 \mu\text{M}$ ) than the starting octapeptide. Removing the primary amine (undecanoyl-SKLS-NH<sub>2</sub>), or replacing it with a Me group (dodecanoyl-SKLS-NH<sub>2</sub>), resulted in 26- and 34-fold increases in IC<sub>50</sub>, confirming the important contribution of the amine to recognition. Removal of Leu-Ser from the C terminus (11-aminoundecanoyl-SK-NH<sub>2</sub>) yielded a competitive dipeptide inhibitor with a  $K_i$  ( $11.7 \pm 0.4 \mu\text{M}$ ) equiv. to that of the starting octapeptide, ALYASKLS-NH<sub>2</sub>. Substitution of Ser with homoserine, cis-4-hydroxyproline, or tyrosine reduces potency by 3-70-fold, emphasizing the requirement for proper presentation of the hydroxyl group in the dipeptide inhibitor. Substituting D- for L-Lys decreases its inhibitory activity >100-fold, while deletion of the .epsilon.-amino group (Nle) or masking its charge (.epsilon.-N-acetyllysine) produces 4-7-fold attenuations. L-His, but not its D-isomer, can fully substitute for L-Lys, producing a competitive dipeptide inhibitor with similar potency ( $K_i = 11.9 \pm 1.0 \mu\text{M}$ ). 11-Aminoundecanoyl-SK-NH<sub>2</sub> and 11-aminoundecanoyl-SH-NH<sub>2</sub> establish that a simple alkyl backbone can maintain an appropriate distance between three elements crit. for recognition by the fungal enzyme's peptide-binding site: a simple .omega.-terminal amino group, a .beta.-hydroxyl, and an .epsilon.-amino group or an imidazole. These compds. contain one peptide bond and two chiral centers, suggesting that it may be feasible to incorporate these elements of recognition, or functionally equiv. mimics, into a fully de-peptidized Nmt inhibitor.

L4 ANSWER 61 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:278955 CAPLUS

DN 126:264355

TI Preparation of N-containing compounds as Fas ligand solubilization inhibitors

IN Hirano, Takao; Yagita, Hideo; Okumura, Ko; Hirayama, Ryoichi; Yamamoto, Minoru; Ebata, Tomohiko; Ohmoto, Hiroshi; Ikeda, Shoji; Yoshino, Kohichiro

PA Kanebo, Ltd., Japan; Hirano, Takao; Yagita, Hideo; Okumura, Ko; Hirayama, Ryoichi; Yamamoto, Minoru; Ebata, Tomohiko; Ohmoto, Hiroshi; Ikeda, Shoji; Yoshino, Kohichiro

SO PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709066	A1	19970313	WO 1996-JP2492	19960904
	W: CA, CN, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				JP 1995-256897	19950908
				JP 1995-317136	19951109
	EP 848957	A1	19980624	EP 1996-929510	19960904
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				JP 1995-256897	19950908
				JP 1995-317136	19951109

			WO 1996-JP2492	19960904
JP 09188631	A2	19970722	JP 1996-257868	19960906
			JP 1995-256897	19950908
			JP 1995-317136	19951109

OS MARPAT 126:264355


IT **188728-61-2P 188728-67-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of N-contg. compds. as Fas ligand solubilization inhibitors)

RN 188728-61-2 CAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]-2-(2-phenylethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188728-67-8 CAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]-2-(3-phenylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT **188729-03-5P 188729-04-6P 188729-09-1P****188729-10-4P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of N-contg. compds. as Fas ligand solubilization inhibitors)

RN 188729-03-5 CAPLUS

CN Benzenepentanoic acid, .beta.-[[[2-(methylamino)-2-oxo-1-phenylethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 188729-04-6 CAPLUS

CN Benzenepentanoic acid, .beta.-[[[2-(methylamino)-2-oxo-1-phenylethyl]amino]carbonyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188729-09-1 CAPLUS

CN Benzenhexanoic acid, .beta.-[[[2-(methylamino)-2-oxo-1-phenylethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 188729-10-4 CAPLUS

CN Benzenhexanoic acid, .beta.-[[[2-(methylamino)-2-oxo-1-phenylethyl]amino]carbonyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




GI



AB The title compds. (I; A = N-hydroxyaminocarbonyl, CO<sub>2</sub>H, SH, etc.; R<sub>1</sub> = H, NH<sub>2</sub>, OH, SH, C<sub>1</sub>-6 alkoxy or alkyl, etc.; R<sub>2</sub> = H, C<sub>1</sub>-6 alkyl or alkylthio, C<sub>2</sub>-6 alkenyl, etc.; R<sub>3</sub> = C<sub>1</sub>-6 alkyl, C<sub>2</sub>-6 alkenyl, etc.; R<sub>4</sub> = H, C<sub>1</sub>-6 alkyl or alkoxy, etc.; R<sub>5</sub> = H, C<sub>1</sub>-6 alkyl, etc.; R<sub>6</sub> = H, OH, C<sub>1</sub>-6 alkoxy, etc.; R<sub>7</sub> = H, OH, OMe; n = 5-7) or pharmaceutically acceptable salts thereof are prepd. I, having a matrix metalloprotease inhibitory activity, are useful as Fas ligand solubilization inhibitors in the prevention or treatment of diseases caused by solubilized Fas ligands such as hepatitis, GVHD, AIDS, and autoimmune diseases. Thus, L-alanine deriv. (II) was hydrogenated over Pd/C, reacted with C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>ONH<sub>2</sub>.HCl in the presence of WSC, Et<sub>3</sub>N, and hydroxybenzotriazole, and then hydrogenated again over Pd/C to give the title compd. (III). III showed 50% Fas ligand secretion inhibitory when tested on mouse p.o.


L4 ANSWER 62 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1997:196190 CAPLUS  
 DN 126:293596

TI Synthesis and Conformational Properties of the M(4-6)(5-7) Bicyclic Tetrapeptide Common to the Vancomycin Antibiotics  
AU Evans, David A.; Dinsmore, Christopher J.; Ratz, Andrew M.; Evrard, Deborah A.; Barrow, James C.  
CS Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA  
SO Journal of the American Chemical Society (1997), 119(14), 3417-3418  
CODEN: JACSAT; ISSN: 0002-7863  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 126:293596  
IT **149623-65-4**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. and conformational properties of bicyclic tetrapeptides common to vancomycin antibiotics)  
RN 149623-65-4 CAPLUS  
CN Glycinamide, (.beta.R)-3,5-dichloro-N-[(1,1-dimethylethoxy)carbonyl]-.beta.-hydroxy-O-2-propenyl-L-tyrosyl-(2S)-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



IT **189005-38-7P 189005-39-8P 189005-40-1P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and conformational properties of bicyclic tetrapeptides common to vancomycin antibiotics)  
RN 189005-38-7 CAPLUS  
CN Glycinamide, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-[4-methoxy-2-(phenylmethoxy)phenyl]glycyl-(.beta.R)-3,5-dichloro-.beta.-hydroxy-O-2-propenyl-L-tyrosyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189005-39-8 CAPLUS

CN Glycinamide, (2R)-2-(3,5-dibromo-4-hydroxyphenyl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(2R)-2-[4-methoxy-2-(phenylmethoxy)phenyl]glycyl-(.beta.R)-3,5-dichloro-.beta.-hydroxy-O-2-propenyl-L-tyrosyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 189005-40-1 CAPLUS

CN Glycinamide, (2R)-2-(3,5-dibromo-4-hydroxyphenyl)-N-[(1,1-

dimethylethoxy) carbonyl]glycyl-(2R)-2-[4-methoxy-2-(phenylmethoxy)phenyl]glycyl-(.beta.R)-3,5-dichloro-.beta.-hydroxy-L-tyrosyl-2-(3,5-dimethoxyphenyl)-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The prepn. and conformational anal. of fully functionalized vancomycin M(4-6) (5-7) tetrapeptide (S)-atropisomer I (R = CH<sub>2</sub>Ph; R<sub>1</sub> = CO<sub>2</sub>CMe<sub>3</sub>, R<sub>2</sub> = R<sub>4</sub> = H, R<sub>3</sub> = iodo) is described. The key step involves oxidative biaryl cyclization of monocyclic tetrapeptide II with VOF<sub>3</sub>, BF<sub>3</sub>·OEt<sub>2</sub>, AgBF<sub>4</sub>, and CF<sub>3</sub>CO<sub>2</sub>H to give highly strained, unnatural (R)-atropisomer I (R = Me, R<sub>1</sub> = COCF<sub>3</sub>, R<sub>2</sub> = SO<sub>2</sub>Me, R<sub>3</sub> = Br, R<sub>4</sub> = OH). The ring 5 phenol was removed conversion to the triflate followed by reductive cleavage, and removal of the Me ether protecting groups from rings 5 and 7 was followed by atropisomerization to give (S)-atropisomer I (R = R<sub>3</sub> = R<sub>4</sub> = H, R<sub>1</sub> = COCF<sub>3</sub>, R<sub>2</sub> = SO<sub>2</sub>Me) as a single stereoisomer. Conformational properties of I (R = R<sub>3</sub> = R<sub>4</sub> = H, R<sub>1</sub> = COCF<sub>3</sub>, R<sub>2</sub> = SO<sub>2</sub>Me) and related biaryl tetrapeptides and tripeptides shows that the M(4-6) macrocycle has a profound influence on the kinetic and thermodyn. stability of the atropisomers. The presence of the M(4-6) macrocycle reinforces both the stability of the (S) biaryl atropisomer (>98:2) and the bias for the cis configuration of the (5-6) amide bond found in the natural vancomycin structure.

L4 ANSWER 63 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:105321 CAPLUS  
 DN 126:118205  
 TI Preparation of 5-amino-1,3,4-thiadiazone amino acid and peptide amides as inhibitors for matrix metalloproteinases  
 IN Oleksyszyn, Josef; Jacobson, Alan R.  
 PA Osteoarthritis Sciences, Inc., USA; Oleksyszyn, Josef; Jacobson, Alan R.  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640745	A2	19961219	WO 1996-US9095	19960606
	WO 9640745	A3	19970130		
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA			
				US 1995-473143 A	19950607
	US 5677282	A	19971014	US 1995-473143	19950607
	CA 2224113	AA	19961219	CA 1996-2224113	19960606
				US 1995-473143 A	19950607
	AU 9660496	A1	19961230	AU 1996-60496	19960606
				US 1995-473143 A	19950607
				WO 1996-US9095 W	19960606
	EP 845002	A2	19980603	EP 1996-918174	19960606
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
				US 1995-473143 A	19950607
				WO 1996-US9095 W	19960606
	JP 11506784	T2	19990615	JP 1996-501497	19960606
				US 1995-473143 A	19950607
				WO 1996-US9095 W	19960606
	ZA 9604830	A	19970609	ZA 1996-4830	19960607
				US 1995-473143 A	19950607

OS MARPAT 126:118205

IT **186098-36-2P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of aminothiadiazoethione amino acid and peptide amides as matrix metalloproteinase inhibitors)

RN 186098-36-2 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 186097-89-2P 186098-00-0P 186098-04-4P  
186098-07-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of aminothiadiazoethione amino acid and peptide amides as matrix metalloproteinase inhibitors)

RN 186097-89-2 CAPLUS

CN Glycinamide, N-[(phenylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186098-00-0 CAPLUS

CN Glycinamide, 4-[bis(phenylmethyl)amino]-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186098-04-4 CAPLUS

CN Glycinamide, N-[(phenylmethoxy)carbonyl]glycyl-L-tyrosyl-O-(phenylmethyl)-

L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 186098-07-7 CAPLUS

CN Glycinamide, 1-[(phenylmethoxy)carbonyl]-L-prolyl-L-phenylalanyl-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 186098-66-8 186098-67-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(prepn. of aminothiadiazoethione amino acid and peptide amides as matrix metalloproteinase inhibitors)

RN 186098-66-8 CAPLUS

CN Glycinamide, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysyl-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 186098-67-9 CAPLUS

CN Glycinamide, N2-[(phenylmethoxy)carbonyl]-L-lysyl-O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 186098-37-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of aminothiadiazoethione amino acid and peptide amides as matrix metalloproteinase inhibitors)

RN 186098-37-3 CAPLUS


CN Glycinamide, O-(phenylmethyl)-L-tyrosyl-N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

GI



AB Title amino acid and peptide amides I [Q, A = independently S, O, with at least one Q, A being S; n = pos. integer; R1 = H, lower alkyl, acyl; each R2 = independently (un)substituted C1-10 straight or branched alkyl, C3-8 cycloalkyl, C1-10 straight or branched alkenyl, C1-10 straight or branched alkynyl; aryl, heteroaryl; R3 = amine protecting group, physiol. active salt] are disclosed. These compds. inhibit matrix metalloproteinase enzymes and cartilage degrading. Methods of treating diseases caused by over-activity of matrix metalloproteinases, such as osteoarthritis and rheumatoid arthritis, are also disclosed. Thus, coupling of Z-Glu[N(CH<sub>2</sub>Ph)<sub>2</sub>]-Phg-OH (Z = PhCH<sub>2</sub>O<sub>2</sub>C; Phg = phenylglycine) with 5-amino-1,3,4-thiadiazole-2-thiol gave peptide thiadiazolylamide II. II inhibited stromelysin with K<sub>i</sub> = 19 nM in a competitive inhibition assay.

L4 ANSWER 64 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1997:9227 CAPLUS

DN 126:31668

TI Preparation of cyclic pentapeptide LH-RH receptor antagonists

IN Kitada, Chieko; Furuya, Shuichi; Kato, Koichi

PA Takeda Chemical Industries, Ltd., Japan; Kitada, Chieko; Furuya, Shuichi; Kato, Koichi

SO PCT Int. Appl., 199 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9634012	A1	19961031	WO 1996-JP1140	19960425
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				JP 1995-106775 A	19950428
				JP 1995-110933 A	19950509
CA	2215737	AA	19961031	CA 1996-2215737	19960425
				JP 1995-106775 A	19950428
				JP 1995-110933 A	19950509
AU	9655143	A1	19961118	AU 1996-55143	19960425
				JP 1995-106775 A	19950428
				JP 1995-110933 A	19950509
				WO 1996-JP1140 W	19960425
EP	822939	A1	19980211	EP 1996-912247	19960425

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

			JP 1995-106775 A	19950428
			JP 1995-110933 A	19950509
			WO 1996-JP1140 W	19960425
CN 1183104	A	19980527	CN 1996-193586	19960425
			JP 1995-106775 A	19950428
			JP 1995-110933 A	19950509
JP 09025294	A2	19970128	JP 1996-107405	19960426
			JP 1995-106775 A	19950428
			JP 1995-110933 A	19950509
US 6136781	A	20001024	US 1996-656244	19960606
			JP 1995-106775 A	19950428
			JP 1995-110933 A	19950509
			WO 1996-JP1140 W	19960425

OS MARPAT 126:31668

IT **184836-92-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of cyclic pentapeptide LH-RH receptor antagonists)


RN 184836-92-8 CAPLUS

CN D-Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-(2S)-2-phenylglycyl-N5-[imino[(4-methylphenyl)sulfonyl]amino]methyl]-D-ornithyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





AB LH-RH receptor antagonists contg. cyclic pentapeptides or salts thereof and novel cyclic pentapeptide or salts thereof are provided. These LH-RH receptor antagonists are effective as medicines for preventing and curing sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, mammary cancer, pituitary tumor, etc.), prostatomegaly, endometriosis, hysterymyoma, puberty precox, amenorrheal syndromes, multilocular ovarian syndromes, comedo, etc, and are also effective as pregnancy controlling agents (e.g., contraceptives, etc.) and menstrual cycle controlling agents. Moreover, these are also useful in the livestock industry for the control fo the estrus of animals and also for the improvement in the quality of meat and for the control of the growth of animals, as well as in the marine products industry as spawning promoters for fishes. Thus, cyclo(Phg-D-Arg(Tos)-Phe-D-Ala-Trp) (Phg = L-phenylglycine, Tos = tosyl), prepd. by std. 9-fluorenylmethoxycarbonyl (Fmoc) chem. on a Wang resin, exhibited IC50 = 0.07 .mu.M in a LH-RH receptor assay. Ref. compd. cyclo(Tyr-D-Trp-Leu-Arg-Trp-Pro) showed IC50 = 10 .mu.M in the same assay.

L4 ANSWER 65 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1996:734039 CAPLUS

DN 126:60327

TI Synthesis of Modified Carboxyl Binding Pockets of Vancomycin and Teicoplanin

AU Bois-Choussy, Michele; Neuville, Luc; Beugelmans, Rene; Zhu, Jieping  
CS Institut de Chimie des Substances Naturelles, CNRS, Gif-sur-Yvette, 91198, Fr.

SO Journal of Organic Chemistry (1996), 61(26), 9309-9322

CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

OS CASREACT 126:60327

IT **173775-55-8P 174759-45-6P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of modified carboxyl binding pockets of vancomycin and teicoplanin)

RN 173775-55-8 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-3-nitro-D-phenylalanyl-N-[(1R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethyl]-2-[3-(1-methylethoxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).





RN 174759-45-6 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-3-nitro-D-phenylalanyl-N-[(1R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethyl]-2-[3-(1-methylethoxy)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



AB Sixteen-membered macrocycle I (R = H) and 16+14 bicyclic compd. II, incorporating a terminal primary hydroxyl group in the peptide sequence, have been designed and synthesized. The syntheses feature the use of an efficient cycloetherification based on an intramol. SNAr reaction for the formation of biaryl ether bonds. Cyclization of a linear tetrapeptide, prep'd. via a convergent [2+2] segment coupling, gave macrocycle I (R = Boc) (P configuration) as a single isolable atropisomer. Removal of the Boc protecting group afforded the modified carboxyl binding pocket of vancomycin (I; R = H). A sequential 2-fold intramol. SNAr reaction has been used to construct the model bicyclic system (i.e. II) of the D-O-E-F-O-G ring of teicoplanin. Cyclization conditions (CsF, DMF, room temp.) are sufficiently mild that the configuration of the racemization-prone arylglycine residue was not affected. Chiral amino acid and amino alc. building blocks were prep'd. using Evans' asym. azidation method and Schollkopf's bislactim ether as a chiral glycine template. I showed interesting conformational properties compared to vancomycin and its binding with Ac-D-Ala was studied by NMR titrn. expts. A dissociation const. ( $K_d = 5 \times 10^{-4}$ ) was calcd. by a curve fitting method. II is currently the most advanced synthetic intermediate toward the total synthesis of teicoplanin.

L4 ANSWER 66 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1996:380219 CAPLUS

DN 125:114281

TI Acyclic ethylenediamine derivatives

IN O'Neill, Brian T.

PA Pfizer Inc., USA

SO U.S., 16 pp., Cont.-in-part of U.S. Ser. No. 790,934, abandoned.

CODEN: USXXAM

DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5521220	A	19960528	US 1994-240657	19940720
				US 1991-790934 B2	19911112
				WO 1992-US7730 W	19920918
				WO 1992-US7730	19920918
	WO 9310073	A1	19930527		
	W: AU, CA, FI, HU, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
				US 1991-790934 A2	19911112
	CA 2324959	C	20021112	CA 1992-2324959	19920918
				US 1991-790934 A	19911112
				CA 1992-2123403A3	19920918

## PATENT FAMILY INFORMATION:

FAN 1993:670782

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9310073	A1	19930527	WO 1992-US7730	19920918
	W: AU, CA, FI, HU, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
				US 1991-790934 A2	19911112
	AU 9226813	A1	19930615	AU 1992-26813	19920918
				US 1991-790934 A	19911112
				WO 1992-US7730 A	19920918
	EP 613458	A1	19940907	EP 1992-921029	19920918
	EP 613458	B1	19980107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
				US 1991-790934 A	19911112
				WO 1992-US7730 W	19920918
	JP 06510792	T2	19941201	JP 1992-509229	19920918
	JP 2614408	B2	19970528		
				US 1991-790934 A	19911112
				WO 1992-US7730 W	19920918
	HU 70741	A2	19951030	HU 1994-1337	19920918
				US 1991-790934 A	19911112
	AT 161821	E	19980115	AT 1992-921029	19920918
				US 1991-790934 A	19911112
	ES 2111650	T3	19980316	ES 1992-921029	19920918
				US 1991-790934 A	19911112
	CA 2324959	C	20021112	CA 1992-2324959	19920918
				US 1991-790934 A	19911112
				CA 1992-2123403A3	19920918
	ZA 9208682	A	19940511	ZA 1992-8682	19921111
				US 1991-790934 A	19911112
	FI 9402187	A	19940511	FI 1994-2187	19940511
				US 1991-790934 A	19911112
				WO 1992-US7730 W	19920918
	NO 9401784	A	19940511	NO 1994-1784	19940511
				US 1991-790934 A	19911112
				WO 1992-US7730 A	19920918
	US 5521220	A	19960528	US 1994-240657	19940720
				US 1991-790934 B2	19911112
				WO 1992-US7730 W	19920918
	FI 2001000083	A	20010115	FI 2001-83	20010115
				US 1991-790934 A	19911112


WO 1992-US7730 W 19920918

OS MARPAT 125:114281

IT **150917-46-7P**RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 150917-46-7 CAPLUS

CN 1,2-Ethanediamine, N1-cyclohexyl-N2-[(2-methoxyphenyl)methyl]-1-phenyl-N1-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



AB PhCH(NHR1)CH2NHCH2R2 (I; R1 = alkyl, cycloalkyl; R2 = aryl) and their salts were prepd. for treatment of inflammatory and central nervous system disorders. Thus, .alpha.-(cyclohexylamino)benzeneacetonitrile, which was prepd. from BzH, cyclohexylamine, and KCN, was reduced with diisobutylaluminum hydride to give N-cyclohexyl-1-phenyl-1,2-ethanediamine, which reacted with o-anisaldehyde and Na triacetoxyborohydride to give I (R1 = cyclohexyl, R2 = 2-methoxyphenyl). The dihydrochloride of this product was also described.

L4 ANSWER 67 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1996:379679 CAPLUS

DN 125:59130

TI Preparation of ethers of aspartate protease substrate isosteres as antivirals.

IN Bold, Guido; Capraro, Hans-Georg; Faessler, Alexander; Lang, Marc; Bhagwat, Shripad Subray; Khanna, Satish Chandra; Lazdins, Janis Karlis; Mestan, Juergen

PA Ciba-Geigy A.-G., Switz.

SO Eur. Pat. Appl., 131 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 708085	A2	19960424	EP 1995-115938	19951010
	EP 708085	A3	19971008		
	EP 708085	B1	20020717		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				CH 1994-3140	A 19941019
				CH 1995-2382	A 19950821
	AT 220661	E	20020815	AT 1995-115938	19951010
				CH 1994-3140	A 19941019
				CH 1995-2382	A 19950821
	ES 2180600	T3	20030216	ES 1995-115938	19951010
			CH 1994-3140	A 19941019	
			CH 1995-2382	A 19950821	
AU 9534279	A1	19960502	AU 1995-34279	19951012	
AU 707283	B2	19990708			
			CH 1994-3140	A 19941019	



FI 9504913	A	19960420	CH 1995-2382	A 19950821
			FI 1995-4913	19951016
			CH 1994-3140	A 19941019
CA 2160763	AA	19960420	CH 1995-2382	A 19950821
			CA 1995-2160763	19951017
			CH 1994-3140	A 19941019
BG 63042	B1	20010228	CH 1995-2382	A 19950821
			BG 1995-100067	19951017
			CH 1994-3140	A 19941019
SK 282339	B6	20020107	CH 1995-2382	A 19950821
			SK 1995-1285	19951017
			CH 1994-3140	A 19941019
CZ 290123	B6	20020612	CH 1995-2382	A 19950821
			CZ 1995-2713	19951017
			CH 1994-3140	A 19941019
ZA 9508782	A	19960419	CH 1995-2382	A 19950821
			ZA 1995-8782	19951018
NO 9504142	A	19960422	CH 1994-3140	A 19941019
			NO 1995-4142	19951018
			CH 1994-3140	A 19941019
CN 1132756	A	19961009	CH 1995-2382	A 19950821
			CN 1995-120506	19951018
			CH 1994-3140	A 19941019
HU 74744	A2	19970228	CH 1995-2382	A 19950821
			HU 1995-3007	19951018
			CH 1994-3140	A 19941019
RU 2164229	C2	20010320	CH 1995-2382	A 19950821
			RU 1995-118112	19951018
			CH 1994-3140	A 19941019
JP 08208580	A2	19960813	CH 1995-2382	A 19950821
JP 3192070	B2	20010723	JP 1995-295024	19951019
			CH 1994-3140	A 19941019
BR 9504466	A	19970520	CH 1995-2382	A 19950821
			BR 1995-4466	19951019
			CH 1994-3140	A 19941019
US 5663200	A	19970902	CH 1995-2382	A 19950821
			US 1995-545170	19951019
			CH 1994-3140	A 19941019
PL 184292	B1	20020930	CH 1995-2382	A 19950821
			PL 1995-311027	19951019
			CH 1994-3140	A 19941019
TW 397813	B	20000711	CH 1995-2382	A 19950821
			TW 1995-84111501	19951101
			CH 1994-3140	A 19941019
US 5807891	A	19980915	US 1997-838347	19970408
			CH 1994-3140	A 19941019
			CH 1995-2382	A 19950821
US 5935976	A	19990810	US 1995-545170	A319951019
			US 1998-138076	19980821
			CH 1994-3140	A 19941019
			CH 1995-2382	A 19950821
			US 1995-545170	A319951019
			US 1997-838347	A319970408

OS MARPAT 125:59130

IT 178048-10-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of ethers of aspartate protease substrate isosteres as antivirals)

RN 178048-10-7 CAPLUS

CN 2-Oxa-5,8,14-triazapentadecan-15-oic acid, 12-hydroxy-6,9-dioxo-7-phenyl-10,13-bis(phenylmethyl)-, 1,1-dimethylethyl ester, [7S-(7R\*,10S\*,12R\*,13R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 178049-01-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of ethers of aspartate protease substrate isosteres as antivirals)



RN 178049-01-9 CAPLUS

CN 2-Oxa-5,8,14-triazapentadecan-15-oic acid, 12-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-6,9-dioxo-7-phenyl-10,13-bis(phenylmethyl)-, 1,1-dimethylethyl ester, [7S-(7R\*,10S\*,12R\*,13R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. [I; R1 = (substituted) alkoxyalkanoyl, alkoxy carbonyl, alkanoyl, arylcarbonyl, heterocyclylcarbonyl, phenylalkanoyl, arylsulfonyl, amino acid residue; R2, R3 = (substituted) cyclohexyl, cyclohexenyl, Ph, naphthyl, tetrahydronaphthyl; R4 = alkyl, cyclohexyl, Ph; R5 = alkyl; n = 1, 2; provided .gtoreq.1 salt forming group is present], were prepd. Thus, title compd. (II), prepd. via 5(S)-[1(S)-(tert-butoxycarbonylamino)-2-phenylethyl]-3(R)-[(2,3,4-trimethoxyphenyl)methyl]dihydrofuran-2(3H)-one, at 12.5 nM combined with 12.5 nM indavir gave 76.6% inhibition of reverse transcriptase in a coculture of CEM-SS and H9/HIV-1/IIIB. Capsule formulations contg. II are given.

L4 ANSWER 68 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1996:285987 CAPLUS

DN 124:333315

TI Study on the activation mechanism of neurokinin receptors

AU Abe, Junko; Fujinaka, Hidetake; Mukai, Hidehito; Munekata, Eisuke

CS Institute Applied Biochemistry, University Tsukuba, Tsukuba, 305, Japan

SO Peptide Chemistry (1996), Volume Date 1995, 33rd, 277-80

CODEN: PECHDP; ISSN: 0388-3698

PB Protein Research Foundation

DT Journal

LA English

IT **176840-46-3**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (activation mechanism of neurokinin receptors)

RN 176840-46-3 CAPLUS


CN Neurokinin B (swine spinal cord), 6-(L-2-phenylglycine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB The peptide analogs of substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) in which Phe residue at the 5th position from carboxyl-terminus are replaced by phenylglycine (Phg) and homophenylalanine (Hph) were prepd. and the pharmacol. significances of the arom. amino acid at this position were comparatively investigated.

L4 ANSWER 69 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1996:271993 CAPLUS

DN 125:59116

TI Synthetic studies towards glycopeptide antibiotics: synthesis of the 16-membered cyclic tripeptide (DOEG ring) system of teicoplanin

AU Rao, A. V. Rama; Reddy, K. Laxma; Rao, A. Srinivasa; Vittal, T. V. S. K.; Reddy, M. M.; Pathi, P. L.

CS Indian Inst. Chem. Technol., Hyderabad, 500 007, India


SO Tetrahedron Letters (1996), 37(17), 3023-6

CODEN: TELEAY; ISSN: 0040-4039


PB Elsevier

DT Journal  
 LA English  
 IT **178217-07-7P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of the 16-membered cyclic tripeptide system of teicoplanin)  
 RN 178217-07-7 CAPLUS  
 CN Glycine, N-[L-2-(3,5-dimethoxyphenyl)-N-[N-[(1,1-dimethylethoxy)carbonyl]-  
 4-fluoro-3-nitro-D-phenylalanyl]glycyl]-D-2-(3-hydroxy-4-methoxyphenyl)-,  
 methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The synthesis of the 16-membered cyclic DOEG ring system I of teicoplanin, which forms the binding pocket for the carboxylate region of terminal D-Ala-D-Ala of the bacterial cell wall, via macroetherification of a linear tripeptide is described.

L4 ANSWER 70 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1996:241976 CAPLUS  
 DN 124:331828

TI Inhibitors of Human Immunodeficiency Virus Type 1 Protease Containing  
2-Aminobenzyl-Substituted 4-Amino-3-hydroxy-5-phenylpentanoic acid:  
Synthesis, Activity, and Oral Bioavailability

AU Lehr, Philipp; Billich, Andreas; Charpiot, Brigitte; Ettmayer, Peter;  
Scholz, Dieter; Rosenwirth, Brigitte; Gstach, Hubert

CS Sandoz Research Institute, Vienna, A-1235, Austria

SO Journal of Medicinal Chemistry (1996), 39(10), 2060-7  
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal


LA English

IT **176388-97-9P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. and bioavailability and HIV-1 protease inhibitory activity of  
(aminobenzyl)hydroxyphenylpentanoates)

RN 176388-97-9 CAPLUS

CN L-Lyxonamide, N-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxo-1-  
phenylethyl]-2,4,5-trideoxy-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-  
phenyl-2-[(phenylmethyl)amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Systematic modifications of HIV protease inhibitor (2R,3S,4S)-4-  
[[[(benzyloxycarbonyl)-L-valyl]amino]-3-hydroxy-2-[(4-methoxybenzyl)amino]-  
5-(phenylpentanoyl)-L-valine 2-(aminomethyl)benzimidazole amide led to a  
novel series of inhibitors with a shortened, modified carboxy terminus.  
Their synthesis, in vitro enzyme inhibitory data, and antiviral activities  
are reported. Of particular interest are derivs. featuring the  
(1S,2R)-1-amino-2-hydroxyindan moiety at the P2'-position since some of  
them exhibit substantial oral bioavailability in mice. The influence of  
aq. soly. and structural parameters on the oral resorption of the  
inhibitors is discussed. Optimum enhancement of oral bioavailability was  
obsd. with L-tert-leucine in P2-position, resulting in the discovery of  
(2R,3S,4S)-4-[[[(benzyloxycarbonyl)-L-tert-leucyl]amino]-3-hydroxy-2-[(4-  
methoxybenzyl)amino]-5-phenylpentanoic acid (1S,2R)-1-amino-2-hydroxyindan  
amide which combines high antiviral activity (IC<sub>50</sub> = 250 nM) with a good  
pharmacokinetic profile (AUC = 82.5 .mu.M.cntdot.h at a dose of 125 mg/kg  
po in mice).


L4 ANSWER 71 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1996:211368 CAPLUS


DN 124:344085

TI Solid-phase, parallel syntheses by Ugi multicomponent condensation


AU Tempest, Paul A.; Brown, S. David; Armstrong, Robert W.  
 CS Dep. Chem. Biochem., Univ. California, Los Angeles, CA, 90095-1569, USA  
 SO Angewandte Chemie, International Edition in English (1996), 35(6), 640-2  
 CODEN: ACIEAY; ISSN: 0570-0833  
 PB VCH  
 DT Journal  
 LA English  
 IT **176845-79-7P 176845-81-1P 176845-82-2P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of amino acid amides and dipeptides by Ugi multicomponent  
 condensations on a solid support)  
 RN 176845-79-7 CAPLUS  
 CN Glycine, N-[N-[3-(4-hydroxyphenyl)-1-oxopropyl]-2-phenylglycyl]-, methyl  
 ester (9CI) (CA INDEX NAME)



RN 176845-81-1 CAPLUS  
 CN Glycine, N-[N-[3-(4-hydroxyphenyl)-1-oxopropyl]-2-(4-propoxyphenyl)glycyl]-,  
 methyl ester (9CI) (CA INDEX NAME)



RN 176845-82-2 CAPLUS  
 CN Glycine, N-[N-[3-(4-hydroxyphenyl)-1-oxopropyl]-2-(3-nitrophenyl)glycyl]-,  
 methyl ester (9CI) (CA INDEX NAME)



AB Ugi multicomponent condensation is used to prep. a 96-member library of  
 amino acid amides and dipeptides, e.g. R2CONHCHR1CO-Gly-OMe (R1 = Et, Ph,  
 cyclohexylmethyl, etc., R2 = H, cyclopropyl, Ph2CH, etc.), on a solid  
 support.

L4 ANSWER 72 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1996:209976 CAPLUS

DN 124:242373

TI Treatment of diseases caused by sebaceous gland disorders with acyl coA cholesterol acyl transferase inhibitors

IN Mayne, James T.

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 699439	A2	19960306	EP 1995-305594	19950810
	EP 699439	A3	19960626		
	EP 699439	B1	19991006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 6133326	A	20001017	US 1994-298735 A	19940831
	AT 185271	E	19991015	US 1994-298735	19940831
				AT 1995-305594	19950810
	ES 2136252	T3	19991116	US 1994-298735 A	19940831
				ES 1995-305594	19950810
	CA 2157142	AA	19960301	US 1994-298735 A	19940831
	CA 2157142	C	19980609	CA 1995-2157142	19950829
				US 1994-298735 A	19940831
	JP 08099903	A2	19960416	JP 1995-242297	19950829
	JP 3266473	B2	20020318		
				US 1994-298735 A	19940831
	JP 2002053494	A2	20020219	JP 2001-241766	19950829
				US 1994-298735 A	19940831
				JP 1995-242297 A3	19950829
	US 6271268	B1	20010807	US 2000-536480	20000327
				US 1994-298735 A1	19940831

IT 157548-92-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (treatment of sebaceous gland disorders with cholesterol acyl transferase inhibitors)

RN 157548-92-0 CAPLUS

CN Urea, N-[2,4-bis(ethylthio)-6-methyl-3-pyridinyl]-N'-[2-(2,5-dimethylphenyl)-6-phenylhexyl]- (9CI) (CA INDEX NAME)



AB A method of treating diseases caused by sebaceous gland disorders, e.g. acne, comprises administering a compn. contg. an acyl coA cholesterol acyl



transferase (ACAT) inhibitor or prodrug therefor. S-N-[2,4-bis(methylthio)-6-methylpyrid-3-yl]-(2-hexylthio)decanamide (I) was formulated into topical preps. Oral administration of I to beagle dogs at a dose of 50 mg/kg/day for 14 days resulted in almost complete atrophy of the acinar components of the eyelid sebaceous glands with dilation of the central collecting duct.

L4 ANSWER 73 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1995:998406 CAPLUS

DN 124:203098

TI Preparation of peptide factor Xa inhibitors as antithrombotics.

IN Al-Obeidi, Fahad; Lebl, Michal; Ostrem, James A.; Safar, Pavel; Stierandova, Alena; Strop, Peter; Walser, Armin

PA Selectide Corp., USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9529189	A1	19951102	WO 1995-US5268	19950425
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2186497	AA	19951102	US 1994-233054 A	19940426
				CA 1995-2186497	19950425
				US 1994-233054 A	19940426
	AU 9523683	A1	19951116	AU 1995-23683	19950425
	AU 707653	B2	19990715		
				US 1994-233054 A	19940426
				WO 1995-US5268 W	19950425
	ZA 9503361	A	19960112	ZA 1995-3361	19950425
				US 1994-233054 A	19940426
	EP 758341	A1	19970219	EP 1995-917736	19950425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1994-233054 A	19940426
				WO 1995-US5268 W	19950425
	CN 1147261	A	19970409	CN 1995-192811	19950425
				US 1994-233054 A	19940426
	HU 76346	A2	19970828	HU 1996-2954	19950425
				US 1994-233054 A	19940426
	JP 10503477	T2	19980331	JP 1995-527853	19950425
				US 1994-233054 A	19940426
				WO 1995-US5268 W	19950425
	RU 2152954	C1	20000720	RU 1996-122647	19950425
				US 1994-233054 A	19940426
				WO 1995-US5268 W	19950425
	EE 3973	B1	20030217	EE 1996-146	19950425
				US 1994-233054 A	19940426
				WO 1995-US5268 W	19950425
	IL 113505	A1	19991231	IL 1995-113505	19950426
				US 1994-233054 A	19940426
	TW 409129	B	20001021	TW 1995-84104681	19950511

FI 9604317	A	19961025	US 1994-233054 A 19940426
			FI 1996-4317 19961025
			US 1994-233054 A 19940426
NO 9604553	A	19961227	WO 1995-US5268 W 19950425
			NO 1996-4553 19961025
			US 1994-233054 A 19940426
LT 4218	B	19970925	WO 1995-US5268 W 19950425
			LT 1996-151 19961025
LV 11740	B	19971220	US 1994-233054 A 19940426
			LV 1996-410 19961115
US 5849510	A	19981215	US 1994-233054 A 19940426
			US 1997-947794 19971008
			US 1994-233054 B219940426
			US 1995-428404 B119950425

OS MARPAT 124:203098


IT **174132-22-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of peptide factor Xa inhibitors as antithrombotics)

RN 174132-22-0 CAPLUS

CN L-Prolinamide, N-acetyl-L-tyrosyl-L-2-phenylglycyl-L-arginyl-L-leucyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A1-A2-(A3)<sub>m</sub>-B [m = 0, 1; A1 = R1-R2-R3; A2 = R4-R5-R6; A3 = R7-R8-R9; R1 = (substituted) 1-20 amino acid residues, R11CO, R11R12X; X = N, CH, NCO; R11, R12 = H, alkyl, acyl, aryl, aralkyl, protecting group; R2 = CR99R100; R99, R100 = H, (substituted) alkyl, aralkyl, heteroaralkyl, heteroaryl; R3 = CO, CH2, CHR99CO, etc.; R4 = CH2, imino; R5 = CR201R202; R201, R202 = H, (substituted) alkyl, aryl, aralkyl; R6 = CO, CH2, CHR99CO; R7 = (substituted) R4; R8 = CR210R211; R210, R211 = H, (substituted) alkyl, alkylaryl, heterocyclyl; R9 = CO, CH2, CHR99CO; B = (substituted) 1-20 amino acid residues, amino, OH, alkoxy, acyloxy, etc.; with provisos], were prepd. Thus, Ac-Tyr-Chg-Arg-NH<sub>2</sub> (Chg = cyclohexylglycyl) inhibited coagulation in human plasma with EC<sub>50</sub> = 2.5 .mu.M.

L4 ANSWER 74 OF 148 CAPLUS COPYRIGHT 2003 ACS


AN 1995:968838 CAPLUS

DN 124:176884

TI The first synthesis of a model bicyclic D-O-E-F-O-G ring of teicoplanin via sequential intramolecular SNAr reactions


AU Beugelmans, Rene; Neuville, Luc; Bois-Choussy, Michele; Zhu, Jieping  
CS Inst. Chimie Substances Naturelles, Gif-sur-Yvette, 91198, Fr.  
SO Tetrahedron Letters (1995), 36(48), 8787-90  
CODEN: TELEAY; ISSN: 0040-4039  
PB Elsevier  
DT Journal  
LA English  
OS CASREACT 124:176884  
IT **173775-55-8P 174759-45-6P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis of model bicyclic ring of teicoplanin via sequential  
intramol. reactions)  
RN 173775-55-8 CAPLUS  
CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-3-nitro-D-  
phenylalanyl-N-[(1R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-[3-[[[(1,1-  
dimethylethyl)dimethylsilyl]oxy]phenyl]ethyl]-2-[3-(1-methylethoxy)phenyl]-  
, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 174759-45-6 CAPLUS  
CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-3-nitro-D-  
phenylalanyl-N-[(1R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-[3-[[[(1,1-  
dimethylethyl)dimethylsilyl]oxy]phenyl]ethyl]-2-[3-(1-methylethoxy)phenyl]-  
, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



AB A model bicyclic D-O-E-F-O-G ring (I) of teicoplanin has been efficiently synthesized via sequential intramol. SNAr reactions.

L4 ANSWER 75 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1995:938729 CAPLUS

DN 124:105558

TI 3D-Quantitative Structure-Activity Relationships of Human Immunodeficiency Virus Type-1 Proteinase Inhibitors: Comparative Molecular Field Analysis of 2-Heterosubstituted Statine Derivatives-Implications for the Design of Novel Inhibitors

AU Kroemer, Romano T.; Ettmayer, Peter; Hecht, Peter

CS SANDOZ Forschungsinstitut Ges. m. b. H, Vienna, A-1235, Austria

SO Journal of Medicinal Chemistry (1995), 38(25), 4917-28

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

IT 172215-84-8, SDZ 283559


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(3D-quant. structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors using comparative mol. field anal. of 2-heterosubstituted statine derivs.)

RN 172215-84-8 CAPLUS

CN L-Lyxonamide, 4-amino-N-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxo-1-phenylethyl]-2,4,5-trideoxy-2-[[[4-methoxyphenyl)methyl]amino]-5-phenyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A set of 100 novel 2-heterosubstituted statine derivs. inhibiting human immunodeficiency virus type-1 proteinase has been investigated by comparative mol. field anal. To combine the structural information available from x-ray analyses with a predictive quant. structure-activity relation (QSAR) model, docking expts. of a prototype compd. into the receptor were performed, and the 'active conformation' was detd. The structure of the receptor was taken from the published x-ray anal. of the proteinase with bound MVT-101, the latter compd. exhibiting high structural similarity with the inhibitors investigated. The validity of the resulting QSARs was confirmed in four different ways. (1) The common parameters, namely, the cross-validated  $r^2$  values obtained by the leave-one-out (LOO) method ( $r^2_{ev} = 0.572-0.593$ ), and (2) the accurate prediction of a test set of 67 compds. ( $q^2 = 0.552-0.569$ ) indicated a high consistency of the models. (3) Repeated analyses with two randomly selected cross-validation groups were performed and the cross-validated  $r^2$  values monitored. The resulting av.  $r^2$  values were of similar magnitudes compared to those obtained by the LOO method. (4) The coeff. fields were compared with the steric and electrostatic properties of the receptor and showed a high level of compatibility. Further anal. of the results led to the design of a novel class of highly active compds. contg. an addnl. linkage between P1' and P3'. The predicted activities of these inhibitors were also in good agreement with the exptl. detd. values.

L4 ANSWER 76 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1995:835557 CAPLUS

DN 123:256542

TI Preparation of annelated dihydropyridines

IN Roos, Otto; Loesel, Walter; Arndts, Dietrich

PA Boehringer Ingelheim KG, Germany

SO Ger. Offen., 28 pp.

CODEN: GWXXBX

DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4343683	A1	19950622	DE 1993-4343683	19931221
	CA 2178209	AA	19950629	CA 1994-2178209	19941214
	WO 9517389	A1	19950629	DE 1993-4343683A	19931221
				WO 1994-EP4150	19941214
	W: AU, CA, CN, JP, KR, PL, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			DE 1993-4343683A	19931221
	AU 9512433	A1	19950710	AU 1995-12433	19941214
	AU 699208	B2	19981126		
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	EP 736011	A1	19961009	EP 1995-903342	19941214
	EP 736011	B1	20000726		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	CN 1138325	A	19961218	CN 1994-194572	19941214
	CN 1044905	B	19990901		
				DE 1993-4343683A	19931221
	JP 09506882	T2	19970708	JP 1994-517154	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	RU 2136664	C1	19990910	RU 1996-115153	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	AT 194978	E	20000815	AT 1995-903342	19941214
				DE 1993-4343683A	19931221
				WO 1994-EP4150 W	19941214
	ES 2149958	T3	20001116	ES 1995-903342	19941214
				DE 1993-4343683A	19931221
	ZA 9410115	A	19950621	ZA 1994-10115	19941220
				DE 1993-4343683A	19931221
	US 5661157	A	19970826	US 1994-360867	19941221
				DE 1993-4343683A	19931221
	TW 404941	B	20000911	TW 1994-83112295	19941228
				DE 1993-4343683A	19931221
	US 5968948	A	19991019	US 1997-857643	19970516
				DE 1993-4343683A	19931221
				US 1994-360867 A3	19941221
	US 6136819	A	20001024	US 1999-329443	19990610
				DE 1993-4343683A	19931221
				US 1994-360867 A3	19941221
				US 1997-857643 A3	19970516

OS MARPAT 123:256542


IT **168545-16-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of annelated dihydropyridines from)

RN 168545-16-2 CAPLUS

CN Benzeneacetamide, N-[2-(3,4-dimethoxy-2,4-cyclohexadien-1-yl)ethyl]-  
 .alpha.-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = benzo, thieno, indolo; B = O, S, (un)substituted CH<sub>2</sub>; R<sub>2</sub> = OH, alkoxy, benzyloxy, halogen, alkyl, methanesulfonyloxy, etc.; R<sub>3</sub> = 2- or 3-thienyl, (un)substituted Ph, alkyl, cycloalkylalkyl; R<sub>4</sub> = (un)branched alkenyl or alkynyl, alkoxy, dialkylamino, heterocyclyl, Ph, etc.; m = 0-3] (e.g., II), useful as calcium-channel blockers (no data), are prepd. by the intramol. cyclocondensation of arom. amides (III) (e.g., IV) in the presence of condensing agents (e.g., POCl<sub>3</sub>), and I-contg. formulations are also presented.

L4 ANSWER 77 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1995:701735 CAPLUS

DN 123:112727

TI Preparation of dipeptide derivatives of 5-amino-4-hydroxyhexanoic acid as HIV protease inhibitors.

IN Bold, Guido; Lang, Marc; Faessler, Alexander; Capraro, Hans-Georg; Bhagwat, Shripad

PA Ciba-Geigy A.-G., Switz.

SO Eur. Pat. Appl., 116 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 618222	A2	19941005	EP 1994-810133	19940302
	EP 618222	A3	19970102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AU 9457588	A1	19940915	CH 1993-772	19930311
	AU 678202	B2	19970522	AU 1994-57588	19940304
				CH 1993-772	19930311
	FI 9401064	A	19940912	FI 1994-1064	19940307
				CH 1993-772	19930311
	CA 2118661	AA	19940912	CA 1994-2118661	19940309
				CH 1993-772	19930311
	NO 9400853	A	19940912	NO 1994-853	19940310
				CH 1993-772	19930311
	ZA 9401668	A	19940913	ZA 1994-1668	19940310
				CH 1993-772	19930311
	HU 67089	A2	19950130	HU 1994-720	19940310
				CH 1993-772	19930311
	CN 1112125	A	19951122	CN 1994-104099	19940310
				CH 1993-772	19930311
	JP 07316191	A2	19951205	JP 1994-67908	19940311
				CH 1993-772	19930311

OS MARPAT 123:112727


IT 165453-83-8P 165453-86-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of dipeptide derivs. of 5-amino-4-hydroxyhexanoic acid as HIV protease inhibitors)

RN 165453-83-8 CAPLUS

CN Carbamic acid, [2-hydroxy-5-[[2-[[1-[(4-methoxyphenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]amino]-2-oxo-1-phenylethyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5[R\*(R\*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 165453-86-1 CAPLUS

CN Carbamic acid, [2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[2-[[1-[(4-methoxyphenyl)methyl]-2-(4-morpholinyl)-2-oxoethyl]amino]-2-oxo-1-phenylethyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5[R\*(R\*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.








GI



I



II

AB Title compds. [I; T = R<sub>6</sub>CO; R<sub>6</sub> = (substituted) hydrocarbyl in which .gtoreq.1 C atom is replaced by a heteroatom; R<sub>1</sub> = H, alkoxycarbonyl, heterocyclylcarbonyl, (substituted) benzyloxycarbonyl, heterocyclyloxycarbonyl, etc.; A<sub>1</sub>, B<sub>1</sub> = bond, amino acid residue; R<sub>2</sub>, R<sub>3</sub> = (substituted) Ph, cyclohexyl; A<sub>2</sub> = amino acid residue; A<sub>1</sub>A<sub>2</sub> = dipeptide residue whose central amide bond is reduced; NR<sub>4</sub>R<sub>5</sub> = (substituted) morpholino, thiomorpholino], were prepd. Title compd. II was prepd. by soln. phase coupling reactions. I inhibited HIV-1 protease with IC<sub>50</sub> = 10<sup>-7</sup>-10<sup>-9</sup> M.

L4 ANSWER 78 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1995:679270 CAPLUS

DN 123:75087

TI Structure-activity relationships of dermorphin analogs containing

N-substituted amino acids in the 2-position of the peptide sequence

AU Schmidt, Ralf; Kalman, Andras; Chung, Nga N.; Lemieux, Carole; Horvath, Csaba; Schiller, Peter W.

CS Lab. Chem. Biol. Peptide Res., Clin. Res. Inst. Montreal, Quebec, Can.

SO International Journal of Peptide & Protein Research (1995), 46(1), 47-55  
CODEN: IJPPC3; ISSN: 0367-8377

PB Munksgaard

DT Journal

LA English

IT **165128-29-0**

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)


(structure-activity relationships of dermorphin analogs contg.  
N-substituted amino acids in the 2-position of the peptide sequence)

RN 165128-29-0 CAPLUS

CN Dermorphin, 2-(N-methyl-L-2-phenylglycine)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OH




AB A series of dermorphin analogs contg. an N-alkylated amino acid residue Xaa in the 2-position of the peptide sequence was synthesized (Xaa =

N-methylalanine, proline, pipecolic acid, N-methylphenylalanine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [Tic])). These peptides have the potential of assuming a cis Tyr1-Xaa2 peptide bond. Their in vitro opioid activity profiles were detd. in .mu.- and .delta.-receptor-representative binding assays and bioassays. Aside from [D-Pro2]dermorphin, all analogs showed high affinity for .mu.- and/or .delta.-opioid receptors. Whereas most compds. were full .mu.-agonists in the guinea pig ileum (GPI) assay, [Tic2]dermorphin (compd. 7) was a partial .mu.-agonist. Replacement of Gly4 in 7 with Phe resulted in an analog (8) with weak .mu.-antagonist activity. Furthermore, analogs 7 and 8 both were potent .delta.-antagonists (Kc = 3-40 nM) against the .delta.-agonists Leu-enkephalin, DPDPE and deltorphin I in the mouse vas deferens (MVD) assay. Compd. 3, contg. L-Pro in the 2-position, turned out to be one of the most .mu.-receptor-selective linear dermorphin analogs reported to date. Low-temp. HPLC expts. using micropellicular octadecyl silica as stationary phase revealed conformational heterogeneity of the dermorphin analogs which was ascribed to cis-trans isomerization around the Tyr1-Xaa2- and Tyr5-Pro6 peptide bonds. In the case of analog 7 four sep. peaks corresponding to the four possible isomers were apparent at -5.degree.. Since opioid peptide analogs with a non-N-alkylated L-amino acid residue in the 2-position are nearly inactive and cannot assume a cis peptide bond at the 1-2 position, these results support the hypothesis that the bioactive conformation of opioid peptides contg. an N-alkylated L-amino acid residue in position 2 is characterized by a cis Tyr1-Xaa2 peptide bond.

L4 ANSWER 79 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 1995:568922 CAPLUS  
DN 123:111518  
TI Enantioselective Synthesis of Tertiary Homoallylic Alcohols via  
Diastereoselective Addition of Allylsilanes to Ketones  
AU Tietze, Lutz F.; Schiemann, Kai; Wegner, Christoph  
CS Institute of Organic Chemistry, Georg-August-Universitaet, Goettingen,  
D-37077, Germany  
SO Journal of the American Chemical Society (1995), 117(21), 5851-2  
CODEN: JACSAT; ISSN: 0002-7863  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 123:111518  
IT **165823-95-0P 166021-67-6P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(enantioselective synthesis of tertiary homoallylic alcs. via  
diastereoselective addn. of allylsilanes to ketones)  
RN 165823-95-0 CAPLUS  
CN Acetamide, 2,2,2-trifluoro-N-[(1R,2R)-1-methyl-2-[[ (1S)-1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 166021-67-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[1-methyl-2-[[1-methyl-1-(2-phenylethyl)-3-butenyl]oxy]-2-phenylethyl]-, [1R-[1R\*,2R\*(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Enantiopure tertiary homoallylic alcs.  $\text{CH}_2\text{:CHCH}_2\text{CRMeOH}$  ( $\text{R} = \text{alkyl}$ ) can be obtained from the corresponding homoallylic ethers  $\text{CH}_2\text{:CHCH}_2\text{CRMeOR1}$  [4,  $\text{R1} = \text{residue of (1R,2R)-N-(trifluoroacetyl)norpseudoephedrine}$ ] by treatment with sodium in liq. ammonia. The ethers 4 are formed highly selectively by treatment of the ketones  $\text{MeCOR}$  with the trimethylsilyl ether of N-trifluoroacetylnorpseudoephedrine in the presence of catalytic amts. of  $\text{Me}_3\text{SiB(OTf)}_4$  or  $\text{Me}_3\text{SiOTf/TfOH}$  ( $\text{Tf} = \text{CF}_3\text{SO}_2$ ) followed by addn. of allyltrimethylsilane. The yield was about 90% (based on conversion) and the diastereoselectivity was about 90:10. Using iso-Pr Me ketone a selectivity of >95:5 was obtained; thus only one diastereomer could be detected.

L4 ANSWER 80 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1995:480169 CAPLUS

DN 122:240447

TI Preparation of peptideamide analogs as tachykinin antagonists.

IN Pieper, Helmut; Austel, Volkhard; Jung, Birgit; Buerger, Erich; Entzeroth, Michael

PA Karl Thomas GmbH, Germany

SO Ger. Offen., 101 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

PI	DE 4243858	A1	19940630	DE 1992-4243858	19921223
				DE 1992-4243858	19921223

OS MARPAT 122:240447


IT **162177-25-5P 162177-26-6P 162177-27-7P**  
**162177-28-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as tachykinin antagonist)

RN 162177-25-5 CAPLUS

CN L-Lysinamide, N-(1-oxo-4-phenylbutyl)-L-2-phenylglycyl-N-(2-phenylethyl)-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162177-26-6 CAPLUS

CN L-Lysinamide, N-(1-oxo-4-phenylbutyl)-L-2-phenylglycyl-N-(2-phenylethyl)-, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HBr

RN 162177-27-7 CAPLUS

CN L-Lysinamide, N-(1-oxo-4-phenylbutyl)-D-2-phenylglycyl-N-(2-phenylethyl)-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162177-28-8 CAPLUS


CN L-Lysinamide, N-(1-oxo-4-phenylbutyl)-D-2-phenylglycyl-N-(2-phenylethyl)-, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

GI



I

AB R4R5NACONHCHR3CXNR1R2 [A = 1,2-cyclopentylene, CHR6; R6 = H, (substituted) alkyl, Ph; R1 = H, (Ph- or pyridyl-substituted) alkyl; R2 = H, (amino- or

guanidino-substituted) Ph, pyridyl, (cyclohexyl-, Ph-, or pyridyl-substituted) alkyl, etc.; R1R2N = (substituted) piperazinyl; R3 = H, (phenyl)alkyl, guanidino- or amino-substituted alkyl, aminocarbonylalkyl, etc.; R4 = H, (phenyl)alkyl; R5 = protecting group, (substituted) alkyl, alkanoyl, alkoxy carbonyl, alkylaminocarbonyl, PhCO, naphthylcarbonyl, biphenylcarbonyl, PhSO2, etc.; X = (H, H), O, S; the C atom bearing the R3 substituent is L; the C atom bearing the R6 substituent is D or L], were prepd. Thus, title compd. I (prepd. by soln. phase methods) showed IC50 = 2 nM for neurokinin-1 receptor binding with IM-9 cells. Tablets were prepd. contg. I.

L4 ANSWER 81 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1995:409660 CAPLUS

DN 123:9907

TI Prerequisite for His4 in deltorphin A for high .delta. opioid receptor selectivity

AU Salvadori, S.; Guerrini, R.; Forlani, V.; Bryant, S. D.; Attila, M.; Lazarus, L. H.

CS Dept. Pharm. Sci., Univ. Ferrara, Ferrara, Italy

SO Amino Acids (1994), 7(3), 291-304

CODEN: AACIE6; ISSN: 0939-4451

PB Springer

DT Journal

LA English

IT **163679-50-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(.delta. opioid receptor selectivity of deltorphin A position 4 analogs)

RN 163679-50-3 CAPLUS

CN Deltorphin A, 4-(L-2-phenylglycine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



— SMe

AB Anal. of deltorphin A position 4 analogs included: backbone constrained MeHis, spinacine (Spi), MePhe, and tetrahydroisoquinoline-3-carboxylic acid (Tic); spatially confined side-chain phenylglycine (Phg); and imidazole alkylation of L- and D-His4 enantiomers. High  $\delta$  selectivity was lost with the following replacements; MeHis4, MePhe4 and Phg4 reduced  $\delta$  binding and the constrained residues also increased  $\mu$  binding; ring closure between the side-chain and amino group to yield Spi4 or Tic4 increased  $\mu$  affinity. Imidazole methylation of His4 marginally affected opioid binding and doubled  $\delta$  selectivity; alkylated D-His4 derivs. generally maintained  $\delta$  selectivity in spite of decreased  $\delta$  binding and by repulsion at the  $\mu$  receptor. Several low energy conformers of deltorphin A indicated that the His4 imidazole preferred a spatial orientation parallel to the phenolic side-chain of Tyr1 suggestive that this conformation might contribute to high  $\delta$  affinity and selectivity.

L4 ANSWER 82 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1994:557528 CAPLUS

DN 121:157528

TI Preparation of N-aryl- and N-heteroarylureas as inhibitors of cholesterol acyltransferase

IN Hamanaka, Ernest S.

PA Pfizer Inc., USA

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9324458	A1	19931209	WO 1993-US3539	19930420
	W: AU, BG, BR, CA, CZ, DE, JP, KR, NO, NZ, RO, RU, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-890050 A2	19920528
	AU 9340283	A1	19931230	AU 1993-40283	19930420
				US 1992-890050 A	19920528
				WO 1993-US3539 A	19930420
	EP 642498	A1	19950315	EP 1993-909519	19930420
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				US 1992-890050 A	19920528
				WO 1993-US3539 W	19930420
	JP 07503737	T2	19950420	JP 1994-500522	19930420
				US 1992-890050 A	19920528



CA 2134359	C	19970701	WO 1993-US3539 W 19930420
BR 9306421	A	19980915	CA 1993-2134359 19930420
			US 1992-890050 A 19920528
HU 64303	A2	19931228	BR 1993-6421 19930420
CN 1080919	A	19940119	US 1992-890050 A 19920528
NO 9404530	A	19941125	WO 1993-US3539 W 19930420
US 6001860	A	19991214	HU 1993-1552 19930527
			US 1992-890050 A 19920528
			CN 1993-106774 19930527
			US 1992-890050 A 19920528
			NO 1994-4530 19941125
			US 1992-890050 A 19920528
			WO 1993-US3539 A 19930420
			US 1995-343557 19950117
			US 1992-890050 B219920528
			WO 1993-US3539 W 19930420

## PATENT FAMILY INFORMATION:

FAN 1999:794333

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6001860	A	19991214	US 1995-343557	19950117
				US 1992-890050 B219920528	
				WO 1993-US3539 W 19930420	
	WO 9324458	A1	19931209	WO 1993-US3539	19930420
	W:	AU, BG, BR, CA, CZ, DE, JP, KR, NO, NZ, RO, RU, SK, UA, US			
	RW:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
				US 1992-890050 A219920528	


OS MARPAT 121:157528

IT **157548-92-0P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as cholesterol acyltransferase inhibitor)

RN 157548-92-0 CAPLUS

CN Urea, N-[2,4-bis(ethylthio)-6-methyl-3-pyridinyl]-N'-[2-(2,5-dimethylphenyl)-6-phenylhexyl]- (9CI) (CA INDEX NAME)



GI



AB R1NHC(:X)NR17R18 [R1 = (hetero)aryl; R17 = (CH2)n(CR19R20)z(CH2)rR; R = aryl, heterocyclyl, etc.; R18 = H, (cyclo)alkyl, aralkyl, etc.; R19,R20 = H, (halo)alkyl, aralkyl, etc.; R19R20 = atoms to form a ring; X = O or S; n = 0-13; r = 0-4; z = 0 or 1] were prep'd. as inhibitors of cholesterol acyltransferase (no data). Thus, 2-(4-isopropylbenzylamino)indane was condensed with 2,4-bis(methylthio)-6-methylpyridin-3-yl isocyanate to give title comp'd. I [R18 = 4-(Me2HC)C6H4CH2].

L4 ANSWER 83 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1994:271122 CAPLUS

DN 120:271122

TI Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides

AU Chapman, Kevin T.; Kopka, Thor E.; Durette, Philippe L.; Esser, Craig K.; Lanza, Thomas J.; Izquierdo-Martin, Maria; Niedzwiecki, Lisa; Chang, Benedict; Harrison, Richard K.; et al.

CS Dep. Med. Chem. Res., Merck Res. Lab., Rahway, NJ, 07065-0900, USA

SO Journal of Medicinal Chemistry (1993), 36(26), 4293-301

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English


IT **147472-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. and inhibition by, of stromelysin, collagenase, and gelatinase A)

RN 147472-95-5 CAPLUS

CN Glycinamide, N-(1-carboxyethyl)-4-phenyl-L-2-aminobutanoyl-L-N,2-diphenyl-, (R)- (9CI) (CA INDEX NAME)



GI




AB An extensive study of the requirements for effective binding of

N-carboxyalkyl peptides to human stromelysin, collagenase, and to a lesser extent, gelatinase A has been investigated. These efforts afforded inhibitors generally in the 100-400 nM range for these matrix metalloproteinases. The most significant increase in potency was obtained with the introduction of a .beta.-phenylethyl group at the P1' position, suggesting a small hydrophobic channel into the S1' subsite of stromelysin. Compd. I is relatively selective for rabbit stromelysin with a  $K_i = 6.5$  nM and may prove useful for elucidating the role of endogenously-produced stromelysin in lapine models of tissue degra.


L4 ANSWER 84 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1994:271119 CAPLUS  
 DN 120:271119  
 TI Kinetic and thermodynamic atropdiastereoselection in the synthesis of the M(5-7) tripeptide portion of vancomycin  
 AU Evans, David A.; Dinsmore, Christopher J.  
 CS Dep. Chem., Harvard Univ., Cambridge, MA, 02138, USA  
 SO Tetrahedron Letters (1993), 34(38), 6029-32  
 CODEN: TELEAY; ISSN: 0040-4039  
 DT Journal  
 LA English  
 IT **154578-63-9 154578-65-1 154578-67-3**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cyclization of, stereochem. of vanadium oxyfluoride-promoted)  
 RN 154578-63-9 CAPLUS  
 CN Glycinamide, N-acetyl-D-2-(2,4-dimethoxyphenyl)glycyl-O-benzoyl-3,5-dichloro-threo-.beta.-hydroxy-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154578-65-1 CAPLUS  
 CN Glycinamide, D-2-(2,4-dimethoxyphenyl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-O-benzoyl-3,5-dichloro-threo-.beta.-hydroxy-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 154578-67-3 CAPLUS

CN Glycinamide, N-acetyl-L-2-(2,4-dimethoxyphenyl)glycyl-O-benzoyl-3,5-dichloro-threo-.beta.-hydroxy-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I

AB The C.alpha. stereochem. of the position-5 arylglycine plays a pivotal role in detg. the kinetic atropdiastereoselection in the oxidative biaryl cyclization reaction, they key step in a biomimetic strategy directed toward the synthesis of the M(5-7) vancomycin fragment I. The equil. ratio of biaryl and amide conformations within the 12-membered macrocycle is significantly influenced by interaction of this same center with adjacent substituents.

L4 ANSWER 85 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1994:244406 CAPLUS

DN 120:244406

TI Semisynthetic .beta.-lactam antibiotics. Synthesis and antibacterial activity of 6.beta.-[(R)-2-((3,4-disubstituted phenyl)-alkancarboxyamido)phenylacetamido]penicillanic acids

AU Tsou, Tai Li; Ho, Su Neng; Chang, Li Ren

CS Inst. Prevent. Med., Natl. Def. Med. Cent., Taipei, Taiwan

SO Zhonghua Yaoxue Zazhi (1993), 45(6), 563-72

CODEN: CYHCEX; ISSN: 1016-1015

DT Journal

LA English

IT 21488-22-2P 154315-81-8P 154315-82-9P

154315-83-0P 154315-84-1P 154315-86-3P

154315-87-4P 154315-88-5P 154315-89-6P


154315-90-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and bactericidal activity of)

RN 21488-22-2 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[(1-oxo-3-phenylpropyl)amino]phenylacetyl]amino]-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 154315-81-8 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[4-[3,4-bis(acetyloxy)phenyl]-1-oxobutyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 154315-82-9 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[4-[3,4-bis(acetyloxy)phenyl]-1-oxobutyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154315-83-0 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-[3,4-bis(acetyloxy)phenyl]-1-oxopropyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-

oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 154315-84-1 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-[3,4-bis(acetyloxy)phenyl]-1-oxopropyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 154315-86-3 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-[4-(acetyloxy)phenyl]-1-oxopropyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 154315-87-4 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-[4-(acetyloxy)phenyl]-1-oxopropyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 154315-88-5 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[4-hydroxyphenyl][(1-oxo-3-phenylpropyl)amino]acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 154315-89-6 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(3,4-dimethoxyphenyl)-1-oxopropyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.









RN 154315-90-9 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(3,4-dimethoxyphenyl)-1-oxopropyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



GI



T



II

AB In order to improve the antibacterial activity, a series of 6.beta.-[(R)-.alpha.-amino-phenylacetamido]penicillanic acids I (R = H, OH, R3, R4 = OAc, H, OMe, n = 0-3) with various substituents at the .alpha.-amino group were prepd. by reacting ampicillin or amoxicillin with N-succinamido-substituted phenylalkanes II. Structures of these products were detd. by 1H NMR, FAB-MS, and FT-IR spectral analyses. In comparison with the parent drugs, I (R3 = R4 = OAc, n = 0-3), having a [(diacetoxyphenyl)alkyl]carbonyl group, are active in vitro against gram pos. and gram neg. bacteria, including *Pseudomonas aeruginosa*. The other compds., I (R3 = H, R4 = OAc, n = 2; R3 = R4 = OMe, n = 2) displayed activity only in *Staphylococcus* and *Streptococcus* strains. For the .beta.-lactamase producing strains, all of the derivs. are inferior to the parents. The structure activity relationships of these derivs. indicated some facts. First, compds. with increasing no. of carbon atoms between the diacetoxyphenyl moiety and .alpha.-amino group of ampicillin or amoxicillin would retain the potency against all the tested strains. Second, compds. with increasing lipophilicity of the side chains exhibited less activity against gram neg. bacteria.

L4 ANSWER 86 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1994:134999 CAPLUS

DN 120:134999

TI HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptide mimetics

AU Ghosh, Arun K.; McKee, Sean P.; Sanders, William M.; Darke, Paul L.;  
Zugay, Joan A.; Emini, Emilio A.; Schleif, William A.; Quintero, Julio C.;  
Huff, Joel R.; Anderson, Paul S.

CS Dep. Med. Chem., Mol. Biol., Merck Research Lab., West Point, PA, 19486,  
USA

SO Drug Design and Discovery (1993), 10(1), 77-88  
CODEN: DDDIEV; ISSN: 1055-9612

DT Journal

LA English


IT 152843-94-2P 152886-93-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and antiviral activity of)


RN 152843-94-2 CAPLUS

CN .beta.-D-Xylofuranoside, methyl 5-deoxy-5-[[[5-[[[1,1-dimethylethoxy)carbonyl]amino]-4-hydroxy-1-oxo-6-phenyl-2-(3-phenyl-2-propenyl)hexyl]amino]phenylacetyl]amino]-, [2R-[1(S\*),2R\*,4S\*,5S\*]]- (9CI)  
(CA INDEX NAME)




RN 152886-93-6 CAPLUS

CN .alpha.-D-Xylofuranoside, methyl 5-deoxy-5-[[[5-[[[1,1-dimethylethoxy)carbonyl]amino]-4-hydroxy-1-oxo-6-phenyl-2-(3-phenyl-2-propenyl)hexyl]amino]phenylacetyl]amino]-, [2R-[1(S\*),2R\*(E),4S\*,5S\*]]- (9CI) (CA INDEX NAME)



GI



AB A series of glycopeptide mimetics, e.g. I, based on the hydroxyethylene Phe-Phe isostere have been synthesized and evaluated for their ability to inhibit the enzyme HIV-1 protease. Within this series, compd. I was the most potent inhibitor (ED<sub>50</sub> value 0.17 nM). This compd. has also shown to block the spread of HIV-1 in T-lymphoid cells at an inhibitor concn. of 200 nM.

L4 ANSWER 87 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1993:670782 CAPLUS

DN 119:270782

TI Preparation of acyclic ethylenediamine derivatives as substance P receptor antagonists

IN O'Neill, Brian T.

PA Pfizer Inc., USA

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9310073	A1	19930527	WO 1992-US7730	19920918
	W: AU, CA, FI, HU, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	AU 9226813	A1	19930615	AU 1992-26813	19920918
				US 1991-790934 A	19911112
				WO 1992-US7730 A	19920918
	EP 613458	A1	19940907	EP 1992-921029	19920918
	EP 613458	B1	19980107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
				US 1991-790934 A	19911112
				WO 1992-US7730 W	19920918
	JP 06510792	T2	19941201	JP 1992-509229	19920918
	JP 2614408	B2	19970528		
				US 1991-790934 A	19911112
				WO 1992-US7730 W	19920918
	HU 70741	A2	19951030	HU 1994-1337	19920918
				US 1991-790934 A	19911112
	AT 161821	E	19980115	AT 1992-921029	19920918
				US 1991-790934 A	19911112
	ES 2111650	T3	19980316	ES 1992-921029	19920918
				US 1991-790934 A	19911112
	CA 2324959	C	20021112	CA 1992-2324959	19920918
				US 1991-790934 A	19911112

ZA 9208682	A	19940511	CA 1992-2123403A319920918
FI 9402187	A	19940511	ZA 1992-8682 19921111
			US 1991-790934 A 19911112
NO 9401784	A	19940511	FI 1994-2187 19940511
			US 1991-790934 A 19911112
US 5521220	A	19960528	WO 1992-US7730 W 19920918
			NO 1994-1784 19940511
			US 1991-790934 A 19911112
			WO 1992-US7730 A 19920918
			US 1994-240657 19940720
FI 2001000083	A	20010115	US 1991-790934 B219911112
			WO 1992-US7730 W 19920918
			FI 2001-83 20010115
			US 1991-790934 A 19911112
			WO 1992-US7730 W 19920918

## PATENT FAMILY INFORMATION:

FAN 1996:380219

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5521220	A	19960528	US 1994-240657	19940720
				US 1991-790934 B219911112	
				WO 1992-US7730 W 19920918	
	WO 9310073	A1	19930527	WO 1992-US7730	19920918
	W: AU, CA, FI, HU, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	CA 2324959	C	20021112	US 1991-790934 A219911112	
				CA 1992-2324959	19920918
				US 1991-790934 A 19911112	
				CA 1992-2123403A319920918	


OS CASREACT 119:270782; MARPAT 119:270782

IT **150917-46-7P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as substance P receptor antagonist)

RN 150917-46-7 CAPLUS

CN 1,2-Ethanediamine, N1-cyclohexyl-N2-[(2-methoxyphenyl)methyl]-1-phenyl-N1-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1 = H, C1-8 alkyl, C6-10 carbocyclic two-fused-ring system or a bridged two ring system, benzyl, substituted benzyl; R2 = H, benzyl, R(CH<sub>2</sub>)<sub>m</sub> (m = 0-12), the chain may contain C=C or C.tplbond.C bonds and may be substituted; R1R2N = C3-8 satd. or unsatd. heterocycle, or a fused or bridged heterocyclic system; R3 = H, C3-8 cycloalkyl, C1-6 (un)branched alkyl, (un)substituted Ph, or fluoroalkylphenyl or fluoroalkoxy; R4, R5 = aryl (e.g., Ph, naphthyl, or heteroaryl; R5 = H, alkyl, Ph, or alkyl- or alkoxyphenyl which may be fluorinated in the side chain; R6 = H, (un)branched alkyl, cycloalkyl, aryl, heteroaryl], useful as substance P receptor antagonists (no data), are prepd. Thus, aq. NaHSO<sub>3</sub> was treated with PHCHO-MeOH and then cyclohexylamine and KCN to give 79.6% .alpha.-cyclohexylaminobenzeneacetonitrile which was reduced by DIBAL in PhMe to give 74% 1-N-cyclohexyl-1-phenyl-1,2-ethanediamine. This diamine in HOAc contg. 3 .ANG. mol. sieves was treated with anisaldehyde and Na(AcO)3BH to give 41% 1-N-cyclohexyl-1-phenyl-2-N'[(2-methoxyphenyl)methyl]-1,2-ethanediamine.

L4 ANSWER 88 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1993:603857 CAPLUS

DN 119:203857

TI Preparation of modified peptides transportable into the central nervous system

IN Arvantis, Argyrios; Cain, Gary Avonn; Christos, Thomas Eugene; Confalone, Pasquale Nicholas; Pottorf, Richard Scott; Schmidt, William Koch

PA Du Pont Merck Pharmaceutical Co., USA

SO PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9300359	A1	19930107	WO 1992-US4968	19920618
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
				US 1991-723616	19910627
	AU 9222381	A1	19930125	AU 1992-22381	19920618
				US 1991-723616	19910627
				WO 1992-US4968	19920618

OS MARPAT 119:203857


IT **150435-49-7P 150435-50-0P 150435-51-1P**  
**150435-52-2P 150435-53-3P 150463-78-8P**  
**150463-79-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as intermediate for neurotensin analog)

RN 150435-49-7 CAPLUS

CN L-Leucine, N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl]-L-2-phenylglycyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150435-50-0 CAPLUS

CN L-Leucine, N-[L-2-phenyl-N-[O-(phenylmethyl)-L-tyrosyl]glycyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 150435-51-1 CAPLUS

CN L-Leucine, N-[L-2-phenyl-N-[O-(phenylmethyl)-N-L-prolyl-L-tyrosyl]glycyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 150435-52-2 CAPLUS

CN L-Leucine, N-[L-2-phenyl-N-[N-[1-[N6-[(phenylmethoxy)carbonyl]-L-lysyl]-L-prolyl]-O-(phenylmethyl)-L-tyrosyl]glycyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 150435-53-3 CAPLUS

CN L-Leucine, N-[L-2-phenyl-N-[N-[1-[N6-[(phenylmethoxy)carbonyl]-N2-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylcarbonyl)-L-lysyl]-L-prolyl]-O-(phenylmethyl)-L-tyrosyl]glycyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 150463-78-8 CAPLUS

CN L-Leucine, N-[N-[N-[1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl]-O-(phenylmethyl)-L-tyrosyl]-L-2-phenylglycyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 150463-79-9 CAPLUS

CN L-Leucine, N-[N-[N-[1-[N2-[(1,1-dimethylethoxy) carbonyl]-N6-[(phenylmethoxy) carbonyl]-L-lysyl]-L-prolyl]-O-(phenylmethyl)-L-tyrosyl]-L-2-phenylglycyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Ph


IT 150434-66-5P 150434-67-6P 150435-05-5P  
150435-92-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as neurotensin analog)

RN 150434-66-5 CAPLUS

CN L-Leucine, N-[L-2-phenyl-N-[N-[1-[N2-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylcarbonyl)-L-lysyl]-L-prolyl]-L-tyrosyl]glycyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150434-67-6 CAPLUS


CN L-Leucine, N-[L-2-phenyl-N-[N-[1-[N2-(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)-L-lysyl]-L-prolyl]-L-tyrosyl]glycyl]-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 150434-66-5

CMF C45 H62 N6 O8


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 150435-05-5 CAPLUS

CN L-Leucine, N-[N-[N-[1-[N2-(N2-acetyl-L-arginyl)-L-arginyl]-L-prolyl]-L-tyrosyl]-L-2-phenylglycyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150435-92-0 CAPLUS

CN L-Leucine, N-[N-[N-[1-[N2-[(1,1-dimethylethoxy) carbonyl]-L-lysyl]-L-prolyl]-L-tyrosyl]-L-2-phenylglycyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB YWmXnA1-H-A-B-C-D-E-F-Z [Y = lipophilic moiety LCO, R(CH<sub>2</sub>)<sub>p</sub> (O(CH<sub>2</sub>)<sub>r</sub>); p, r = 0-6; L = (substituted) alkyl, perfluoroalkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, etc.; R = cycloalkyl, heterocyclyl, (substituted) aryl; W = Arg, D-Arg, D-Lys, Pro, Nle, Lys, Orn, homoarginine, 2,4-diaminobutyric acid, 2,3-diaminopropionic acid, N-methylnorleucine, 4-aminocyclohexylalanine residues; X = W, Ala, etc.; m, n = 0,1; A, A1, C, E = CONH, CONMe, NMeCO, CH<sub>2</sub>NH, CH<sub>2</sub>O, CH<sub>2</sub>S, CSNH, NHCONH, SOCH<sub>2</sub>, SO<sub>2</sub>CH<sub>2</sub>, NHSC, CH:CH, CH<sub>2</sub>CH<sub>2</sub>, CF<sub>2</sub>CF<sub>2</sub>, CF:CF, CF:CH, CH<sub>2</sub>CH(OH), cyclopropylene, 4,5-tetrazolyldiyl, etc.; H = Pro, N-methylaminobutyric acid residue; B = Tyr, Phe, Trp, naphthylalanine, phenylglycine, .beta.-phenylproline residues; D = Ile, Leu, tert-leucine, phenylglycine residues; F = Leu, Val, Met; Z = OH, alkoxy], were prepd. Thus, Q-Arg-Pro-Tyr-Ile-Leu-OH.HOAC (Q = 1-adamantanecarbonyl), prepd. by solid phase coupling on phenylacetamidomethyl resin using BOC-protected amino acids and DCC/1-hydroxybenzotriazole, showed K<sub>i</sub> = 144 nM in a neurotensin binding assay and ED<sub>50</sub> = 14 mg/kg i.v. in the phenylquinone writhing test in mice.

L4 ANSWER 89 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1993:539766 CAPLUS

DN 119:139766

TI Oxidative coupling of arylglycine-containing peptides. A biomimetic approach to the synthesis of the macrocyclic actinoidinic-containing vancomycin subunit

AU Evans, David A.; Dinsmore, Christopher J.; Evrard, Deborah A.; DeVries, Keith M.

CS Dep. Chem., Harvard Univ., Cambridge, MA, 02138, USA

SO Journal of the American Chemical Society (1993), 115(14), 6426-7  
CODEN: JACSAT; ISSN: 0002-7863

DT Journal


LA English

OS CASREACT 119:139766

IT **149623-79-0P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and benzylation of)

RN 149623-79-0 CAPLUS



CN Glycinamide, 3,5-dichloro-N-[(1,1-dimethylethoxy)carbonyl]-threo-.beta.-hydroxy-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



IT **149623-51-8P 149623-52-9P 149623-69-8P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and intramol. oxidative biaryl coupling of, with vanadium oxyfluoride)


RN 149623-51-8 CAPLUS

CN Glycinamide, N-acetyl-D-2-(2,4-dimethoxyphenyl)glycyl-3,5-dichloro-threo-.beta.-hydroxy-O-propyl-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 149623-52-9 CAPLUS


CN Glycinamide, D-2-[2-[(3,4-dichlorophenyl)methoxy]-4-methoxyphenyl]-N-(trifluoroacetyl)glycyl-O-benzoyl-3,5-dichloro-threo-.beta.-hydroxy-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 149623-69-8 CAPLUS

CN Glycinamide, N-acetyl-D-2-(2,4-dimethoxyphenyl)glycyl-3,5-dichloro-threo-.beta.-hydroxy-O-2-propenyl-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

IT **149623-80-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and peptide coupling of, with arylglycine deriv., in prepn. of vancomycin fragment)

RN 149623-80-3 CAPLUS


CN Glycinamide, O-benzoyl-3,5-dichloro-N-[(1,1-dimethylethoxy)carbonyl]-threo-.beta.-hydroxy-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

IT **149623-66-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and peptide coupling of, with arylglycine deriv., in prepn. of vancomycin fragment model)

RN 149623-66-5 CAPLUS


CN Glycinamide, 3,5-dichloro-N-[(1,1-dimethylethoxy)carbonyl]-threo-.beta.-hydroxy-O-propyl-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

IT **149623-65-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn., catalytic hydrogenation, or deallylation of)

RN 149623-65-4 CAPLUS



CN Glycinamide, (.beta.R)-3,5-dichloro-N-[(1,1-dimethylethoxy)carbonyl]-  
.beta.-hydroxy-O-2-propenyl-L-tyrosyl-(2S)-2-(3,5-dimethoxyphenyl)-N-  
methyl- (9CI) (CA INDEX NAME)

IT **149623-67-6P 149623-68-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn., deblocking, and acetylation of)



RN 149623-67-6 CAPLUS

CN Glycinamide, D-2-(2,4-dimethoxyphenyl)-N-[(1,1-  
dimethylethoxy)carbonyl]glycyl-3,5-dichloro-threo-.beta.-hydroxy-O-propyl-  
L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 149623-68-7 CAPLUS

CN Glycinamide, D-2-(2,4-dimethoxyphenyl)-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3,5-dichloro-threo-.beta.-hydroxy-O-2-propenyl-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




IT 149623-81-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn., deblocking, and trifluoroacetylation of)

RN 149623-81-4 CAPLUS



CN Glycinamide, D-2-[2-[(3,4-dichlorophenyl)methoxy]-4-methoxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]glycyl-O-benzoyl-3,5-dichloro-threo-.beta.-hydroxy-L-tyrosyl-L-2-(3,5-dimethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A biomimetic approach to the synthesis of the 12-membered cyclic tripeptide M(5-7) macrocyclic fragment I (R = R1 = H) (II), which comprises three of the seven amino acid constituents of the vancomycin aglycon is reported. The macrocyclization of the linear tripeptide precursor III to the cyclic 12-membered tripeptide I (R = OCH2C6H3Cl2-3,4, R1 = Me) was achieved by an efficient intramol. oxidative biaryl coupling with VOF3 in 64% yield. After removal of the requisite ortho phenolic residue and subsequent demethylation to the unnatural atropisomer II, atropisomerization to the M(5-7) macrocyclic tripeptide vancomycin subunit was achieved. The rotational barrier for this conformational change was 21 kcal mol<sup>-1</sup>.

L4 ANSWER 90 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1993:247987 CAPLUS

DN 118:247987

TI The action of LH-releasing hormone and five analogs on estradiol, oxytocin and vasopressin secretion by bovine granulosa cells in culture

AU Sirotkin, A. V.; Nitray, J.; Nikolajev, S. V.; Burov, S. V.

CS Dep. Exp. Endocrinol., Res. Inst. Anim. Prod., Nitra, 949 92, Czech.

SO Journal of Endocrinology (1993), 136(3), 491-6

CODEN: JOENAK; ISSN: 0022-0795

DT Journal

LA English

IT 126609-83-4

RL: BIOL (Biological study)


(estradiol and oxytocin and vasopressin secretion response to, in ovary granulosa cell)

RN 126609-83-4 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 2-D-phenylalanine-6-(4-amino-D-phenylalanine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=NH

AB The release of oxytocin, AVP, and estradiol by bovine granulosa cells in culture was analyzed either with or without LH-RH, its agonists (cyclo[Prol,D-Phe6]LH-RH and de-(1-3,10)-[D-Ala6]LH-RH) or antagonists ([D-Phe2,D-Phe6]LH-RH, [D-Phe2,D-Phe(NH2)6]LH-RH, or cyclo[Prol,D-Phe2,D-Phe6]LH-RH). All preps. used stimulated granulosa oxytocin and estradiol secretion. Vasopressin release was increased after all treatments with LH-RH antagonists, but not after LH-RH or its agonists. The data demonstrate a direct influence of LH-RH and its analogs on the secretion of estrogen and nonapeptide hormones by bovine granulosa cells. A

comparison of the effects of LH-RH and its agonists and antagonists suggests that the action of these peptides at the hypophyseal and ovarian level is relatively independent.

L4 ANSWER 91 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1993:234493 CAPLUS

DN 118:234493

TI Preparation of substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents

IN Sahoo, Soumya P.; Polo, Scott A.; Durette, Philippe L.; Esser, Craig K.; Hagmann, William K.; Kopka, Ihor E.; Chapman, Kevin T.; Caldwell, Charles G.

PA Merck and Co., Inc., USA

SO PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9221360	A1	19921210	WO 1992-US3809	19920501
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
				US 1991-705826	19910528
				US 1992-873905	19920424
	CA 2102890	AA	19921129	CA 1992-2102890	19920501
				US 1991-705826	19910528
	EP 586537	A1	19940316	EP 1992-912475	19920501
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1991-705826	19910528
				US 1992-873905	19920424
				WO 1992-US3809	19920501
	US 5932551	A	19990803	US 1997-848766	19970501
				US 1992-873905	19920424
				US 1995-397538	19950302
				US 1995-533879	19950926


OS MARPAT 118:234493

IT **147472-95-5P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and stromelysin, collagenase, and gelatinase inhibitory activity of)

RN 147472-95-5 CAPLUS

CN Glycinamide, N-(1-carboxyethyl)-4-phenyl-L-2-aminobutanoyl-L-N,2-diphenyl-, (R)- (9CI) (CA INDEX NAME)



GI



AB Title compds. R3O2CCHR1NHCH(CHR7R8)CO-AA-NR5R6 [R3 = H, C1-C10 alkyl, (un)substituted C6-C10 (hetero)aryl, (un)substituted C6-C10 (hetero)aryl-C1-C3 alkyl; R1 = C1-C6 (un)substituted alkyl; R7 = H, C1-C3 alkyl, OH; R8 = (un)substituted C6-C10 (hetero)aryl-C1-C2 alkyl; AA = amino acid residue; R5, R6 = independently H, C1-C10 alkyl, C6-C10 (un)substituted (hetero)aryl, C6-C10 (un)substituted (hetero)aryl-C1-C6 alkyl] and pharmaceutically acceptable salts thereof were prepd. as inhibitors of matrix metalloendoproteinase-mediated diseases, e.g. osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophic epidermolysis bullosa, and coronary thrombosis assocd. with atherosclerotic plaque rupture. These claimed inhibitors may also be useful in preventing the pathol. sequelae following a traumatic injury that could lead to a permanent disability, and may also have utility as a means of birth control by preventing ovulation or implantation. Thus, reductive alkylation of 10.5 g (S)-H2NCH(CH2CH2Ph)CO2CMe3.HCl by 18.1 mL MeCOCO2CH2Ph with NaBH3CN in AcOH/pyridine gave 6.40 g adduct I (R9 = CH2Ph, R10 = OCMe3) (II). Deblocking of II with HCl, coupling with H-Leu-NHPh.HCl, and catalytic hydrogenolysis gave title adduct I (R9 = H, R10 = Leu-NHPh) (III). III inhibited stromelysin, collagenase, and 72 kD gelatinase with IC50 = 0.32, 0.06, and 0.93 .mu.M, resp.

L4 ANSWER 92 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1993:116751 CAPLUS

DN 118:116751

TI Recombinant thrombin receptor, agonist and antagonist peptides, and (monoclonal) antibodies

IN Coughlin, Shaun R.; Scarborough, Robert M.

PA University of California, Oakland, USA; Cor Therapeutics, Inc.

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9214750	A1	19920903	WO 1992-US1312	19920219
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
	US 5256766	A	19931026	US 1991-657769	19910219
	US 5688768	A	19971118	US 1991-789184	19911107
				US 1991-657769 A2	19910219
	AU 9214568	A1	19920915	AU 1992-14568	19920219
	AU 665752	B2	19960118		
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
				WO 1992-US1312 A	19920219

EP 572553 A1 19931208 EP 1992-907700 19920219  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE  
 US 1991-657769 A 19910219  
 US 1991-789184 A 19911107  
 WO 1992-US1312 W 19920219  
 JP 06508742 T2 19941006 JP 1992-507331 19920219  
 US 1991-657769 A 19910219  
 US 1991-789184 A 19911107  
 WO 1992-US1312 W 19920219

## PATENT FAMILY INFORMATION:

FAN 1997:761604

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5688768	A	19971118	US 1991-789184	19911107
				US 1991-657769 A2	19910219
	US 5256766	A	19931026	US 1991-657769	19910219
	CA 2104394	AA	19920820	CA 1992-2104394	19920219
				US 1991-657769 A	19910219
	WO 9214750	A1	19920903	WO 1992-US1312	19920219
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
	AU 9214568	A1	19920915	AU 1992-14568	19920219
	AU 665752	B2	19960118		
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
				WO 1992-US1312 A	19920219
	EP 572553	A1	19931208	EP 1992-907700	19920219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
				WO 1992-US1312 W	19920219
	JP 06508742	T2	19941006	JP 1992-507331	19920219
				US 1991-657769 A	19910219
				US 1991-789184 A	19911107
				WO 1992-US1312 W	19920219
	US 6197541	B1	20010306	US 1993-18760	19930217
				US 1991-657769 A1	19910219
				US 1991-789184 A3	19911107
	US 5759994	A	19980602	US 1995-475263	19950607
				US 1991-657769 A2	19910219
				US 1991-789184 A1	19911107
	US 5798248	A	19980825	US 1995-485886	19950607
				US 1991-657769 A2	19910219
				US 1991-789184 A3	19911107
	US 5849507	A	19981215	US 1995-477362	19950607
				US 1991-657769 A2	19910219
				US 1991-789184 A3	19911107
	US 5856448	A	19990105	US 1995-477134	19950607
				US 1991-657769 A2	19910219
				US 1991-789184 A3	19911107
	US 6024936	A	20000215	US 1995-473489	19950607
				US 1991-657769 A2	19910219
				US 1991-789184 A3	19911107

OS MARPAT 118:116751


IT **145230-57-5**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(thrombin agonist activity of)

RN 145230-57-5 CAPLUS

CN L-Argininamide, L-seryl-L-phenylalanyl-(2S)-2-phenylglycyl-L-leucyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


IT **145229-80-7**

RL: BIOL (Biological study)  
(thrombin receptor agonist)

RN 145229-80-7 CAPLUS

CN L-Arginine, L-seryl-L-phenylalanyl-(2S)-2-phenylglycyl-L-leucyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




AB The DNA encoding the cell-surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant

prodn. of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the thrombin receptor permits the design of agonist and antagonist compds. which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits prodn. of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically. Prepn. of a cDNA encoding the human thrombin receptor is described. Activity of a large variety of thrombin agonist and antagonist peptides is reported. Also reported are the prepn., using oligonucleotide-directed mutagenesis, of active-site thrombin mutants and the activity thereof, as well as prepn. and testing of (monoclonal) antibodies.

L4 ANSWER 93 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1992:470301 CAPLUS  
 DN 117:70301  
 TI Synthesis of peptides containing .alpha.,.alpha.-diphenylglycine  
 AU Yamada, Takashi; Omote, Yuichiro; Miyazawa, Toshifumi; Kuwata, Shigeru; Matsumoto, Kiyoshi  
 CS Fac. Sci., Konan Univ., Kobe, 658, Japan  
 SO Peptide Chemistry (1992), Volume Date 1991, 29th, 367-72  
 CODEN: PECHDP; ISSN: 0388-3698  
 DT Journal  
 LA English  
 OS CASREACT 117:70301  
 IT **142618-65-3P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and hydrogenolysis of)  
 RN 142618-65-3 CAPLUS  
 CN L-Leucine, N-[N-[N-[2,2-diphenyl-N-[(phenylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl]glycyl]glycyl]-L-phenylalanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



—Bu-i

## IT 142618-63-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and peptide coupling of, with dipeptide Me ester)

RN 142618-63-1 CAPLUS

CN Glycine, N-[2,2-diphenyl-N-[N-[(phenylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl]glycyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



## IT 142618-64-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and sapon. of)

RN 142618-64-2 CAPLUS

CN L-Leucine, N-[N-[N-[2,2-diphenyl-N-[N-[(phenylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl]glycyl]glycyl]-L-phenylalanyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






—Bu-i

IT **142618-66-4P**RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 142618-66-4 CAPLUS

CN L-Leucine, N-[N-[N-(2,2-diphenyl-N-L-tyrosylglycyl)glycyl]-L-phenylalanyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.

IT **142618-58-4P 142618-59-5P**RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, by Ugi reaction)

RN 142618-58-4 CAPLUS

CN Glycine, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-2,2-diphenylglycyl-,  
methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142618-59-5 CAPLUS

CN Glycine, N-[2,2-diphenyl-N-[N-[(phenylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl]glycyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Peptides contg. .alpha.,.alpha.-diphenylglycine (Dpg) were prepd. using the Ugi reaction. The Ugi reaction of Z-AA-OH [Z = PhCH2O2C; AA = Ala, Val, Leu, Phe, Tyr(Bzl) (Bzl = benzyl), .alpha.-aminoisobutyric acid (Aib), Ac5C, Dph] with HN:CPh2 and CNCH2CO2Me gave Z-AA-Dph-Gly-OMe. The above reactions were done at 9 kbar and 1 bar pressure; the effect of high pressure was scarcely obsd. Z-Tyr(Bzl)-Dph-Gly-OMe was used in the synthesis of enkephalin analog H-Tyr-Dph-Gly-Phe-Leu-OH. HCO-Aib-OMe was treated with diphosgene to give isocyanide CHCMe2CO2Me, which underwent the Ugi reaction with Z-AA-OH (AA = Aib, Ac3c, Ac5c, Dph) and HN:CPh2 gave Z-AA-Dph-Aib-OMe. HCO2H was treated with HN:CPh2 and CNcHex (cHex = cyclohexyl) to give HCO-Dph-NHcHex, which was treated with diphosgene to give CNCPh2CONHcHex, which was treated with Z-Dph-OH and HN:CPh2 to give Z-Dph-Dph-Dph-NHcHex.

L4 ANSWER 94 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1991:608499 CAPLUS

DN 115:208499

TI Design and synthesis of HIV protease inhibitors. Variations of the carboxyterminus of the HIV protease inhibitor L-682,679

AU DeSolms, S. Jane; Giuliani, Elizabeth A.; Guare, James P.; Vacca, Joseph P.; Sanders, William M.; Graham, Samuel L.; Wiggins, J. Mark; Darke, Paul L.; Sigal, Irving S.; et al.

CS Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA

SO Journal of Medicinal Chemistry (1991), 34(9), 2852-7

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 115:208499

IT **135832-68-7P 135832-70-1P 135911-86-3P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. and HIV protease-inhibiting activity of)

RN 135832-68-7 CAPLUS

CN Carbamic acid, [2-hydroxy-5-oxo-5-[[2-oxo-1-phenyl-2-[(phenylmethyl)amino]ethyl]amino]-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5(R\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 135832-70-1 CAPLUS

CN 2,6,9,15-Tetraazaahexadecan-16-oic acid, 13-hydroxy-2-methyl-7,10-dioxo-8-phenyl-11,14-bis(phenylmethyl)-, 1,1-dimethylethyl ester, [8S-(8R\*,11S\*,13R\*,14R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 135911-86-3 CAPLUS

CN Carbamic acid, [5-[[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxo-1-phenylethyl]amino]-2-hydroxy-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5(R\*)]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB L-682,679 (I, Boc = Me<sub>3</sub>CO<sub>2</sub>C) tetrapeptide analogs, in which the carboxy terminus has been shortened and modified, were prepd. and their inhibitory activity measured against the HIV protease in a peptide cleavage assay. Selected examples were tested as inhibitors of virus spread in cell culture. Analog II was a 10-fold more potent enzyme inhibitor than I in vitro and 30-fold more potent in inhibiting the viral spread in cells.

L4 ANSWER 95 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1991:508772 CAPLUS

DN 115:108772

TI Site-specific incorporation of non-natural residues into peptides: effect of residue structure on suppression and translation efficiencies

AU Bain, J. D.; Wacker, Dean A.; Kuo, Eric E.; Chamberlain, A. Richard

CS Dep. Chem., Univ. California, Irvine, CA, 92717, USA

SO Tetrahedron (1991), 47(14-15), 2389-400

CODEN: TETRAB; ISSN: 0040-4020

DT Journal

LA English

IT **135674-10-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. of, by site-specific mutagenesis with unnatural acylated tRNAs, translation efficiency in)

RN 135674-10-1 CAPLUS


CN L-Phenylalanine, L-methionylglycyl-L-leucyl-L-tyrosyl-L-leucylglycyl-L-leucyl-L-phenylalanyl-L-2-phenylglycylglycyl-L-leucyl-L-tyrosyl-L-leucylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB A systematic survey of the structural requirements for biosynthetic incorporation of nonnatural residues into a polypeptide is presented. Relative translation efficiencies for a series of 12 semisynthetic acylated suppressor tRNAs ranged from 0 to 91%, depending on the structure of the residue incorporated.

L4 ANSWER 96 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1991:49567 CAPLUS

DN 114:49567

TI Dihydropyridine derivative redox systems for brain-targeted drug delivery

IN Bodor, Nicholas S.

PA University of Florida, USA

SO Eur. Pat. Appl., 120 pp.

CODEN: EPXXDW


DT Patent

LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 327766	A2	19890816	EP 1988-312016	19881219
	EP 327766	A3	19900926		
	EP 327766	B1	19980408		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5002935	A	19910326	US 1987-139755 A	19871230
	CA 1331564	A1	19940823	US 1987-139755	19871230
				CA 1988-585791	19881213
	AT 164855	E	19980415	US 1987-139755 A	19871230
				AT 1988-312016	19881219
	ES 2118707	T3	19981001	US 1987-139755 A	19871230
				ES 1988-312016	19881219
	AU 8827339	A1	19890706	US 1987-139755 A	19871230
	AU 619788	B2	19920206	AU 1988-27339	19881221
				US 1987-139755 A	19871230
	ZA 8809679	A	19900829	ZA 1988-9679	19881228
				US 1987-139755 A	19871230
	JP 01294663	A2	19891128	JP 1989-37	19890104
	JP 3038715	B2	20000508		
				US 1987-139755 A	19871230
	EP 335545	A2	19891004	EP 1989-302719	19890320
	EP 335545	A3	19900926		
	EP 335545	B1	19930609		
	EP 335545	B2	19980923		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1988-174945 A	19880329
	AT 90200	E	19930615	EP 1988-312016 A	19881219
				AT 1989-302719	19890320
				US 1988-174945 A	19880329
	ES 2058503	T3	19941101	EP 1988-312016 A	19881219
				EP 1989-302719 A	19890320
				ES 1989-302719	19890320
				US 1988-174945 A	19880329
	AU 8931762	A1	19890727	EP 1988-312016 A	19881219
	AU 618995	B2	19920116	AU 1989-31762	19890328
				US 1987-139755 A	19871230
				US 1988-174945 A	19880329
	US 5017566	A	19910521	US 1989-431222	19891103
				US 1987-139755 A2	19871230
				US 1988-174945 A2	19880329
				CA 1988-585791 A	19881213
				IE 1988-3717 A	19881213
				IE 1989-810 A	19890314
	US 5024998	A	19910618	US 1989-448655	19891211
				US 1987-139755 A2	19871230
				US 1988-174945 A2	19880329
				CA 1988-585791 A	19881213
				IE 1988-3717 A	19881213
				IE 1989-810 A	19890314
				US 1989-431222 A2	19891103

PATENT FAMILY INFORMATION:  
FAN 1990:446267

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 335545	A2	19891004	EP 1989-302719	19890320
	EP 335545	A3	19900926		
	EP 335545	B1	19930609		
	EP 335545	B2	19980923		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1988-174945 A	19880329
				EP 1988-312016 A	19881219
US 4983586	A	19910108		US 1988-174945	19880329
				US 1987-139755 A2	19871230
EP 327766	A2	19890816		EP 1988-312016	19881219
EP 327766	A3	19900926			
EP 327766	B1	19980408			
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1987-139755 A	19871230
AT 90200	E	19930615		AT 1989-302719	19890320
				US 1988-174945 A	19880329
				EP 1988-312016 A	19881219
				EP 1989-302719 A	19890320
AU 8931762	A1	19890727		AU 1989-31762	19890328
AU 618995	B2	19920116			
				US 1987-139755 A	19871230
				US 1988-174945 A	19880329
CA 1336498	A1	19950801		CA 1989-594911	19890328
				US 1988-174945 A	19880329
JP 02009825	A2	19900112		JP 1989-77938	19890329
JP 2643426	B2	19970820			
				US 1988-174945 A	19880329
ZA 8902315	A	19901228		ZA 1989-2315	19890329
				US 1988-174945 A	19880329
US 5017566	A	19910521		US 1989-431222	19891103
				US 1987-139755 A2	19871230
				US 1988-174945 A2	19880329
				CA 1988-585791 A	19881213
				IE 1988-3717 A	19881213
				IE 1989-810 A	19890314
US 5024998	A	19910618		US 1989-448655	19891211
				US 1987-139755 A2	19871230
				US 1988-174945 A2	19880329
				CA 1988-585791 A	19881213
				IE 1988-3717 A	19881213
				IE 1989-810 A	19890314
				US 1989-431222 A2	19891103
IT	<b>123630-90-0P 123630-97-7P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(prepn. and reaction of, in drug delivery system prepn.)				
RN	123630-90-0 CAPLUS				
CN	Pyridinium, 3-[[[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-2-phenylethyl]amino]carbonyl]-1-methyl-, methyl sulfate (9CI) (CA INDEX NAME)				
CM	1				
CRN	123630-89-7				
CMF	C29 H34 Cl2 N3 O3				



CM 2


CRN 21228-90-0

CMF C H3 O4 S

Me-O-SO<sub>3</sub><sup>-</sup>

RN 123630-97-7 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-, 1-phenyl-2-[(3-pyridinylcarbonyl)amino]ethyl ester (9CI) (CA INDEX NAME)


IT **123630-82-ODP**, inclusion complexes with cyclodextrin derivs.

RL: PREP (Preparation)

(prepn. of, for brain targeting)

RN 123630-82-0 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-, 2-[[[1,4-dihydro-1-methyl-3-pyridinyl)carbonyl]amino]-1-phenylethyl ester (9CI) (CA INDEX NAME)



AB Inclusion complexes of hydroxypropyl, hydroxyethyl, glucosyl, maltosyl or maltotriosyl derivs. of .beta.- or .gamma.- cyclodextrin with the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal forms of dihydropyridine pyridinium salt redox systems for brain-targeted drug delivery provide a means for stabilizing the redox systems, particularly against oxidn. The redox inclusion complexes also provide a means for decreasing initial drug concns. in the lungs after administration of the



systems, leading to decreased toxicity. In selected instances, complexation results in substantially improved water soly. of the redox systems as well. The dihydropyridine lipidal forms are e.g. 1-methyl-3-[[N-.beta.-[3,4-bis(pivalyloxy)phenyl]ethylcarbamoyl]]-1,4-dihydropyridine and 3-hydroxy-17.beta.-[(methyl-1,4-dihydropyridin-3-yl)carbonyl]oxyetra-1,3,5(10)-triene (E2-CDS). Thus, the soly. of E2-CDS-2-hydroxypropyl .beta. -cyclodextrin complexes was .apprx.30 mg/mL vs. 0.0002 mg/mL for E2-CDS. In Sprague-Dawley rats, the lung level of a quaternary ammonium salt after i.v. administration of the complex was lower than that after i.v. administration of E2CDS.

L4 ANSWER 97 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1990:446267 CAPLUS  
 DN 113:46267  
 TI Pharmaceutical formulations for parenteral use containing cyclodextrins and dihydropyridine redox systems  
 IN Bodor, Nicholas S.  
 PA University of Florida, USA  
 SO Eur. Pat. Appl., 125 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 335545	A2	19891004	EP 1989-302719	19890320
	EP 335545	A3	19900926		
	EP 335545	B1	19930609		
	EP 335545	B2	19980923		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1988-174945 A	19880329
				EP 1988-312016 A	19881219
	US 4983586	A	19910108	US 1988-174945	19880329
				US 1987-139755 A2	19871230
	EP 327766	A2	19890816	EP 1988-312016	19881219
	EP 327766	A3	19900926		
	EP 327766	B1	19980408		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1987-139755 A	19871230
	AT 90200	E	19930615	AT 1989-302719	19890320
				US 1988-174945 A	19880329
				EP 1988-312016 A	19881219
				EP 1989-302719 A	19890320
	AU 8931762	A1	19890727	AU 1989-31762	19890328
	AU 618995	B2	19920116		
				US 1987-139755 A	19871230
				US 1988-174945 A	19880329
	CA 1336498	A1	19950801	CA 1989-594911	19890328
				US 1988-174945 A	19880329
	JP 02009825	A2	19900112	JP 1989-77938	19890329
	JP 2643426	B2	19970820		
				US 1988-174945 A	19880329
	ZA 8902315	A	19901228	ZA 1989-2315	19890329
				US 1988-174945 A	19880329
	US 5017566	A	19910521	US 1989-431222	19891103
				US 1987-139755 A2	19871230
				US 1988-174945 A2	19880329

US 5024998 A 19910618

CA 1988-585791 A 19881213  
 IE 1988-3717 A 19881213  
 IE 1989-810 A 19890314  
 US 1989-448655 19891211  
 US 1987-139755 A219871230  
 US 1988-174945 A219880329  
 CA 1988-585791 A 19881213  
 IE 1988-3717 A 19881213  
 IE 1989-810 A 19890314  
 US 1989-431222 A219891103

PATENT FAMILY INFORMATION:

FAN 1991:49567

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 327766	A2	19890816	EP 1988-312016	19881219
	EP 327766	A3	19900926		
	EP 327766	B1	19980408		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5002935	A	19910326	US 1987-139755 A	19871230
	CA 1331564	A1	19940823	US 1987-139755	19871230
				CA 1988-585791	19881213
	AT 164855	E	19980415	US 1987-139755 A	19871230
				AT 1988-312016	19881219
	ES 2118707	T3	19981001	US 1987-139755 A	19871230
				ES 1988-312016	19881219
	AU 8827339	A1	19890706	US 1987-139755 A	19871230
	AU 619788	B2	19920206	AU 1988-27339	19881221
				US 1987-139755 A	19871230
	ZA 8809679	A	19900829	ZA 1988-9679	19881228
				US 1987-139755 A	19871230
	JP 01294663	A2	19891128	JP 1989-37	19890104
	JP 3038715	B2	20000508		
				US 1987-139755 A	19871230
	EP 335545	A2	19891004	EP 1989-302719	19890320
	EP 335545	A3	19900926		
	EP 335545	B1	19930609		
	EP 335545	B2	19980923		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1988-174945 A	19880329
	AT 90200	E	19930615	EP 1988-312016 A	19881219
				AT 1989-302719	19890320
				US 1988-174945 A	19880329
	ES 2058503	T3	19941101	EP 1988-312016 A	19881219
				EP 1989-302719 A	19890320
				ES 1989-302719	19890320
				US 1988-174945 A	19880329
	AU 8931762	A1	19890727	EP 1988-312016 A	19881219
	AU 618995	B2	19920116	AU 1989-31762	19890328
				US 1987-139755 A	19871230
				US 1988-174945 A	19880329
	US 5017566	A	19910521	US 1989-431222	19891103
				US 1987-139755 A219871230	
				US 1988-174945 A219880329	
				CA 1988-585791 A 19881213	
				IE 1988-3717 A 19881213	


US 5024998	A	19910618	IE 1989-810	A 19890314
			US 1989-448655	19891211
			US 1987-139755	A219871230
			US 1988-174945	A219880329
			CA 1988-585791	A 19881213
			IE 1988-3717	A 19881213
			IE 1989-810	A 19890314
			US 1989-431222	A219891103

## IT 123630-97-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and quaternization of)

RN 123630-97-7 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-, 1-phenyl-2-[(3-pyridinylcarbonyl)amino]ethyl ester (9CI) (CA INDEX NAME)



## IT 123630-90-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and redn. of)


RN 123630-90-0 CAPLUS

CN Pyridinium, 3-[[[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-2-phenylethyl]amino]carbonyl]-1-methyl-, methyl sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 123630-89-7

CMF C29 H34 Cl2 N3 O3



CM 2

CRN 21228-90-0

CMF C H3 O4 S

Me-O-SO<sub>3</sub><sup>-</sup>


IT 123630-82-0P

RL: PREP (Preparation)

(prepn. of, for redox parenteral drug delivery systems)

RN 123630-82-0 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-, 2-[[[(1,4-dihydro-1-methyl-3-pyridinyl)carbonyl]amino]-1-phenylethyl ester (9CI) (CA INDEX NAME)



AB Aq. parenteral solns. of drugs which are insol. or only sparingly sol. and/or which are unstable in water, are combined with a cyclodextrin deriv. to provide a means for alleviating problems assocd. with drug pptn. at the injection site and/or in the lungs or other organs following parenteral administration. Another approach is use of the dihydropyridine-pyridinium redox delivery system. A large no. of examples are given for synthesis of dihydropyridine and pyridinium derivs. of drugs. Data are also presented showing drug solubilization by cyclodextrin derivs.

L4 ANSWER 98 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1990:217522 CAPLUS

DN 112:217522

TI Improved solid-phase synthesis of luteinizing hormone releasing hormone analogs using 9-fluorenylmethoxycarbonyl amino acid active esters and catalytic transfer hydrogenation with minimal side-chain protection and their biological activities

AU Sivanandaiah, K. M.; Gurusiddappa, S.; Gowda, D. Channe; Babu, V. V. Suresh

CS Cent. Coll., Bangalore Univ., Bangalore, 560 001, India

SO Journal of Biosciences (Bangalore, India) (1989), 14(3), 311-17

CODEN: JOBSDN; ISSN: 0250-5991

DT Journal

LA English

IT 126706-24-9P 126706-26-1P 126706-29-4P

126733-80-0P 126733-81-1P

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. and LH-releasing activity of)

RN 126706-24-9 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 6-[D-2-(4-hydroxyphenyl)glycine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




=NH

RN 126706-26-1 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 2-L-tyrosine-6-[D-2-(4-hydroxyphenyl)glycine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 126706-29-4 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 1-(N-acetyl-D-phenylalanine)-  
2-[D-2-(4-hydroxyphenyl)glycine]-3-D-tryptophan-6-L-tryptophan- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



=NH


RN 126733-81-1 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 1-D-phenylalanine-2-[D-2-(4-hydroxyphenyl)glycine]-3-D-tryptophan-6-L-tryptophan- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



IT 126733-86-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. and catalytic transfer hydrogenolysis of)

RN 126733-86-6 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 1-[5-oxo-1-[(phenylmethoxy)carbonyl]-L-proline]-6-[D-2-(4-hydroxyphenyl)glycine]-8-[N5-[imino(nitroamino)methyl]-L-ornithine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT **126706-32-9DP**, ester with benzyloxybenzyl alc. resin  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and resin cleavage of, by ammonolysis)  
 RN 126706-32-9 CAPLUS  
 CN Luteinizing hormone-releasing factor (swine), 1-[5-oxo-1-  
 [(phenylmethoxy) carbonyl]-L-proline]-6-[D-2-(4-hydroxyphenyl)glycine]-8-  
 [N5-[imino(nitroamino)methyl]-L-ornithine]-10-glycine- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=NH

IT 127146-47-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 127146-47-8 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 6-[D-2-(4-

hydroxyphenyl)glycine]-, triacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 126706-24-9


CMF C61 H79 N17 O14

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



=NH

CM 2

CRN 64-19-7  
CMF C2 H4 O2

AB Using mainly 9-fluorenylmethoxycarbonyl amino acid 2,4,5-trichlorophenyl esters in the presence of 1-hydroxybenzotriazole and the solid support p-alkoxybenzyl alc. resin, synthesis of LH releasing hormone analogs was carried out with minimal side-chain protection. Catalytic transfer hydrogenation was employed for removal of NO<sub>2</sub> and Z-groups from Arg and pyroglutamic acid, resp., avoiding the use of HF; this led to good yields. An arom., hydrophilic amino acid, D-(p-hydroxyphenyl)glycine was incorporated into LH releasing hormone mol. along with other modifications. The agonistic as well as antagonistic activities of all the peptides were studied.

L4 ANSWER 99 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1990:199132 CAPLUS

DN 112:199132

TI Preparation of human immunodeficiency virus (HIV) protease inhibitors for treatment of AIDS

IN Sigal, Irving S.; Huff, Joel R.; Darke, Paul L.; Vacca, Joseph P.; Young, Steven D.; Desolms, S. Jane; Thompson, Wayne J.; Lyle, Terry A.; Graham, Samuel L.; Ghosh, Arun K.

PA Merck and Co., Inc., USA

SO Eur. Pat. Appl., 94 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 337714	A2	19891018	EP 1989-303539	19890411
	EP 337714	A3	19910807		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1988-180507	19880412
				US 1988-236084	19880824
				US 1989-328643	19890328
	FI 8901716	A	19891013	FI 1989-1716	19890411
				US 1988-180507	19880412
				US 1988-236084	19880824
				US 1989-328643	19890328
	NO 8901489	A	19891013	NO 1989-1489	19890411
				US 1988-180507	19880412
				US 1988-236084	19880824
				US 1989-328643	19890328
	ZA 8902627	A	19891129	ZA 1989-2627	19890411
				US 1988-180507	19880412
	DK 8901723	A	19891211	DK 1989-1723	19890411
				US 1988-180507	19880412

			US 1988-236084	19880824
			US 1989-328643	19890328
AU 8932706	A1	19891019	AU 1989-32706	19890412
AU 620084	B2	19920213		
			US 1988-180507	19880412
			US 1988-236084	19880824
			US 1989-328643	19890328
JP 02209854	A2	19900821	JP 1989-92762	19890412
			US 1988-180507	19880412
			US 1988-236084	19880824
			US 1989-328643	19890328

OS MARPAT 112:199132

IT 126409-55-0P 126409-69-6P 126409-80-1P

126409-84-5P 126409-99-2P 126410-16-0P


126438-28-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as HIV protease inhibitor for AIDS treatment)


RN 126409-55-0 CAPLUS

CN L-Phenylalaninamide, N-[5-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-hydroxy-1-oxo-2,6-diphenylhexyl]-L-leucyl-, [2R-(2R\*,4S\*,5S\*)]- (9CI) (CA INDEX NAME)




RN 126409-69-6 CAPLUS

CN Carbamic acid, [2-hydroxy-4-[[[2-[(2-hydroxyethyl)amino]-2-oxo-1-phenylethyl]amino]carbonyl]-7-phenyl-1-(phenylmethyl)-6-heptenyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*(R\*)]]- (9CI) (CA INDEX NAME)




RN 126409-80-1 CAPLUS

CN Carbamic acid, [5-[[2-[(2,3-dihydroxypropyl)amino]-2-oxo-1-phenylethyl]amino]-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(3-phenyl-2-propenyl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 126409-84-5 CAPLUS

CN Carbamic acid, [4-[[[2-[(2,3-dihydroxypropyl)amino]-2-oxo-1-phenylethyl]amino]carbonyl]-2-hydroxy-7-phenyl-1-(phenylmethyl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 126409-99-2 CAPLUS

CN Carbamic acid, [5-[[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxo-1-phenylethyl]amino]-2-hydroxy-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 126410-16-0 CAPLUS

CN Carbamic acid, [2-hydroxy-5-[[2-[(2-hydroxyethyl)amino]-2-oxo-1-phenylethyl]amino]-4-[(4-nitrophenyl)methyl]-5-oxo-1-(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 126438-28-6 CAPLUS

CN Carbamic acid, [2-hydroxy-5-[[2-[(2-hydroxyethyl)amino]-2-oxo-1-phenylethyl]amino]-5-oxo-1-(phenylmethyl)-4-[(phenylthio)methyl]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 126410-96-6P 126411-01-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as intermediate for HIV protease inhibitor)

RN 126410-96-6 CAPLUS


CN Carbamic acid, [2-[[[(1,1-dimethylethyl)dimethylsilyl]oxyl]-4-[[[2-[(2-hydroxyethyl)amino]-2-oxo-1-phenylethyl]amino]carbonyl]-7-phenyl-1-(phenylmethyl)-6-heptenyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*(R\*)]]- (9CI) (CA INDEX NAME)



RN 126411-01-6 CAPLUS

CN Carbamic acid, [2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[2-[(2-hydroxyethyl)amino]-2-oxo-1-phenylethyl]amino]-5-oxo-1-(phenylmethyl)-4-[(phenylthio)methyl]pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI For diagram(s), see printed CA Issue.

AB Dipeptides or amino acid amides or carboxamides A-G-B-B-J [I; A = Ph<sub>3</sub>C, H, CHO, (un)substituted C2-5 alkanoyl, phthaloyl, MeO<sub>2</sub>C, H<sub>2</sub>NOC(O), or




arylsulfonylcarbamoyl, etc.; G = NHCHRCHR1QC(O), NHCHRQ1CHRC(:Z); Z = O, S, H<sub>2</sub>; R = H, OH, C1-4 alkoxy, NH<sub>2</sub>, etc.; R1 = OH, (un)substituted NH<sub>2</sub>; Q = (un)substituted C3-7 alicyclic, benzene, or 5- to 7-membered heterocyclic ring; Q1 = CH(OH)CHR, CH<sub>2</sub>NH, P(O)(OH)CH<sub>2</sub>, CH(OH), etc.; B = null, NHCHRC(:Z); J = OH, NH<sub>2</sub>, (un)substituted C1-6 alkoxy or C1-6 alkylamino, etc.], are prepd. Thus, condensation of a hexanoic acid deriv. (II; R<sub>2</sub> = SiMe<sub>2</sub>CMe<sub>3</sub>, R<sub>3</sub> = OH, BOC = Me<sub>3</sub>CO<sub>2</sub>C) (prepn. given) with H-Leu-Phe-NH<sub>2</sub>.HCl.1/2H<sub>2</sub>O in the presence of 1-hydroxybenzotriazole.H<sub>2</sub>O, dimethyl-3-(3-dimethylaminopropyl)carbodiimide.HCl, and Et<sub>3</sub>N in DMF gave, after disilylation with Bu<sub>4</sub>NF in THF, II (R<sub>2</sub> = H, R<sub>3</sub> = Leu-Phe-NH<sub>2</sub>). The latter compd. inhibited synthetic and Escherichia coli-expressed HIV protease with IC<sub>50</sub> values of 2 and 0.6 nM, resp. Approx. 130 I were prepd.


L4 ANSWER 100 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1990:172583 CAPLUS  
 DN 112:172583  
 TI Comparison of the hormonal and behavioral effect of LH-RH and its analogs  
 AU Makusheva, V. P.; Bakharev, V. D.; Nikolaev, S. V.; Lupanova, G. E.  
 CS Inst. Akush. Ginekol., Leningrad, USSR  
 SO Problemy Endokrinologii (1990), 36(1), 72-4  
 CODEN: PROEAS; ISSN: 0375-9660  
 DT Journal  
 LA Russian  
 IT **126609-80-1 126609-83-4**  
 RL: BIOL (Biological study)  
 (learning and ovulation and stress response to)  
 RN 126609-80-1 CAPLUS  
 CN Luteinizing hormone-releasing factor (swine), 2-D-phenylalanine-6-(4-nitro-D-phenylalanine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 126609-83-4 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 2-D-phenylalanine-6-(4-amino-D-phenylalanine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





=NH

AB LH-RH and 9 analogs were compared for their abilities to induce ovulation in immature and mature rats, for their effects on learning, and for their abilities to reduce the response to immobilization stress. Like LH-RH, the 3 analogs pGlu-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-Gly-NH<sub>2</sub>, where X = D-Phe, D-Phe(NH<sub>2</sub>), and D-Phe(NO<sub>2</sub>), stimulated ovulation, accelerated learning, and attenuated responses to the stress. The 3 LH-RH analog antagonists which inhibited ovulation, pGlu-X-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH<sub>2</sub>, where X = D-Phe, D-Phe(NO<sub>2</sub>), and D-Phe(NH<sub>2</sub>), had even greater effects than LH-RH and the agonist analogs. The analogs pGlu-His-Trp-OH, Ser-Tyr-D-Phe(NO<sub>2</sub>)-Leu-Arg-Pro-Gly-NH<sub>2</sub>, and pGlu-His-Trp-Ser-Tyr-Arg-Pro-Gly-NH<sub>2</sub> were essentially inactive.

L4 ANSWER 101 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1990:139785 CAPLUS

DN 112:139785

TI Synthesis and biological activities of new analogs of dermorphin substituted at position-2

AU Sivanandaiah, K. M.; Gurusiddappa, S.; Babu, V. V. Suresh

CS Cent. Coll., Bangalore Univ., Bangalore, 560 001, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1989), 28B(4), 338-41

CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 112:139785

IT **125943-14-8P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and analgesic and antidiarrheal activities of)

RN 125943-14-8 CAPLUS

CN Dermorphin, 2-(D-2-phenylglycine)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OH

IT **125943-07-9P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deblocking of, with formic acid)

RN 125943-07-9 CAPLUS

CN Dermorphin, N-[(1,1-dimethylethoxy)carbonyl]-2-(D-2-phenylglycine)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OH



IT **125943-00-2DP**, ester with Merrifield resin  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and resin cleavage-amidation of, with ammonia)  
 RN 125943-00-2 CAPLUS  
 CN Dermorphin, N-[(1,1-dimethylethoxy)carbonyl]-2-(D-2-phenylglycine)-7-L-serine- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OH



AB Seven analogs of demorphin with different D-amino acids at position 2 have been obtained by the solid-phase method using mainly 9-fluorenylmethoxycarbonyl amino acid active esters in the presence of 1-hydroxybenzotriazole, the solid support being the Merrifield resin. Their pharmacol. effects have been studied in vitro by the guinea pig ileum (GPI) assay and in vivo by the hot plate method. The antidiarrheal properties of these peptides have also studied in mice (in vivo). [D-Nva2]- and [D-Eth2]-dermorphin (Nva = norvaline; Eth = ethionine) approach morphine in the GPI assay and hot plate test resp. Though, in general, replacement of D-Ala2 by other D-amino acids leads to lower GPI and analgesic activities, there is an enhancement of antidiarrheal potency in the case of four analogs, the most active one being [D-Phe2]-dermorphin, which is 2.7 times more potent than morphine.

L4 ANSWER 102 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1990:119450 CAPLUS

DN 112:119450

TI Preparation of neurotensin fragment analogs as central nervous system agents and pharmaceutical compositions containing them

IN Tsuchiya, Yutaka; Sasaki, Atsushi; Yoshino, Hiroshi; Karibe, Norio; Sugimoto, Hachiro; Kubota, Atsuhiko; Kosasa, Michiko; Araki, Shin; Ikeda, Masuhiro; et al.

PA Eisai Co., Ltd., Japan

SO Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 333071	A2	19890920	EP 1989-104302	19890310
	EP 333071	A3	19900926		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
	FI 8900918	A	19890912	JP 1988-57985	19880311
				FI 1989-918	19890227
				JP 1988-57985	19880311
	AU 8931083	A1	19890914	AU 1989-31083	19890307
				JP 1988-57985	19880311
	JP 01316399	A2	19891221	JP 1989-55941	19890308
				JP 1988-57985	19880311
	NO 8901006	A	19890912	NO 1989-1006	19890309
				JP 1988-57985	19880311
	DK 8901169	A	19890912	DK 1989-1169	19890310
				JP 1988-57985	19880311
	HU 49370	A2	19890928	HU 1989-1180	19890310
	HU 199879	B	19900328		
				JP 1988-57985	19880311

IT 125600-89-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of, as central nervous system agent)

RN 125600-89-7 CAPLUS

CN L-Leucine, N-[N-[N-[1-[N2-(6-amino-1-oxohexyl)-L-arginyl]-L-prolyl]-L-tyrosyl]-L-2-phenylglycyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A-B-C-D-E-F-R1; [A = amino acid residue, guanidinoalkylcarbonyl, piperidinyllalkylcarbonyl, aminoalkylcarbonyl; B, E, F = amino acid

residue, residue of an alkyl deriv. of amino acid; C = L-Pro or deriv.; D = L-amino acid residue; R1 = (substituted) amino] useful as central nervous system agents (antipsychotics, analgesics) were prepd. H-Gb-Arg-Pro-Trp-Pgl-Leu-OEt (II; Gb = residue of .omega.-guanidinobutanoic acid, Pgl = phenylglycine residue) was prepd. in many steps by the soln. method starting from BOC-Pgl-OH and H-Leu-OEt.HCl. II at 0.2 mg/kg s.c. showed 20.6% antagonism of methamphetamine in mice.

L4 ANSWER 103 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1990:118534 CAPLUS

DN 112:118534

TI Preparation of 1-sulfo-2-oxoazetidines as antibacterial agents

IN Ochiai, Michihiko; Kishimoto, Shoji; Matsuo, Taisuke

PA Takeda Chemical Industries, Ltd., Japan

SO U.S., 252 pp. Cont.-in-part of U.S. Ser. No. 326,938.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4782147	A	19881101	US 1983-499802	19830531
				WO 1980-JP297	19801205
				WO 1981-JP103	19810430
				WO 1981-JP183	19810821
				WO 1981-JP252	19810924
				US 1981-326938	19811203
				JP 1982-93463	19820531
	WO 8201873	A1	19820610	WO 1980-JP297	19801205
	W: MC				
	WO 8203859	A1	19821111	WO 1981-JP103	19810430
	W: MC				
	WO 8300689	A1	19830303	WO 1981-JP183	19810821
	W: MC				
	WO 8301063	A1	19830331	WO 1981-JP252	19810924
	W: MC				
	US 4822788	A	19890418	US 1981-326938	19811203
				WO 1980-JP297	19801205
				WO 1981-JP103	19810430
				WO 1981-JP183	19810821
				WO 1981-JP252	19810924
	JP 58210061	A2	19831207	JP 1982-93463	19820531
	JP 04066865	B4	19921026		
	US 4572801	A	19860225	US 1983-499801	19830531
				WO 1981-WO103	19810430
				WO 1981-WO183	19810821
				WO 1981-WO252	19810924
				US 1981-326938	19811203
				JP 1982-73728	19820430
				JP 1982-93463	19820531
				US 1982-405592	19820805
	GB 2156350	A1	19851009	GB 1985-9070	19850409
	GB 2156350	B2	19860604		
				JP 1982-73728	19820430
				JP 1982-93463	19820531
				GB 1983-10520	19830419
	NO 8700981	A	19831031	NO 1987-981	19870310



FI 8801563 A 19880405

JP 1982-73728 19820430  
 JP 1982-93463 19820531  
 NO 1983-1514 19830429  
 FI 1988-1563 19880405  
 JP 1982-73728 19820430  
 JP 1982-93463 19820531  
 FI 1983-1457 19830428

## PATENT FAMILY INFORMATION:

FAN 1982:562692

	PATENT NO.	KIND	DATE
PI	WO 8201551 W: MC	A1	19820513
	EP 50965 R: CH, DE, FR, GB, IT	A1	19820505
	JP 57098258	A2	19820618
	JP 04024326	B4	19920424
	US 4725591	A	19880216

	APPLICATION NO.	DATE
	WO 1980-JP255	19801023
	EP 1981-304996	19811023
	WO 1980-JP255	19801023
	WO 1980-JP295	19801204
	JP 1981-170634	19811023
	WO 1980-JP255	19801023
	US 1984-576776	19840203
	WO 1980-JP255	19801023
	WO 1980-JP295	19801204
	US 1981-314512	19811023

FAN 1982:562701

	PATENT NO.	KIND	DATE
PI	WO 8201820 W: MC	A1	19820610
	EP 50965 R: CH, DE, FR, GB, IT	A1	19820505
	CA 1338539	A1	19960820
	US 4725591	A	19880216

	APPLICATION NO.	DATE
	WO 1980-JP295	19801204
	EP 1981-304996	19811023
	WO 1980-JP255	19801023
	WO 1980-JP295	19801204
	CA 1981-391401	19811203
	WO 1980-JP295	19801204
	WO 1980-JP297	19801205
	WO 1981-JP103	19810430
	WO 1981-JP183	19810821
	WO 1981-JP252	19810924
	EP 1981-304996	19811023
	JP 1981-170634	19811023
	US 1984-576776	19840203
	WO 1980-JP255	19801023
	WO 1980-JP295	19801204
	US 1981-314512	19811023

FAN 1982:598037

	PATENT NO.	KIND	DATE
PI	WO 8201873 W: MC	A1	19820610
	IL 64315	A1	19880429
	AU 8177829	A1	19820610
	AU 557689	B2	19870108

	APPLICATION NO.	DATE
	WO 1980-JP297	19801205
	IL 1981-64315	19811119
	WO 1980-JP297	19801205
	WO 1981-JP103	19810430
	WO 1981-JP183	19810821
	WO 1981-JP252	19810924
	AU 1981-77829	19811125

			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
HU 31125	O	19840428	HU 1981-3577	19811126
HU 194870	B	19880328		
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
CS 253565	B2	19871112	CS 1981-8834	19811130
			WO 1980-JP297	19801205
DK 8105344	A	19820606	DK 1981-5344	19811202
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
FI 8103852	A	19820606	FI 1981-3852	19811202
FI 81085	B	19900531		
FI 81085	C	19900910		
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
NO 8104112	A	19820607	NO 1981-4112	19811202
NO 160577	B	19890123		
NO 160577	C	19890503		
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
SU 1396962	A3	19880515	SU 1981-3364401	19811202
			WO 1980-JP297	19801205
JP 01003189	B4	19890119	JP 1981-194311	19811202
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
BR 8107866	A	19820908	BR 1981-7866	19811203
			WO 1980-JP297	19801205
US 4550105	A	19851029	US 1981-326937	19811203
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
US 4822788	A	19890418	US 1981-326938	19811203
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
CA 1338539	A1	19960820	CA 1981-391401	19811203
			WO 1980-JP295	19801204
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
			EP 1981-304996	19811023

BE 891366	A1	19820604	JP 1981-170634	19811023
			BE 1981-206752	19811204
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
			SE 1981-7274	19811204
SE 8107274	A	19820606		
SE 457256	B	19881212		
SE 457256	C	19890413		
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
FR 2495613	A1	19820611	FR 1981-22775	19811204
FR 2495613	B1	19850809		
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
EP 53816	A1	19820616	EP 1981-110155	19811204
EP 53816	B1	19880504		
			R: AT, BE, CH, DE, FR, IT, LU, NL, SE	
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
NL 8105470	A	19820701	NL 1981-5470	19811204
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
GB 2091724	A	19820804	GB 1981-36619	19811204
GB 2091724	B2	19850731		
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
DE 3148021	A1	19821021	DE 1981-3148021	19811204
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
ZA 8108444	A	19821027	ZA 1981-8444	19811204
ES 507715	A1	19830201	WO 1980-JP297	19801205
			ES 1981-507715	19811204
			WO 1980-JP297	19801205
AT 8105208	A	19850215	AT 1981-5208	19811204
AT 378768	B	19850925		
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
CH 657610	A	19860915	CH 1981-7787	19811204
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924

AT 33981	E	19880515	AT 1981-110155	19811204
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
			EP 1981-110155	19811204
WO 8202043	A1	19820624	WO 1981-JP369	19811205
W: SU				
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
US 4675397	A	19870623	US 1982-405592	19820805
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
			US 1981-326938	19811203
			JP 1982-73728	19820430
ES 516254	A1	19831016	ES 1982-516254	19821006
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
CS 253572	B2	19871112	CS 1982-7585	19821025
			WO 1980-JP297	19801205
			CS 1981-8834	19811130
SU 1484294	A3	19890530	SU 1983-3556253	19830215
			WO 1980-JP297	19801205
US 4782147	A	19881101	US 1983-499802	19830531
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
			US 1981-326938	19811203
			JP 1982-93463	19820531
AT 8401647	A	19860515	AT 1984-1647	19840518
AT 381932	B	19861210		
			WO 1980-JP297	19801205
			WO 1981-JP369	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
			WO 1981-JP103	19811205
US 4665067	A	19870512	US 1985-741741	19850605
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
			US 1981-326938	19811203
US 4673739	A	19870616	US 1985-778219	19850918
			WO 1980-JP297	19801205
			WO 1981-JP103	19810430
			WO 1981-JP183	19810821
			WO 1981-JP252	19810924
			US 1981-326938	19811203
			JP 1982-73728	19820430
			JP 1982-93463	19820531

				US 1982-405592	19820805
				US 1983-499801	19830531
FAN.	1983:143181				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 53816	A1	19820616	EP 1981-110155	19811204
	EP 53816	B1	19880504		
	R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
				WO 1980-JP297	19801205
				WO 1981-JP103	19810430
				WO 1981-JP183	19810821
				WO 1981-JP252	19810924
	WO 8201873	A1	19820610	WO 1980-JP297	19801205
	W: MC				
	WO 8203859	A1	19821111	WO 1981-JP103	19810430
	W: MC				
	WO 8300689	A1	19830303	WO 1981-JP183	19810821
	W: MC				
	WO 8301063	A1	19830331	WO 1981-JP252	19810924
	W: MC				
	AT 33981	E	19880515	AT 1981-110155	19811204
				WO 1980-JP297	19801205
				WO 1981-JP103	19810430
				WO 1981-JP183	19810821
				WO 1981-JP252	19810924
				EP 1981-110155	19811204
FAN	1984:209515				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 93376	A2	19831109	EP 1983-104061	19830426
	EP 93376	A3	19861015		
	EP 93376	B1	19900321		
	EP 93376	B2	19990407		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
				JP 1982-73728	19820430
				JP 1982-93463	19820531
	JP 58189176	A2	19831104	JP 1982-73728	19820430
	JP 63034155	B4	19880708		
	JP 58210061	A2	19831207	JP 1982-93463	19820531
	JP 04066865	B4	19921026		
	AU 8313445	A1	19831103	AU 1983-13445	19830412
	AU 564150	B2	19870806		
				JP 1982-73728	19820430
				JP 1982-93463	19820531
	ZA 8302742	A	19831228	ZA 1983-2742	19830419
				JP 1982-73728	19820430
	GB 2124207	A1	19840215	GB 1983-10520	19830419
	GB 2124207	B2	19861008		
				JP 1982-73728	19820430
				JP 1982-93463	19820531
	AT 51223	E	19900415	AT 1983-104061	19830426
				JP 1982-73728	19820430
				JP 1982-93463	19820531
				EP 1983-104061	19830426
	DK 8301889	A	19831031	DK 1983-1889	19830428
	DK 161832	B	19910819		
	DK 161832	C	19920120		

			JP 1982-73728	19820430
			JP 1982-93463	19820531
FI 8301457	A	19831031	FI 1983-1457	19830428
			JP 1982-73728	19820430
			JP 1982-93463	19820531
SU 1480763	A3	19890515	SU 1983-3590552	19830428
			JP 1982-73728	19820430
			JP 1982-93463	19820531
NO 8301514	A	19831031	NO 1983-1514	19830429
NO 160581	B	19890123		
NO 160581	C	19890503		
			JP 1982-73728	19820430
			JP 1982-93463	19820531
HU 30672	O	19840328	HU 1983-1486	19830429
HU 194876	B	19880328		
			JP 1982-73728	19820430
			JP 1982-93463	19820531
DD 212510	A5	19840815	DD 1983-250410	19830429
DD 212510	B3	19891108		
			JP 1982-73728	19820430
			JP 1982-93463	19820531
ES 521954	A1	19850516	ES 1983-521954	19830429
			JP 1982-73728	19820430
			JP 1982-93463	19820531
DD 236930	A5	19860625	DD 1983-280483	19830429
			JP 1982-73728	19820430
HU 199115	B	19900129	HU 1988-2264	19830429
			JP 1982-73728	19820430
			JP 1982-93463	19820531
US 4572801	A	19860225	US 1983-499801	19830531
			WO 1981-WO103	19810430
			WO 1981-WO183	19810821
			WO 1981-WO252	19810924
			US 1981-326938	19811203
			JP 1982-73728	19820430
			JP 1982-93463	19820531
			US 1982-405592	19820805
ES 528562	A1	19860601	ES 1983-528562	19831230
			JP 1982-73728	19820430
			JP 1982-93463	19820531
DD 232490	A5	19860129	DD 1984-267015	19840905
			JP 1982-73728	19820430
GB 2156350	A1	19851009	GB 1985-9070	19850409
GB 2156350	B2	19860604		
			JP 1982-73728	19820430
			JP 1982-93463	19820531
			GB 1983-10520	19830419
ES 543809	A1	19860901	ES 1985-543809	19850601
			JP 1982-73728	19820430
			JP 1982-93463	19820531
SU 1380612	A3	19880307	SU 1985-3909204	19850620
			JP 1982-73728	19820430
ES 551942	A1	19871016	ES 1986-551942	19860213
			JP 1982-73728	19820430
			JP 1982-93463	19820531
JP 62215586	A2	19870922	JP 1987-28496	19870210
JP 03021542	B4	19910322		

NO 8700981	A	19831031	JP 1982-73728	19820430
			NO 1987-981	19870310
			JP 1982-73728	19820430
			JP 1982-93463	19820531
FI 8801563	A	19880405	NO 1983-1514	19830429
			FI 1988-1563	19880405
			JP 1982-73728	19820430
			JP 1982-93463	19820531
			FI 1983-1457	19830428

OS MARPAT 112:118534


IT 122666-89-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. and reaction of, in prepn. of antibacterial agents)

RN 122666-89-1 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-tyrosyl-N-(2-oxo-3-azetidiny)-D-2-phenyl-(9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R = H, N3, halo, NH2, acylamino, OR5, SOnR5, P(O)(OR5)2, SSR5, C-attached org. residue; R1 = (protected) NH2, acylamino; R5 = org. residue; X = H, MeO; n = 0-2] and their salts were prepd. 2-Oxoazetidine II [R1 = PhCH2O2CNH, R2 = OMe, R3 = 2,4-(MeO)2C6H3CH2] (prepn. from corresponding 3-amino deriv. given) was stirred 3 h at 90-95.degree. with K2S2O8 in aq. MeCN contg. K2HPO4 to give II (R1 and R2 as above, R3 = H) which was stirred 19 h in THF contg. aq. NH3 to give II (R1 as above, R2 = NH2, R3 = H). The latter was hydrogenolyzed over Pd/C and the product stirred with 4-O2NC6H4CH2O2CCMe2ON:CQCOC1 [Q = 2-(2-chloroacetamido)-4-thiazolyl] (prepn.

given) to give II (R1 = 4-O2NC6H4CH2O2CCMe2ON:CQCONH, R2 = NH2, R3 = H) which was treated overnight at 4.degree. with SO3.DMF in DMF to give, after ion-exchange chromatog., II (R1, R2 unchanged, R3 = SO3Na). Deprotection of the latter in 2 steps gave title compd. III, which had min. inhibitory concn. of 1.56 and 0.39 .mu.g/mL against Enterobacter cloacae IFO 129537 and Klebsiella pneumoniae TN 1711, resp.

L4 ANSWER 104 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1989:601478 CAPLUS

DN 111:201478

TI Improved delivery through biological membranes. XLI. Brain-enhanced delivery of chlorambucil

AU Bodor, Nicholas; Venkatraghavan, Vasudevan; Winwood, David; Estes, Kerry; Brewster, Marcus E.

CS Pharmatec. Inc., Alachua, FL, 32615, USA

SO International Journal of Pharmaceutics (1989), 53(3), 195-208

CODEN: IJPHDE; ISSN: 0378-5173

DT Journal

LA English


IT **123630-97-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and quaternization of, with Me sulfate)

RN 123630-97-7 CAPLUS

CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-, 1-phenyl-2-[(3-pyridinylcarbonyl)amino]ethyl ester (9CI) (CA INDEX NAME)



IT **123630-90-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and redn. of, in brain-enhanced delivery of chlorambucil)


RN 123630-90-0 CAPLUS

CN Pyridinium, 3-[[[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-2-phenylethyl]amino]carbonyl]-1-methyl-, methyl sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 123630-89-7

CMF C29 H34 Cl2 N3 O3







CM 2

CRN 21228-90-0

CMF C H3 O4 S


Me-O-SO<sub>3</sub><sup>-</sup>

IT 123630-82-0P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as brain-enhanced delivery system for chlorambucil)

RN 123630-82-0 CAPLUS


CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-, 2-[[[(1,4-dihydro-1-methyl-3-pyridinyl)carbonyl]amino]-1-phenylethyl ester (9CI) (CA INDEX NAME)



GI



I



II

AB Brain-enhanced delivery of chlorambucil (I) was achieved using a dihydropyridine pyridinium salt chem. delivery system (CDS). Application of the CDS approach to the carboxylic acid-contg. anticancer agent required the development of novel, alc. redox carriers. Several N'-(.omega.-hydroxyalkyl), -(.omega.-hydroxycycloalkyl) and -(.omega.-hydroxy-branched alkyl)nicotinamide derivs. were therefore

synthesized. After in vitro characterization of the dihydropyridine delivery forms of I, these compds. were tested in vivo in the rat. The CDS deriv. in which an Et group sepd. the 1-methyl-1,4-dihydronicotinamide and I fragments generated sustained levels of I in the brains of test animals after i.v. administration ( $t_{1/2}$  in brain = 2.4 days), while blood levels rapidly fell ( $t_{1/2}$  = 2 h) producing a favorable brain/blood ratio. This compd. (II) was well tolerated at doses of 60 mg/kg, while equimolar I (39 mg/kg) caused >80% mortality in test animals within 2 h. Subsequently, a cyclohexyl-contg. CDS deriv. was tested. This sterically more hindered system produced a lower level of I in the periphery but also reduced central nervous system concn. of the drug.

L4 ANSWER 105 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1989:553339 CAPLUS

DN 111:153339

TI Preparation of esterified N-(dibenzocycloheptenylideneethyl)ephedrine derivatives with prolonged antiulcer activity

IN Butelman, Federico

PA Etablissement Texcontor, Liechtenstein

SO Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 313885	A1	19890503	EP 1988-116449	19881005
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4935444	A	19900619	IT 1987-22407	19871023
				US 1988-254220	19881006
				IT 1987-22407	19871023
	JP 01135748	A2	19890529	JP 1988-264240	19881021
				IT 1987-22407	19871023
	US 4990522	A	19910205	US 1990-487277	19900302
				IT 1987-22407	19871023
				US 1988-254220	19881006


IT **122881-51-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and N-alkylation of, with (haloethylidene)dibenzocycloheptene)


RN 122881-51-0 CAPLUS

CN Benzenepropanoic acid, 2-(methylamino)-1-phenylpropyl ester, [R-(R\*,S\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. [I; R = C<sub>9</sub>H<sub>19</sub>, C<sub>15</sub>H<sub>31</sub>, CH(NH<sub>2</sub>)(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>H, (CH<sub>2</sub>)<sub>2</sub>Ph, CMe<sub>3</sub>, p-HOC<sub>6</sub>H<sub>4</sub>, 2-thienyl, 3-pyridyl, 1-amino-2-(5-imidazolyl)ethyl, pamoic acid residue] are prepd. by esterification of ephedrine (II) with RCOCl to give PhCH(O<sub>2</sub>CR)CHMeNHMe (III), followed by N-alkylation with a (haloethylidene)dibenzocycloheptene IV (X = halo). II was esterified by decanoyl chloride (prepd. from the acid) to give 65% III [R = Me(CH<sub>2</sub>)<sub>8</sub>], which was refluxed in MeCN with IV (X = halo, not specified) to give 54% I [R = MeC(CH<sub>2</sub>)<sub>2</sub>]. The latter inhibited stress-induced ulcers in rats with ED<sub>50</sub> of 0.4 and 2.1 mg/kg orally, administered 6 and 36 h prior to commencement of the stress, resp.

L4 ANSWER 106 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1989:115313 CAPLUS

DN 110:115313

TI Peptides related to leucine-/methionine-enkephalinamides: synthesis and biological activities

AU Sivanandaiah, K. M.; Gurusiddappa, S.; Suresh Babu, V. V.

CS Cent. Coll., Bangalore Univ., Bangalore, 560 001, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1988), 27B(7), 645-8  
CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English.

OS CASREACT 110:115313


IT **119221-28-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deblocking of, with formic acid and anisole)

RN 119221-28-2 CAPLUS

CN L-Norleucinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-D-2-(4-hydroxyphenyl)glycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 119221-23-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and morphine-like, analgesic, and antidiarrheal activities of)

RN 119221-23-7 CAPLUS

CN L-Norleucinamide, L-tyrosyl-D-2-(4-hydroxyphenyl)glycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 119221-28-2DP, resin-bound

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and resin cleavage and side chain deblocking of, with ammonia)

RN 119221-28-2 CAPLUS

CN L-Norleucinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-D-2-(4-hydroxyphenyl)glycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Six analogs of leucine- and methionine-enkephalinamides have been synthesized by substitution of D-amino acids at position 2 and Nle or Eth (Eth = ethionine) at position 5 by solid phase techniques employing the base labile 9-fluorenylmethoxycarbonyl group for N.alpha. protection. One of the analogs, H-Tyr-D-Nva-Gly-Phe-Eth-NH<sub>2</sub>, is 21.6 times more potent than morphine in the guinea pig ileum assay.

L4 ANSWER 107 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1989:58089 CAPLUS

DN 110:58089

TI Potent angiotensin II antagonists with non-.beta.-branched amino acids in position 5

AU Samanen, J.; Narindray, D.; Cash, T.; Brandeis, E.; Adams, W., Jr.; Yellin, T.; Eggleston, D.; DeBrosse, C.; Regoli, D.

CS Pept. Chem. Dep., Smith Kline and French Lab., Swedeland, PA, 19406-0939, USA

SO Journal of Medicinal Chemistry (1989), 32(2), 466-72

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 110:58089

IT **117940-34-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. and angiotensin II agonistic and antagonistic activities of)

RN 117940-34-8 CAPLUS


CN Angiotensin II, 1-(N-methylglycine)-5-(L-2-phenylglycine)-8-L-isoleucine-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB Amino acids with lipophilic side chains that contain more than one functional group on the .beta.-carbon, i.e. a .beta.-branched hydrocarbon moiety, are required in position 5 of angiotensin II (AII) analogs with potent agonist activity. This requirement for agonist activity does not follow for AII analogs with potent antagonist activity. Straight-chain amino acids may be substituted into position 5 of [Sar1,X5,Ile8]AII (Sar = sarcosine, X = amino acid) with retention or enhancement of antagonist activity. .beta.-Branched side chains can still enhance the antagonist activities of [Sar1,X5,Ile8]AII. An x-ray crystal structure of Me3CO2C-(.beta.Me)Phe-OH dicyclohexylamine salt, prepd. for the solid-phase synthesis of [Sar1,(.beta.Me)Phe5,Ile8]AII, revealed an S,S-configuration for the .alpha.- and .beta.-carbon atoms. Contrary to previous literature reports, chem. nonequivalence of the .delta.-protons of Pro was obsd. in the 1H NMR spectra of [Sar1,X5,Ile8]AII analogs bearing both .beta.-branched X5 side chains (X5 = Ile) and non-.beta.-branched X5 side chains (X5 = Ala, His).

L4 ANSWER 108 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1989:1065 CAPLUS

DN 110:1065


TI Synthesis and biological activity of analogs of leucine-/methionine-enkephalin

AU Sivanandaiah, K. M.; Gurusiddappa, S.; Palgunachari, M. N.

CS Cent. Coll., Bangalore Univ., Bangalore, 560 001, India


SO Indian Journal of Biochemistry & Biophysics (1988), 25(4), 356-9  
 CODEN: IJBBBQ; ISSN: 0301-1208  
 DT Journal  
 LA English  
 OS CASREACT 110:1065  
 IT **117747-75-8P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and biol activity of, mol. structure in relation to)  
 RN 117747-75-8 CAPLUS  
 CN D-Methioninamide, L-tyrosyl-D-2-(4-hydroxyphenyl)glycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **117747-81-6DP**, polymer-bound **117747-81-6P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and deprotection of)  
 RN 117747-81-6 CAPLUS  
 CN D-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-D-2-(4-hydroxyphenyl)glycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117747-81-6 CAPLUS  
 CN D-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-D-2-(4-hydroxyphenyl)glycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Seven analogs of the opioid pentapeptides leucine- and methionine-enkephalinamides were synthesized by the solid-phase technique employing mainly 9-fluorenylmethyloxycarbonyl amino acid active esters in the presence of 1-hydroxybenzotriazole and the conventional chloromethylated copolystyrene-2% divinylbenzene (Merrifield) resin as the solid support. The analogs varied by replacing the amino acids at positions 2 and 5. Some of the analogs were highly potent in the guinea pig ileum assay. The analog Tyr-D-Met-Gly-Phe-D-Nva-NH<sub>2</sub> was the most potent analog of the series with analgesic and antidiarrheal activities of 0.6053 and 0.7129, resp., as compared to the ref. compd. morphine (1.0).

L4 ANSWER 109 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1988:132326 CAPLUS

DN 108:132326

TI Preparation of orally active luteinizing hormone-releasing hormone (LHRH) analogs

IN Almquist, Ronald G.; Olsen, Cris M.

PA SRI International, USA

SO U.S., 17 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4705778	A	19871110	US 1985-790031	19851022
				US 1985-790031	19851022



IT **113422-21-2P 113422-48-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as antitumor agent and contraceptive)

RN 113422-21-2 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 6-(D-2-phenylglycine)-9-( $\gamma$ -oxo-2-pyrrolidinebutanamide)-10-deglycinamide-, (S)- (9CI) (CA INDEX NAME)






RN 113422-48-3 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 6-(D-2-phenylglycine)-9-(.gamma.-hydroxy-2-pyrrolidinebutanamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB R1-R2-R3-Tyr-R4-R5-Arg-Pro-X-Gly-OH [I; R1 = H-pGlu, H-D-pGlu, Ac-D-Pro, Ac-Pro, Ac-Trp, Ac-D-Pr(halo-p), (un)substituted H-D-Ala, Ac-D-Phe, Ac-D-Phe(halo-p), D-Phe, D-Nal, or Ac-D-Nal, or (un)substituted H-Gly, H-D-Ala, H-ala, H-D-Trp, or H-D-Phe with benzoylalkanoyl, Bz, alkanoyl, acyl and HO<sub>2</sub>C(CH<sub>2</sub>)<sub>n</sub>CO (n = 2-6); R2 = His, Phe(halo), D-Phe(NO<sub>2</sub>), D-Phe(dihalo), (un)substituted D-Phe, Phe, (un)substituted D-Ala, diphenyl-Gly; R3 = Trp, D-Trp, Phe, (un)substituted D-Phe, substituted D-Ala, D-Nal; R4 = Gly, D-aminoacyl residue; R5 = Leu, MeLeu; X = COCH<sub>2</sub> or CH(OH)CH<sub>2</sub> replacing CONH linkage], useful as antitumor agents (no data) and male or female contraceptives, were prepd. [Ac-D-Phe<sub>1</sub>, D-Phe(Cl-p)<sub>2</sub>, D-Trp<sub>3</sub>, D-Arg<sub>6</sub>, Pro-COCH<sub>2</sub>Gly<sub>9,10</sub>]LHRH (II) was prepd. by the solid phase method using BOC-Pro-COCH<sub>2</sub>Gly-OH coupled to a benzhydrylaminopolystyrene-

2% divinylbenzene resin. The antioviulatory activity of II in rats was more than twice that of its regular amide-bonded counterpart (III).

L4 ANSWER 110 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1988:38432 CAPLUS

DN 108:38432

TI Preparation of renin-inhibiting peptides for treatment of hypertension and cardiac insufficiency

IN Breipohl, Gerhard; Knolle, Jochen; Wegmann, Helmut; Ruppert, Dieter

PA Hoechst A.-G. , Fed. Rep. Ger.

SO Ger. Offen., 22 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3601248	A1	19870723	DE 1986-3601248	19860117
	EP 230242	A2	19870729	EP 1987-100275	19870112
	EP 230242	A3	19900117		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DK 8700236	A	19870718	DK 1987-236	19870116
	JP 62265263	A2	19871118	JP 1987-6308	19870116
				DE 1986-3601248	19860117

OS CASREACT 108:38432


IT **110695-52-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of, as antihypertensive)

RN 110695-52-8 CAPLUS

CN L-threo-Pentonamide, 2,4,5-trideoxy-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-2-phenylglycyl]amino]-N-[3-methyl-1-[(2-pyridinylmethyl)amino]carbonyl]butyl]-5-phenyl-, (S)- (9CI)  
(CA INDEX NAME)



AB The title compds. R1ABNHCHR2CHOHCHR3COR4 [I; R1 = null, H, (substituted) alkyl, acyl; R2 = H, (substituted) alkyl, alkylcycloalkyl, aralkyl, aryl; R3 = H, (substituted) alkyl; R4 = amino; A, B = amino acid residue] were prepd. as antihypertensives (no data). BOC-Phe-His(DNP)-OH (BOC =

tert-butoxycarbonyl, DNP = 2,4-dinitrophenyl) and H-Sta-Leu-Asn-NH<sub>2</sub> [Sta = [3S,4S]-4-amino-3-hydroxy-6-methylheptanoic acid residue] were coupled using dicyclohexylcarbodiimide and 1-hydroxybenzotriazole. The resulting peptide was treated with thiophenol in DMF to give BOC-Phe-His-Sta-Leu-Asn-NH<sub>2</sub>.

L4 ANSWER 111 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1988:22252 CAPLUS

DN 108:22252

TI Syntheses and biological activities of neurokinin B analogs modified at positions 2, 3, and 6

AU Uchida, Yoshiki; Okimura, Keiko; Kurosawa, Katsuro; Sakura, Naoki; Hirose, Kyoko; Hashimoto, Tadashi

CS Sch. Pharm., Hokuriku Univ., Kanazawa, 920-11, Japan

SO Bulletin of the Chemical Society of Japan (1987), 60(4), 1561-3

CODEN: BCSJA8; ISSN: 0009-2673

DT Journal

LA English

IT 111895-96-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 111895-96-6 CAPLUS


CN L-Methioninamide, L-arginyl-L-.alpha.-aspartyl-L-phenylalanyl-D-2-phenylglycyl-L-valylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




AB Title analogs H-His-Asp-Phe-X-X1-Gly-Leu-Met-NH<sub>2</sub> (X-X1 = Gly-Val, Phe-Gly), H-Arg-Asp-Phe-X-Val-Gly-Leu-Met-NH<sub>2</sub> (I; X = MeGly, D-Ala, D-Phe, D-Trp, D-2-phenylglycine residue), and H-Arg-His-Asp-Phe-X-Val-Gly-Leu-Met-NH<sub>2</sub> (X = D-Arg, D-Pro, D-homoglutamine residue, D-homoglutamic acid residue) were prepd. by the solid-phase method. The biol. activity of the above peptides were assayed on isolated guinea pig ileum. I (D-Ala) acts as an antagonist of neurokinin B.

L4 ANSWER 112 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1987:593937 CAPLUS  
 DN 107:193937  
 TI Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogs on plasma renin  
 AU Nisato, Dino; Wagnon, Jean; Callet, Georges; Mettefeu, Daniel; Assens, Jean Louis; Plouzane, Claude; Tonnerre, Bernard; Pliska, Vladimir; Fauchere, Jean Luc  
 CS SANOFI Rech., Montpellier, F-34082, Fr.  
 SO Journal of Medicinal Chemistry (1987), 30(12), 2287-91  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 IT **105382-21-6**  
 RL: BIOL (Biological study)  
 (renin inhibition by, Free-Wilson and correlation anal. of)  
 RN 105382-21-6 CAPLUS  
 CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[2-hydroxy-4-[[2-[[2-hydroxy-4-methoxy-1-(2-methylpropyl)-4-oxobutyl]amino]-1-methyl-2-oxoethyl]amino]-1-(2-methylpropyl)-4-oxobutyl]-L-2-phenyl-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



AB Free-Wilson and correlation anal. were combined to study a series of 34 pepstatin analogs in which mainly position 2 was varied. A statistically highly significant correlation was found between the inhibitory activity of the analogs on an enriched plasma renin prepn. and structural parameters of the amino acid side chain in position 2. The crucial parameters were found to be the NMR chem. shift of the .alpha.-C, the localized elec. (inductive) effect, and the van der Waals radius-related

steric parameter, which demonstrated the dominating influence of electronic inductive effects compared to steric bulk. The model gives insight into the structural requirements for effective inhibition and suggests the histidine-2 deriv., a pos. outlier in this series, as a lead compd. for further structure-activity studies.

L4 ANSWER 113 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1987:554732 CAPLUS

DN 107:154732

TI Solid phase synthesis of substance P and its analogs employing 9-fluorenylmethoxycarbonyl amino acid active esters

AU Sivanandaiah, K. M.; Rangaraju, N. S.

CS Cent. Coll., Bangalore Univ., Bangalore, 560 001, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1986), 25B(10), 1045-9

CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 107:154732

IT **110449-80-4P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deblocking of)

RN 110449-80-4 CAPLUS


CN Substance P, 1-[N5-[imino(nitroamino)methyl]-N2-[(phenylmethoxy)carbonyl]-L-ornithine]-3-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-8-[D-2-(4-hydroxyphenyl)glycine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



IT 110449-68-8DP, p-alkoxybenzyl alc. resin-bound

110449-71-3DP, p-alkoxybenzyl alc. resin-bound


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and resin cleavage of, by ammonolysis)

RN 110449-68-8 CAPLUS


CN Substance P, 1-de-L-arginine-2-de-L-proline-3-de-L-lysine-8-[D-2-(4-hydroxyphenyl)glycine]-11-L-methionine- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 110449-71-3 CAPLUS

CN Substance P, 1-[N5-[imino(nitroamino)methyl]-N2-[(phenylmethoxy)carbonyl]-L-ornithine]-3-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-8-[D-2-(4-hydroxyphenyl)glycine]-11-L-methionine- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A



PAGE 1-B



PAGE 2-A



IT 110449-76-8P 110465-51-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, by solid-phase method on alkoxybenzyl alc. resin)

RN 110449-76-8 CAPLUS

CN Substance P, 1-de-L-arginine-2-de-L-proline-3-de-L-lysine-8-[D-2-(4-hydroxyphenyl)glycine]-, monoacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 110449-75-7


CMF C45 H65 N11 O11 S

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 110465-51-5 CAPLUS

CN Substance P, 8-[D-2-(4-hydroxyphenyl)glycine]-, triacetate (salt) (9CI)  
(CA INDEX NAME)


CM 1

CRN 110465-50-4


CMF C62 H96 N18 O14 S

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 64-19-7  
CMF C2 H4 O2



AB Substance P, H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH<sub>2</sub>, and analogs H-Pro-Gln-Gln-X-X<sub>1</sub>-Gly-Leu-Met-NH<sub>2</sub> [X-X<sub>1</sub> = D-Phg(4-OH)-Phe [Phg(4-OH) = NHCH(C<sub>6</sub>H<sub>4</sub>OH-4)CO], Phe-D-Phg(4-OH), D-Phg(4-OH)-D-Phg(4-OH)] and H-Arg-Pro-Lys-Pro-Gln-Gln-X-X<sub>1</sub>-Gly-Leu-Met-NH<sub>2</sub> (X-X<sub>1</sub> = same) were prepd. by the solid-phase method on p-alkoxybenzyl alc. resin using 9-fluorenylmethoxycarbonyl (Fmoc) amino acid trichlorophenyl active esters in the presence of 1-hydroxybenzotriazole. The Fmoc groups were cleaved by Et<sub>2</sub>NH. Agonistic and antagonistic activities of the peptides were studied.

L4 ANSWER 114 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1986:627342 CAPLUS

DN 105:227342

TI Pepstatin analogs

IN Wagnon, Jean le Hameau de la Rauze; Callet, Georges; Gagnol, Jean Pierre; Nisato, Dino; Cazaubon, Catherine

PA SANOFI, Fr.; Institut National de la Sante et de la Recherche Medicale (INSERM)

SO Eur. Pat. Appl., 38 pp.

CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 192554	A1	19860827	EP 1986-400271	19860210
	EP 192554	B1	19920102		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
				FR 1985-1981	19850212
				FR 1985-1982	19850212
	FR 2577225	A1	19860814	FR 1985-1981	19850212
	FR 2577225	B1	19870828		
	FR 2577226	A1	19860814	FR 1985-1982	19850212
	FR 2577226	B1	19900615		
	CA 1286846	A1	19910723	CA 1986-500927	19860203
				FR 1985-1981	19850212
				FR 1985-1982	19850212
	US 4725580	A	19880216	US 1986-826349	19860205
				FR 1985-1981	19850212
				FR 1985-1982	19850212
	US 4746648	A	19880524	US 1986-826375	19860205
				FR 1985-1981	19850212
				FR 1985-1982	19850212
	CA 1286847	A1	19910723	CA 1986-501163	19860205
				FR 1985-1981	19850212

AU 8653272	A1	19860814	FR 1985-1982	19850212
AU 606312	B2	19910207	AU 1986-53272	19860206
			FR 1985-1981	19850212
AU 8653273	A1	19860821	FR 1985-1982	19850212
AU 606572	B2	19910214	AU 1986-53273	19860206
			FR 1985-1981	19850212
DK 8600640	A	19860813	FR 1985-1982	19850212
			DK 1986-640	19860210
			FR 1985-1981	19850212
DK 8600641	A	19860813	FR 1985-1982	19850212
			DK 1986-641	19860210
			FR 1985-1981	19850212
EP 193445	A1	19860903	FR 1985-1982	19850212
EP 193445	B1	19900509	EP 1986-400272	19860210
			R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE	
			FR 1985-1981	19850212
ZA 8600960	A	19861029	FR 1985-1982	19850212
			ZA 1986-960	19860210
ZA 8600961	A	19861029	FR 1985-1981	19850212
			ZA 1986-961	19860210
AT 52518	E	19900515	FR 1985-1981	19850212
			AT 1986-400272	19860210
			FR 1985-1981	19850212
			FR 1985-1982	19850212
AT 71111	E	19920115	EP 1986-400272	19860210
			AT 1986-400271	19860210
			FR 1985-1981	19850212
			FR 1985-1982	19850212
ES 551820	A1	19861216	EP 1986-400271	19860210
			ES 1986-551820	19860211
			FR 1985-1981	19850212
ES 551821	A1	19870101	FR 1985-1982	19850212
			ES 1986-551821	19860211
			FR 1985-1981	19850212
JP 61186397	A2	19860820	FR 1985-1982	19850212
			JP 1986-28747	19860212
			FR 1985-1981	19850212
JP 61186398	A2	19860820	FR 1985-1982	19850212
			JP 1986-28748	19860212
			FR 1985-1981	19850212
			FR 1985-1982	19850212

OS CASREACT 105:227342

IT **105382-21-6P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of, as renin inhibitor)



RN 105382-21-6 CAPLUS

CN Glycinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[2-hydroxy-4-[[2-[[2-hydroxy-4-methoxy-1-(2-methylpropyl)-4-oxobutyl]amino]-1-methyl-2-oxoethyl]amino]-1-(2-methylpropyl)-4-oxobutyl]-L-2-phenyl-, stereoisomer (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



GI



AB Title peptides I (R1 = alkanoyl, arylcarbonyl, carbalkoxy, etc.; R2 = alkyl, phenylalkyl, naphthylalkyl, pyridylalkyl, etc.; R3 = H, alkenyl, Ph, naphthyl, etc.; R4 = CHMe2, Ph, cyclohexyl; R5 = OH, alkoxy, NH2, etc.; X1X2 = Ala-Sta, Ala-Leu, Leu-Phe, Val-Sta, etc.) (Sta = statine) were prepd., and they exhibited renin-inhibiting activity. Thus, BOC-Phe-Asp(CH2Ph)-Sta-Ala-Leu-OMe was prepd. by soln. method peptide synthesis.

L4 ANSWER 115 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1986:514756 CAPLUS

DN 105:114756

TI Anilide derivatives of substituted arylacetic acids

IN Kawakami, Hajime; Hashimoto, Katsuhiko; Tamoto, Katsumi; Ono, Keiichi; Yamamoto, Michihiro

PA Sumitomo Pharmaceuticals Co., Ltd., Japan

SO Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 184822	A2	19860618	EP 1985-115720	19851210
	EP 184822	A3	19871209		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
				JP 1984-261197	19841211
	JP 61140556	A2	19860627	JP 1984-261197	19841211
	AU 8551065	A1	19860619	AU 1985-51065	19851210
				JP 1984-261197	19841211
	ES 549853	A1	19870416	ES 1985-549853	19851211
				JP 1984-261197	19841211


OS CASREACT 105:114756

IT **104122-31-8P 104122-32-9P 104122-33-0P**  
**104122-34-1P 104122-35-2P 104122-36-3P**  
**104122-37-4P 104122-38-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as nootropic and cerebral metabolic stimulant)


RN 104122-31-8 CAPLUS

CN Benzenhexanamide, N-[2-(aminocarbonyl)phenyl]-.alpha.-phenyl- (9CI) (CA  
 INDEX NAME)




RN 104122-32-9 CAPLUS

CN Benzenhexanamide, N-[3-(aminocarbonyl)phenyl]-.alpha.-phenyl- (9CI) (CA  
 INDEX NAME)




RN 104122-33-0 CAPLUS

CN Benzenhexanamide, N-[4-(aminocarbonyl)phenyl]-.alpha.-phenyl- (9CI) (CA  
 INDEX NAME)




RN 104122-34-1 CAPLUS

CN Benzenhexanamide, N-[3-(aminosulfonyl)phenyl]-.alpha.-phenyl- (9CI) (CA  
 INDEX NAME)




RN 104122-35-2 CAPLUS

CN Benzenhexanamide, N-[4-(aminosulfonyl)phenyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 104122-36-3 CAPLUS

CN Benzenhexanamide, N-(2-hydroxyphenyl)-.alpha.-phenyl- (9CI) (CA INDEX NAME)



RN 104122-37-4 CAPLUS


CN Benzenhexanamide, N-(3-hydroxyphenyl)-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 104122-38-5 CAPLUS

CN Benzenhexanamide, N-(4-hydroxyphenyl)-.alpha.-phenyl- (9CI) (CA INDEX NAME)





GI



I

AB Arylacetanilides I [R = OH, CONR<sub>3</sub>R<sub>4</sub>, SO<sub>2</sub>NR<sub>3</sub>R<sub>4</sub>; R<sub>1</sub> = (un)substituted heterocyclyl, arom. hydrocarbyl; R<sub>2</sub> = heterocyclyl, arom. hydrocarbyl; R<sub>3</sub>, R<sub>4</sub> = H, alkyl; NR<sub>3</sub>R<sub>4</sub> = pyrrolidino, piperidino, morpholino, N-alkyl- or N-phenylpiperazino; n = 1-4] are prepd. (50 examples) as nootropics and cerebral metabolic stimulants. Thus, PhCH<sub>2</sub>CHPhCO<sub>2</sub>H was refluxed with SOCl<sub>2</sub>, the mixt. distd., and the residue dissolved in THF and added to 3-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CONH<sub>2</sub> and Et<sub>3</sub>N in THF to give I (R = 3-CONH<sub>2</sub>, R<sub>1</sub> = R<sub>2</sub> = Ph, n = 1) (II). Whereas the survival times of hypoxic mice were effectively extended (to >140 s) by bencyclane, papaverine, and vincamine at 30 mg/kg, only 10 mg II/kg was required.

L4 ANSWER 116 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1986:435745 CAPLUS

DN 105:35745

TI Synthesis and biological activity of some new leucine-enkephalin analogs

AU Sivanandaiah, K. M.; Gurusiddappa, S.; Rangaraju, N. S.

CS Cent. Coll., Bangalore Univ., Bangalore, 560 001, India

SO Journal of Biosciences (Bangalore, India) (1985), 8(1-2), 263-71

CODEN: JOBSDN; ISSN: 0250-4774

DT Journal

LA English

IT 103144-89-4DP, resin complexes


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and aminolysis of)

RN 103144-89-4 CAPLUS

CN L-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl]-D-2-(4-hydroxyphenyl)glycyl]glycyl]-L-phenylalanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **103144-99-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deprotection of)

RN 103144-99-6 CAPLUS

CN L-Leucinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-D-2-(4-hydroxyphenyl)glycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **103175-20-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and muscle contraction inhibition by)

RN 103175-20-8 CAPLUS

CN L-Leucinamide, L-tyrosyl-D-2-(4-hydroxyphenyl)glycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The opioid pentapeptide leucine-enkephalinamide and 11 of its analogs were synthesized by the solid-phase technique employing mostly 9-fluorenylmethoxycarbonyl amino acid active esters in the presence of 1-hydroxybenzotriazole. Both the conventional chloromethylated copolystyrene-2% divinylbenzene resin as well as p-alkoxybenzyl alc. resin were employed and yields were uniformly better with the latter resin. The analogs were made by affecting single or multiple replacements of amino acids involving positions 1, 2, and 5. Some of the analogs were more potent than morphine in inhibiting elec. induced contraction in the guinea pig ileum assay.

L4 ANSWER 117 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1984:591513 CAPLUS

DN 101:191513

TI Cephalosporin derivatives, and prophylactic and therapeutic agents for bacterial infection

IN Kakeya, Nobuharu; Nishizawa, Susumu; Tamaki, Satoshi; Kitao, Kazuhiko

PA Kyoto Pharmaceutical Industries, Ltd., Japan

SO Eur. Pat. Appl., 84 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 108942	A2	19840523	EP 1983-110284	19831015
	EP 108942	A3	19850515		
	EP 108942	B1	19880302		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	WO 8401949	A1	19840524	WO 1982-JP437	19821110
	W: MC			WO 1982-JP437	19821110
	US 4605651	A	19860812	US 1983-540676	19831011
				WO 1982-JP437	19821110
	ZA 8307635	A	19841128	ZA 1983-7635	19831013
				WO 1982-JP437	19821110
	AU 8320199	A1	19840517	AU 1983-20199	19831014
	AU 568094	B2	19871217		
				WO 1982-JP437	19821110
	AT 32724	E	19880315	AT 1983-110284	19831015
				WO 1982-JP437	19821110
				EP 1983-110284	19831015
	NO 8303807	A	19840511	NO 1983-3807	19831019
	NO 162240	B	19890821		

NO 162240	C	19891129
ES 526561	A1	19850416
SU 1331432	A3	19870815
FI 8303839	A	19840511
FI 75348	B	19880229
FI 75348	C	19880609
DK 8304818	A	19840511
JP 59116292	A2	19840705
CA 1239928	A1	19880802
ES 532996	A1	19850816
ES 532997	A1	19850816
SU 1322983	A3	19870707

WO 1982-JP437	19821110
ES 1983-526561	19831019
WO 1982-JP437	19821110
SU 1983-3655401	19831019
WO 1982-JP437	19821110
FI 1983-3839	19831020
WO 1982-JP437	19821110
DK 1983-4818	19831020
WO 1982-JP437	19821110
JP 1983-197458	19831020
WO 1982-JP437	19821110
CA 1983-439358	19831020
WO 1982-JP437	19821110
ES 1984-532996	19840531
WO 1982-JP437	19821110
ES 1984-532997	19840531
WO 1982-JP437	19821110
SU 1984-3827995	19841224
WO 1982-JP437	19821110

## PATENT FAMILY INFORMATION:

FAN 1987:636362


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 1309912	A3	19870507	SU 1984-3826171	19841224
	WO 8401949	A1	19840524	WO 1982-JP437	19821110
	W: MC			WO 1982-JP437	19821110
	US 4605651	A	19860812	US 1983-540676	19831011
	ZA 8307635	A	19841128	WO 1982-JP437	19821110
	AU 8320199	A1	19840517	ZA 1983-7635	19831013
	AU 568094	B2	19871217	WO 1982-JP437	19821110
	NO 8303807	A	19840511	AU 1983-20199	19831014
	NO 162240	B	19890821	WO 1982-JP437	19821110
	NO 162240	C	19891129	NO 1983-3807	19831019
	ES 526561	A1	19850416	WO 1982-JP437	19821110
	SU 1331432	A3	19870815	ES 1983-526561	19831019
	FI 8303839	A	19840511	WO 1982-JP437	19821110
	FI 75348	B	19880229	SU 1983-3655401	19831019
	FI 75348	C	19880609	WO 1982-JP437	19821110
	DK 8304818	A	19840511	FI 1983-3839	19831020
	JP 59116292	A2	19840705	WO 1982-JP437	19821110
	CA 1239928	A1	19880802	DK 1983-4818	19831020
	ES 532996	A1	19850816	WO 1982-JP437	19821110
				JP 1983-197458	19831020
				WO 1982-JP437	19821110
				CA 1983-439358	19831020
				WO 1982-JP437	19821110
				ES 1984-532996	19840531
				WO 1982-JP437	19821110

ES 532997	A1	19850816	ES 1984-532997	19840531
			WO 1982-JP437	19821110
SU 1322983	A3	19870707	SU 1984-3827995	19841224
			WO 1982-JP437	19821110

IT **92602-27-2P**RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 92602-27-2 CAPLUS

CN L-Phenylalanine, 2-[[2-[[1-(acetyloxy)ethoxy]carbonyl]-3-[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, monohydrochloride, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI) (CA INDEX NAME)



● HCl

GI




AB Cephalosporins I (R = H, OH; R1 = amino acid residue; R2 = 1-alkanoyloxyalkyl, 1-alkoxycarbonyloxyalkyl, phthalidyl, 5-methyl-2-oxo-1,3-dioxolan-4-ylmethyl; R3 = carbamoyloxymethyl, heterocyclylthiomethyl) were prepd. Thus D-HOCHPhCO2CHPh2 was treated with Me3CO2CNHCH2CO2H to give D-Me3CO2CNHCH2CO2CHPhCO2CHPh2 which was hydrogenolyzed and used to acylate the 7-aminocephem, followed by deblocking, to give I (R = H, R1 = H2NCH2CO, R2 = CH2O2CCMe3, R3 = 1-methyl-5-tetrazolylthiomethyl, II). At a dose corresponding to 125 mg of the free acid II was 38.0% excreted in the urine in 8 h.

L4 ANSWER 118 OF 148 CAPLUS COPYRIGHT 2003 ACS


AN 1984:451568 CAPLUS  
 DN 101:51568  
 TI Binding of  $^{125}\text{I}$ -labeled .beta.-lactam antibiotics to the penicillin binding proteins of *Escherichia coli*  
 AU Rojo, Fernando; Ayala, Juan A.; De la Rosa, Enrique J.; De Pedro, Miguel A.; Aran, Vicente; Berenguer, Jose; Vazquez, David  
 CS Fac. Cien., Univ. Auton. Madrid, Madrid, Spain  
 SO Journal of Antibiotics (1984), 37(4), 389-93  
 CODEN: JANTAJ; ISSN: 0021-8820  
 DT Journal  
 LA English  
 IT **90986-75-7 90986-77-9**  
 RL: PROC (Process)  
 (penicillin-binding proteins preferential binding of)  
 RN 90986-75-7 CAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[3-[4-hydroxy-3-(iodo- $^{125}\text{I}$ )phenyl]-1-oxopropyl]amino]phenylacetyl]amino]-3-methyl-8-oxo-, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 90986-77-9 CAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-chloro-7-[[[3-[4-hydroxy-3-(iodo- $^{125}\text{I}$ )phenyl]-1-oxopropyl]amino]phenylacetyl]amino]-8-oxo-, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB  $^{125}\text{I}$ -labeled derivs. of the .beta.-lactam antibiotics cephalexin, cephradine, cefaclor, and 6-.alpha.-aminopenicillanic acid were obtained by reacting these compds. with ( $^{125}\text{I}$ )-Bolton-Hunter reagent. Target proteins were found in *E. coli*. The derivs. of cephalexin, cefaclor, and cephradine preferentially interact with the high-mol.-wt. penicillin binding proteins (PBP1a and PBP1b). The  $^{125}\text{I}$ -deriv. of

6-.alpha.-aminopenicillanic acid was preferentially bound by the low-mol.-wt. penicillin binding proteins 4 and 5/6. The iodinated derivs. showed a very high affinity of binding to their target proteins with apparent half-satg. concns. in the nM range.

L4 ANSWER 119 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1984:47629 CAPLUS

DN 100:47629

TI Binding specificities of penicillin-binding proteins - a conformational approach

AU Rao, V. S. R.

CS Mol. Biophys. Unit, Indian Inst. Sci., Bangalore, 560 012, India

SO Target Penicillin: Murein Sacculus Bact. Cell Walls Archit. Growth, Proc., Int. FEMS Symp. (1983), 359-67. Editor(s): Hakenbeck, Regine; Hoeltje, Joachim-Volker; Labischinski, Harald. Publisher: de Gruyter, Berlin, Fed. Rep. Ger.

CODEN: 50ODAA

DT Conference

LA English


IT **54984-13-3 68964-66-9 68964-69-2**  
**68985-99-9**

RL: PRP (Properties)

(conformation of, .beta.-lactamase and transpeptidase binding in relation to)


RN 54984-13-3 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-L-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 68964-66-9 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 68964-69-2 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-L-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-L-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)



RN 68985-99-9 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-L-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)



AB Ab initio MO calcns. of the .beta.-lactam antibiotics (cephams, phenams, thienamycins, penicillins) indicate that the nonplanarity of the N atom and conjugation by inclusion of a double bond leads to weakening of the peptide bond, the bond susceptible to .beta.-lactamase hydrolysis. Thus, the peptide bond in penicillins is weakened mainly due to the pyramidal character of N and in cepham (cephalosporins) due to resonance with the double bond; in highly active thienamycins, the peptide bond is weakened by both mechanisms. The overall shape of the antibiotic is also of importance in achieving a proper conformational fit in the .beta.-lactamase or transpeptidase active site. The compact conformation favored by penicillin G1, D-ampicillin, and 3-pyridylmethylpenicillin may be assocd. with, or initiate, the binding process in interactions with transpeptidase of gram-pos. bacteria. Substitutions at the 6.beta. side group of penicillanic acid, which favor extended conformation, result in good antibacterial properties against gram-pos. bacteria; the chiral center at C-27 does not affect those properties. However, changes in conformation beyond C-17 do affect the antibacterial activity against gram-neg. bacteria, suggesting that their transpeptidases are more specific than those of gram-pos. bacteria.

L4 ANSWER 120 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1983:505050 CAPLUS

DN 99:105050




TI .beta.-Lactam antibacterial agents  
 IN Milner, Peter Henry  
 PA Beecham Group PLC, UK  
 SO Eur. Pat. Appl., 282 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 71395	A1	19830209	EP 1982-303821	19820721
	EP 71395	B1	19880810		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
				GB 1981-23033	19810725
				GB 1981-23034	19810725
				GB 1981-36823	19811207
				GB 1981-36824	19811207
				GB 1982-7966	19820318
				GB 1982-9953	19820403
				GB 1982-9954	19820403
				GB 1982-15007	19820522
				GB 1982-21059	19820721
	GB 2107307	A1	19830427		
	GB 2107307	B2	19860226		
				GB 1981-23033	19810725
				GB 1981-23034	19810725
				GB 1981-36823	19811207
				GB 1981-36824	19811207
				GB 1982-7966	19820318
				GB 1982-9953	19820403
				GB 1982-9954	19820403
				GB 1982-15007	19820522
	AT 36334	E	19880815	AT 1982-303821	19820721
				GB 1981-23033	19810725
				GB 1981-23034	19810725
				GB 1981-36823	19811207
				GB 1981-36824	19811207
				GB 1982-7966	19820318
				GB 1982-9953	19820403
				GB 1982-9954	19820403
				GB 1982-15007	19820522
				EP 1982-303821	19820721
	NO 8202538	A	19830126	NO 1982-2538	19820723
	NO 162192	B	19890814		
	NO 162192	C	19891122		
				GB 1981-23033	19810725
				GB 1981-23034	19810725
				GB 1981-36823	19811207
				GB 1981-36824	19811207
				GB 1982-7966	19820318
				GB 1982-9953	19820403
				GB 1982-9954	19820403
				GB 1982-15007	19820522
	FI 8202606	A	19830126	FI 1982-2606	19820723
	FI 78702	B	19890531		
	FI 78702	C	19890911		
				GB 1981-23033	19810725
				GB 1981-23034	19810725

			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
			GB 1982-15007	19820522
DK 8203309	A	19830126	DK 1982-3309	19820723
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
ZA 8205296	A	19830525	ZA 1982-5296	19820723
HU 27347	O	19831028	GB 1981-23033	19810725
HU 188983	B	19860528	HU 1982-2381	19820723
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
			GB 1982-15007	19820522
ES 514308	A1	19831201	ES 1982-514308	19820723
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
AU 8286351	A1	19841018	AU 1982-86351	19820723
AU 568062	B2	19871217		
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
			GB 1982-15007	19820522
US 4539149	A	19850903	US 1982-401266	19820723
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
			GB 1982-15007	19820522
CA 1216576	A1	19870113	CA 1982-407903	19820723
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403


PL 145252	B1	19880831	GB 1982-15007	19820522
			PL 1982-237640	19820723
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
PL 146092	B1	19881231	GB 1982-15007	19820522
			PL 1982-261915	19820723
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-9953	19820403
			GB 1982-9954	19820403
PL 146182	B1	19890131	GB 1982-15007	19820522
			PL 1982-248815	19820723
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
JP 58038288	A2	19830305	GB 1982-15007	19820522
			JP 1982-128353	19820724
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
IL 67222	A1	19860429	GB 1982-15007	19820522
			IL 1982-67222	19821110
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
ES 520953	A1	19840516	GB 1982-15007	19820522
			ES 1983-520953	19830324
			GB 1981-23033	19810725
US 4609652	A	19860902	GB 1981-23034	19810725
			US 1985-694592	19850124
			GB 1981-23033	19810725
			GB 1981-23034	19810725
			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
US 4877783	A	19891031	GB 1982-15007	19820522
			US 1982-401266	19820723
			US 1985-694622	19850124
			GB 1981-23033	19810725
			GB 1981-23034	19810725

			GB 1981-36823	19811207
			GB 1981-36824	19811207
			GB 1982-7966	19820318
			GB 1982-9953	19820403
			GB 1982-9954	19820403
			GB 1982-15007	19820522
			US 1982-401266	19820723
			GB 1985-14519	19850607
			GB 1982-21059	19820721
OS	CASREACT 99:105050			
IT	<b>86061-97-4P</b>			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)			
	(prepn. and bactericidal activity of)			
RN	86061-97-4 CAPLUS			
CN	Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-N-[2-carboxy-6-(formylamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-D-2-(4-hydroxyphenyl)-, monosodium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)			




● Na

IT	<b>86117-42-2P</b>			
	RL: SPN (Synthetic preparation); PREP (Preparation)			
	(prepn. of)			
RN	86117-42-2 CAPLUS			
CN	Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-N-[2-carboxy-6-(formylamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-D-2-(4-hydroxyphenyl)-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)			



GI



AB .beta.-Lactams I (R = H, acyl; R1R2 = atoms required to complete a penam, cephem, or oxadithiacephem system) were prepd. Thus II (R3 = SMe, R4 = CH2Ph) was treated with NH3 to give II (R3 = NH2, R4 = CH2Ph) which was formylated with HCO2Ac to give II (R3 = NHCHO, R4 = CH2Ph). Hydrogenolysis of the ester group and treatment with BuCH<sub>2</sub>EtCO<sub>2</sub>Na gave II (R3 = NHCHO, R4 = Na) which had a min. inhibitory concn. against *Proteus mirabilis* 889 of 0.2 .mu.g/mL.

L4 ANSWER 121 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1983:499494 CAPLUS

DN 99:99494

TI A study of the applicability of QSAR calculations for peptide hormones

AU Nadasdi, L.; Medzihradszky, K.

CS Peptidkem. Tansz. Kutato Csoport, Magy. Tud. Akad., Budapest, Hung.

SO Kemiai Kozlomenyek (1982), 58(4), 410-15

CODEN: KEKOAS; ISSN: 0022-9814

DT Journal

LA Hungarian

IT 57356-92-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (biol. activity of, structure in relation to)

RN 57356-92-0 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 6-(D-2-phenylglycine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB Quant. structure-activity relations were calcd. for LH-RH analogs substituted in position 6 with D-Ala, D-Leu, D-Glu, D-Phe, D-Trp, and other D-amino acids, and compared with data from the literature (Coy, D. H., et al., 1979). A very high correlation and statistically-significant equations at a 95% confidence limit were obtained using lipophilic .pi. and steric .gamma. parameters. The lipophilic parameters are the most important with resp. to biol. activity.

L4 ANSWER 122 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1983:59889 CAPLUS  
 DN 98:59889

TI Improving intestinal absorption of cephalosporin derivatives  
 IN Nishikido, Joji; Kodama, Eiji; Shibukawa, Mitsuru  
 PA Asahi Chemical Industry Co., Ltd., Japan  
 SO Eur. Pat. Appl., 63 pp.  
 CODEN: EPXXDW

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 60422	A2	19820922	EP 1982-101508	19820226
	EP 60422	A3	19830824		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
				JP 1981-26743	19810227
				JP 1981-128688	19810819
	JP 57142988	A2	19820903	JP 1981-26743	19810227
	JP 58032885	A2	19830225	JP 1981-128688	19810819
	US 4465668	A	19840814	US 1982-351613	19820224
				JP 1981-26743	19810227
				JP 1981-128688	19810819


IT 84294-10-0 84330-79-0

RL: PROC (Process)

(absorption of, by intestine)

RN 84294-10-0 CAPLUS

CN L-Phenylalanine, N-(N-acetyl-L-leucyl)-, 2-[[2-carboxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI)  
 (CA INDEX NAME)




RN 84330-79-0 CAPLUS

CN L-Phenylalanine, 2-[[2-carboxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]-, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 84330-78-9

CMF C27 H27 N7 O6 S2



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

IT 84330-75-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and intestinal absorption of)


RN 84330-75-6 CAPLUS

CN L-Phenylalanine, N-L-leucyl-, 2-[[[2-carboxy-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]-, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 84330-74-5

CMF C33 H38 N8 O7 S2



CM 2


CRN 64-18-6

CMF C H2 O2



O=CH-OH

GI



AB Intestinal absorption of cephalosporins with low oral activity is improved by binding to any side chain in the 3-, 4-, or 7-position of a 7-aminocephalosporanic acid deriv., an oligopeptide  $X(NHCHR_1CO)nNHCHR_2CO$  ( $X = H$ , C1-15 alkyl or  $R_3CO$ ;  $R_1$  and  $R_2$  = side chain of an amino acid constituting the oligopeptide;  $R_3 = H$  or C1-15 alkyl or protective group easily removable by acid hydrolysis, hydrogenolysis, or enzyme existing in a living body;  $n = 1-3$ ). Thus, 7-[D-(O-L-leucyl-L-phenylalanyl)mandelamido]-3-[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid monoformate (I) [84330-75-6] was prepd. and administered to male rats at 50 mg/kg. The blood concn. was 4.51  $\mu\text{g/mL}$  30 min after administration, as compared with 0.29  $\mu\text{g/mL}$  for the cephemcarboxylic acid deriv. without the oligopeptide.

L4 ANSWER 123 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1982:174580 CAPLUS

DN 96:174580

TI Evolution of design and achievement of inhibitors of the luteinizing hormone-releasing hormone as inhibitors of ovulation

AU Folkers, Karl; Humphries, John; Bowers, Cyril Y.

CS Inst. Biomed. Res., Univ. Texas, Austin, TX, 78712, USA

SO Zeitschrift fuer Naturforschung, Teil B: Anorganische Chemie, Organische Chemie (1982), 37B(2), 246-59  
CODEN: ZNBAD2; ISSN: 0340-5087

DT Journal

LA English

IT 81419-11-6


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ovulation-inhibiting activity of, structure in relation to)

RN 81419-11-6 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 2-D-phenylalanine-3-L-leucine-6-(D-2-phenylglycine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB Structure-activity relations of LH-RH [9034-40-6] analogs as inhibitors of LH [9002-67-9] release and ovulation in rats and rhesus monkeys were studied. Inhibitory activities for >100 peptides are given. However, some analogs, e.g. [D-Phe<sub>2</sub>,Ala<sub>4</sub>,D-Phe<sub>6</sub>]-LH-RH [81419-23-0] (100 .mu.g) released LH and FSH [9002-68-0] at a ratio of LH/FSH greater than that induced by LH-RH. [D-Phe<sub>2</sub>,Pro<sub>3</sub>,D-Phe<sub>6</sub>]-LH-RH [64789-67-9] (6 S.c. injections of 50 mg every 8 h) inhibited ovulation and the action of endogenous LH-RH in cycling rhesus monkeys. Infusion of [D-Phe<sub>2</sub>,Pro<sub>3</sub>,D-Trp<sub>6</sub>]-LH-RH [60961-52-6] (375 .mu.g/day for 4 days) from a s.c. implanted minipump inhibited ovulation in cycling female rats and inhibited LH release in castrated male rats. Infusion of LH-RH (375 .mu.g/day, 4 days) and [D-Ala<sub>6</sub>,de-Gly<sub>10</sub>]-LH-RH EtNH<sub>2</sub> [52435-06-0] (6 .mu.g/day, 4 days) blocked uterine implantation sites of mated rats. Antagonist analogs with 3-proline and 3-leucine residues did not block the implantation sites indicating a difference in mechanism of contraception for agonists and antagonists of LH-RH. Solid phase synthesis of the peptides is also discussed.

L4 ANSWER 124 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1981:462724 CAPLUS  
 DN 95:62724  
 TI Antioviulatory decapeptides  
 IN Sarantakis, Dimitrios

PA American Home Products Corp., USA

SO U.S., 4 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4253997	A	19810303	US 1979-104599	19791217
				US 1979-104599	19791217

IT 78255-76-2P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 78255-76-2 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 1-(5-oxo-D-proline)-2-D-phenylalanine-3-[3-(1-naphthalenyl)-D-alanine]-6-(D-2-phenylglycine)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB LH-releasing hormone antagonists D-pyroGlu-D-Phe-D-Nal-Ser-Tyr-X-Leu-Arg-Pro-Gly-NH<sub>2</sub> [I; D-Nal = 3-(1-naphthyl)-D-alanine residue; X = D-Nal, D-Trp, D-Phe, D-Tyr, D-Lys, D-Met, D-Ala, D-NHCHPhCO] were prepd. as ovulation inhibitors. Thus, I (X = D-Nal) (II) was prepd. by the solid-phase method on a benzhydrylamine resin. II at 500 .mu.g (s.c.) inhibited ovulation in rats by 70%.

L4 ANSWER 125 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1981:443678 CAPLUS

DN 95:43678

TI Pharmacologically active peptides

IN Gesellchen, Paul D.; Smiley, David L.

PA Lilly, Eli, and Co., USA

SO U.S., 12 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4251439	A	19810217	US 1979-104345	19791217
	EP 30846	A2	19810624	EP 1980-304474	19801211
	EP 30846	A3	19811223		
	EP 30846	B1	19840509		
	R: DE, GB, LU, NL, SE				
				US 1979-104345	19791217
	GB 2065134	A	19810624	GB 1980-39662	19801211
	GB 2065134	B2	19830602		
				US 1979-104345	19791217
	CA 1140539	A1	19830201	CA 1980-366540	19801211
				US 1979-104345	19791217
	IL 61701	A1	19840531	IL 1980-61701	19801212
				US 1979-104345	19791217
	BE 886676	A1	19810616	BE 1980-10077	19801216
				US 1979-104345	19791217
	FR 2471969	A1	19810626	FR 1980-26690	19801216
	FR 2471969	B1	19821105		
				US 1979-104345	19791217
	JP 56097258	A2	19810805	JP 1980-179640	19801216
				US 1979-104345	19791217
	HU 29354	O	19840130	HU 1980-3010	19801216
	HU 185230	B	19841228		
				US 1979-104345	19791217
	CH 646685	A	19841214	CH 1980-9272	19801216
				US 1979-104345	19791217

IT 78255-91-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and analgesic activity of)

RN 78255-91-1 CAPLUS


CN Glycinamide, L-tyrosyl-D-alanylglycyl-L-phenylalanyl-N-methyl-D-2-phenyl-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 78255-90-0

CMF C32 H38 N6 O6


Absolute stereochemistry.




CM 2

CRN 64-19-7

CMF C2 H4 O2



GI



AB Enkephalin analogs I [R = H, C1-3 alkyl; R1 = C1-4 alkyl, allyl, cyclopropylmethyl, C1-2 hydroxyalkyl, (CH2)mZMe (m = 1, 2; Z = S, SO); R2 = H, C1-4 alkyl, allyl, cyclopropylmethyl; R3 = H, halo, OH, C1-3 alkoxy, NO2, C1-3 alkyl, CF3; R4 = CH2OR5 (R5 = H, C1-3 alkyl), CONHR5, CO2R6 (R6 = C1-3 alkyl)] were prep'd. as analgesics. Thus, phenylglycinamide II (BOC = Me3CO2C) was BOC-deblocked and then coupled with BOC-Phe-OH by

DCC/1-hydroxybenzotriazole (HOBT) to give the protected dipeptide, which was BOC-deblocked and then coupled to BOC-Tyr-D-Ala-Gly-OH by DCC/HOBT to give peptide III (R7 = BOC). The latter was BOC-deblocked to give III (R7 = H). The analgesic activities of I were detd. in mice by the hot plate test.

L4 ANSWER 126 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1981:170508 CAPLUS

DN 94:170508

TI Penicillin-binding proteins of *Escherichia coli* identified with a 125I-derivative of ampicillin

AU Schwarz, U.; Seeger, K.; Wengenmayer, F.; Strecker, H.

CS Abt. Biochem., Max-Planck-Inst. Virusforsch., Tuebingen, Fed. Rep. Ger.

SO FEMS Microbiology Letters (1981), 10(2), 107-9

CODEN: FMLED7; ISSN: 0378-1097

DT Journal

LA English

IT 77471-26-2P


RL: PREP (Preparation)

(prepn. of and labeling by, of penicillin-binding proteins of *Escherichia coli*)

RN 77471-26-2 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(4-hydroxy-3-iodophenyl)-1-oxopropyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A 125I-labeled deriv. of ampicillin with high sp. activity was prepd. by using the Bolton-Hunter reagent, and the deriv. was used for the labeling of penicillin-binding proteins (PBPs) of *E. coli* membranes. The radiolabeled deriv. was purified by chromatog. on a Bio-Gel column before use in the binding assays. The binding pattern of 125I-labeled ampicillin, as detd. by autoradiog., was similar but not identical to that of penicillin G-14C. A new band was detected between PBP 1B and PBP 2. In competition studies with different .beta.-lactam antibiotics (mecillinam, cefotaxime, cefoxitin), the qual. and quant. competition in binding of 125I-labeled ampicillin was similar to that obtained with penicillin G-14C.

L4 ANSWER 127 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1981:168311 CAPLUS

DN 94:168311

TI A study of the applicability of QSAR calculation for peptide hormones


AU Nadasdi, Laszlo; Medzihradszky, Kalman

CS Inst. Org. Chem., Eotvos Lorand Univ., Budapest, 1088, Hung.


SO Biochemical and Biophysical Research Communications (1981), 99(2), 451-7  
CODEN: BBRCA9; ISSN: 0006-291X  
DT Journal  
LA English  
IT **57356-92-0**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(biol. activity of, structure in relation to)  
RN 57356-92-0 CAPLUS  
CN Luteinizing hormone-releasing factor (swine), 6-(D-2-phenylglycine)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB A quant. structure-activity relation (QSAR) was calcd. for the hypothalamic hormone LH-RH [33515-09-2]. A very good correlation and statistically significant equations at 95% confidence limit were obtained using information on the lipophilic nature and steric characteristics of the amino acid side chains.

L4 ANSWER 128 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1980:604632 CAPLUS

DN 93:204632

TI .beta.-Lactam compounds

IN Fujimoto, Yasuo

PA Nippon Chemiphar Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 55040631	A2	19800322	JP 1978-113666	19780918
				JP 1978-113666	19780918

IT 75354-91-5P 75354-92-6P 75354-93-7P

75354-94-8P 75354-96-0P 75430-91-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and bactericidal activity of)

RN 75354-91-5 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(2-iodo-1-oxo-3-phenylpropyl)amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 75354-92-6 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid, 7-[[[(2-iodo-1-oxo-3-phenylpropyl)amino]phenylacetyl]amino]-8-oxo-, [6R-(6.alpha.,7.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 75354-93-7 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
7-[[[(2-bromo-1-oxo-3-phenylpropyl)amino]phenylacetyl]amino]-8-oxo-,  
[6R-(6.alpha.,7.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 75354-94-8 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(2-azido-2-iodo-1-oxo-3-phenylpropyl)amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-,  
[2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 75354-96-0 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(2-azido-1-oxo-3-phenylpropyl)amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-,  
[2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 75430-91-0 CAPLUS


CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(2-bromo-1-oxo-3-phenylpropyl)amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





GI

PhCRR<sup>2</sup>CR<sup>1</sup>R<sup>3</sup>CONHCHPhCONH



I



II

AB Seven .beta.-lactams D(-)-I (X = Q, Q1; R, R1 = H, a single bond; R2, R3 = H, halo, N3, or R2R3 form an aziridine ring) were prep'd. by reaction of PhCRR<sup>2</sup>CR<sup>1</sup>R<sup>3</sup>CO<sub>2</sub>H with II. Min. inhibitory concns. of I were given against *S. aureus*, *E. coli*, *Kl. pneumoniae*, *P. vulgaris*, and *P. aeruginosa*. Thus, 102 g PhCH<sub>2</sub>CHICO<sub>2</sub>H was stirred with (COCl)<sub>2</sub> in THF 1 h with ice cooling, stripped of excess (COCl)<sub>2</sub>, a mixt. of 150 mg ampicillin and KHCO<sub>3</sub> in aq. THF added at pH 7.5-8.0, and the whole stirred 40 m with ice cooling to give D(-)-I 89.8% (X = Q, R = R2 = R3 = H, R1 = iodo).

L4 ANSWER 129 OF 148 CAPLUS COPYRIGHT 2003 ACS


AN 1980:472308 CAPLUS  
 DN 93:72308  
 TI Analgesic polypeptide  
 IN Sarantakis, Dimitrios  
 PA American Home Products Corp., USA  
 SO U.S., 4 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4196122	A	19800401	US 1977-812039	19770701
				US 1977-812039	19770701

IT **74412-05-8P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and analgesic activity of)  
 RN 74412-05-8 CAPLUS  
 CN D-Lysinamide, L-tyrosyl-D-2-phenylglycylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NH2


IT **74412-04-7DP**, resin-bound  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and resin-cleavage and deblocking of)  
 RN 74412-04-7 CAPLUS  
 CN D-Lysinamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-D-2-phenylglycylglycyl-L-phenylalanyl-N6-[(2-chlorophenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 74412-06-9P 74412-07-0P 74412-08-1P  
 74412-09-2P 74412-10-5P 74412-11-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 74412-06-9 CAPLUS  
 CN D-Argininamide, L-tyrosyl-D-2-phenylglycylglycyl-L-phenylalanyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 74412-07-0 CAPLUS

CN D-Leucinamide, L-arginyl-L-tyrosyl-D-2-phenylglycylglycyl-L-phenylalanyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 74412-08-1 CAPLUS

CN D-Leucinamide, L-ornithyl-L-tyrosyl-D-2-phenylglycylglycyl-L-phenylalanyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74412-09-2 CAPLUS

CN D-Lysine, N2-[N-[N-(D-2-phenyl-N-L-tyrosylglycyl)glycyl]-L-phenylalanyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NH<sub>2</sub>

RN 74412-10-5 CAPLUS

CN D-Lysinamide, L-tyrosyl-D-2-phenylglycylglycyl-L-phenylalanyl-N-ethyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NH<sub>2</sub>

RN 74412-11-6 CAPLUS

CN D-Lysinamide, L-lysyl-N-methyl-L-tyrosyl-D-2-phenylglycylglycyl-L-  
phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH<sub>2</sub>

AB Enkephalin analogs H-X-X1-D-Phg-Gly-Phe-X3-R (Phg = HNCHPhCO; X = null, Arg, Lys, Orn; X1 = Tyr, MeTyr, N-allyl- or N-cyclopropylmethyltyrosine residue; X3 = D-Lys, D-Arg, D-Met, D-Leu; R = OH, NH<sub>2</sub>, NHCnH<sub>2n+1</sub> where n = 1-4) were prepd. as analgesics. Thus, BOC-D-Lys(ZCl-2)-OH (BOC = Me<sub>3</sub>CO<sub>2</sub>C, ZCl-2 = CO<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>Cl-2) was amidated with benzhydrylamine resin (BHA-resin) to give BOC-D-Lys(ZCl-2)-NH-BHA-resin, which was extended by stepwise peptide couplings to BOC-Tyr(CH<sub>2</sub>Ph)-D-Phg-Gly-Phe-D-Lys(ZCl-2)-NH-BHA-resin. The latter was resin-cleaved and deblocked by HF/anisole to give H-Tyr-D-Phg-Gly-Phe-D-Lys-NH<sub>2</sub> (I). I at 1 mg/kg (i.v.) induced analgesic activity according to the rat-tail flick test.

L4 ANSWER 130 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1979:439466 CAPLUS

DN 91:39466

TI Penicillanic acid derivatives

IN Schwarz, Uli

PA Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Fed. Rep. Ger.

SO Ger. Offen., 12 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2739922	A1	19790308	DE 1977-2739922	19770905
	GB 2005254	A	19790419	GB 1978-35511	19780904
				DE 1977-2739922	19770905
	FR 2403344	A1	19790413	FR 1978-25546	19780905
				DE 1977-2739922	19770905
	JP 54048788	A2	19790417	JP 1978-109050	19780905
				DE 1977-2739922	19770905


IT **70343-46-3P 70343-48-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 70343-46-3 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-[4-hydroxy-3-(iodo-125I)phenyl]-1-oxopropyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 70343-48-5 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Penicillanic acid derivs. I ( $n = 1-11$ ;  $R = H, \text{halo}, OH, NO_2, \text{Cl-4 alkyl or alkoxy}$ ;  $Z = NH, NHCHPhCONH$ ) were prepd. by the reaction of N-acyloxysuccinimides II with ampicillin or 6-aminopenicillanic acid. Thus, ampicillin reacted with II ( $R = 125I, n = 2$ ) to give I ( $R = 125I, n = 2, Z = NHCHPhCONH$ ).

L4 ANSWER 131 OF 148 CAPLUS COPYRIGHT 2003 ACS



AN 1979:121187 CAPLUS  
 DN 90:121187  
 TI Aminoalcohol derivative  
 IN Lambelin, Georges; Roncucci, Romeo; Roba, Joseph; Gillet, Claude; Snyers, Michel  
 PA Continental Pharma, Belg.  
 SO Ger. Offen., 48 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2817494	A1	19781109	DE 1978-2817494	19780421
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	GB 1603379	A	19811125	GB 1978-27732	19780427
				LU 1977-77236	19770503
				LU 1977-77237	19770503
				GB 1978-16813	19780427
	GB 1603378	A	19811125	GB 1978-16813	19780427
				LU 1977-77237	19770503
	SE 7804897	A	19781104	SE 1978-4897	19780428
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	NL 7804621	A	19781107	NL 1978-4621	19780428
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	CA 1118438	A1	19820216	CA 1978-302239	19780428
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	US 4474977	A	19841002	US 1978-901223	19780428
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	IL 54608	A1	19840131	IL 1978-54608	19780501
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	FI 7801347	A	19781104	FI 1978-1347	19780502
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	DK 7801898	A	19781104	DK 1978-1898	19780502
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	NO 7801554	A	19781106	NO 1978-1554	19780502
	NO 146057	B	19820413		
	NO 146057	C	19820721		
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	ZA 7802507	A	19790725	ZA 1978-2507	19780502
				LU 1977-77236	19770503
	ES 469843	A1	19790916	ES 1978-469843	19780502
				LU 1977-77236	19770503
				LU 1977-77237	19770503
	AT 7803179	A	19800115	AT 1978-3179	19780502
	AT 358020	B	19800811		
				LU 1977-77236	19770503
				LU 1977-77237	19770503

FR 2389597	A1	19781201	FR 1978-13202	19780503
FR 2389597	B1	19830819		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
AU 7835733	A1	19791108	AU 1978-35733	19780503
AU 517255	B2	19810716		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
CH 635570	A	19830415	CH 1978-4836	19780503
			LU 1977-77236	19770503
			LU 1977-77237	19770503
JP 53141230	A2	19781208	JP 1978-53627	19780504
JP 59040140	B4	19840928		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
AT 7906288	A	19810715	AT 1979-6288	19790925
AT 366023	B	19820310		
			LU 1977-77236	19770503
			LU 1977-77237	19770503
			AT 1978-3179	19780502


IT **69145-90-0**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. as muscle relaxant)

RN 69145-90-0 CAPLUS

CN Benzenepropanoic acid, 1-[4-[(1-methylethyl)thio]phenyl]-2-(octylamino)propyl ester, hydrochloride, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


IT **69145-94-4P 69145-97-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 69145-94-4 CAPLUS

CN Benzenebutanoic acid, 1-[4-[(1-methylethyl)thio]phenyl]-2-(octylamino)propyl ester, hydrochloride, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 69145-97-7 CAPLUS


CN Benzenebutanoic acid, 2-[(1-methylethyl)amino]-1-[4-[(1-methylethyl)thio]phenyl]propyl ester, hydrochloride, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

GI



AB One hundred three amino alcs. I [R1 = H, C1-5 alkylthio, alkoxy, alkyl, C5-6 cycloalkylthio, cycloalkoxy, cycloalkyl, halo; R2 = C1-3 alkyl; R3 = C1-8 alkyl, C1-4 alkyl, optionally substituted with Ph, PhO, Bz, (un)substituted with alkyl, alkoxy, halo, C6-18 alkenyl, C5-9 cycloalkyl; R4 = COR5 [R5 = C1-10 alkyl, C2-4 alkenyl, C3-8 cycloalkyl, Ph (un)substituted with C1-3 alkyl, alkoxy, halo, C1-4 alkyl, (un)substituted with C1-3 carbalkoxy, alkoxy, NH2, acylamino, C5-6 cycloalkyl, PhO, Ph, optionally substituted with alkyl, alkoxy, halo, cinnamyl], H], useful as

antihypertensives, peripheral vasodilators, muscle relaxants, platelet aggregation inhibitors, hypolipemics, and thrombosis inhibitors, were prepd. Thus, acylation of 4-Me2CHSC6H4CH(OH)CHMeNH(CH2)7Me by refluxing with AcCl in C6H6 or PrCOCl gave 70 or 52%, resp. of the corresponding 4-Me2CHSC6H4CH(OR4)CHMeNH(CH2)7Me (R4 = Ac, PrCO).

L4 ANSWER 132 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1979:49012 CAPLUS

DN 90:49012

TI .beta.-Lactam antibiotics. II. Structure-activity relationships of 6-[.alpha.-(.alpha.'-ureidoacylamino) acylamino] penicillanic acids

AU Ferres, Harry; Basker, Michael J.; Best, Desmond J.; Harrington, Frank P.; O'Hanlon, Peter J.

CS Chemother. Res. Cent., Beecham Pharm., Brockham Park/Betchworth/Surrey, UK

SO Journal of Antibiotics (1978), 31(10), 1013-22

CODEN: JANTAJ; ISSN: 0021-8820

DT Journal

LA English

IT 54896-24-1 54896-25-2 54896-27-4

54896-30-9 54896-31-0 54896-32-1

54896-34-3 54896-35-4 54896-46-7

54896-47-8 54896-49-0 54984-13-3

68929-98-6 68930-07-4 68964-66-9


68964-69-2 68964-77-2 68985-99-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(bactericidal activity of)


RN 54896-24-1 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-tyrosyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 54896-25-2 CAPLUS  
 CN Glycinamide, N-(aminocarbonyl)-D-tyrosyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-(4-hydroxyphenyl)-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-27-4 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-4-nitrophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-(4-hydroxyphenyl)-, (2R)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-30-9 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-4-chlorophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-(4-hydroxyphenyl)-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 54896-31-0 CAPLUS


CN Glycinamide, N-(aminocarbonyl)-4-fluorophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)-(9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 54896-32-1 CAPLUS  
 CN Glycinamide, N-(aminocarbonyl)-4-chlorophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 54896-34-3 CAPLUS  
 CN Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-(4-hydroxyphenyl)-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 54896-35-4 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-4-fluorophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-(4-hydroxyphenyl)-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 54896-46-7 CAPLUS


CN Glycinamide, N-(aminocarbonyl)phenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI)  
(CA INDEX NAME)




RN 54896-47-8 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-O-methyl-L-tyrosyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-49-0 CAPLUS


CN Glycinamide, N-(aminocarbonyl)-3-hydroxyphenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)



RN 54984-13-3 CAPLUS


CN Glycinamide, N-(aminocarbonyl)-L-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)






RN 68929-98-6 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[2-[(aminocarbonyl)amino]-1-oxo-4-phenylbutyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, stereoisomer (9CI) (CA INDEX NAME)




RN 68930-07-4 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-D-2-[4-(acetyloxy)phenyl]-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 68964-66-9 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)



RN 68964-69-2 CAPLUS


CN Glycinamide, N-(aminocarbonyl)-L-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-L-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 68964-77-2 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-4-nitrophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 68985-99-9 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-L-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




GI

Patel

&lt;5/25/2003&gt;





AB Alkyl, aryl, aralkyl, and heterocyclic substituted 6-[.alpha.-(.alpha.'-ureidoacylamino)acylamino]penicillanic acids (I) were synthesized by the reaction of appropriate .alpha.-aminopenicillins with either the isobutoxy formic anhydrides or the N-succinimido esters of ureido acids. The effects of the substitutions on the in vitro antibacterial activities of the compds. indicated that size, shape, and stereochem. of a substituent were of greater influence than its lipophilic or electronic properties. Some of the more active derivs. [e.g., I(R = PhCH<sub>2</sub>, R<sub>1</sub> = C<sub>6</sub>H<sub>4</sub>OH-4) [54896-34-3] and I(R = 3-indolylmethyl, R<sub>1</sub> = Ph) [54896-37-6]] were more effective than com. available penicillins.

L4 ANSWER 133 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1978:597534 CAPLUS

DN 89:197534

TI Penicillins

IN Ferres, Harry; Kemmenoe, Adrian Victor; Best, Desmond John

PA Beecham Group Ltd., UK

SO Brit., 7 pp.

CODEN: BRXXAA

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1509924	A	19780504	GB 1974-25182	19750604
				GB 1974-25182	19750604


IT 68196-68-9P 68196-69-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(bactericide, prepn. of)

RN 68196-68-9 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-[(aminocarbonyl)amino]-1-oxo-3-phenylpropyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 68196-69-0 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-  
 [[[[[1-oxo-3-[(2-oxo-1-imidazolidinyl)carbonyl]amino]-3-  
 phenylpropyl]amino]phenylacetyl]amino]-, [2S-(2.alpha.,5.alpha.,6.beta.)]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The prepn. is described of penicillins I (R, R<sub>1</sub> = H, C<sub>1</sub>-6 alkyl, PhCH<sub>2</sub>, C<sub>1</sub>-6 alkanoyl, Ph optionally substituted by 1 or 2 C<sub>1</sub>-6 alkyl groups; NRR<sub>1</sub> = ring), which have broad spectrum antibacterial activity (no data). Thus, I (R = R<sub>1</sub> = H) was prepd. (29.8%) from DL-.beta.-phenyl-.beta.-ureidopropionic acid by sequential treatment with ClCO<sub>2</sub>CH<sub>2</sub>CHMe<sub>2</sub>-Et<sub>3</sub>N (in Me<sub>2</sub>CO, -10.degree., 0.5 h) and aq. D-(.alpha.-aminophenylacetamido)penicillanic acid-Et<sub>3</sub>N (in Me<sub>2</sub>CO, -40.degree. to room temp., 40 min).

L4 ANSWER 134 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1976:121815 CAPLUS

DN 84:121815

TI Penicillins

IN Ferres, Harry

PA Beecham Group Ltd., UK

SO Ger. Offen., 24 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2526924	A1	19760102	DE 1975-2526924	19750616
				GB 1974-26887	19740618
	GB 1503918	A	19780315	GB 1974-26887	19740618
	US 3987032	A	19761019	US 1975-583278	19750603
				GB 1974-26887	19740618
	ZA 7503621	A	19760526	ZA 1975-3621	19750604

AU 7582049	A1	19761216	GB 1974-26887	19740618
SE 7506835	A	19751219	AU 1975-82049	19750611
NL 7507056	A	19751222	GB 1974-26887	19740618
FR 2275208	A1	19760116	SE 1975-6835	19750613
BE 830347	A1	19751217	GB 1974-26887	19740618
DK 7502720	A	19751219	NL 1975-7056	19750613
ES 438658	A1	19770616	GB 1974-26887	19740618
CH 611903	A	19790629	FR 1975-18707	19750616
JP 51013792	A2	19760203	GB 1974-26887	19740618
			BE 1975-157424	19750617
			GB 1974-26887	19740618
			DK 1975-2720	19750617
			GB 1974-26887	19740618
			ES 1975-438658	19750617
			GB 1974-26887	19740618
			CH 1975-7876	19750617
			GB 1974-26887	19740618
			JP 1975-74234	19750618
			GB 1974-26887	19740618

IT 58606-90-9P 58641-47-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 58606-90-9 CAPLUS

CN Glycinamide, N-sulfo-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, dipotassium salt,  
[2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

● 2 K

RN 58641-47-7 CAPLUS


CN Glycinamide, N-sulfophenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 58641-46-6

CMF C25 H28 N4 O8 S2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



IT 18416-41-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with sulfur trioxide trimethylamine complex)


RN 18416-41-6 CAPLUS

CN Glycinamide, D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI




AB Penicillins I (R = Ph, Me, R1 = SO3R2, R2 = K; R = 3-indolyl, MeSCH2, R1 = SO3R2, R3 = Na; R = Ph, R1 = SO3R2, R2 = NHET3) were prepd. by treating I (R1 = H) with SO3-NMe3 and the salt-forming cation.

L4 ANSWER 135 OF 148 CAPLUS COPYRIGHT 2003 ACS  
AN 1976:12740 CAPLUS


DN 84:12740  
TI Luteinizing hormone-releasing hormone. Antiovulatory activity of analogs substituted in positions 2 and 6  
AU Beattie, C. W.; Corbin, A.; Foell, T. J.; Garsky, V.; McKinley, W. A.; Rees, R. W. A.; Sarantakis, D.; Yardley, J. P.  
CS Res. Dev. Div., Wyeth Lab., Philadelphia, PA, USA  
SO Journal of Medicinal Chemistry (1975), 18(12), 1247-50  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
IT **56558-32-8P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and contraceptive activity of)  
RN 56558-32-8 CAPLUS  
CN Luteinizing hormone-releasing factor (swine), 2-D-phenylalanine-6-(D-2-phenylglycine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=NH

AB Ten analogs of LH-releasing hormone [33515-09-2] substituted in position 2 with D-amino acids and at 6 with a .beta.-amino acid or nonasymmetric amino acid were prepd. by solid-phase synthesis and assayed for antiovarulatory activity in rats. One of the most active compds. was [D-p-F-Phe2-D-Ala6]-LH-RH [57383-17-2]. Structure-activity relations were discussed.

L4 ANSWER 136 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1975:606562 CAPLUS

DN 83:206562

TI PyroGlu-His-Trp-Ser-Tyr-D-Pgl-Leu-Arg-Pro-Gly-NH2 and intermediates

IN McKinley, Wayne A.; Sarantakis, Dimitrios

PA American Home Products Corp., USA

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3901872	A	19750826	US 1974-450909	19740313
				US 1974-450909	19740313

IT **57356-92-0P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and LH releasing activity of)

RN 57356-92-0 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 6-(D-2-phenylglycine)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB The title compd., [D-Pgl]6-LRF (Pgl = phenylglycine residue), which stimulated LH relief at a concn. of 0.05 mg/ml and increased the plasma LH level from .apprx.146 to 367 with a dose of 200 mg/rat, was prepd. by solid-phase coupling of the tert-butoxycarbonyl blocked amino acids.

L4 ANSWER 137 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1975:593736 CAPLUS

DN 83:193736

TI PyroGlu-Trp-Ser-Tyr-D-Pgl-Leu-Arg-Pro-Gly-NH2 (Pgl = phenylglycine) and intermediates

IN McKinley, Wayne A.; Sarantakis, Dimitrios

PA American Home Products Corp., USA

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3892723	A	19750701	US 1974-439490	19740204
				US 1974-439490	19740204

IT **57225-54-4P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and ovulation inhibiting activity of)

RN 57225-54-4 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 2-de-L-histidine-6-(D-2-phenylglycine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=NH



AB The title compd., I, was prepd. by solid phase synthesis on a benzhydrylamine hydrochloride resin and removed with anhyd. liq. HF. I achieved 40% ovulation inhibition in rats at a dose of .apprx.24 mg/kg.

L4 ANSWER 138 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1975:497942 CAPLUS

DN 83:97942

TI Pyro-Glu-D-Phe-Trp-Ser-Tyr-D-Pgl-Leu-Arg-Pro-Gly-NH2 and intermediates

IN McKinley, Wayne A.; Sarantakis, Dimitrios

PA American Home Products Corp., USA

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3886135	A	19750527	US 1974-459513	19740410
	GB 1473020	A	19770511	GB 1975-14281	19750408
				US 1974-459513	19740410
	DE 2515495	A1	19751030	DE 1975-2515495	19750409
				US 1974-459513	19740410
	ZA 7502270	A	19761124	ZA 1975-2270	19750409
				US 1974-459513	19740410
	CA 1052773	A1	19790417	CA 1975-224216	19750409
				US 1974-459513	19740410
	BE 827793	A1	19751010	BE 1975-155284	19750410
				US 1974-459513	19740410
	NL 7504296	A	19751014	NL 1975-4296	19750410
				US 1974-459513	19740410
	FR 2267114	A1	19751107	FR 1975-11217	19750410
	FR 2267114	B1	19781222		
				US 1974-459513	19740410
	JP 50154240	A2	19751212	JP 1975-44160	19750410
				US 1974-459513	19740410
	AU 7580019	A1	19761014	AU 1975-80019	19750410
				US 1974-459513	19740410
				GB 1974-45657	19741022
	IN 142254	A	19770618	IN 1975-CA1962	19751010
				US 1974-459513	19740410
				GB 1974-45657	19741022

IT 56558-32-8P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and ovulation inhibiting activity of)

RN 56558-32-8 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 2-D-phenylalanine-6-(D-2-phenylglycine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=NH

AB The title compd. (Pgl = phenylglycine residue), effective at inhibiting ovulation in rats at 24 mg/kg s.c., was prepd. by stepwise condensation of the tert-butoxycarbonyl blocked amino acids on a benzhydrylamine resin followed by deblocking and resin release with liq. HF.

L4 ANSWER 139 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1975:410895 CAPLUS  
 DN 83:10895  
 TI Nonapeptideamide derivatives  
 IN Fujino, Masahiko; Fukuda, Tsunehiko; Shinagawa, Susumu  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Ger. Offen., 54 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2446005	A1	19750403	DE 1974-2446005	19740926
	DE 2446005	C2	19820318		
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	JP 50059370	A2	19750522	JP 1973-109951	19730929
	JP 50121277	A2	19750923	JP 1974-27442	19740308
	JP 57026506	B4	19820604		
	AU 7473694	A1	19760401	AU 1974-73694	19740925
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	AT 347054	B	19781211	AT 1974-7726	19740925
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	SE 7412140	A	19750401	SE 1974-12140	19740926
	SE 420717	B	19811026		
	SE 420717	C	19820204		
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	ZA 7406118	A	19751126	ZA 1974-6118	19740926
				JP 1973-109951	19730929
	GB 1434694	A	19760505	GB 1974-41882	19740926
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	CH 603559	A	19780831	CH 1974-13047	19740926
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	BE 820451	A1	19750327	BE 1974-148990	19740927
				JP 1973-109951	19730929
	NL 7412837	A	19750402	NL 1974-12837	19740927
	NL 179289	B	19860317		
	NL 179289	C	19860818		
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	FR 2245375	A1	19750425	FR 1974-32580	19740927
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	DK 7405103	A	19750526	DK 1974-5103	19740927
	DK 148305	B	19850603		
	DK 148305	C	19851202		
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	HU 173783	P	19790828	HU 1974-TA1323	19740927
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	ES 430495	A1	19770116	ES 1974-430495	19740928
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	FI 7402847	A	19750330	FI 1974-2847	19740930
	FI 61028	B	19820129		
	FI 61028	C	19820510		
				JP 1973-109951	19730929
				JP 1974-27442	19740308
	NO 7403538	A	19750402	NO 1974-3538	19740930
	NO 143218	B	19800922		
	NO 143218	C	19810102		

US 4008209 A 19770215

JP 58055137 B4 19831208

PATENT FAMILY INFORMATION:

FAN 1976:5401

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2509783	A1	19750911	DE 1975-2509783	19750306
	DE 2509783	C2	19830217		
	JP 50121277	A2	19750923	JP 1974-27442	19740308
	JP 57026506	B4	19820604	JP 1974-27442	19740308
	AT 348693	B	19790226	AT 1975-1380	19750224
	AU 7578594	A1	19760826	JP 1974-27442	19740308
	ZA 7501306	A	19760128	AU 1975-78594	19750226
	CA 1072953	A1	19800304	JP 1974-27442	19740308
	NL 7502564	A	19750910	ZA 1975-1306	19750303
	NL 181658	B	19870504	JP 1974-27442	19740308
	NL 181658	C	19871001	CA 1975-221126	19750303
	US 3972859	A	19760803	JP 1974-27442	19740308
	CS 186284	P	19781130	US 1975-555126	19750304
	SE 7502520	A	19750909	JP 1974-27442	19740308
	SE 420718	B	19811026	CS 1975-1485	19750305
	SE 420718	C	19820204	JP 1974-27442	19740308
	FR 2262995	A1	19751003	SE 1975-2520	19750306
	BE 826430	A1	19750908	JP 1974-27442	19740308
	NO 7500763	A	19750909	FR 1975-7065	19750306
	NO 145691	B	19820201	JP 1974-27442	19740308
	NO 145691	C	19820512	BE 1975-154128	19750307
	DK 7500927	A	19750909	JP 1974-27442	19740308
	DK 149862	B	19861013	NO 1975-763	19750307
	DK 149862	C	19870615		
	ES 435405	A1	19761201	JP 1974-27442	19740308
	GB 1498048	A	19780118	ES 1975-435405	19750307
	HU 174077	P	19791028	JP 1974-27442	19740308
	CH 615661	A	19800215	GB 1975-9539	19750307
				JP 1974-27442	19740308
				HU 1975-TA1346	19750307
				JP 1974-27442	19740308
				CH 1975-2947	19750307
				JP 1974-27442	19740308

FI 7500682	A	19750909	FI 1975-682	19750310
FI 60859	B	19811231		
FI 60859	C	19820413		
US 4008209	A	19770215	JP 1974-27442	19740308
			US 1975-595308	19750711
			JP 1973-109951	19730929
			JP 1974-27442	19740308
			US 1974-509357	19740924


IT **55674-53-8P**RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and LH releasing activity of)

RN 55674-53-8 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 6-(D-2-phenylglycine)-9-(N-ethyl-L-prolinamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



AB Approx. 18 pyroGlu-His-Trp-Ser-X1-X2-X3-Arg-Pro-NHR (I; X1 = Tyr, Phe; X2 = D-Leu, D-Ile, D-Nle, D-Val, D-Nva, D-Abu, .alpha.-Aibu, D-Phe, D-Phg, D-Ser, D-Tyr, D-Met; X3 = Leu, Ile, Nle; R = Et, Me2CH, Pr; Abu = .alpha.-aminobutyric acid, .alpha.-Aibu = .alpha.-aminoisobutyric acid, Phg = .alpha.-phenylglycine residues) with LH releasing hormone activity 5-60 times greater than found in nature at 2ng-2.mu.g, were prepd. by fragment coupling methods. Thus, N-benzyloxycarbonyl-D-leucine was coupled with Leu-Arg(NO2)-Pro-NHEt followed by coupling with pyroGlu-His-Trp-Ser-Tyr to give I (X1 = Tyr, X2 = D-Leu, X3 = Leu, R = Et).

L4 ANSWER 140 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1975:86286 CAPLUS

DN 82:86286

TI Penicillin derivatives

IN Ferres, Harry; Kemmenoe, Adrian V.; Best, Desmond J.

PA Beecham Group Ltd.

SO Ger. Offen., 81 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2421030	A1	19741121	DE 1974-2421030	19740430
				GB 1973-21203	19730504
	GB 1479267	A	19770713	GB 1973-21203	19730504
	FI 58778	B	19801231	FI 1974-1265	19740424
	FI 58778	C	19810410		
				GB 1973-21203	19730504
	SU 668606	D	19790615	SU 1974-2026174	19740430
				GB 1973-21203	19730504
	FR 2227858	A1	19741129	FR 1974-15192	19740502
				GB 1973-21203	19730504
	ZA 7402788	A	19750528	ZA 1974-2788	19740502
				GB 1973-21203	19730504
	AT 7403643	A	19751015	AT 1974-3643	19740502
	AT 330957	B	19760726		
				GB 1973-21203	19730504

AU 7468534	A1	19751106	AU 1974-68534	19740502
BE 814559	A1	19741104	GB 1973-21203	19730504
NL 7406024	A	19741106	BE 1974-143931	19740503
US 3923788	A	19751202	GB 1973-21203	19730504
ES 425945	A1	19761216	NL 1974-6024	19740503
HU 169830	P	19770228	GB 1973-21203	19730504
CH 603663	A	19780831	US 1974-466814	19740503
CS 197231	P	19800430	GB 1973-21203	19730504
RO 67060	P	19821026	ES 1974-425945	19740503
JP 50040589	A2	19750414	GB 1973-21203	19730504
JP 57056479	B4	19821130	HU 1974-BE1197	19740503
DD 111579	C	19750220	GB 1973-21203	19730504
US 3926960	A	19751216	CH 1974-6057	19740503
US 3962216	A	19760608	GB 1973-21203	19730504
US 3935189	A	19760127	CS 1974-3212	19740503
US 3935192	A	19760127	GB 1973-21203	19730504
US 3957759	A	19760518	RO 1974-78669	19740503
SE 7703567	A	19770328	GB 1973-21203	19730504
FI 7900883	A	19790315	JP 1974-50193	19740504
FI 59252	B	19810331	GB 1973-21203	19730504
FI 59252	C	19810710	DD 1974-178296	19740506
DK 8001263	A	19800324	GB 1973-21203	19730504
			US 1975-543070	19750122
			GB 1973-21203	19730504
			US 1974-466184	19740503
			US 1975-543064	19750122
			GB 1973-21203	19730504
			US 1974-466814	19740503
			US 1975-577715	19750515
			GB 1973-21203	19730504
			US 1974-466814	19740503
			US 1975-578262	19750516
			GB 1973-21203	19730504
			US 1974-466814	19740503
			US 1975-578722	19750519
			GB 1973-21203	19730504
			US 1974-466814	19740503
			SE 1977-3567	19770328
			GB 1973-21203	19730504
			FI 1979-883	19790315
			GB 1973-21203	19730504
			FI 1974-1265	19740424
			DK 1980-1263	19800324
			GB 1973-21203	19730504
			DK 1974-2433	19740503


IT 54896-14-9P 54896-15-0P 54896-16-1P  
 54896-24-1P 54896-25-2P 54896-27-4P  
 54896-30-9P 54896-31-0P 54896-32-1P  
 54896-33-2P 54896-34-3P 54896-35-4P  
 54896-46-7P 54896-47-8P 54896-49-0P  
 54896-77-4P 54896-78-5P 54896-82-1P  
 54896-84-3P 54896-85-4P 54896-86-5P  
 54896-87-6P 54896-88-7P 54896-89-8P  
 54896-90-1P 54896-91-2P 54896-92-3P

54896-93-4P 54896-94-5P 54896-95-6P  
 54942-90-4P 54984-13-3P 54984-14-4P  
 54984-15-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)


RN 54896-14-9 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-.alpha.-methylphenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)



RN 54896-15-0 CAPLUS

CN Glycinamide, N-(aminoiminomethyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, monohydrochloride, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




● HCl

RN 54896-16-1 CAPLUS

CN Glycinamide, N-(aminoiminomethyl)-D-phenylalanyl-N-[2-[[[1,3-dihydro-3-oxo-1-isobenzofuranyl]oxy]carbonyl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-D-2-phenyl-, monohydrochloride, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)






● HCl


RN 54896-24-1 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-tyrosyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-25-2 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-D-tyrosyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-(4-hydroxyphenyl)-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-27-4 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-4-nitrophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-(4-hydroxyphenyl)-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-30-9 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-4-chlorophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-(4-hydroxyphenyl)-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-31-0 CAPLUS  
 CN Glycinamide, N-(aminocarbonyl)-4-fluorophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-32-1 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-4-chlorophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-33-2 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-4-nitrophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, monosodium salt, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● Na


RN 54896-34-3 CAPLUS  
 CN Glycinamide, N-(aminocarbonyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-(4-hydroxyphenyl)-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)



RN 54896-35-4 CAPLUS


CN Glycinamide, N-(aminocarbonyl)-4-fluorophenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-(4-hydroxyphenyl)-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A



RN 54896-46-7 CAPLUS


CN Glycinamide, N-(aminocarbonyl)phenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI)  
(CA INDEX NAME)




RN 54896-47-8 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-O-methyl-L-tyrosyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-49-0 CAPLUS

CN Glycinamide, N-(aminocarbonyl)-3-hydroxyphenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)



RN 54896-77-4 CAPLUS


CN Glycinamide, N-acetylphenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)




RN 54896-78-5 CAPLUS

CN Glycinamide, N-formyltyrosyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 54896-82-1 CAPLUS

CN Glycinamide, N-acetylphenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-(4-hydroxyphenyl)-, (2R)- (9CI) (CA INDEX NAME)




RN 54896-84-3 CAPLUS

CN Glycinamide, N-[(methylamino)carbonyl]phenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)-(9CI) (CA INDEX NAME)




RN 54896-85-4 CAPLUS

CN Glycinamide, N-[(ethylamino)carbonyl]phenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)-(9CI) (CA INDEX NAME)




RN 54896-86-5 CAPLUS

CN Glycinamide, N-[(propylamino)carbonyl]-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)



RN 54896-87-6 CAPLUS


CN Glycinamide, N-[[[(1-methylethyl)amino]carbonyl]-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 54896-88-7 CAPLUS

CN Glycinamide, N-[(cyclohexylamino)carbonyl]-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, monopotassium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● K


RN 54896-89-8 CAPLUS  
 CN Glycinamide, N-[[ (1,1-dimethylethyl) amino] carbonyl] phenylalanyl-N-  
 [(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-  
 yl]-2-phenyl-, monopotassium salt, (2R)- (9CI) (CA INDEX NAME)



● K


RN 54896-90-1 CAPLUS

CN Glycinamide, N-(1-oxopentyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 54896-91-2 CAPLUS

CN Glycinamide, N-(2,2-dimethyl-1-oxopropyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 54896-92-3 CAPLUS

CN Glycinamide, N-benzoylphenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)




RN 54896-93-4 CAPLUS

CN Glycinamide, N-formylphenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME)



RN 54896-94-5 CAPLUS


CN Glycinamide, N-(1-oxopropyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)



RN 54896-95-6 CAPLUS


CN Glycinamide, N-(2-methyl-1-oxopropyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)






RN 54942-90-4 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[2-  
 [(aminocarbonyl)amino]-1-oxo-4-phenylbutyl]amino] (4-  
 hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, stereoisomer (9CI) (CA  
 INDEX NAME)



RN 54984-13-3 CAPLUS


CN Glycinamide, N-(aminocarbonyl)-L-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-  
 oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-  
 (2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




RN 54984-14-4 CAPLUS

CN Glycinamide, N-(aminocarbonyl)tyrosyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-  
 7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA  
 INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 54984-15-5 CAPLUS

CN Glycinamide, N-[(ethylamino)carbonyl]-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, monopotassium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)



● K

GI For diagram(s), see printed CA Issue.

AB Sixty-five penicillins I [R = Ph, p-HO-C<sub>6</sub>H<sub>4</sub>, 3-thienyl, 2-thienyl, cyclopropyl, benzyl; R<sub>1</sub> = p-R<sub>4</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub> (R<sub>4</sub> = HO, O<sub>2</sub>N, Cl, F, H, MeO), MeS(CH<sub>2</sub>)<sub>2</sub>, Me<sub>2</sub>CHCH<sub>2</sub>, Ph(CH<sub>2</sub>)<sub>2</sub>, indol-3-ylmethyl, H<sub>2</sub>NCO(CH<sub>2</sub>)<sub>2</sub>, PhCH<sub>2</sub>OCH<sub>2</sub>, Me, MeOCH<sub>2</sub>, 2-thienylmethyl, m-HOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, Me(CH<sub>2</sub>)<sub>5</sub>, Me(CH<sub>2</sub>)<sub>3</sub>, Me<sub>2</sub>CH, 1,4-cyclohexadien-1-ylmethyl; R<sub>2</sub> = CONH<sub>2</sub>, NCHO, Ac, CONHMe, COBu, COCMe<sub>3</sub>, C<sup>OPh</sup>, COEt, COCHMe<sub>2</sub>, C(:NH)NH<sub>2</sub>.HCl, CONHEt, CONHPr, 3-cyclohexylcarbonyl, CONHCMe<sub>3</sub>; R<sub>3</sub> = H, Me; .alpha. = D, DL, L; R<sub>5</sub> = H, Na, NH<sub>4</sub><sup>+</sup>, 3-phthalidyl, K], with min. inhibitory concns. against .beta.-lactamase-producing Staphylococcus strains 5-12.5 .gamma./ml, were prepd. A) A soln. of D-.alpha.-guanidino-.beta.-phenylpropionic acid (II) and HCl in DMF was added to 3-phthalidyl D-.alpha.-aminophenylacetamidopenicillanate at 0.degree. and the mixt. stirred 0.5 hr at 0.degree. and 1.5 hr at room temp. to give I [R = Ph, R<sub>1</sub> = PhCH<sub>2</sub>, R<sub>2</sub> = NHC(:NH)NH<sub>2</sub>.HCl, R<sub>3</sub> = H, R<sub>5</sub> = 3-phthalidyl, .alpha. = D]. B) A ureido or substituted-ureido acid in acetone was treated with Et<sub>3</sub>N (or N-methylmorpholine) and ClCO<sub>2</sub>CH<sub>2</sub>CHMe<sub>2</sub> (or ClCO<sub>2</sub>Et) at -10.degree. and after 30 min, cooled to -40.degree. and added to D-.alpha.-aminophenyl(p-hydroxyphenyl, 2- or 3-thienyl, 1,4-cyclohexadien-1-yl, cyclopropyl)acetamido-penicillanic acid-3H<sub>2</sub>O and Et<sub>3</sub>N in aq. acetone. D-.alpha.-Aminovaleramido- and D-.alpha.-aminopropionamidopenicillanic acid were also used. C) D-.alpha.-Aminophenylacetamidopenicillanic acid (III) in CH<sub>2</sub>Cl<sub>2</sub> was treated with NEt<sub>3</sub>, then Me<sub>3</sub>SiCl, the mixt. heated 1 hr under N, cooled, and treated with II in DMF previously treated with CH<sub>2</sub>Cl<sub>2</sub> and dicyclohexylcarbodiimide (DCC), and the whole stirred at 0.degree. 1 hr to give I (R = Ph, R<sub>1</sub> = PhCH<sub>2</sub>, R<sub>2</sub> = NHC(:NH)NH<sub>2</sub>, R<sub>3</sub> = H, R<sub>5</sub> = H, .alpha. = D). D) DCC was added at 0.degree. to N-substituted amino acid in acetone and kept overnight. III.3H<sub>2</sub>O was dissolved in acetone, H<sub>2</sub>O, and Et<sub>3</sub>N. The hydroxysuccinimide ester was hydrolyzed to give the free acid. DMF, acetone-DMF, or (MeOCH<sub>2</sub>)<sub>2</sub> were also used as solvents.

L4 ANSWER 141 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1973:147610 CAPLUS

DN 78:147610

TI Thiamphenicol phenylalaninate

IN Saiga, Akisuke; Yamanaka, Motosuke; Sato, Takashi

PA Eisai Co., Ltd.

SO Jpn. Kokai Tokkyo Koho, 2 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 48004446	B4	19730120	JP 1971-27212	19710427
IT	<b>41570-11-0P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	41570-11-0	CAPLUS			
CN	L-Phenylalanine, 2-[(dichloroacetyl)amino]-1-[4-(methylsulfonyl)phenyl]-1,3-propanediyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)				



AB A soln. of thiamphenicol and PhCH<sub>2</sub>CH(NH<sub>2</sub>)COCl.HCl (1:2 by mole) in anhyd. dioxane was stirred 7 hr at 13-17.degree. to give 61.2% thiamphenicol phenylalaninate, which was sol. and stable in H<sub>2</sub>O.

L4 ANSWER 142 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1972:488521 CAPLUS  
 DN 77:88521  
 TI 7-(D-Mandelamido)cephalosporanic acid derivatives  
 IN Berges, David Alan; Dunn, George Lawrence; Hoover, John R. E.  
 PA Smith Kline and French Laboratories  
 SO Ger. Offen., 54 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2158330	A	19720608	DE 1971-2158330	19711124
	US 3701775	A	19721031	US 1970-92860	19701125
	ZA 7107133	A	19720726	US 1970-92860	19701125
	CA 960662	A1	19750107	US 1970-92860	19711026
	BE 775458	A1	19720517	CA 1971-126096	19701125
	GB 1327510	A	19730822	US 1970-92860	19711117
	CH 567515	A	19751015	BE 1971-110605	19701125
	FR 2115363	A5	19720707	US 1970-92860	19711123
	FR 2115363	B1	19750613	GB 1971-54335	19701125
	ES 397308	A1	19740516	US 1970-92860	19711124
				FR 1971-42022	19701125
				US 1970-92860	19711124
				ES 1971-397308	19701125


			US 1970-92860	19701125
NL 7116207	A	19720529	NL 1971-16207	19711125
			US 1970-92860	19701125

IT **37650-89-8P 37650-90-1P 37651-00-6P**  
**37651-01-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 37650-89-8 CAPLUS

CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, 2-[[3-[(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI)  
(CA INDEX NAME)




RN 37650-90-1 CAPLUS

CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, 2-[[3-[(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI)  
(CA INDEX NAME)




RN 37651-00-6 CAPLUS

CN D-Phenylalanine, 2-[[3-[(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI) (CA INDEX NAME)



RN 37651-01-7 CAPLUS

CN L-Phenylalanine, 2-[[3-[(acetyloxy)methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-phenylethyl ester, [6R-[6.alpha.,7.beta.(R\*)]]- (9CI) (CA INDEX NAME)



AB Fifty-nine title compds. [I, R = e.g., N3CH2CO, H2NCH2CO, Boc-L-methionyl (Boc = Me3CO2C), Boc-D-alanyl, L-methionyl, MeSCH2CO, 2-thenoyl, etc., R1 = e.g., OAc, H, MeO], bactericides, were prepd. via O-acylation of I (R = H) in the presence of N, N -carbonyldiimidazole (II). Thus, II and then I (R = H, R1 = OAc) were added to Boc-methionine in THF, the mixt. was kept 20 hr, and the imidazole salt hydrolyzed to give 50% I (R = Boc-methionyl, R1 = OAc), from which the Boc group was cleaved with CF3CO2H.

L4 ANSWER 143 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1970:67270 CAPLUS

DN 72:67270

TI Water soluble antibiotic chloramphenicol .beta.-phenylalanine ester salts

IN Zumin, Silva T.; Mosna, Sergio

PA Pierrel S.p.A.

SO Brit., 8 pp.

CODEN: BRXXAA


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1173562		19691210	GB	19660425
IT	25613-59-6P 25613-62-1P 25613-63-2P 25613-64-3P 25616-21-1P 25616-22-2P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	25613-59-6	CAPLUS			
CN	Alanine, N-carboxy-3-phenyl-, N-benzyl ester, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-				

nitrophenethylacetamide (8CI) (CA INDEX NAME)



RN 25613-62-1 CAPLUS

Alanine, N-carboxy-3-phenyl-, N-benzyl ester, DL-, diester with  
D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-  
nitrophenethyl]acetamide (8CI) (CA INDEX NAME)




RN 25613-63-2 CAPLUS

CN Alanine, phenyl-, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, bis(trifluoroacetate)  
(8CI) (CA INDEX NAME)

CM 1


CRN 47832-98-4

CMF C29 H30 C12 N4 O7




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 25613-64-3 CAPLUS  
CN Alanine, phenyl-, L-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, dihydrochloride (8CI)  
(CA INDEX NAME)




● 2 HCl

RN 25616-21-1 CAPLUS  
CN Alanine, N-acetyl-3-phenyl-, L-, compd. with L-phenylalanine diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide (2:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47832-98-4  
CMF C29 H30 Cl2 N4 O7




CM 2




CRN 2018-61-3  
CMF C11 H13 N O3

Absolute stereochemistry. Rotation (+).



RN 25616-22-2 CAPLUS

CN Alanine, phenyl-, DL-, diester with D-threo-2,2-dichloro-N-[.beta.-hydroxy-.alpha.-(hydroxymethyl)-p-nitrophenethyl]acetamide, dihydrobromide (8CI)  
(CA INDEX NAME)



● 2 HBr

AB Salts of chloramphenicol 1,3-bis(L-.beta.-phenylalaninate) (I) and chloramphenicol 3-L-.beta.-phenylalaninate (II), useful for parenteral administration, with antibiotic activity, were prepd. by reacting D-(-)-threo-1-p-nitrophenyl-2-dichloroacetamido-1,3-propanediol (chloramphenicol) (III) either with N-carbobenzoxyl-L-.beta.-phenylalanine (IV) in the presence of dicyclo-hexylcarbodiimide (V) and anhyd. pyridine (VI) or with IV anhydride (VII) in the presence of VI to give chloramphenicol 1,3-bis(N-carbobenzoxyl-L-.beta.-phenylalaninate) (VIII) and chloramphenicol 3-(N-carbobenzoxyl-L-.beta.-phenylalaninate) (IX), resp., followed by removal of the protecting group(s) by treatment with aq. HBr or anhyd. CF<sub>3</sub>CO<sub>2</sub>H. I and II are hydrolyzed in vivo to III and phenylalanine. Thus, addn. of 10.30 g V at 15.degree. to a stirred soln. of 29.93 g IV in 150 ml Me<sub>2</sub>CO, and the mixt. stirred 3 hr gave 96.5% VII. Racemic N-carbobenzoxyl-DL-.beta.-phenylalanine anhydride (X) (93.5%) was prepd. similarly. III (5.82 g) in 10 ml VI was added to 180 ml of an Me<sub>2</sub>CO soln. of 25.2 g VII and the mixt. stirred 5-6 hr at room temp. and poured on ice-HCl to give, after treatment with 3.5 ml p-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NMe<sub>2</sub> (XI) in dry C<sub>6</sub>H<sub>6</sub> to remove excess VII, 90% VIII, m. 95-7.degree.. Racemic chloramphenicol 1,3-bis(N-carbobenzoxyl-.beta.-phenylalaninate) (XII) (94%), a yellow oil, was prepd. similarly from X. IV (22.45 g) and 15 ml VI added to a stirred soln. of 9.69 g III in 60 ml HCONMe<sub>2</sub>, the soln. cooled to -5 to -8.degree., 18.57 g V added slowly, the mixt. stirred 1 hr, kept 3 hr at -5.degree. and poured on a mixt. of 50 ml concd. HCl, 50 ml H<sub>2</sub>O, and 100 g ice gave a ppt., which was centrifuged off and extd.


with C<sub>6</sub>H<sub>6</sub>. Treatment of the C<sub>6</sub>H<sub>6</sub> ext. with 3.5 ml XI gave 93% VIII, m. 95-7.degree.. IX, m. 145-7.degree., was prepd. similarly using 19.39 g III, 60 ml HCONMe<sub>2</sub>, 17.96 g IV, 15 ml VI, and 12.38 g V. A mixt. of 17.72 g VIII and 40 ml anhyd. CF<sub>3</sub>CO<sub>2</sub>H refluxed 1 hr in the presence of 8 g resorcinol gave 16.30 g I.CF<sub>3</sub>CO<sub>2</sub>H (XIII). Addn. of XIII to satd. aq. NaHCO<sub>3</sub>, extn. of the free base with CH<sub>2</sub>Cl<sub>2</sub>, and treatment of the ext. with HCl gave I.HCl, m. 220-222.degree. (decompn.). II.HCl, [.alpha.]2D<sub>0</sub> 10.77.degree. (c 2, H<sub>2</sub>O), was prepd. similarly from IX. A soln. of 5 g XII in 60 ml 2.5N HBr in AcOH stirred 10 min at 25 .degree. gave 85% a mixt. of chloramphenicol 1,3-bis(D- and L-.beta.-phenylalaninate-HBr) sep'd. by chromatog. XIII (13 g) treated with satd. aq. NaHCO<sub>3</sub>, extn. of the free base with CH<sub>2</sub>Cl<sub>2</sub>, and treatment of the ext. with N-acetyl-L-phenylalanine gave III 1,3-bis(L-.beta.-phenylalaninate N-acetyl-L-phenylalaninate); III 3-(L-.beta.-phenylalaninate N-acetyl-L-phenylalaninate) was prepd. similarly.

L4 ANSWER 144 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1969:524426 CAPLUS  
 DN 71:124426  
 TI Penicillins  
 IN Hardy, Kenneth D.  
 PA Beecham Group Ltd.  
 SO Ger. Offen., 16 pp. Addn. to Ger. Offen. 1545615  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1901918	A	19690911	DE 1969-1901918	19690115
				GB 1968-2968	19680119
	GB 1210472	A	19701028	GB 1968-2968	19680119
	BE 726979	A	19690716	BE 1969-726979	19690116
				GB 1968-2968	19680119
	AT 296498	B	19720210	AT 1969-440	19690116
				GB 1968-2968	19680119
	NL 6900875	A	19690722	NL 1969-875	19690117
				GB 1968-2968	19680119
	FR 2000429	A6	19690905	FR 1969-714	19690117
				GB 1968-2968	19680119
	ES 362645	A2	19701201	ES 1969-362645	19690117
				GB 1968-2968	19680119
	BR 6905659	A0	19730208	BR 1969-205659	19690117
				GB 1968-2968	19680119
	CH 499548	A	19701130	CH 1969-499548	19690120
				GB 1968-2968	19680119
	US 3647780	A	19720307	US 1970-20457	19700323
				GB 1968-2968	19680119

IT **24121-58-2P 24121-65-1P 24170-67-0P**  
**24199-64-2P 25671-21-0P 26088-51-7P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 24121-58-2 CAPLUS  
 CN Malonamic acid, 2-benzyl-N-[.alpha.-[(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)carbamoyl]benzyl]-, 1-benzyl ester,  
 monosodium salt (8CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 24121-65-1 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[1,3-dioxo-3-phenoxy-2-(phenylmethyl)propyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 24170-67-0 CAPLUS

CN Malonamic acid, N-[.alpha.-[(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)carbamoyl]benzyl]-2-(p-methoxybenzyl)-, disodium salt (8CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 Na

RN 24199-64-2 CAPLUS

CN Malonamic acid, N-[.alpha.-[(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)carbamoyl]benzyl]-2-(p-chlorobenzyl)-, 1-benzyl ester (8CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 25671-21-0 CAPLUS

CN Malonamic acid, 2-benzyl-N-[.alpha.-[(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)carbamoyl]benzyl]-, disodium salt (8CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 26088-51-7 CAPLUS

CN Malonamic acid, N-[.alpha.-[(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)carbamoyl]benzyl]-2-(p-methoxybenzyl)-, 1-benzyl ester (8CI) (CA INDEX NAME)

Absolute stereochemistry.



GI For diagram(s), see printed CA Issue.

AB Penicillins (I) are prepd. by treating .alpha.-aminobenzylpenicillin with R1R2C(CO2R)COCl (II). In general, the D-epimers are the most active compds. Thus, a soln. of 9.7 g. PhCH2CH(CO2H)2 in 40 ml. dry Et2O is treated with 5.95 g. SOCl2 and 1 drop HCONMe2 and the mixt. refluxed 3 hrs. to give a residue which is dissolved in 40 ml. Et2O, 5.4 g. PhCH2OH added, the mixt. refluxed 2 hrs., and worked up to give 7 g. PhCH2CH(CO2CH2Ph)CO2H (III), m. 62-4.degree. (C6H6-petroleum ether). A

mixt. of 2.84 g. III and 10 ml. SOCl<sub>2</sub> is heated to 75.degree. to give a residue which is dissolved in 50 ml. dry Me<sub>2</sub>CO, a cold soln. (12.degree.) of 4.03 g. D-.alpha.-aminobenzylpenicillin-3H<sub>2</sub>O 10 ml. N NaOH, 15 ml. N NaHCO<sub>3</sub>, 50 ml. H<sub>2</sub>O, and 25 ml. Me<sub>2</sub>CO added with stirring, the mixt. stirred at room temp. 2 hrs., and worked up to give 5.8 g. Na salt of the D-epimer (IV) of I (R<sub>1</sub> = CH<sub>2</sub>Ph, R<sub>2</sub> = H, R = CH<sub>2</sub>Ph). A soln. of 3 g. IV in 100 ml. H<sub>2</sub>O, added to a prehydrogenated mixt. of 9 g. CaCO<sub>3</sub> (contg. 5% Pd) in 50 ml. H<sub>2</sub>O, is hydrogenated, and worked up to yield 1.5 g. disodium salt of the D-epimer of I (R<sub>1</sub> = CH<sub>2</sub>Ph, R<sub>2</sub> = H, R = Na). Similarly are prepd. the following II and I (R<sub>1</sub>, R<sub>2</sub>, R, % yield of II, m.p. of II and % yield of I given): Ph, Me, CH<sub>2</sub>Ph, 70, 76-8.degree., 90.3; n-Bu, H, CH<sub>2</sub>Ph, 65.5, oil, 90.2; 3-thienyl, H, CH<sub>2</sub>Ph, 38.8, 91-2.degree., 50; PhO, H, CH<sub>2</sub>Ph, 26.6, 89-91.degree., 82.5; PhCH<sub>2</sub>, H, Ph, 37, 59-61.degree., 71.6; Ph, H, o-C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>CH<sub>2</sub>Ph, 27.4, 106-8.degree., 54.5; p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, H, CH<sub>2</sub>Ph, 26.4, 58-60.degree., 79.3; p-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, H, CH<sub>2</sub>Ph, 65, 81-2.degree., 49.2; Ph, H, Et, 48.5, 74-6.degree., 56.0; Ph, H, iso-Pr, 62, 64-6.degree., 83.8; 3-thienyl, H, iso-Pr, 53, 82-3.degree., 63.1. Redn. of I (R = CH<sub>2</sub>Ph) yields the following disodium salts of the D-epimer of I (R = Na) (R<sub>1</sub>, R<sub>2</sub> and % yield given): Ph, Me, 78.4; n-Bu, H, 75.2; 3-thienyl, H, 82.2; PhO, H, 62.7; p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, H, 36.2. Antibacterial data are given.

L4 ANSWER 145 OF 148 CAPLUS COPYRIGHT 2003 ACS  
 AN 1969:68357 CAPLUS  
 DN 70:68357  
 TI Penicillins  
 IN Hatt, Brian W.; Newsome, Peter M.; Smith, Harry  
 PA Beecham Group Ltd.  
 SO S. African, 28 pp.  
 CODEN: SFXXAB  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6705837		19680208	GB	19661004


IT 18416-41-6P 21488-12-0P 21488-13-1P  
 21488-14-2P 21488-15-3P 21488-16-4P  
 21488-17-5P 21488-18-6P 21488-19-7P  
 21488-20-0P 21488-22-2P 21488-24-4P  
 21586-84-5P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)

RN 18416-41-6 CAPLUS

CN Glycinamide, D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 21488-12-0 CAPLUS


CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-[(.beta.-(carboxyamino)hydrocinnamamido]-2-phenylacetamido]-3,3-dimethyl-7-oxo-, N-benzyl ester, monosodium salt (8CI) (CA INDEX NAME)



● Na


RN 21488-13-1 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-[(.beta.-aminohydrocinnamamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-, stereoisomer (8CI) (CA INDEX NAME)



RN 21488-14-2 CAPLUS


CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-[(.beta.-(carboxyamino)hydrocinnamamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-, N-benzyl ester, monosodium salt (8CI) (CA INDEX NAME)



● Na


RN 21488-15-3 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(.beta.-formamidohydrocinnamamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo- (8CI)  
(CA INDEX NAME)



RN 21488-16-4 CAPLUS

CN Glycinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, monosodium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




● Na

RN 21488-17-5 CAPLUS


CN Glycinamide, L-phenylalanyl-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenyl-, (2R)- (9CI) (CA INDEX NAME).

Absolute stereochemistry.



RN 21488-18-6 CAPLUS

CN Glycinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-L-2-phenyl-, monosodium salt, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)




● Na

RN 21488-19-7 CAPLUS

CN Glycinamide, L-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-L-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 21488-20-0 CAPLUS

CN Glycinamide, N-[(phenylmethoxy)carbonyl]-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)






RN 21488-22-2 CAPLUS


CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[(1-oxo-3-phenylpropyl)amino]phenylacetyl]amino]-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 21488-24-4 CAPLUS


CN Glycinamide, N-(ethoxycarbonyl)-D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)



RN 21586-84-5 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(.beta.-aminohydrocinnamamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-, stereoisomer (8CI) (CA INDEX NAME)





GI For diagram(s), see printed CA Issue.

AB New penicillins I are prepd. by acylating stereoisomeric 6-.alpha.-phenyl-.alpha.-aminoacetyl-amino- or 6-.alpha.-thienyl-.alpha.-aminoacetylaminopenicillanic acids with the mixed anhydrides prepd. from the appropriate acid and ClCO<sub>2</sub>Et. Thus, 12.0 g. L-.beta.-(benzyloxycarbonylamino)-.beta.-phenylpropionic acid (L-II) [.alpha.]20D 24.7.degree. (c 1, EtOH), was dissolved in 120 cc. dry tetrahydrofuran contg. 5.6 cc. NEt<sub>3</sub>. The soln. was stirred vigorously and kept at -5.degree. as 3.82 cc. ClCO<sub>2</sub>Et was added. Stirring at -5 to -10.degree. was continued 25 min. The suspension was cooled to -15.degree. and stirred vigorously as a soln. of 16.2 g. of 6-(D-.alpha.-amino-.alpha.-phenylacetamido)penicillanic acid trihydrate (D-III) in 40 cc. H<sub>2</sub>O and 40 cc. tetrahydrofuran (THF) contg. enough NEt<sub>3</sub> to raise the pH to 9.5 was added, the soln. stood 40 min. without cooling, and evapd. at 20.degree. in vacuo, the gelatinous residue was covered with 100 cc. iso-BuCO-Me, stirred vigorously, the ppt. kept at pH 2 by the addn. of 5N HCl, as enough BuOH was added to dissolve the residue, the small residue was filtered, the phases sepd., and the org. phase washed with H<sub>2</sub>O and worked up to give 23.3 g. Na 6-[D-(L-.beta.-benzyloxycarbonylamino) - .beta. - phenylpropionamido - .alpha. - phenylacetamido]penicillanate (D,L-IV) (procedure A). Pd on CaCO<sub>3</sub> (5%) (60 g.) was suspended in 20 cc. H<sub>2</sub>O and shaken with H at room temp. and atm. pressure for 1 hr. A soln. of 10 g. IV in 250 cc. H<sub>2</sub>O was added and the shaking in an atm. of H 45 min. gave 1.5 g. I (R<sub>1</sub> = Ph, Y = NH<sub>2</sub>, X = H, R = Ph) (D,LV) (70% pure) (procedure B). D-III was treated with 12.0 g. DII, [.alpha.]20D -24.8.degree. (c 1, EtOH), to give 22.5 g. D,D-IV (99% pure) using procedure A. D,D-IV (10 g.) was hydrogenated to give 1.2 g. I (R<sub>1</sub> = Ph, Y = NH<sub>2</sub>, X = H, R = Ph) (73% pure) using procedure B. III (2.02 g.) was treated with the reaction product of 0.48 g. ClCO<sub>2</sub>Et 0.97 g. D-.beta.-formamido-.beta.-phenylpropionic acid using procedure A to give 1.3 g. of 6-[D-.alpha.-(D-.beta.-formamido-.beta.-phenylpropionamido)-.alpha.-phenylacetamido]penicillanic acid I (R<sub>1</sub> = Ph, Y = NHCOH, X = H, R = Ph) (85% pure). III (8.06 g.) was treated with the reaction product of 1.91 cc. ClCO<sub>2</sub>Et with 5.98 g. L-.alpha.-benzyloxycarbonylamino-.beta.-phenylpropionic acid (VI) using procedure A to give 9.5 g. Na 6-[D-.alpha.-benzyl-oxycarbonylamino-.beta.-phenylpropionamido)-.alpha.-phenylacetamido]-penicillinate (D,L-VII) (74% pure). D,L-VII was hydrogenated using procedure B to give 0.8 g. 6-[D-.alpha.-(L-.alpha.-amino-.beta.-phenylpropionamido)-.alpha.-phenylacetamido]penicillanic acid I (R<sub>1</sub> = Ph, Y = H, X = NH<sub>2</sub>, R = Ph) (D,L-VIII) (75% pure). L-III (7 g.) was treated with the reaction product of 1.91 cc. ClCO<sub>2</sub>Et with 5.98 g. VI using procedure A to give 10.3 g. L,L-VII (55% pure). L,L-VII (5 g.) was hydrogenated using procedure B to give 2.5 g. I (R<sub>1</sub> = Ph, Y = H, X = NH<sub>2</sub>, R = Ph) (L,L-VIII) (40% pure). D-III (8.06 g.) was treated with 5.98 g. D-VI using procedure A to give 4.6 g. D,D-VII as the free acid, m. 148-9.degree. (MeOH) (decompn.), [.alpha.]2D0 131.5.degree. (c 0.5, MeOH). D,D-VII (2.1 g.) was hydrogenated using procedure B to give 1.5 g. I (R<sub>1</sub> = Ph, Y = H, X = NH<sub>2</sub>, R = Ph) (D,D-VIII) (57% pure). D-III (16 g.) was dissolved in 50 cc. H<sub>2</sub>O

by the dropwise addn. with stirring of 2N NaOH, keeping the pH below 8.5. To this soln., there was added a soln. of 6 cc. .beta.-propionic acid in 40 cc. iso-BuCOMe and the mixt. was stirred vigorously at room temp. 1 hr. to give 8.8 g. 6-[D-.alpha.-(.beta.-phenylpropionamido)-.alpha.-phenylacetamido]penicillanic acid I (R1 = Ph, Y = X = H, R = Ph) (89% pure). A soln. of 4.96 g. D-.alpha.-amino-.beta.-phenylpropionic acid in 100 cc. H2O and 30 cc. 2N NaOH was cooled to 5.degree., 3.3 cc. ClCO2Et was added in one portion and the mixt. stirred without cooling 1 hr. as the pH was kept at 8 by the addn. of 2N NaOH; the soln. was worked up to give 4.3 g. D-.alpha.-(ethoxycarbonylamino)-.beta.-phenylpropionic acid (IX), m. 83-4.degree. (AcOEt-hexane), [.alpha.]20.5D -11.8.degree. (c 2, MeOH). A soln. of 2.37 g. IX in 30 cc. dry Me2CO contg. 1.4 cc. NEt3 was cooled to -5.degree., 0.95 cc. ClCO2Et was added, and the mixt. stirred at -5.degree. for 20 min., cooled to -15.degree., and a soln. of 4.03 g. D-III in 10 cc. H2O, 10 cc. THF, and enough 2N NaOH soln. to give pH 8. The clear soln. was kept 30 min. and worked up to give 3 g. 6-[D-.alpha.-(D-.alpha.-ethoxycarbonylamino-.beta.-phenyl-propionamido)-.alpha.-phenylacetamido]penicillanic acid I (R1 = Ph, Y = H, X = EtOCONH, R = Ph) (88% pure). V was also prepd. as follows: .beta.-amino-L-.beta.-phenylpropionic acid (8.26 g.) was dissolved in 25 cc. 2N NaOH and the clear soln. evapd. to dryness <30.degree. in vacuo over P2O5 to give 9.3 g. of the Na salt. This pulverized Na salt (10.5 g.) was refluxed with 250 cc. EtOH contg. 5.5 cc. Me acetoacetate 15 min., the soln. filtered, kept in a refrigerator overnight, the ppt. filtered, washed, and dried in vacuo over P2O5 to give 9.6 g. Na L-.beta.-(1-methoxycarbonylpro-pen-2-ylamino)-.beta.-phenylpropionate (L-X), m. 260-2.degree. (EtOH) (decompn.). Evapn. of the filtrate gave a second crop (2.6 g.). Dry Me2CO (35 cc.) was cooled to -15.degree. (anhyd. conditions) and 0.96 cc. ClCO2Et was added, followed rapidly by 1 drop of N-methylmorpholine and 2.85 g. X; the temp. was kept at -15.degree. for 25 min. Meanwhile, 4.03 g. III was dissolved in 15 cc. H2O with enough NEt3 to just dissolve the penicillin at pH 8.3. The soln. was cooled to 0-5.degree., 15 cc. Me2CO added, the soln. rapidly cooled to 0.degree. and immediately added to the stirred anhydride. The resulting clear soln. was stirred 20 min. without cooling, concd. in vacuo <25.degree., the viscous residual syrup dild. with 500 cc. distd. H2O, covered with 100 cc. iso-BuCOMe, the vigorously stirred mixt. adjusted to pH 1.5 with 5N HCl, kept at this pH 30 min., the org. phase sepd., the aq. phase re-extd. with iso-BuCOMe, the aq. phase readjusted to pH 4.5 with 40% NaOH soln. and evapd. in vacuo below 30.degree.. When the vol. of the conc. was .apprx.40 cc., the first crop of crystals were filtered, washed, and air-dried at 35.degree. to give 27% V. The filtrate and washings were evapd. <30.degree. to 20 cc. to give a second crop (13%) (procedure C). In the following examples, the 6-(.alpha.-amino-.alpha.-thien-2-ylacetamido)-penicillanic acid was the epimer prepd. from (-)-.alpha.-amino-2-thienylacetic acid (XI), [.alpha.]20D -74.degree. (c 1, H2O). D-.beta.-(Benzyloxy-carbonylamino)-.beta.-phenylpropionic acid was dissolved in 30 cc. dry THF contg. 1.4 cc. NEt3, the soln. was stirred vigorously and kept at -15.degree. as 0.96 cc. ClCO2Et was added in one portion. After keeping at -15.degree. for 20 min., a soln. of 3.55 g. XI, 10 cc. H2O, and enough NEt3 to raise the pH to 9.1 was added to the vigorously stirred soln. at 0.degree.. The resulting soln. was worked up and added dropwise with stirring to 37% Na 2-ethylhexanoate in 4.5 g. iso-BuCOMe dild. with dry Et2O (1:1). The ppt. was filtered off to give 3.8 g. Na [.alpha.-(D-.beta.-benzyloxycarbonylamino-.beta.-phenylpropionamido)-.alpha.-thien-2-ylacetamido]penicillinate. 6-[.alpha.-(L-.beta.-Amino-.beta.-phenylpropionamido)-.alpha.-thien-2-ylacetamido]penicillanic acid I (R1 =

Ph, Y = NH<sub>2</sub>, X = H, R = thienyl) (74% pure) (1.56 g.) was prepd. from 3.55 g. XI using procedure C. D-X, m. 261-2.degree., was prepd. from 8.4 g. D-.beta.-amino-.beta.-phenylpropionate using procedure C and used to prep. 6-[.alpha.-(D-.beta.-amino-.beta.-phenylpropionamido)-.alpha.-thien-2-ylacetamido]penicillanic acid I (R<sub>1</sub> = Ph, Y = NH<sub>2</sub>, X = H, R = thienyl). (97% pure).

L4 ANSWER 146 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1967:520181 CAPLUS

DN 67:120181

TI Amino-acylaminopenicillanic acids

IN Alburn, Harvey E.; Grant, Norman H.

PA American Home Products Corp.

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3340252		19670905	US	19640407


IT **18416-41-6**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(as bactericide)

RN 18416-41-6 CAPLUS

CN Glycinamide, D-phenylalanyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



AB Continuation-in-part of U.S. 3,268,513 (CA 65: 16976c). Reaction of 290 mg. 6-(DL-N-methyl-2-aminophenylacetamido)penicillanic acid (I) and 130 mg. isatoic anhydride in 200 ml. H<sub>2</sub>O at 1-2.degree. for 1 hr., maintaining the pH at 6 with 1N NaOH, filtration, and freeze drying gave 6-[DL-2-(o-aminobenzamido)-N-methyl-2-phenylacetamido]-penicillanic acid active against Staphylococcus aureus and Escherichia coli. Similarly prepd. were, using equimolar amts. of the penicillanic acid and an N-carboxy anhydride, the following compds. active against gram-pos. and gram-neg. microorganisms: 6-[DL-2-(2-amino-5-nitrobenzamido)-N-methyl-2-phenylacetamido]penicillanic acid, 6-[DL-2-(2-amino-5-methyl-N-methylbenzamido)-2-phenylacetamido]penicillanic acid, 6-[2-(D-2-amino-N-phenylacetamido)acetamido]penicillanic acid, 6-[L-2-(D-2-amino-2-phenylacetamido)-4-methylvaleramido]penicillanic acid, and 6-[2-(D-2-amino-4-methylvaleramido)acetamido]penicillanic acid.


L4 ANSWER 147 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1967:402830 CAPLUS  
 DN 67:2830  
 TI Separation of the organic bases by Craig partition. VII. Acyl migration in the stereoisomeric N-(N,N-dimethylphenylalanyl)ephedrines  
 AU Schoenenberger, Helmut; Fuchsberger, K. D.; Brinkmann, Rolf  
 CS Univ. Munich, Munich, Fed. Rep. Ger.  
 SO Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft (1967), 300(2), 126-35  
 CODEN: APBDAJ; ISSN: 0376-0367  
 DT Journal  
 LA German  
 IT **14355-01-2P 14355-02-3P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 14355-01-2 CAPLUS  
 CN Alanine, N,N-dimethyl-3-phenyl-, ester with (-)-pseudoephedrine, dihydrochloride, L- (8CI) (CA INDEX NAME)



● 2 HCl

RN 14355-02-3 CAPLUS  
 CN Alanine, N,N-dimethyl-3-phenyl-, ester with (-)-pseudoephedrine, dihydrochloride, D- (8CI) (CA INDEX NAME)



● 2 HCl

AB cf. CA 66: 49281u. The compds. studied were N-(L-N,N-dimethylphenylalanyl)-L-ephedrine (I), N-(D-N,N-dimethylphenylalanyl)-L-ephedrine (II), N-(L-N,N-dimethylphenylalanyl)-L-pseudoephedrine (III), and N-(D-N,N-dimethylphenylalanyl)-L-pseudoephedrine (IV). In every case, only the ester of L-pseudoephedrine resulted, even under mild conditions (room temp., acetone-HCl). Complete inversion of the erythro derivs. occurred. In 2N HCl at 80.degree., the ester from I formed quant. in 10 min. while that from III (retention of configuration) required 25 hrs. With II, 5 hrs. and with IV, 22 hrs. were required. The 4 amides pass through either of 2 cyclic intermediates during the migration, L,L-(V) or D,L-pseudooxazolidine (VI). The rates are explained by steric considerations of the mechanism, V resulting from I via inversion and from III with retention, and VI, from II via inversion and IV with retention. Craig partition as described previously (loc. cit.) was used to sep. and det. the reaction products. Twenty-four partition steps using a solvent

mixt. of 0.5M citrate buffer (pH 4/5)-MeOH-CHCl<sub>3</sub> (9:1:10 parts by vol.) were required for sepn. into N- and O-aminoacylephedrine. The O-(L-N,N-dimethylphenylalanyl)-L-pseudoephedrine m. 170-2.degree., [ $\alpha$ ]<sub>D</sub> + 114.degree. (c = 0.0055 g./ml., 5N HCl) and the O-(D-N,N-dimethyl-) ester melts at 174-6.degree., [ $\alpha$ ]<sub>D</sub> 48.degree. (c 0.0055 g./ml., 5N HCl).

L4 ANSWER 148 OF 148 CAPLUS COPYRIGHT 2003 ACS

AN 1965:83974 CAPLUS

DN 62:83974

OREF 62:15015a-b

TI .alpha.-Aminobenzylpenicillin

PA Novo Terapeutisk Laboratorium A/S.

SO 3 pp.

DT Patent

LA Unavailable

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 985688		19650310	GB	19620828
DE 1208302			DE	
NL 297126			NL	

IT **2474-95-5**, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,  
6-[2-(.alpha.-benzamido-p-hydroxyhydrocinnamamido)-2-phenylacetamido]-3,3-  
dimethyl-7-oxo-  
(hydrolysis by chymotrypsin)


RN 2474-95-5 CAPLUS

CN Glycinamide, N-benzoyltyrosyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-phenyl-, [2S-(2.alpha.,5.alpha.,6.beta.)]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The title compd. (I) is produced by enzymic cleavage of 6-(N-benzoyl-2-tyrosyl-D( - )-.alpha.-amino-.alpha.-phenylacetamido)penicillanic acid (II) with .alpha.-chymotrypsin (III). The cleavage is selective irresp. of the configuration. Thus, a soln. of 5 mg. III in 0.5 ml. H2O was added to 220 mg. of the Na salt of II dissolved in 30 ml. H2O. The mixt. was left for 2 hrs. at 35.degree. and pH 6.5 to give 95% I, a broad spectrum antibiotic.

=&gt; d cost

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

CONNECT CHARGES

2.38 3.21

NETWORK CHARGES

0.42 0.60

SEARCH CHARGES

6.56 154.31

DISPLAY CHARGES

731.36 731.36

---

740.72	889.48
--------	--------

CAPLUS FEE (5%)

37.02 37.02

FULL ESTIMATED COST

---

777.74	926.50
--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-96.35 -96.35

IN FILE 'CAPLUS' AT 15:22:02 ON 26 MAY 2003